Large artery properties : relation to cardiovascular risk factors and therapy

Citation for published version (APA):

Kool, M. J. F. (1995). *Large artery properties : relation to cardiovascular risk factors and therapy*. [Doctoral Thesis, Maastricht University]. Rijksuniversiteit Limburg. <https://doi.org/10.26481/dis.19950921mk>

Document status and date:

Published: 01/01/1995

DOI:

[10.26481/dis.19950921mk](https://doi.org/10.26481/dis.19950921mk)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

LARGE ARTERY PROPERTIES

relation to cardiovascular risk factors and therapy

Mirian Kool

Publication of this thesis was financially supported by Bristol Myers Squibb The Netherlands, E. Merck Nederland B.V., Servier Nederland & Servier R&D Benelux and Pie Medical Equipment B.V.
Financial support by the Netherlands Heart Foundation for the publication of this thesis is also gratefully acknowledged.

Omslagillustratie: mevr. Mimi Limpens

LARGE ARTERY PROPERTIES

relation to cardiovascular risk factors and therapy

Proefschrift

ter verkrijging van de graad van doctor
aan de Rijksuniversiteit Limburg te Maastricht,
op gezag van de Rector Magnificus, Prof. mr. M.J. Cohen,
volgens het besluit van het College van Dekanen,
op donderdag 21 september 1995 om 14.00 uur

door

Mirian Josephina Francina Kool

Promotores :

Prof. dr. H.A.J. Struijker Boudier

Prof. dr. R.S. Reneman

Prof. dr. ir. A.P.G. Hoeks

Co-promotor:

Dr. L.M.A.B. Van Bortel

Beoordelingscommissie:

Prof. dr. P.W. de Leeuw (voorzitter)

Prof. dr. J. de Haan

Prof. dr. St. Laurent (Paris, France)

Table of contents

1	General introduction	1
1.1	Introduction to vessel wall properties of large arteries	2
1.2	Measurement of large artery wall properties in humans. Definitions, determinants and techniques	3
1.3	Vessel wall properties in various conditions	9
1	Age	9
2	Gender	9
3	Race and environmental factors	10
4	Physical activity	10
5	Obesity	10
6	Salt intake	11
1.4	Vessel wall properties and disease	11
1	Essential hypertension	11
2	Borderline hypertension	12
3	Systolic hypertension	12
4	Atherosclerosis	13
5	Diabetes mellitus	13
6	Other diseases	14
1.5	Effects of pharmacological interventions on vessel wall properties	14
1.6	Outline of this thesis	16
2	Methods used for haemodynamic measurements	29
2.1	Vessel wall properties	30
2.2	Venous compliance	32
2.3	Cardiac output	33
2.4	Blood pressure and heart rate	33
2.5	Other measurements and analyses	33
3	Evaluation of reproducibility of a vessel wall movement detector system for assessment of large artery properties	35
4	Diurnal variation	
4.1	Diurnal pattern of vessel wall properties of large arteries in healthy men	45
4.2	Diurnal variation in prorenin in relation to other humoral factors and haemodynamics	51
5	Short- and long-term effects of smoking on arterial wall properties in habitual smokers	63
6	Vessel wall properties of large arteries in uncomplicated insulin-dependent diabetes mellitus (IDDM)	75

7	The influence of perindopril and the diuretic combination amiloride/hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients	87
8	Does lowering of cholesterol levels influence functional properties of large arteries?	103
9	Acute and subacute effects of nicorandil and isosorbide dinitrate on vessel wall properties of large arteries and haemodynamics in healthy volunteers	115
10	General discussion	127
11	Summary	149
12	Samenvatting	153
	Dankwoord	155
	Publications	159
	Curriculum vitae	167

CHAPTER 1

GENERAL INTRODUCTION

1.1 Introduction to vessel wall properties of large arteries

From a physiological point of view, systolic and diastolic blood pressure are determined by the mean arterial pressure and the pulse pressure oscillating around this mean arterial pressure.

Mean arterial pressure - the static component of blood pressure - is determined by cardiac output and systemic vascular resistance (148). Cardiac output is a function of heart rate and stroke volume. Stroke volume is determined by cardiac preload, afterload and contractility and diastolic ventricular compliance (78). Systemic vascular resistance is influenced by blood viscosity and the diameter, length and number of resistance vessels, according to Poiseuille's law (166). Resistance vessels are mainly capillaries, arterioles and small arteries.

Pulse pressure - the dynamic component of blood pressure - is determined by stroke volume, the velocity of ejection of the blood from the heart, reflected pulse waves and compliance of the arterial capacitance vessels (212). Arterial capacitance vessels are predominantly large arteries and to a certain degree small arteries. Consequently, for a given cardiac output, mean arterial pressure is largely determined by the diameter and length of the arterioles and capillaries (microcirculation), while pulse pressure is determined by large artery properties (macrocirculation).

Systolic blood pressure is more closely related to pulse pressure, while diastolic pressure better reflects mean arterial pressure (208). Epidemiological studies (105,206,229) have directed attention away from diastolic pressure towards systolic pressure. Systolic pressure level has been mentioned as an independent and - sometimes even more - important risk factor than diastolic blood pressure for cardiovascular mortality and morbidity (i.e. stroke, cardiac failure and left ventricular hypertrophy) (105). As a consequence of the findings of these epidemiological studies large arteries, which buffer the output of the heart and partly determine systolic pressure level (182), have increasingly become a subject of research.

The arterial system is a complex network of elastic and muscular tubes, which exerts a conduit and a cushioning function. Because of the conduit function, blood from the left ventricle is delivered to the peripheral tissues with a minimal fall in mean arterial blood pressure (216). The cushioning function means that the blood, ejected with each heart beat, is temporarily "stored" during systole (91). This enables a more continuous flow for tissue perfusion during diastole (Figure 1.1). Distensibility and compliance are vessel wall properties of large arteries that play an important role in the dynamic behaviour of these vessels. Distensibility is defined as the relative increase in arterial volume for a given increase in arterial pressure, given as $(\Delta V/V)/\Delta P$. Compliance is defined as the absolute increase in arterial volume for a given increase in arterial pressure $(\Delta V/\Delta P)$.

Figure 1.1. Cushioning function of arterial capacitance vessels. The blood ejected with each heart beat is temporarily stored during systole. This enables a more continuous flow for tissue perfusion during diastole. The buffering function of large arteries depends on arterial compliance.

A decrease in arterial distensibility means a stiffer artery. In stiff arteries endothelial lesions may occur more rapidly. These lesions in turn may facilitate atherosclerotic changes and may lead to cardiovascular disease (65). A decrease in compliance is related to an increase in systolic blood pressure, pulse pressure and end-systolic stress, while diastolic pressure decreases (65,72,208). Consequently, a decrease in distensibility and compliance may increase the risk of cerebrovascular and cardiovascular disease (Table 1.1).

Table 1.1. Consequences of a decrease in distensibility and compliance.

1.2

Measurement of large artery wall properties in humans. Definitions, determinants and techniques

In general, the arterial system is described as a Windkessel system (Figure 1.2.1) in which the distensible Windkessel functions as a cushion linked to peripheral resistance by a rigid conduit. Frank (63) extended this theory towards a basic arterial pulse with surmounted on it wave reflections that determine wave shape and behaviour.

Figure 1.2.1. Cushioning function of the arterial system according to the Windkessel concept. The distensible Windkessel (arterial distensibility) is linked to the nozzle (peripheral resistance) by the fire hose acting as a rigid conduit. The Windkessel smoothed out the intermittent spurts from the pump so that water was delivered through the hose in a steady stream.

Distensibility and compliance are important parameters of the dynamic behaviour of a large artery. In the literature, arterial compliance is often used for compliance as well as for distensibility. This can be explained by the fact that until a few years ago, no accurate means were available to measure distensibility and compliance separately. However, there is an obvious difference between them. Distensibility reflects the intrinsic elastic properties of the arterial wall and is directly related to circumferential strain. It describes the strain on the arterial wall exerted by the pressure on this wall (91). Compliance determines the buffering function of the arterial system: the ability of the arterial lumen to store the volume energy after the systolic flow jet from the heart (216).

According to Guyton (80), arterial compliance is related to arterial distensibility and arterial volume. Some problems may arise with regard to the investigation of arterial compliance. Therefore, the determinants of compliance have to be taken into account (Table 1.2.1).

Table 1.2.1. Determinants of arterial compliance according to the Guyton model.

Arterial volume	Arterial diameter	
	Vessel length	
Arterial distensibility	Mean arterial pressure	Cardiac output Systemic vascular resistance Early pulse wave reflections
	Arterial wall	Elastin and collagen Smooth muscle tone Wall thickness Wall vicosity

Guyton model: arterial compliance = arterial volume x arterial distensibility (80).

First, the capacity to store the blood volume from the systolic jet from the heart (arterial compliance) is determined as $\Delta V/\Delta P$ (201). The inability to measure arterial volume directly requires the use of simplified models. Most techniques assume that the change in volume is due to a change in arterial cross-section rather than a change in length of the artery (201). Therefore, cross-sectional compliance is defined as a change in cross-sectional area of the artery divided by the change in pressure ($\Delta A/\Delta P$). As the artery is supposed to have a circular shape, changes in arterial diameter can be used to calculate arterial compliance ($\pi \cdot D \Delta D/2 \Delta P$). These changes in arterial diameter now can be measured accurately (90,94,117).

Secondly, mean arterial blood pressure and pulse pressure play a role. Changes in arterial compliance due to changes in pressure are said to be passive and reflect the effect of pressure acting on non-muscular components in the arterial wall (269). The two components of blood pressure are tightly interrelated (221). With a high mean arterial pressure or a high pulse pressure, as is seen in essential hypertension and isolated systolic hypertension respectively, arterial compliance is decreased (216,221). At a high distending pressure the arterial wall gets stiffer (less compliant). The tension in the arterial wall is born predominantly by the less extensible collagen fibers. Apart from the pressure effect, additional functional and/or structural alterations of the arterial wall are assumed in hypertensive patients, since at the same operating pressure compliance of hypertensive patients was reduced compared to normotensive subjects (221).

Since wave reflection plays a role in governing pulse pressure, it has to be taken into account when studying arterial compliance. In general, a pressure wave travels along the arterial tree at a speed of 5-15 m/s. Important factors that affect wave propagation are peripheral resistance, pulse wave velocity, and, related to this, vessel wall properties of large arteries also play a role. The shape of the pulse wave has been related to body height (93), but largely depends on vascular impedance and for a minor part also on ventricular ejection (175). Arterial compliance is usually determined at a certain site or segment of the arterial system. However, it differs along the arterial tree, because of differences in wave travelling properties (distensibility) and differences in arterial diameter (182). At proximal sites arteries are of the elastic type, while at distal sites they are more of the muscular type. These naturally occurring differences in vessel wall structure result in differences in distensibility along the arterial tree (35,156,200). Early wave reflections may also influence arterial compliance. These early wave reflections are increased in patients with hypertension and in the elderly, resulting in an increased mean blood and pulse pressure, and consequently, a reduction of arterial compliance (180). Changes in impedance - producing early wave reflections - mainly occur at arterial bifurcations and at sites where low resistance conduit arteries over a short distance terminate in high resistance arterioles.

Finally, the composition of the arterial wall plays an important role with respect to arterial compliance. It is known that the arterial wall consists of elastin and collagen and a smooth muscle component in the medial layer. At low pressures the relatively extensible elastin fibres "absorb" the stress on the arterial wall, while at higher pressures the non-extensible collagen fibres become more important. An increased influence of collagen may increase arterial wall stiffness (41). This means that the pressure-area curve might not be linear (Figure 1.2.2). In fact, cross-sectional compliance is given by the slope of the pressure-area (and indirectly also pressure-diameter) curve and can only be determined at a certain pressure (143).

Figure 1.2.2. Theoretical model of the presumed pressure/diameter relation (originally pressure/volume curve). Arterial compliance is defined as the slope of the curve, but may change at different pressures (182).

In contrast to passive changes in arterial compliance (due to a change in pressure), active changes in compliance are caused by changes in smooth muscle tone, since smooth muscle fibres are sensitive to various vasoactive substances released by neurohumoral stimulation (38,94). A change in smooth muscle tone may change arterial diameter for a given pressure and consequently influence arterial compliance (53,177).

Pressure-volume relationships are also dependent on wall thickness and wall viscosity. Viscosity creates a lag between the stress on the wall and the change in arterial diameter (183). Since the wall thickness of elastic and muscular large arteries is small compared to their lumen radius (75) the influence of wall thickness on arterial compliance is considered relatively low. However, with increasing wall thickness

compliance of large arteries is supposed to diminish (73,74,123,124). Now different methods to assess arterial wall thickness are proposed based on ultrasound devices (52,192,250,261). They indicate that ultrasonic wall thickness may be in close agreement with the histologically determined value (38).

Arterial compliance can be measured at different levels. *Systemic* arterial compliance gives an overall index of compliance in the whole arterial system and is an important factor in determining cardiac afterload. *Regional* arterial compliance - also described as volumetric distensibility - describes compliance in an arterial segment, such as the forearm, the leg or the aorta. With this approach generalised arterial stiffening can not be distinguished from a very localised stiffness. *Local* compliance - also described as cross-sectional distensibility - can be measured at various large arteries. At present, in humans local compliance of superficial large arteries, such as the carotid, brachial, radial and femoral arteries and compliance of the abdominal aorta have been investigated (89,117,251).

Total systemic vascular compliance is difficult to measure directly in man, since the measurement requires sudden arrest of the heart and rapid distribution of blood between the arteries and the veins. Therefore, previously total systemic vascular compliance has been calculated as the ratio between changes in central venous pressure and changes in blood volume after rapid Dextran infusion (120,147,222). Changes in total systemic vascular compliance may involve alterations in left ventricular diastolic compliance, venous or arterial compliance (218). For assessment of *arterial* compliance usually indirect techniques are used. In that case, propagative and non-propagative models are used to estimate compliance. The non-propagative models are based on the Windkessel concept, which assumes an infinite pulse wave velocity (Figure 1.2.1). These pressure-dependent methods define arterial compliance as the change in volume due to a change in pressure. Compliance then may be determined from the slope of the pressure-volume curve (143,234). However, pressure changes do not occur simultaneously, pulse wave velocity varies along the arterial tree and pulse wave reflections are not accounted for with these methods. Propagative models, which are based on pulse wave velocity measurements, seem to offer more advantages.

Systemic arterial compliance is mostly determined from a Windkessel model of the arterial system in which the slope of the pressure/volume curve represents compliance. In that case, aortic as well as brachial pressure may be measured, generally with an invasive technique. Volume changes may be derived from cardiac output measurements (59,120). Although stroke volume is influenced by other haemodynamic factors the non-invasively determined stroke volume/pulse pressure ratio has also been used as a measure for systemic compliance (165).

Regional compliance is mostly estimated from pulse wave velocity measurements in combination with arterial diameter measurements. Various relationships are suggested in the literature to quantify the elastic behaviour of (a segment of) an artery. The most important expressions used are shown in Table 1.2.2.

The Moens-Korteweg equation defines pulse wave velocity from Young's elastic modulus, wall thickness, blood density and the arterial radius. The Bramwell-Hill equation determines pulse wave velocity from changes in pressure and volume, related to the initial arterial volume (36,167,176). Pulse wave velocity may also be measured with transit-time techniques. The time interval between the arrival of the arterial pulse at two sites of the arterial system and the distance between these sites are used to calculate pulse wave velocity (44,176,182,266). Pulse wave velocity techniques have been applied to different arterial segments, such as the brachio-radial and carotido-femoral segment. In the latter, it is a surrogate for aortic distensibility. For the non-invasive determination of pulse wave velocity, ultrasound techniques have been employed. Based on the Doppler principle regional distensibility could be estimated (118). A disadvantage of this technique is that the distance between the sites of measurement should be long enough to avoid time resolution problems. Unfortunately, the method only provides an indirect measure of distensibility, not of compliance. In addition, local inhomogeneities remain undetected (198). Only distensibility of a certain arterial segment can be studied. In that case, arterial compliance is equal to the product of arterial volume (or cross-sectional area per unit of length) and distensibility (pulse wave velocity). The pressure-strain elastic modulus (Peterson modulus) can be used (3) to assess arterial distensibility. The relationship between arterial distensibility and pulse wave velocity is given by the Young's elastic modulus, which

Table 1.2.2. Expressions to qualify elastic behaviour of an artery.

Moens-Korteweg	$PWV = \sqrt{E \cdot h / 2\rho r} = \sqrt{1/\rho DC} \text{ [m/s]}$
Bramwell-Hill	$PWV = 0.357 \cdot \sqrt{V/(\Delta V \Delta P)} \text{ [m/s]}$
Transit time technique	$PWV = L/T \text{ [m/s]}$
Elastic (Peterson) modulus	$E_p = (D \cdot \Delta P / \Delta D) = 1/(2 \cdot DC) \text{ [Pa]}$
Young's modulus	$E = \rho(PWV)^2 D/h = (D/h)/DC \text{ [Pa]}$
Distensibility coefficient	$DC = (\Delta A/A)/\Delta P \approx 2 \cdot (\Delta D/D)/\Delta P \text{ [Pa}^{-1}\text{]}$
Compliance coefficient	$CC = (\Delta V/L)/\Delta P = \Delta A/\Delta P \approx \pi \cdot D \cdot \Delta D / 2\Delta P \text{ [mm}^2/\text{kPa]}$

A, cross-sectional area; ΔA , change in cross-sectional area during the heart cycle; CC, compliance coefficient; D, end-diastolic diameter; ΔD , change in arterial diameter from diastole to systole; DC, distensibility coefficient; h, wall thickness; L, length of arterial segment; ΔP , pulse pressure, systolic minus diastolic pressure; PWV, pulse wave velocity; ρ , blood density; T, time delay needed for pulse wave to travel between two arterial sites; V, arterial volume; ΔV change in arterial volume.

represents arterial strain in relation to the thickness of the arterial wall (181). Finally, non-invasive determination of regional aortic compliance has been described with magnetic resonance imaging techniques (168).

Techniques to measure non-invasively *local* compliance have been developed in the last two decades (Table 1.2.3). Arndt (4) was the first who used the change in distance between the ultrasound reflections of the anterior and posterior arterial wall for measuring changes in arterial diameter during the cardiac cycle, to calculate local compliance. An A-mode technique was used, which resulted in an overestimation of arterial diameter and diameter change.

Table 1.2.3. Methods for non-invasive assesment of local compliance.

✓ Windkessel model (44,120,143,234)	✓ Continuous wave Doppler (179)
✓ A-mode echo (4)	✓ Pulsed wave Doppler (137,263)
✓ B-mode echo (21)	✓ Multi-gate pulsed Doppler (201)
✓ M-mode echo (29,38,58,202)	✓ Doppler-tracking (92,95,251)

Later, a B-mode system has been developed to measure the relative increase in arterial diameter during the heart cycle (21). However, this is a time-consuming technique and the accuracy of the measurements is hampered by the spatial resolution of the echo-system.

Subsequently, M-mode techniques that could visualize moving structures have been used (29,58,202) to measure changes in arterial diameter. However, also this technique is time-consuming and not accurate enough to study arterial compliance. In addition, any information about the distension waveform is lacking (92).

Furthermore, continuous wave and pulsed wave Doppler techniques have been used to detect vessel wall movements. The disadvantage of continuous Doppler systems is that they can not assess initial arterial diameter and may only measure vessel wall movements if both walls move with the same speed in opposite directions (179). With pulsed Doppler systems the detection of vessel wall movements is based on the positioning of two sample volumes coinciding with the vessel wall or with the wall-blood interface (263). The difference in displacement of the sample volumes describes the change in arterial diameter during the heart cycle, while the distance between the sample volumes gives the initial arterial diameter. Levenson et al developed a modified pulsed Doppler device in order to minimise the error resulting from the determination of the angle between the ultrasound beam and the vessel axis (137). Still this method may result in a slight overestimation of arterial diameter and mean blood flow velocity (224).

Multi-gated pulsed Doppler systems have been developed to measure arterial diameter and diameter changes on line (199). With this system the carotid and femoral artery have been investigated (42,159). It has shown good accuracy, but a disadvantage of this technique is that the sample volume is fixed in size and position (198). Consequently, it becomes difficult to assess arterial distensibility, especially when the artery is moving. Hokanson was the first to use the phase of the radiofrequency (RF) signal and the positioning of windows at both arterial walls (95,169). This method was far more accurate to detect diameter changes during the heart cycle. A few years later, Hoeks et al developed a system based on tracking the position of the vessel wall during the heart cycle, using this radiofrequency signal (92,93). With the first devices sample volumes coinciding with the vessel walls were fixed (93), but later sample volumes could track the moving position of the anterior and posterior vessel wall by means of Doppler tracking (92). Arterial diameter (D) and change in arterial diameter during the heart cycle (ΔD) can be measured with this system. Simultaneously blood pressure is recorded with a non-invasive device. From D , ΔD and pulse pressure, distensibility (coefficient) and cross-sectional compliance (coefficient) of superficial large arteries can be calculated. The vessel wall movement detector system, as originally developed by Hoeks et al, is the system used in the current thesis (Chapter 3).

Recently, another A-mode ultrasonic echo-tracking device has been developed to measure the displacement of the arterial walls over the cardiac cycle and to derive from these parameters arterial compliance of distal large arteries (251). With this technique radial artery displacement is measured together with beat-to-beat blood pressure at the finger with the Finapres device. The technique showed good reproducibility within this muscular artery (230,255).

A problem with any compliance measurement technique is the assessment of blood pressure. Intra-arterial pressure measurements are hitherto considered as a gold standard for measurement of blood pressure. However, the technique is invasive and does not always allow pressure measurements at the site of the compliance measurement. (Semi)automated non-invasive pressure recording techniques are based on plethysmographic, auscultatory or oscillometric recordings (32,184,189,207). Ideally, arterial wall distension measurements should be related to local blood pressure recordings obtained simultaneously, and at the same site. However, in practice this usually is not the case: a pressure recording as close as possible to the location of interest is chosen. For example, continuous non-invasive pressure recording at the finger tip with a Finapres device provides an accurate estimate of mean arterial pressure, but an overestimation of radial pulse pressure (55,96,186), since even over this short distance pulse pressure may change considerably due to pulse wave reflections.

It is generally accepted that in large arteries mean arterial pressure is quite constant, while pulse pressure may differ (112,208). It is known that pulse wave reflections may occur in the carotid artery, while they are uncommon at the brachial site. When carotid pulse wave reflections are absent, there is a good correlation between pressure in the brachial and carotid artery (198). Then the differences between carotid and brachial pressure seem to be systematic. Until now, there is no accurate method to measure blood pressure non-invasely at the carotid and femoral arteries. Applanation tonometry (112) is a non-invasive technique that has been developed to measure pressure at the site of wall distension measurement. In the hand of well trained observers this technique has shown to be acceptable for recording of relative changes in

pressure of superficial large arteries (111,122). A good correlation has been shown between brachial artery and femoral artery pulse pressure (25,26), but this method is not generally accepted, yet. At present, attempts are made to measure local pulse pressure and diameter simultaneously with ultrasound techniques, but these methods still have to be evaluated (27,91,248).

1.3 Vessel wall properties in various conditions

1.3.1 **Age**—Arterial degeneration occurs with ageing and this produces a loss of arterial distensibility (elasticity). This may be responsible for an increase in systolic blood pressure. Results from an in vitro study in 1922 have already demonstrated an increased stiffness in human aorta and carotid, iliac, femoral arteries with ageing (18,127). However, arteries show a stiffer behaviour in vitro than in vivo (77). In vivo, in general a decrease in compliance with advancing age, measured with different methods and at different sites, has been found (46,269). The vascular system may be considered mature at the adolescent age with respect to distensibility and compliance (160), but the point from which compliance starts to decrease is not very well defined. It appears to be about the third decade of life (201), while autopsy studies show a decrease from the age of 20 (173). Aortic compliance (69,168), as well as compliance of other elastic (22,201,204) and muscular large arteries decrease with age (169). At the same mean arterial pressure, the common carotid artery seems to be more influenced by age than the femoral artery (25). In addition, the effects of age do not appear to be similar in different populations (13) and may differ between sexes (14,22,118). A decrease in compliance with ageing can not be fully explained by the presence of other diseases. For example, with hypertension (97,158) and cardiomyopathy (44) there is an age-related decrease in compliance, independent of the state of disease.

Most studies show that with advancing age the diameter of the arteries becomes enlarged, likely an adaptation to the decrease in distensibility in order to keep compliance constant. However, this effect of an increased diameter seems to be most pronounced in elastic arteries (carotid, aorta) and more variable at muscular sites (brachial, femoral) (69,109). In addition, it has been shown that proximal arteries are more dilated with age and that distal arteries react more with thickening of the wall (127). The mechanism by which ageing can cause a decrease in distensibility and compliance is not fully clear. The study of the effect of ageing per se on cardiovascular structure and function is hindered by the occurrence of disease processes and lifestyle changes which are inextricably linked to ageing (longitudinal studies). Cross-sectional studies on the effects of age are often biased due to natural selection within the population. However, some hypotheses can be formulated.

First, the fatiguing effects of cyclic stress on the elastic fibers may result in degeneration of these fibers with subsequent stretching and remodelling of the wall and dilation and stiffening of the artery (180,209). In addition, the amount of collagen increases with age. The decrease in distensibility with age was proportional to the increase in collagen in the media and intima (22,209). Tethering between elastin and collagen is also increased with age (22). *Secondly*, with age vascular smooth muscle cells accumulate in the walls of large arteries, which leads to a decrease in distensibility. *Thirdly*, atherosclerosis could play a role (209). However, in a population without atherosclerosis arterial compliance was also decreased with age, thus changes are not solely the result of atherosclerosis (14). *Finally*, early and enhanced wave reflection is seen with advancing age (13,111), which could boost pulse pressure and decrease distensibility.

1.3.2 **Gender**—Although obvious differences between men and women with respect to the prevalence of cardiovascular disease have been demonstrated in epidemiological studies (107), this phenomenon has not been clarified. Men experience an excess morbidity and mortality through middle age as compared to women with regard to coronary heart disease. For cerebrovascular events adult men have also a higher

risk compared to age-matched women (19). In large arteries, arterial diameter of elastic and muscular arteries were found smaller in women (35,236). This is not a surprising finding, since the calibre of large vessels is influenced by body size (166). In several studies women showed a significant higher arterial distensibility of large arteries, when compared to men (14,22,118,227). However, a decreased distensibility in women, irrespective of age, has also been found (161). The mechanism by which gender differences lead to differences in vessel wall properties of large arteries is not clear, but sex hormones could play a role. However, evidence for a clear relationship between female hormones and cardiovascular disease is lacking (39), because of many other confounding variables. The relation between vessel wall properties and gender seems to be rather complex.

3.3 **Race and environmental factors**—Levels of arterial blood pressure vary between different races and also the risk of complications of cardiovascular disease is not uniformly distributed among different races (99). With regard to large arteries rural and urban communities in China differed in aortic pulse wave velocity (14,16). In addition, occidental populations differ from oriental populations in aorta medial thickness at all ages. Chinese subjects showed a consistently lower medial thickness throughout the aortic trunk (14). Unfortunately, no histological examinations were performed with regard to the elastic and collagen components of the aortic wall.

3.4 **Physical activity**—Acute effects of dynamic exercise have shown an increase in arterial compliance in hypertensives (61). In normotensives and mildly hypertensive patients a decrease in aortic compliance with acute dynamic exercise has been reported (171,178). Aortic distensibility was higher in athletes compared to matched controls (168). In trained cyclists compliance of the muscular arteries was larger compared to sedentary subjects, while the elastic arteries seemed relatively unaffected (115). This suggests a more generalised adaptation of muscular large arteries to regular exercise, although the reduction in blood pressure usually seen with training, may also play a role. Since arterial diameter of the exercising limb was increased in the trained group, it was supposed that the supplying artery may have undergone structural adaptation. In hammer-throwers arterial compliance of the exercising extremity was also increased compared to the non-exercising site (70). In the non-exercising limb compliance was mainly improved by an increased distensibility (115).

Since most studies were cross-sectional studies the effect of training per se could only be suspected. In a short-term study a 4-week exercise training programme improved arterial compliance (40). After a subsequent 8-week sedentary period compliance had returned to pretraining values. Since blood pressure also altered during the study, the effect could have been pressure related (40). On the other hand, in a recent study 6 weeks of training reduced heart rate and improved cardiac function, but did not significantly affect blood pressure or vessel wall properties of elastic and muscular large arteries (262).

The mechanism behind the effects of exercise on the arterial system are not completely clear. Due to exercise various central and peripheral cardiovascular adaptations occur (30). Functional and structural changes, directed towards a better perfusion of the exercising tissues, occur in small blood vessels (226). There may be a direct or indirect effect of training on the arterial system. Increased distensibility might be due to a reduction in smooth muscle tone, associated with an exercise-related decrease in the production of angiotensin and/or a reduction in sympathetic tone. In addition, an increased production of vasodilator metabolites has been mentioned (98,241,244). A reduction in blood pressure on itself may be of importance, too. Finally, a flow-dependent increased production of endothelial relaxing factors must be considered (195).

3.5 **Obesity**—In the Framingham study a relation between obesity and cardiovascular disease has been described (103). With respect to large arteries it was found that for the same blood pressure brachial artery diameter in obese subjects was not different from that in controls. Obese patients seem to have a more

hyperkinetic circulation with a high blood flow and a locally diminished resistance with relative vasodilation (197). In that case, aortic distensibility did not differ between obese and non-obese subjects (170). However, Toto-Moukoko found a decreased distensibility in obese patients when compared to the non-obese. Body weight reduction led to an improvement in arterial wall properties (254). A recent study of Spek et al showed that in obese subjects distensibility, due to a larger diameter, was decreased in muscular large arteries, but not in elastic arteries (245). It is hypothesised that arterial tone might be decreased in obese subjects (245). However, sympathetic activity was not different between obese and non-obese subjects (67). Data on structural changes in obese subjects are not known. Anyhow, increased arterial stiffness in obese patients may place them at a higher cardiovascular risk.

1.3.6 Salt intake — Epidemiological and interventional observations suggest a relation between dietary salt intake and blood pressure (150). Intravenous administration of isotonic saline increased systolic pressure and decreased forearm compliance in elderly subjects (146). Subjects with a low salt-intake showed a larger arterial diameter and a better arterial distensibility than those with a high salt-intake (15,139,214). After 6 months of salt-restriction, distensibility improved, differences being most pronounced in the older age groups (15). In borderline hypertensive subjects it has been shown that for the same blood pressure and arterial diameter, vessel wall properties of the elastic and muscular large arteries were reduced in salt-sensitive subjects when compared to salt-resistant persons (56). Different mechanisms have been proposed to explain the relation between arterial compliance and salt, such as an interaction with the renin-angiotensin system and the sympathetic nervous system (139). In addition, altered salt transport across the cell membrane and changes in the amount of cellular calcium might play a role (64).

1.4 Vessel wall properties and disease

Alteration in mechanical behaviour of the arterial wall has been demonstrated in several diseases, even at early stages of the disease. Although these changes do not yield direct information about the composition of the arterial wall, early alterations in arterial elasticity may have consequences for therapy and predict the course of a disease or the development of complications.

1.4.1 Essential hypertension — Essential hypertension is a multifactorial disease. It has been hypothesised that both a genetic predisposition and environmental factors may result in the development of hypertension (140,264). In the industrialised countries hypertension is an important risk factor of cardiovascular morbidity and mortality (99). The haemodynamic characteristics of hypertension have usually been attributed to an increased mean arterial pressure with an increase in total peripheral resistance (217). The latter may be due to rarefaction of arterioles and capillaries, increased wall thickness of arteries and arterioles, and decreased diameter of arterioles and small arteries (62,82,130). In addition to these changes in total peripheral resistance, the pulsatile component of blood pressure has received more attention in the last few years.

Large arteries do play an important role in the pathophysiology of hypertensive vascular disease. The conduit function is maintained till very advanced stages of the disease, but the buffering function (arterial compliance), which is related to elastic properties (arterial distensibility) and storage of blood flow (arterial volume), is altered even in the early phase of the disease.

Using a non-invasive technique, arterial wall properties were not found different between normotensives and hypertensives at identical distending pressures (79), suggesting that the stiffer arteries, associated with hypertension, are due to an elevated distending pressure. However, in this study changes in arterial volume were not considered. Recent data have also suggested that the stiffened arteries associated with

hypertension are due to an elevated distending pressure rather than to intrinsic changes (123,125). In general, arterial compliance has been shown to be reduced in essential hypertension.

Central aortic compliance (97,143,151,165), as well as compliance of peripheral elastic (33,215) and muscular (58,135,154,224) large arteries have been shown to be decreased. On the one hand under isobaric conditions radial artery compliance in hypertensive patients was increased (125). On the other hand, a recent study could not demonstrate a difference for vessel wall properties of the muscular radial artery between hypertensive and normotensive subjects (84). From these studies it is concluded that arterial compliance is not decreased in hypertensive patients for a given blood pressure level. The difference between proximal large arteries and distal medium-sized arteries might be related to structural vascular changes observed with long-standing hypertension, but this is difficult to analyse (125).

Thus, although low arterial compliance of proximal large arteries seems to be a well accepted finding in hypertension, the possibility that a decreased compliance could be the effect as well as the cause of the disease remains a matter of debate (232). In addition, other factors than blood pressure also influence arterial compliance. Apart from ageing, additional intrinsic alterations in vessel wall properties, (adaptive) functional or structural changes or primary abnormalities of the vessel wall must be considered. Functional changes such as an increased sympathetic tone, activation of the renin-angiotensin system, an altered prostaglandin system, and altered endothelial function all have been associated with a decreased compliance as seen in essential hypertension (217,249). Structural changes such as an increase in the extracellular matrix, arterial wall thickness and smooth muscle mass increase - in which the vascular endothelium is involved - may also be important (217,249). Arterial diameter increases in hypertension (97,224), possibly to compensate for a diminished distensibility and to maintain arterial compliance and blood flow within normal ranges.

In any case, the hypertension-related decrease in arterial compliance increases pulse pressure and systolic pressure, while it decreases diastolic pressure (212). Consequently, the risk for cerebrovascular complications increases. Cardiac perfusion will be negatively influenced and the development of cardiac hypertrophy may be enhanced (185,225). Baroreceptor function may be altered and the development of age-related and atherosclerotic vascular changes may be facilitated (35,65,198).

4.2 **Borderline hypertension**—According to the definition of the WHO, borderline hypertension is defined as systolic/diastolic blood pressure between 140/90 and 160/95 mm Hg (270). Cardiovascular morbidity and mortality in borderline subjects exceeds the rates in normotensive subjects (102). Epidemiological data have shown that despite minimal blood pressure elevation, borderline hypertensive patients exhibit early changes in heart and blood vessels (101). It is assumed that there is a transition from a high cardiac output to a high vascular resistance in a later phase of the disease. The transition occurs through changes in structure and responsiveness of the cardiovascular system (100).

Independently of age and blood pressure, compliance of elastic and muscular large arteries has been found reduced in borderline hypertension (157,233). This could result in faster ageing of large arteries in borderline hypertension (156). In contrast to established hypertension, arterial diameter was not altered (157,233). However, when borderline hypertensives were subdivided into a group with high and normal cardiac output, those with a high cardiac output showed a vasodilation of the brachial artery (190,233). This might suggest that a change in diameter may be present, depending on the phase of borderline hypertension.

In prehypertensive patients, who have a parenteral history of hypertension, arterial compliance has also been found to be decreased (260).

4.3 **Systolic hypertension**—Systolic hypertension may exist as combined systolo-diastolic hypertension, but occurs also as isolated systolic hypertension. Isolated systolic hypertension (ISH) is defined as high systolic blood pressure (≥ 160 mm Hg), while diastolic blood pressure does not exceed 90 mm Hg (104). It has been reported that more than 10% of persons in the US older than 65 years suffers from ISH (228).

Isolated systolic hypertension forms an important and independent risk factor of cardiovascular morbidity and mortality. These patients are more prone to development of ventricular hypertrophy and stroke (47,108,206).

In young patients (<35 years) with isolated systolic hypertension arterial compliance remained within the normal range (240). A more rapid velocity of ventricular ejection during the first part of systole and an increased sympathetic tone are considered responsible for this phenomenon in young subjects. In older subjects, ISH appears to be largely the result of a greatly reduced arterial compliance along with a smaller but significant increase in peripheral resistance (28,47,174,240). In addition, in these patients enhanced early wave reflections play a role. The stiffness of the arteries is accentuated because of the combined effect of age and elevated blood pressure. Structural changes may be assumed because advancing age is associated with a loss of elastic fiber and an increase in collagen and calcium deposition in the arterial wall. Functional changes may consist of an increased responsiveness of arterial smooth muscles to adrenergic stimulation as a result of a decline in β -receptors with age (209).

1.4.4 **Atherosclerosis** — Atherosclerosis is a multifactorial disease. The presence of risk factors such as hypertension, hypercholesterolaemia, cigarette smoking and glucose intolerance may induce atherosclerotic changes (65). Atherosclerosis is responsible for a large part of cardiovascular morbidity and mortality. Chronic minimal endothelial injury plays a role in the onset of atherosclerosis (65,66). Atherosclerosis often has been associated with a decreased arterial compliance. Patients with coronary atherosclerotic disease showed an increased arterial stiffness of the aorta (87,168, 246), while patients with carotid atherosclerotic disease also showed a decreased local distensibility (87,162). Patients with familial hypercholesterolaemia even showed an increased aortic compliance in young subjects (129), but also in older individuals the aorta was found more distensible than in control subjects (48). Since atherosclerosis may be characterised by atherosclerosis in an early phase, followed by sclerosis as the disease progresses (116), these findings of an increased compliance might reflect an early stage of the disease. In turn, this would be compatible with experimental data, also showing an increased aortic compliance during the early phase of atherosclerosis and a decrease in compliance as atherosclerosis progressed (172). Arterial diameter in atherosclerosis often remains unchanged. Probably atherosclerotic arteries undergo remodelling, which preserves the vascular lumen until the lesion becomes moderately advanced (86). It has been hypothesised that arterial stiffening may occur as a consequence of accumulation of collagen, loss of elastin, increased smooth muscle tone - through reduced endothelium-derived relaxing factor release - and increased sodium load (116).

1.4.5 **Diabetes mellitus** — Cardiovascular disease is an important complication in both insulin-dependent and non-insulin dependent diabetes mellitus (106,196). Arterial diabetic disease is assumed to affect predominantly distal large arteries (205), but also proximal arteries may be involved (164). In general, distensibility of the femoral artery and aorta have been studied and found decreased in diabetic subjects (128,144,253,256, 258,259,265). However, in these studies age, duration of the disease, and the existence of complications may also have influenced arterial compliance (128). In addition, the pulse wave velocity techniques used in these studies do not necessarily give a correct estimate of arterial wall elasticity, because, depending on the technique, reflected pressure waves may also play a role. On the other hand, a recent study in non-insulin dependent diabetes mellitus could not reveal differences in large artery compliance when compared to a matched control group. In addition, no positive correlation could be demonstrated between duration of disease or indices of glycemic control and arterial compliance (153). The preferential increase in systolic blood pressure in diabetic subjects could suggest a premature ageing process of the arterial system with subsequent vascular rigidity (252). However, hemostatic abnormalities (68,81), chronic hyperinsulinemia (60,247) and long-standing hyperglycemia (37,114) have also been mentioned as possible mechanisms to explain the increased arterial stiffness.

1.4.6 Other diseases — In congestive heart failure aortic compliance and brachial artery compliance have been found to be decreased (5,54,119,187). However, others could not demonstrate a decrease in compliance (17,120). The divergent data may reflect differences in other determinants of arterial wall properties, such as age, which was not examined in these studies. In addition, in some studies differences in hemodynamic parameters (i.e. blood pressure) could have played a role.

Patients with end-stage renal failure showed a decreased distensibility of elastic and muscular large arteries, while arterial diameter was increased (20,145). In these patients - with the same mean arterial pressure - pulse pressure and early wave reflections were increased compared to controls (145). This decrease in distensibility was related to other factors than blood pressure, age and metabolic disturbances (146,152). Possible changes in sympathetic tone or the activity of the renin-angiotensin system have not been investigated in these studies. Dialysis-induced hypercalcaemia might be responsible for the decreased distensibility, but the precise mechanisms are not clear yet (152).

Aortic distensibility has been found to be decreased in connective tissue diseases such as Marfan's syndrome (88). The amount of wave reflections was higher, while aortic root diameter was increased. Alterations in the organisation of the extracellular matrix with a fragmentation of elastic fibers in the aortic media are probably responsible for these changes (268).

In patients with pulmonary hypertension pulmonary artery distensibility has been found reduced (31). Pulmonary hypertension changes the structure of the pulmonary arteries, which may be associated with the decreased distensibility (83). Patients with arteriosclerosis obliterans of the lower limb show a greatly increased pulse pressure and a decrease in arterial compliance (213). This may be explained by structural alterations of the arterial wall, altered wave reflections and functional changes in vasomotor tone.

1.5 Effects of pharmacological interventions on vessel wall properties

Until recently, pharmacological approaches to the reduction of cardiac afterload in cardiovascular disease were confined to the effects of reduction in total peripheral resistance by reducing smooth muscle tone. However, this has not always led to a diminution of target organ effects in cardiovascular disease (51,191). Another possibility to reduce cardiac afterload is to improve vessel wall properties of large arteries which results in an increased buffering capacity of large arteries and a reduction in wave reflections with a decreased end-systolic pressure (121,122).

It has been shown that well controlled hypertensives after 3 months of therapy had not only a lower blood pressure, but also a lower stiffness of the carotid artery when compared to untreated patients. However, several but not all classes of antihypertensive agents may improve arterial compliance (Table 1.5). In general, from the currently known first-line antihypertensive drugs in humans calcium antagonists and ACE inhibitors increased large artery compliance. Although there are some exceptions (eg, metoprolol), selective β_1 -blockers and β -blockers with ancillary vasodilating properties and nitrates improved arterial wall properties. From the data available, it appeared that diuretics, vasodilators of the hydralazine group, the centrally acting α_2 -agonist clonidine and non-selective β -blockers in general did not affect arterial wall properties favorably. The effect of pure α -blockers is not clearly investigated. Ketanserin (α -blocker + serotonin-2 antagonist) improved arterial compliance, while urapidil (α -blocker + central serotonin-1a agonist) did not change brachial artery diameter and compliance. Labetolol (α - and β -blocker) increased arterial compliance acutely. Pinacidil, a potassium channel opener, was able to decrease systemic vascular resistance and increased large artery compliance in healthy volunteers.

In addition to improvement of arterial compliance, a reduction in early wave reflections may be achieved with some antihypertensive agents (110,113,122,267). Wave reflection may be modified through antihypertensive therapy by an influence on the intensity of the reflected wave and/or an influence on the timing of reflected waves. The first takes place at the arteriolar level through a diminished peripheral

Table 1.5. Effect of antihypertensive agents on large artery properties in humans.

Antihypertensive agents	Acute		Short-term		Long-term	
	Distensibility	Compliance	Distensibility	Compliance	Distensibility	Compliance
ACE inhibitors	↑ 8,23,210	↑ 238	↑ 8,23	↑ 238	↑ 9,11,49,210	↑ 9,11,49,235
Calcium antagonists						
Dihydropyridine	↑ 134, 136,219,220	≅/↑ 45, 134, 136, 139,220	↑ 6,7	↑ 2,7	↑ 134	↑ 134
Non-dihydropyridine	n.i.	n.i.	↑ 163	↑ 163	≅23	n.i.
β-Blockers						
Non-selective	n.i.	n.i.	n.i.	n.i.	n.i.	≅149,255,237
Selective β ₁	↑ 32	↑ 132	≅/↑ 10,50,257	≅/↑ 10,50,203,257	≅/↑ 49, 110, 132, 193	≅/↑ 49, 132, 193
Vasodilating + ISA	n.i.	n.i.	≅/↑ 257	≅203,257	↑ 193	↑ 12, 149, 193,237
Vasodilating - ISA	n.i.	n.i.	↑ 155	↑ 155	n.i.	n.i.
α-Blockers+ancillary properties						
Labetalol (derivatives)	≅219	↑ 194	n.i.	n.i.	↑ 110	n.i.
Urapidil	↑ 142	≅142	n.i.	n.i.	n.i.	n.i.
Ketanserin	n.i.	n.i.	↑ 50	↑ 50	n.i.	n.i.
Direct vasodilators						
Nitrates	↑ 122, 133,219,242	≅/↑ 122, 133,239,267	n.i.	n.i.	n.i.	n.i.
Hydralazine	≅34,220	≅34,220	n.i.	n.i.	n.i.	n.i.
Diuretics						
Indapamide	n.i.	n.i.	≅126	n.i.	≅211	↑ 43
Spironolactone	n.i.	n.i.	≅126	n.i.	n.i.	n.i.
Thiazides	n.i.	n.i.	≅/↑ 243	≅/↑ 243	n.i.	n.i.
Centrally acting agent	n.i.	n.i.	n.i.	n.i.	n.i.	≅1
K-channel openers	↑ 131	↑ 131	n.i.	n.i.	n.i.	n.i.

↑ increase; ≅, no change; n.i., not investigated; acute, <1 day treatment; short-term, >1 day and <3 months treatment; long-term, 3 months treatment; ISA, intrinsic sympathicomimetic activity.

resistance and another pre-arteriolar calibre. The latter occurs by an alteration in vessel wall properties (13,121).

Thus, the effect of different antihypertensive drugs on large artery compliance is not uniform. A large part of the studies are acute or short-term studies up to 3 months of therapy. In these studies, changes in arterial compliance are likely to be due to functional rather than to structural changes.

Changes in arterial diameter and vessel wall properties are not only due to the fall in blood pressure, suggesting an increase in compliance through a passive reduction in pressure with a transfer from the collagen to the elastin fibers. Additional factors such as drug-induced effects on smooth muscle, induction of counterregulatory mechanisms (sympathetic tone, renin-angiotensin system) and non-specific mechanisms related to the myogenic response or flow-dependent endothelial vasodilation may also play a role (221). In general, there are two possible haemodynamic patterns following antihypertensive therapy: a decreased vascular resistance and an unchanged (even a tendency to a reduced) arterial compliance (hydralazine-like agents, propranolol) or a decreased vascular resistance and an increased arterial compliance (nitrates, ACE inhibitors, calcium antagonists) (221).

Chronic treatment with antihypertensive drugs (57,188) may be able to induce structural changes in the arterial wall, but here also not every agent is equally beneficial. On the other hand, normalisation of arterial structure with chronic treatment may not always be beneficial if it is not accompanied by a decrease in blood pressure (24). Short and long-term drug-induced modifications in the buffering function of large arteries parallel the effects of drugs on cardiac mass (225). A few studies have shown that chronic antihypertensive treatment may result in adequate blood pressure lowering and a decrease in cardiac hypertrophy, whereas vascular structure seemed not affected (11,72,76,141). However, in these studies no biopsies were taken. Histologic studies demonstrated that normalisation of blood pressure after treatment with various drugs for more than 3 months (85) did only partially reverse structural abnormalities in hypertensive patients. On the other hand, the results of a recent study of the effect of the ACE inhibitor perindopril versus the diuretic hydrochlorothiazide suggested that in hypertensive patients arterial wall hypertrophy of medium size arteries may regress under treatment, whereas this is more difficult to show at the site of the arterioles (71). In addition, chronic treatment (9 months) with perindopril showed a normalisation of the media/lumen ratio of subcutaneous resistance arteries in hypertensive patients (231).

Outline of this thesis

From the introductory part it can be concluded that vessel wall properties of large arteries - arterial compliance and distensibility - play an important role in cardiovascular disease. With a decrease in compliance and distensibility the risk of stroke and cardiac hypertrophy and failure are enhanced, while the development of atherosclerotic disease may be facilitated. During the last few decades a shift from invasive and in vitro research of vessel wall properties towards a non-invasive and in vivo approach has occurred. Ultrasound techniques to assess vessel wall properties directly seem to be the most promising and accurate methods. The studies as presented in this thesis were intended to obtain more information on vessel wall properties of different large arteries in humans as assessed with a newly developed vessel wall movement detector system based on an echo Doppler tracking principle. The elastic common carotid artery, which is prone to atherosclerosis, was studied. In addition, a muscular artery known for its early atherosclerotic changes (common femoral artery) and a muscular artery where atherosclerosis is uncommon (brachial artery) were investigated.

The methods used in the studies of the present thesis are described in *Chapter 2*. In vitro experiments have shown that diameter changes of the order of a few microns can be resolved with this device (92).

In *Chapter 3* reproducibility measurements of the new technique in man are described in order to assess intraobserver and interobserver variability as well as intra and intersession variability. Diurnal variation in blood pressure and heart rate are well-known phenomena. Whether vessel wall properties also show a

diurnal variation has been investigated in healthy volunteers (*Chapter 4*). Changes in arterial parameters were compared to changes in blood pressure and cardiac function. In addition, a possible relation with fluctuations in plasma levels of noradrenalin, atrial natriuretic factor, renin and prorenin is studied.

From the multiple risk factors for cardiovascular disease, smoking and the presence of hypertension and diabetes mellitus are very important. First, vessel wall properties are compared between habitual smokers and non-smokers (*Chapter 5*). Then the short-term effects of smoking on haemodynamic function and vessel wall properties are investigated.

Since insulin-dependent diabetes mellitus is associated with a high cardiovascular disease and previous data are not consistent, young uncomplicated insulin-dependent diabetic subjects are compared to healthy volunteers (*Chapter 6*). In the last part of this thesis the effect of therapy on vessel wall properties is evaluated. It is a well-known finding that under various pathological states vessel wall properties are diminished. Hypertension is a disease in which vessel wall properties of large arteries are found to be diminished. Studies with antihypertensive drugs have shown that not all drugs favourably influence vessel wall properties. However, most studies with antihypertensive agents are acute studies. In *Chapter 7* the effects of a 6 month treatment with an ACE inhibitor versus a diuretic agent are investigated in order to get more data with regard to long-term effects on functional and structural properties of large arteries. Hypercholesterolaemia is also a risk factor for atherosclerosis and may induce endothelial dysfunction. Physical factors might induce intimal lesions and subsequently development of an atherosclerotic plaque prone to plaque rupture. With progressive atherosclerotic disease arterial stiffness will increase and also the risk for plaque rupture. Therefore, the effect of an eight-week treatment with a cholesterol lowering therapy on vessel wall properties of large arteries, blood pressure and cardiac function has been studied (*Chapter 8*). It is the aim of this study to assess only functional changes. Structural changes are probably not evaluated since the study is of relatively short duration. Finally, the effects of a potassium channel opener are compared with those of a nitrate in healthy volunteers (*Chapter 9*). Acute and subacute effects on vessel wall properties and other haemodynamic parameters are assessed.

Finally, in *Chapter 10* the results of the studies described in the previous chapters are discussed and recommendations for future research are given.

References

1. Achimastos A, Gierd X, Simon AC, Pithois-Merli I, Levenson J. The efficacy of a transdermal formulation of clonidine in mild to moderate hypertension and its effects on the arterial and venous vasculature of the forearm. *Eur J Clin Pharmacol* 1987;33 :111-14.
2. Andersson OK, Persson B, Widgren BR, Wysocki M. Central hemodynamics and brachial artery compliance during therapy with isradipine, a new calcium antagonist. *J Cardiovasc Pharmacol* 1990;15 (Suppl. 1) :87-89.
3. Arcaro G, Laurent S, Jondeau G, Hoeks AP, Safar ME. Stiffness of the common carotid artery in treated hypertensive patients. *J Hypertens* 1991;9 :947-54.
4. Arndt JO, Klauske J, Mersch F. The diameter of the intact carotid artery in man and its change with pulse pressure. *Pflugers Arch* 1968;301 :230-40.
5. Arnold JM, Marchiori GE, Imrie JR, Burton GL, Pflugfelder PW, Kostuk WJ. Large artery function in patients with chronic heart failure. *Circulation* 1991;84 :2418-25.
6. Asmar R, Benetos A, Ghodsi N, Meilhac B, Safar M. Hmodynamique artrielle rgionale et circulation carotidienne dans l'hypertension artrielle essentielle. Application la nitrendipine chez le sujet ag de plus de 40 ans. *Presse Md* 1993;22 :1770-75.

7. Asmar RG, Benetos A, Chaouche-Teyara K, Raveau-Landon CM, Safar ME. Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse wave velocity in essential hypertension. *Am J Cardiol* 1993;72 :794-98.
8. Asmar RG, Iannascoli F, Benetos A, Safar ME. Dose optimization study of arterial changes associated with angiotensin converting enzyme inhibition in hypertension. *J Hypertens* 1992;10 (Suppl. 5) :S13-19.
9. Asmar RG, Journo HJ, Lacolley PJ, Santoni JP, Billaud E, Levy BI, Safar ME. Treatment for one year with perindopril: effect on cardiac mass and arterial compliance in essential hypertension. *J Hypertens* 1988;6 (Suppl. 3) :S33-39.
10. Asmar RG, Keriheul JC, Girerd XJ, Safar ME. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. *Am J Cardiol* 1991;68 :61-64.
11. Asmar RG, Pannier B, Santoni JP, Laurent S, London GM, Levy BI, Safar ME. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. *Circulation* 1988;78 :941-50.
12. Atterhög JH, Duner H, Pernow B. Hemodynamic effect of long-term treatment with pindolol in essential hypertension with special reference to the resistance and capacitance vessels of the forearm. *Acta Med Scand* 1977;202 :517-21.
13. Avolio A. Ageing and wave reflection. *J Hypertens* 1992;10 (suppl 6):S83-86.
14. Avolio AP, Chen SG, Wang RP, Zhang CL, Li MF, O'Rourke MF. Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community. *Circulation* 1983;68 :50-58.
15. Avolio AP, Clyde KM, Beard TC, Cooke HM, Ho KKL, O'Rourke MF. Improved arterial distensibility in normotensive subjects on a low salt diet. *Arteriosclerosis* 1986;6 :166-69.
16. Avolio AP, Deng FQ, Li WQ, Luo YF, Huang ZD, Xing LF, O'Rourke MF. Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: a comparison between urban and rural communities in China. *Circulation* 1985;71 :202-10.
17. Babalis D, Levy BI, Azancot I, Masquet C, Beaufils P. Ventricular function and arterial compliance in patients with congestive cardiomyopathy. *Int J Cardiol* 1984;5 :361-64.
18. Bader H. Dependence of wall stress in the human thoracic aorta on age and pressure. *Circ Res* 1967;20 :354-61.
19. Bamford J, Sandercock P, Dennis M, Warlow C, Jones L, McPherson K, Vessey M, Fowler G, Molyneux A, Hughes T, Burn J, Wade D. A prospective study of acute cerebrovascular disease in community: the Oxfordshire Community Stroke Project 1981-86. I Methodology, demography and incident cases of first-ever stroke. *J Neurol Neurosurg Psychiatry* 1988;51 :1373-80.
20. Barenbrock M, Spieker C, Laske V, Baumgart P, Hoeks APG, Zidek W, Rahn KH. Effect of long-term hemodialysis on arterial compliance in end-stage renal failure. *Nephron* 1993;65 :249-53.
21. Barth JD, Blankenhorn DH, Wickham E, Lai JY, Chin HP, Selzer RH. Quantitative ultrasound pulsation study in human carotid artery disease. *Arteriosclerosis* 1988;8 :778-81.
22. Baskett JJ, Lewis RR, Beasley MG, Gosling RG. Changes in carotid artery compliance with age. *Age Ageing* 1990;19 :241-46.
23. Benetos A, Asmar R, Vasmant D, Thiry P, Safar M. Long lasting arterial effects of the ACE inhibitor ramipril. *J Hum Hypertens* 1991;5 :363-68.
24. Benetos A, Bouaziz H, Albaladejo P, Levy BI, Safar ME. Physiological and pharmacological changes in the carotid artery pressure-volume curve in situ in rats. *J Hypertens* 1992;10 (Suppl. 6) :S127-31.
25. Benetos A, Laurent S, Hoeks AP, Boutouyrie PH, Safar ME. Arterial alterations with aging and high blood pressure. A noninvasive study of carotid and femoral arteries. *Arterioscler Thromb* 1993;13 :90-97.
26. Benetos A, Tsoucaris-Kupfer D, Favereau X, Corcos T, Safar M. Carotid artery tonometry: an accurate non-invasive method for central aortic pulse pressure evaluation. *J Hypertens* 1991;9 (suppl. 6):S144-45.
27. Benthin M, Dahl P, Ruzicka R, Lindström K. Calculation of pulse-wave velocity using cross-correlation effects of reflexes in the arterial tree. *Ultrasound Med Biol* 1991;17 :461-69.
28. Berger DS, Li JK. Concurrent compliance reduction and increased peripheral resistance in the manifestation of isolated systolic hypertension. *Am J Cardiol* 1990;65 :67-71.
29. Blankenhorn DH, Chin HP, Conover DJ, Nessim SA. Ultrasound observation on pulsation in human carotid artery lesions. *Ultrasound Med Biol* 1988;14 :583-87.
30. Blomqvist CG, Saltin B. Cardiovascular adaptations to physical training. *Annu Rev Physiol* 1983;45 :169-89.

31. Bogren HG, Mohiaddin RH, Klipstein RK, Firmin DN, Underwood RS, Rees SR, Longmore DB. The function of the aorta in ischemic heart disease: a magnetic resonance and angiographic study of aortic compliance and blood flow patterns. *Am Heart J* 1989;118 :234-47.
32. Borow KM, Newburger JW. Noninvasive estimation of central aortic pressure using the oscillometric method for analyzing systemic artery pulsatile blood flow: comparative study of indirect systolic, diastolic, and mean brachial artery pressure with simultaneous direct ascending aortic pressure measurements. *Am Heart J* 1982;103 :879-86.
33. Bouthier J, Benetos A, Simon A, Levenson J, Safar M. Pulsed Doppler evaluation of diameter, blood velocity and blood flow of common carotid artery in sustained essential hypertension. *J Cardiovasc Pharmacol* 1985;7 (Suppl. 21) :S99-S104.
34. Bouthier JA, Safar ME, Curien ND, London GM, Levenson JA, Simon AC. Effect of cadralazine on brachial artery hemodynamics and forearm venous tone in essential hypertension. *Clin Pharmacol Ther* 1986;39 :82-88.
35. Boutouyrie P, Laurent S, Benetos A, Girerd XJ, Hoeks APG, Safar ME. Opposing effects of ageing on distal and proximal large arteries in hypertensives. *J Hypertens* 1992;10 (Suppl. 6) :S87-91.
36. Bramwell JC, Hill AV. The velocity of the pulse wave in man. *Proc R Soc Lond B* 1922;93 :298-306.
37. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. *N Engl J Med* 1988;318 :1315-21.
38. Buntin CM, Silver FH. Noninvasive assessment of mechanical properties of peripheral arteries. *Ann Biomed Eng* 1990;18 :549-66.
39. Bush TL. The epidemiology of cardiovascular disease in postmenopausal women. *Ann N Y Acad Sci* 1990;592 :263-71.
40. Cameron JD, Dart AM. Exercise training increases total systemic arterial compliance in humans. *Am J Physiol* 1994;266 :H693-701.
41. Caputo L, Tedgui A, Poitevin P, Levy BI. In vitro assessment of diameter-pressure relationship in carotid arteries from normotensive and spontaneously hypertensive rats. *J Hypertens* 1992;10 (Suppl. 6) :S27-30.
42. Caro CG, Lever MJ, Parker KH, Fish PJ. Effect of cigarette smoking on the pattern of arterial blood flow: possible insight into mechanisms underlying the development of arteriosclerosis. *Lancet* 1987;II :11-13.
43. Carretta R, Fabris B, Bardelli M, Muiesan S, Fischetti F, Vran F, Bianchetti A, Campanacci L. Arterial compliance and baroreceptor sensitivity after chronic treatment with indapamide. *J Hum Hypertens* 1988;2 :171-75.
44. Carroll JD, Shroff S, Wirth P, Halsted M, Rajfer SI. Arterial mechanical properties in dilated cardiomyopathy. *J Clin Invest* 1991;87 :1002-9.
45. Chang KC, Hsieh KS, Kuo TS, Chen HI. Effects of nifedipine on systemic hydraulic vascular load in patients with hypertension. *Cardiovasc Res* 1990;24 :719-26.
46. Cohn JN, Finkelstein SM. Abnormalities of vascular compliance in hypertension, aging and heart failure. *J Hypertens* 1992;10 (Suppl. 6) :S61-64.
47. Dart A, Silagy C, Dewar E, Jennings G, McNeil J. Aortic distensibility and left ventricular structure and function in isolated systolic hypertension. *Eur Heart J* 1993;14 :1465-70.
48. Dart AM, Lacombe F, Yeoh JK, Cameron JD, Jennings GL, Laufer E, Esmore DS. Aortic distensibility in patients with isolated hypercholesterolaemia, coronary artery disease, or cardiac transplant. *Lancet* 1991;338 (II):270-73.
49. De Cesaris R, Ranieri G, Filitti V, Andriani A, Bonfantino MV. Forearm arterial distensibility in patients with hypertension: Comparative effects of long-term ACE inhibition and -blocking. *Clin Pharmacol Ther* 1993;53 :360-67.
50. De Luca N, Rosiello G, Crispino M, Volpe M, Galletti P, Buzzetti G, Trimarco B. Effects of chronic antihypertensive treatment with ketanserin versus metoprolol on blood pressure and large arteries' compliance in humans: a cross-over double-blind study. *J Clin Pharmacol* 1988;28 :332-38.
51. Devereux RB. Toward a more complete understanding of left ventricular afterload. *J Am Coll Cardiol* 1991;17 :122-24.
52. Devereux RB, Waeber B, Roman MJ. Conclusions on the measurement of arterial wall thickness: anatomic, physiologic and methodologic considerations. *J Hypertens* 1992;10 (Suppl. 6) :S119-21.
53. Dobrin PB, Rovick AA. Influence of vascular smooth muscle on contractile mechanisms and elasticity of arteries. *Am J Physiol* 1969;217 :1644-51.
54. Domingo E, Gilbert MR, Alio J, Angel J, Soler-Soler J. Effect of drugs on a noninvasive index of arterial compliance in healthy and heart failure patients. *Cathet Cardiovasc Diagn* 1991;24 :93-98.

55. Dorlas JC, Nijboer JA, Butijn WT, van der Hoeven GMA, Settels JJ, Wesseling KH. Effects of peripheral vasoconstriction on the blood pressure in the finger, measured continuously by a new noninvasive method (the Finapres). *Anesthesiology* 1985;62 :342-45.
56. Draaijer P, Kool MJ, Maessen JM, Van Bortel LM, de Leeuw PW, van Hooff JP, Leunissen KM. Vascular distensibility and compliance in salt-sensitive and salt-resistant borderline hypertension. *J Hypertens* 1993;11 :1199-1207.
57. Dzau VJ, Gibbons GH. Cell biology of vascular hypertrophy in systemic hypertension. *Am J Cardiol* 1988;62 :30G-5G.
58. Eiskjaer H, Christensen T, Pedersen EB. Abnormal structure and increased stiffness of the femoral arterial wall in young patients with sustained hypertension. *J Intern Med* 1989;226 :235-40.
59. Ferguson JJ, Randall O. Hemodynamic correlates of arterial compliance. *Cathet Cardiovasc Diagn* 1986;12 :376-80.
60. Ferrari P, Weidmann P. Insulin, insulin sensitivity and hypertension. *J Hypertens* 1990;8 :491-500.
61. Feske W, Finkelstein SM, Francis G, Cohn JN. Arterial vascular compliance response to exercise in hypertension. *Biomed Sci Instrum* 1988;24 :161-65.
62. Folkow B. Structural factors: the vascular wall. Consequences of treatment. *Hypertension* 1983;5 (III) :III58-62.
63. Frank O. Die Theorie der Pulswellen. *Z Biol* 1926;85 :91-130.
64. Friedman SM. Salt sensitivity and cell permeability. *J Hypertens* 1991;9 :789-98.
65. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. *N Engl J Med* 1992;326 :242-50.
66. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. *N Engl J Med* 1992;326 :310-18.
67. Galitzky J, Barbe P, Riviere D, Senard JM, Lafontan M, Tran MA, Berlan M. Evaluation of sympathetic nervous system activity and alpha2-adrenergic receptivity in obese subjects. *IUPHAR abstract book* 1990 :1494-95.
68. Ganda OP. Pathogenesis of macrovascular disease in the human diabetic. *Diabetes* 1980;29 :931-42.
69. Gerstenblith G, Frederiksen J, Yin FCP, Fortuin NJ, Lakatta EG, Weisfeldt ML. Echocardiographic assessment of a normal aging population. *Circulation* 1977;56 :273-78.
70. Giannattasio C, Cattaneo BM, Mangoni AA, Carugo S, Sampieri L, Cuspidi C, Grassi G, Mancia G. Changes in arterial compliance induced by physical training in hammer-throwers. *J Hypertens* 1992;10 (Suppl. 6) :S53-55.
71. Girerd X, Giannattasio C, Copie X, Caviezel B, Mourad JJ, Chalon S, Laloux B, Safar M, Mancia G, Laurent S. Reduction of radial artery mass after pharmacological treatment in older essential hypertensives. *J Hypertens* 1994;12 (Suppl. 3) :S4.
72. Girerd X, Laurent S, Pannier B, Asmar R, Safar M. Arterial distensibility and left ventricular hypertrophy in patients with sustained essential hypertension. *Am Heart J* 1991;122 :1210-14.
73. Girerd X, Mourad JJ, Acar C, Heudes D, Chiche S, Bruneval P, Mignot JP, Billaud E, Safar M, Laurent S. Noninvasive measurement of medium-sized artery intima-media thickness in humans: in vitro validation. *J Vasc Res* 1994;31 :114-20.
74. Girerd X, Mourad JJ, Copie X, Moulin C, Acar C, Safar M, Laurent S. Noninvasive detection of an increased vascular mass in untreated hypertensive patients. *Am J Hypertens* 1994;7 :1076-84.
75. Glagov S, Vito R, Giddens DP, Zarins CK. Micro-architecture and composition of artery walls: relationship to location, diameter and the distribution of mechanical stress. *J Hypertens* 1992;10 (Suppl. 6) :S101-4.
76. Gohlke P, Stoll M, Lamberty V, Mattfeld T, Mall G, van Even P, Martorana P, Unger T. Cardiac and vascular effects of chronic angiotensin converting enzyme inhibition at subantihypertensive doses. *J Hypertens* 1992;10 (Suppl. 6) :S141-44.
77. Gow BS, Hadfield CD. The elasticity of canine and human coronary arteries with reference to postmortem changes. *Circ Res* 1979;45 :588-94.
78. Greenway CV, Lutt WW. Blood volume, the venous system, preload, and cardiac output. *Can J Physiol Pharmacol* 1986;64 :383-87.
79. Gribbin B, Pickering TG, Sleight P. Arterial distensibility in normal and hypertensive man. *Clin Sci* 1979;56 :413-17.
80. Guyton AC. Physics of blood, blood flow, and pressure: hemodynamics. In: Drebelbis D, ed. *Textbook of medical physiology* 7th ed. Philadelphia: W.B. Saunders Company, 1986 :218-229.

81. Halushka PV, Rogers RC, Loadholt CB, Colwell JA. Increased platelet thromboxane synthesis in diabetes mellitus. *J Lab Clin Med* 1981;97 :87-96.
82. Harper RN, Moore MA, Marr MC, Watts LE, Hutchins PM. Arteriolar rarefaction in the conjunctiva of human essential hypertensives. *Microvasc Res* 1978;16 :369-72.
83. Harris P, Heath D. The effects of hypertension on the structure of the elastic pulmonary arteries. In: Harris P, Heath D, eds. *The human pulmonary circulation* 3rd ed. London: Churchill Livingstone, 1986 :273-83.
84. Hayoz D, Rutschmann B, Perret F, Niederberger M, Tardy Y, Mooser V, Nussberger J, Waeber B, Brunner HR. Conduit artery compliance and distensibility are not necessarily reduced in hypertension. *Hypertension* 1992;20 :1-6.
85. Heagerty AM, Bund SJ, Aalkjaer C. Effects of drug treatment on human resistance arteriole morphology in essential hypertension: direct evidence for structural remodelling of resistance vessels. *Lancet* 1988;II :1209-12.
86. Heistad DD, Lopez AG, Baumbach GL. Hemodynamic determinants of vascular changes in hypertension and atherosclerosis. *Hypertension* 1991;17 (III) :III7-III11.
87. Hirai T, Sasayama S, Kawasaki T, Yagi S. Stiffness of systemic arteries in patients with myocardial infarction. A noninvasive method to predict severity of coronary atherosclerosis. *Circulation* 1989;80 :78-86.
88. Hirata K, Triposkiadis F, Sparks E, Bowen J, Wooley CF, Boudoulas H. The Marfan syndrome: abnormal aortic elastic properties. *J Am Coll Cardiol* 1991;18 :57-63.
89. Hoeks APG. Non-invasive study of the local mechanical arterial characteristics in humans. In: Safar ME, O'Rourke MF, eds. *The arterial system in hypertension* 1st ed. Dordrecht/Boston/London: Kluwer Academic Publisher, 1993 :119-34.
90. Hoeks APG, Brands PJ, Reneman RS. Technical aspects of compliance assessment. *Arch Mal Coeur Vaiss* 1991;84 :77-81.
91. Hoeks APG, Brands PJ, Reneman RS. Assessment of the arterial distension waveform using Doppler signal processing. *J Hypertens* 1992;10 (Suppl. 6) :S19-22.
92. Hoeks APG, Brands PJ, Smeets FAM, Reneman RS. Assessment of the distensibility of superficial arteries. *Ultrasound Med Biol* 1990;16 :121-28.
93. Hoeks APG, Ruijsen CJ, Hick P, Reneman RS. Transcutaneous detection of relative changes in artery diameter. *Ultrasound Med Biol* 1985;11 :51-59.
94. Hofstra L, Willigers JM, Huvers FC, Schaper NC, Kester ADM, Kitslaar PJEHM, Hoeks APG. Short-term variation in the elastic properties of a muscular artery in humans. *Clin Sci* 1994;86 :567-74.
95. Hokanson DE, Mozersky DJ, Sumner DS, Strandness DE. A phase-locked echo tracking system for recording arterial diameter changes in vivo. *J Appl Physiol* 1972;32 :728-33.
96. Idema RN, van den Meiracker AH, Imholz BPM, Man in 't Veld AJ, Settels JJ, Ritsema van Eck HJ, Schalekamp MADH. Comparison of Finapres non-invasive beat-to-beat finger blood pressure with intrabrachial artery pressure during and after bicycle ergometry. *J Hypertens* 1989;7 (Suppl. 6) :S58-59.
97. Isnard RN, Pannier BM, Laurent S, London GM, Diebold B, Safar ME. Pulsatile diameter and elastic modulus of the aortic arch in essential hypertension: a noninvasive study. *J Am Coll Cardiol* 1989;13 :399-405.
98. Jennings G, Nelson L, Nestel P, Esler M, Korner P, Burton D, Bazelmans J. The effects of changes in physical activity on major cardiovascular risk factors, hemodynamics, sympathetic function and glucose utilization in man: a controlled study of four levels of activity. *Circulation* 1986;73 :30-40.
99. 1988 Joint National Committee. The 1988 report of the joint national committee on detection, evaluation, and treatment of high blood pressure. *Arch Intern Med* 1988;148 :1023-37.
100. Julius S. Transition from high cardiac output to elevated vascular resistance in hypertension. *Am Heart J* 1988;116 :600-606.
101. Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K. The association of borderline hypertension with target organ changes and higher coronary risk. *JAMA* 1990;264 :354-58.
102. Julius S, Schork MA. Borderline hypertension: a critical review. *J Chron Dis* 1971;23 :723-54.
103. Kannel WB, Brand N, Skinner JJ, Dawber TR, McNamara PM. The relation of adiposity to blood pressure and development of hypertension: the Framingham study. *Ann Intern Med* 1967;67 :48-59.
104. Kannel WB, Dawber TR, McGee DL. Perspectives on systolic hypertension. The Framingham study. *Circulation* 1980;61-6 :1179-82.

105. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study. *Am J Cardiol* 1971;27 :335-46.
106. Kannel WB, McGee DL. Diabetes and cardiovascular disease. the Framingham study. *JAMA* 1979;241 :2035-38.
107. Kannel WB, Sorlie P. Hypertension in Framingham. In: Paul O, ed. *Epidemiology and control of hypertension* New York: Grune and Stratton, 1975 :553-92.
108. Kannel WB, Wolf PA, McGee DL, Dawber TR, McNamara P, Castelli WP. Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. *JAMA* 1981;245 :1225-29.
109. Kawasaki T, Sasayama S, Yagi S, Asakawa T, Hirai T. Non-invasive assessment of the age related changes in stiffness of major branches of the human arteries. *Cardiovasc Res* 1987;21 :678-87.
110. Kelly R, Daley J, Avolio A, O'Rourke M. Arterial dilation and reduced wave reflection. Benefit of diltiazem in hypertension. *Hypertension* 1989;14 :14-21.
111. Kelly R, Hayward C, Avolio A, O'Rourke M. Noninvasive determination of age-related changes in the human arterial pulse. *Circulation* 1989;80 :1652-59.
112. Kelly R, Hayward C, Ganis J, Daley J, Avolio A, O'Rourke M. Noninvasive registration of the arterial pressure pulse waveform using high-fidelity applanation tonometry. *J Vasc Med Biol* 1989;1 :142-49.
113. Kelly RP, Gibbs HH, O'Rourke MF, Daley JE, Mang K, Morgan JJ, Avolio AP. Nitroglycerin has more favourable effects on left ventricular afterload than apparent from measurement of pressure in a peripheral artery. *Eur Heart J* 1990;11 :138-44.
114. Koibuchi Y, Lee WS, Pratt RE. Glucose directly stimulates the growth of vascular smooth muscle cells in culture. *J Hypertens* 1992;10 (Suppl. 4) :S100.
115. Kool MJF, Struijker-Boudier HA, Wijnen JA, Hoeks APG, Van Bortel LM. Effects of diurnal variability and exercise training on properties of large arteries. *J Hypertens* 1992;10 (Suppl. 6) :S49-52.
116. Krams DM, Blankenhorn DH. Regression of atherosclerosis: which components regress and what influences their reversal. *Wien Klin Wochenschr* 1992;104 :2-9.
117. Länne T, Stale H, Bengtsson H, Gustafsson D, Bergqvist D, Sonesson B, Lecerof H, Dahl P. Noninvasive measurement of diameter changes in the distal abdominal aorta in man. *Ultrasound Med Biol* 1992;18 :451-57.
118. Laogun AA, Gosling RG. In vivo arterial compliance in man. *Clin Phys Physiol Meas* 1982;3 :201-12.
119. Laskey WK, Kussmaul WG. Arterial wave reflection in heart failure. *Circulation* 1987;75 :711-22.
120. Laskey WK, Parker HG, Ferrari VA, Kussmaul WG, Noordergraaf A. Estimation of total systemic arterial compliance in humans. *J Appl Physiol* 1990;69 :112-19.
121. Laurent S. Reduction of arterial wall mechanical stress as a goal for antihypertensive treatment. *J Cardiovasc Pharmacol* 1994;23 (Suppl. 5) :S35-41.
122. Laurent S, Arcaio G, Benetos A, Lalleche A, Hoeks A, Safar M. Mechanism of nitrate-induced improvement on arterial compliance depends on vascular territory. *J Cardiovasc Pharmacol* 1992;19 :641-49.
123. Laurent S, Cavielz B, Beck L, Girerd X, Billaud E, Boutouyrie P, Hoeks A, Safar M. Carotid artery distensibility and distending pressure in hypertensive humans. *Hypertension* 1994;23 :878-83.
124. Laurent S, Girerd X, Mourad JJ, Lacolley P, Beck L, Boutouyrie P, Mignot JP, Safar M. Elastic modulus of the radial artery wall material is not increased in patients with essential hypertension. *Arterioscler Thromb* 1994;14 :1223-31.
125. Laurent S, Hayoz D, Trazzi S, Boutouyrie P, Waeber B, Ombron S, Brunner HR, Mancia G, Safar M. Isobaric compliance of the radial artery is increased in patients with essential hypertension. *J Hypertens* 1993;11 :89-98.
126. Laurent S, Lacolley PM, Cuhe JL, Safar ME. Influence of diuretics on brachial artery diameter and distensibility in hypertensive patients. *Fundam Clin Pharmacol* 1990;4 :685-93.
127. Learoyd BM, Taylor MG. Alterations with age in the viscoelastic properties of human arterial walls. *Circ Res* 1966;18 :278-92.
128. Lehmann ED, Gosling RG, Snksen PH. Arterial wall compliance in diabetes. *Diabetic Med* 1992;9 :114-19.
129. Lehmann ED, Watts GF, Fatemi-Langroudi B, Gosling RG. Aortic compliance in young patients with heterozygous familial hypercholesterolaemia. *Clin Sci* 1992;83 :717-21.

130. Le Noble JLM, Smith TL, Hutchins PM, Struyker-Boudier HAJ. Microvascular alterations in adult conscious spontaneously hypertensive rats. *Hypertension* 1990;15 :415-19.
131. Levenson J, Bouthier J, Chau NP, Rolan E, Simon AC. Effects of nicorandil on arterial and venous vessels of the forearm in systemic hypertension. *Am J Cardiol* 1989;63 :40J-3J.
132. Levenson J, Le Quan Sang KH, Devynck MA, Gitel R, Simon A. The role of antihypertensive drugs in counteracting adverse influence on large arteries. *Am Heart J* 1987;114 :992-97.
133. Levenson J, Simon A, Bouthier J, Benetos A, Safar ME. Isosorbide dinitrate and pulsatile arterial haemodynamic variables in hypertension. *Eur Heart J* 1986;7 :898-903.
134. Levenson J, Simon AC, Bouthier J, Maarek BC, Safar ME. The effect of acute and chronic nicardipine therapy on forearm arterial haemodynamics in essential hypertension. *Br J Clin Pharm* 1985;20 (Suppl. 1) :107S-113S.
135. Levenson J, Simon AC, Bouthier JD, Benetos A, Safar ME. Post-synaptic alpha-blockade and brachial artery compliance in essential hypertension. *J Hypertens* 1984;2 :37-41.
136. Levenson J, Simon AC, Safar ME, Bouthier J, Maarek BC. Large arteries in hypertension: acute effects of a new calcium entry blocker, nitrendipine. *J Cardiovasc Pharmacol* 1984;6 (Suppl. 7) :S1006-10.
137. Levenson JA, Peronneau PA, Simon A, Safar ME. Pulsed Doppler: determination of diameter, blood flow velocity, and volume flow of brachial artery in man. *Cardiovasc Res* 1981;15 :164-70.
138. Levenson JA, Safar ME, Simon AC, Boutier JA, Griener L. Systemic and arterial hemodynamic effects of nifedipine (20 mg) in mild-to-moderate hypertension. *Hypertension* 1983;5 (Suppl. V) :V57-60.
139. Levenson JA, Simon AC, Maarek BE, Gitelman RJ, Fiessinger JN, Safar ME. Regional compliance of brachial artery and saline infusion in patients with arteriosclerosis obliterans. *Arteriosclerosis* 1985;5 :80-87.
140. Lever AF, Harrap SB. Essential hypertension: a disorder of growth with origins in childhood? *J Hypertens* 1992;10 :101-20.
141. Levy BI, Michel J, Salzmann JL, Azizi M, Poitevin P, Camilleri JP, Safar ME. Arterial effects of angiotensin converting enzyme inhibition in renovascular and spontaneously hypertensive rats. *J Hypertens* 1988;6 (Suppl. 3) :S23-25.
142. Levy BI, Poitevin P, Safar ME. Effects of urapidil on the mechanical properties of the arterial wall in hypertension. *Drugs* 1990;40 (Suppl. 4) :9-13.
143. Liu ZR, Ting CT, Zhu SX, Yin FC. Aortic compliance in human hypertension. *Hypertension* 1989;14 :129-36.
144. Lo CS, Relf IRN, Myers KA, Wahlqvist ML. Doppler ultrasound recognition of preclinical changes in arterial wall diabetic subjects: compliance and pulse-wave damping. *Diabetes Care* 1986;9 :27-31.
145. London G, Guerin A, Pannier B, Marchais S, Benetos A, Safar M. Increased systolic pressure in chronic uremia. Role of arterial wave reflections. *Hypertension* 1992;20 :10-19.
146. London GM, Marchais SJ, Safar ME, Genest AF, Guerin AP, Metivier F, Chedid K, London AM. Aortic and large artery compliance in end-stage renal failure. *Kidney Int* 1990;37 :137-42.
147. London GM, Safar ME, Simon AC, Alexandre JM, Levenson JA, Weiss YA. Total effective compliance, cardiac output and fluid volumes in essential hypertension. *Circulation* 1978;57 :995-1000.
148. Lund-Johansen P, Omvik P. Hemodynamic patterns of untreated hypertensive disease. In: Laragh JH, Brenner BM, eds. *Hypertension, Pathophysiology, Diagnosis and Management* New York: Raven Press, 1990 :305-28.
149. Maarek B, Simon AC, Levenson J, Merli I, Bouthier J. Chronic effects of pindolol on the arterioles, large arteries, and veins of the forearm in mild to moderate essential hypertension. *Clin Pharmacol Ther* 1986;39 :403-8.
150. MacGregor GA. Sodium is more important than calcium in essential hypertension. *Hypertension* 1985;7 :628-40.
151. Madkour MA, Levenson J, Bravo EL, Simon A, Fouad-Tarazi FM. Preload, adrenergic activity and aortic compliance in normal and hypertensive patients. *Am J Hypertens* 1989;118 :1243-47.
152. Marchais S, Guerin A, Safar M, London G. Arterial compliance in uraemia. *J Hypertens* 1989;7 (Suppl. 6) :S84-85.
153. McVeigh G, Brennan G, Hayes R, Cohn J, Finkelstein S. Vascular abnormalities in non-insulin-dependent diabetes mellitus identified by arterial waveform analysis. *Am J Med* 1993;95 :424-30.
154. McVeigh GE, Burns DE, Finkelstein SM, McDonald KM, Mock JE, Feske W, Carlyle PF, Flack J, Grimm R, Cohn JN. Reduced vascular compliance as a marker for essential hypertension. *Am J Hypertens* 1991;4 :245-51.

155. van Merode T, van Bortel LM, Smeets FA, Mooij JM, Bohm RO, Rahn KH, Reneman RS. Verapamil and nebulivol improve carotid artery distensibility in hypertensive patients. *J Hypertens* 1989;7 (Suppl. 6) :S262-63.
156. van Merode T, Brands PJ, Hoeks APG, Reneman RS. Faster aging of the carotid artery bifurcation in borderline hypertensive subjects. *J Hypertens* 1993;11 :171-76.
157. van Merode T, Hick PJJ, Hoeks APG, Rahn KH, Reneman RS. Vessel wall properties of the carotid artery in normotensive and borderline hypertensive young male volunteers. *J Hypertens* 1987;5 (Suppl. 5) :S471-73.
158. van Merode T, Hick PJJ, Hoeks APG, Rahn KH, Reneman RS. Carotid artery wall properties in normotensive and borderline hypertensive subjects of various ages. *Ultrasound Med Biol* 1988;14 :563-69.
159. van Merode T, Hick PJJ, Hoeks APG, Reneman RS. The diagnosis of minor to moderate atherosclerotic lesions in the carotid artery bifurcation by means of spectral broadening combined with the direct detection of flow disturbances using a multi-gate pulsed doppler system. *Ultrasound Med Biol* 1988;14 :459-64.
160. van Merode T, Hick PJJ, Hoeks APG, Reneman RS. Noninvasive assessment of artery wall properties in children aged 4-19 years. *Pediatr Res* 1988;25 :94-96.
161. van Merode T, Hick PJJ, Hoeks APG, Smeets FAM, Reneman RS. Differences in carotid artery wall properties between presumed-healthy men and women. *Ultrasound Med Biol* 1988;14 :571-74.
162. van Merode T, Lodder J, Smeets FA, Hoeks AP, Reneman RS. Accurate noninvasive method to diagnose minor atherosclerotic lesions in carotid artery bulb. *Stroke* 1989;20 :1336-40.
163. van Merode T, Van Bortel L, Smeets FAM, Bhm R, Mooy J, Rahn KH, Reneman RS. The effect of verapamil on carotid artery distensibility and cross-sectional compliance in hypertensive patients. *J Cardiovasc Pharmacol* 1989;15 :109-13.
164. Merrin PK, Renton S, Fisher C, Nicholaides A, Elkeles RS. Arterial wall abnormalities in type 1 and type 2 diabetes. *Diabetic Med* 1992;9 (Suppl. 1) :30A.
165. Messeri FH, Frohlich ED, Ventura HO. Arterial compliance in essential hypertension. *J Cardiovasc Pharmacol* 1985;7 (Suppl. 2) :S33-35.
166. Milnor WR. Normal hemodynamic state. In: Milnor WR, ed. *Hemodynamics* Baltimore: Williams and Wilkins, 1982:135-56.
167. Moens. *Die Pulscurve*. EJ Brill, Leiden, 1878.
168. Mohiaddin RH, Underwood SR, Bogren HG, Firmin DN, Kilpstein RH, Rees RS, Longmore DB. Regional aortic compliance studied by magnetic resonance imaging: the effects of age, training and coronary artery disease. *Br Heart J* 1989;62 :90-96.
169. Mozersky DJ, Sumner DS, Hokanson DE, Strandness DE. Transcutaneous measurement of the elastic properties of the human femoral artery. *Circulation* 1972;46 :948-55.
170. Mujais SK, Tarazi RC, Dustan HP, Fouad FM, Bravo EL. Hypertension in obese patients: hemodynamic and volume studies. *Hypertension* 1982;4 :84-92.
171. Murgo JP, Westerhof N, Giolma JP, Altobelli SA. Effects of exercise on aortic input impedance and pressure wave forms in normal humans. *Circ Res* 1981;48 :334-43.
172. Newman DL, Gosling RG, Bowden NLR. Changes in aortic distensibility and area ratio with the development of atherosclerosis. *Atherosclerosis* 1971;14 :231-40.
173. Newman DL, Lallemand RC. The effect of age on the distensibility of the abdominal aorta of man. *Surg Gynecol Obstet* 1978;147 :211-14.
174. Nichols WW, Nicolini FA, Pepine CJ. Determinants of isolated systolic hypertension in the elderly. *J Hypertens* 1992;10 (Suppl. 6) :S73-77.
175. Nichols WW, O'Rourke MF. Contours of pressure and flow waves in arteries. In: Nichols WW, O'Rourke MF, eds. *Mc Donald's Blood Flow in Arteries. Theoretic, experimental and clinical principles* 3rd ed. London: E. Arnold, 1990 :216-50.
176. Nichols WW, O'Rourke MF. Properties of the arterial wall. In: Nichols WW, O'Rourke MF, eds. *Mc Donald's Blood Flow in Arteries. Theoretic, experimental and clinical principles* 3rd ed. London: E. Arnold, 1990 :77-124.
177. Nichols WW, O'Rourke MF. Pulsatile pressure/flow relations. In: Nichols WW, O'Rourke MF, eds. *Mc Donald's Blood Flow in Arteries. Theoretic, experimental and clinical principles* 3rd ed. London: E. Arnold, 1990 :125-42.
178. Nichols WW, Pepine CJ, Feldman RL, Christie LG, Conti CR. Exercise induced changes in aortic input impedance in mild hypertension. *Circulation* 1980;62 (suppl III) :III-258.

179. Olsen CF. Doppler ultrasound: A technique for obtaining arterial wall motion parameters. *IEEE Trans Biomed Eng* 1977;SU-24 :354-58.
180. O'Rourke M. Arterial stiffness, systolic blood pressure, and logical treatment of arterial hypertension. *Hypertension* 1990;15 :339-47.
181. O'Rourke M. Arterial compliance and wave reflection. *Arch Mal Coeur Vaiss* 1991;84 :45-48.
182. O'Rourke MF. Function of arteries as vascular conduits. In: O'Rourke MF, ed. *Arterial function in health and disease* Edinburgh London Melbourne New York: Churchill Livingstone, 1982 :53-64.
183. O'Rourke MF. Arterial mechanics and wave reflection with antihypertensive therapy. *J Hypertens* 1992;10 (Suppl. 5) :S43-49.
184. Pace NL, East TD. Simultaneous comparison of intraarterial, oscillometric, and finapres monitoring during anesthesia. *Anesth Analg* 1991;73 :213-20.
185. Pannier B, Brunel P, El Aroussy W, Lacombe P, Safar ME. Pulse pressure and echocardiographic findings in essential hypertension. *J Hypertens* 1989;7 :127-32.
186. Parati G, Casadei R, Groppelli A, Di Rienzo M, Mancia G. Comparison of finger and intra-arterial blood pressure monitoring at rest and during laboratory testing. *Hypertension* 1989;13 :647-55.
187. Pepine CJ, Nichols WW, Conti CR. Aortic input impedance in heart failure. *Circulation* 1978;58 :460-65.
188. Perret F, Mooser V, Hayoz D, Tardy Y, Meister J, Etienne J, Farine P, Marazzi A, Burnier M, Nussberger J, Waeber B, Brunner HR. Evaluation of arterial compliance-pressure curves. Effect of antihypertensive drugs. *Hypertension* 1991;18(II) :II-77-II-83.
189. Pessenhofer H. Single cuff comparison of two methods for indirect measurement of arterial blood pressure: standard auscultatory method versus automatic oscillometric method. *Basic Res Cardiol* 1986;81 :101-9.
190. Petrin J, Egan BM, Julius S. Increased beta-adrenergic tone enhances arterial compliance in hyperkinetic borderline hypertension. *J Hypertens* 1989;7 (Suppl. 6) :S78-79.
191. Pfeffer MA, Pfeffer JM. Left ventricular hypertrophy in hypertension. *N Engl J Med* 1990;323 :1276-79.
192. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. *Circulation* 1986;74 :1399-1406.
193. Pithois-Merli I, Levenson J, Filitti V, Simon A. Comparative long-term vasoactive effects of atenolol and carteolol on the properties of the small and large arteries of the upper extremities in human essential hypertension. *Clin Pharmacol Ther* 1989;46 :686-92.
194. Pithois-Merli IM, Cournot AX, Georges DR, Pappo M, Safar ME. Acute effect of labetalol on hypertensive brachial artery. *J Clin Hypertens* 1987;3 :479-86.
195. Pohl U, Holtz J, Busse R, Bassenge E. Crucial role of endothelium in the vasodilator response to increased flow in vivo. *Hypertension* 1986;8 :37-44.
196. Pyörälä K. Diabetes and coronary artery disease: what a coincidence? *J Cardiovasc Pharmacol* 1990;16 (Suppl. 9) :S8-S14.
197. Raison JM, Safar ME, Cambien FA, London GM. Forearm haemodynamics in obese normotensive and hypertensive subjects. *J Hypertens* 1988;6 :299-303.
198. Reneman RS, van Merode T, Brands PJ, Hoeks APG. Inhomogeneities in arterial wall properties under normal and pathological conditions. *J Hypertens* 1992;10 (Suppl. 6) :S35-40.
199. Reneman RS, van Merode T, Hick P, Hoeks AP. Cardiovascular applications of multi-gate pulsed Doppler systems. *Ultrasound Med Biol* 1986;12 :357-70.
200. Reneman RS, van Merode T, Hick P, Hoeks APG. Flow velocity patterns in and distensibility of the carotid artery bulb in subjects of various ages. *Circulation* 1985;71 :500-509.
201. Reneman RS, van Merode T, Hick P, Muijtens AMM, Hoeks APG. Age-related changes in carotid artery wall properties in men. *Ultrasound Med Biol* 1986;12 :465-71.
202. Roman MJ, Pini R, Pickering TG, Devereux RB. Non-invasive measurements of arterial compliance in hypertensive compared with normotensive adults. *J Hypertens* 1992;10 (Suppl. 6) :S115-18.

203. Roman O, Meza N, Klenner C. Effect of celiprolol on large and small arteries of the forearm circulation in hypertensive patients. *Cardiovasc Drugs Ther* 1990;4 :745-49.
204. Rowe JW. Clinical consequences of age-related impairments in vascular compliance. *Am J Cardiol* 1987;60 :68G-71G.
205. Rubba P, Riccardi G, Pauciullo P, Vaccaro O, Carbone L, Mancini M. Different localization of early arterial lesions in insulin-dependent diabetes mellitus and in familial hypercholesterolemia. *Metabolism* 1989;38 :962-66.
206. Rutan GH, Kuller LH, Neaton JD, Wentworth DN, McDonald RH, Smith WM. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. *Circulation* 1988;77 :504-14.
207. Rutten AJ, Ilesley AH, Skowronski GA, Runciman WB. A comparative study of the measurement of mean arterial pressure using automatic oscillometers, arterial cannulation and auscultation. *Anaesth Intensive Care* 1986;14 :58-65.
208. Safar M. Therapeutic trials and large arteries in hypertension. *Am Heart J* 1988;115 :702-10.
209. Safar M. Ageing and its effects on the cardiovascular system. *Drugs* 1990;39 (Suppl. 1) :1-8.
210. Safar M, Asmar R, Bouthier J, Lacolley P, Laurent S. Converting enzyme inhibition and the common carotid circulation in older patients with sustained essential hypertension. *Eur Heart J* 1988;9 (Suppl. D) :75-78.
211. Safar M, Laurent S, Safavian A, Pannier B, Asmar R. Sodium and large arteries in hypertension. Effects of indapamide. *Am J Med* 1988;84 (Suppl. 1B) :15-19.
212. Safar ME. Pulse Pressure in essential hypertension: clinical and therapeutical implications. *J Hypertens* 1989;7 :769-76.
213. Safar ME. Arteriosclerosis obliterans of the lower limbs as a model of peripheral vascular disease with hypertension. *J Cardiovasc Pharmacol* 1991;18 (Suppl. 4) :S73-77.
214. Safar ME, Asmar R, Benetos A, Levy BI, London GM. Sodium, large arteries, and diuretic compounds in hypertension. *Am J Med Sci* 1994;307 (Suppl. 1) :S3-S8.
215. Safar ME, Laurent S, Benetos A, London GM. The common carotid circulation in patients with essential hypertension. *Stroke* 1988;19 :1198-1202.
216. Safar ME, Laurent S, London GM. The arterial system in hypertension. In: Safar M, ed. *Clinical research in essential hypertension* 1st ed. Stuttgart: Schattauer, 1989 :115-33.
217. Safar ME, Levy BI, Laurent S, London GM. Hypertension and the arterial system: clinical and therapeutic aspects. *J Hypertens* 1990;8 (Suppl. 7) :S113-19.
218. Safar ME, London GM. Arterial and venous compliance in sustained essential hypertension. *Hypertension* 1987;10 :133-39.
219. Safar ME, London GM, Asmar RG, Hugues CJ, Laurent SA. An indirect approach for the study of the elastic modulus of the brachial artery in patients with essential hypertension. *Cardiovasc Res* 1986;20 :563-67.
220. Safar ME, London GM, Bouthier JA, Levenson JA, Laurent S. Brachial artery cross-sectional area and distensibility before and after arteriolar vasodilatation in men with sustained essential hypertension. *J Cardiovasc Pharmacol* 1987;9 :734-42.
221. Safar ME, London GM, Laurent S. Hypertension and the arterial wall. *High blood press* 1993;2 (Suppl. 1) :32-40.
222. Safar ME, London GM, Levenson JA, Simon AC, Chau NP. Rapid dextran infusion in essential hypertension. *Hypertension* 1979;1 :615-23.
223. Safar ME, Pannier BP, Lacolley PJ, Levy BI. Cardiac mass and aortic distensibility following calcium blockade in hypertension. *J Cardiovasc Pharmacol* 1991;17 (Suppl. 2) :S75-80.
224. Safar ME, Peronneau PA, Levenson JA, Toto-Moukoko JA, Simon AC. Pulsed doppler: diameter, blood flow velocity and volumic flow of the brachial artery in sustained essential hypertension. *Circulation* 1981;63 :393-400.
225. Safar ME, Toto-Moukoko JJ, Bouthier JA, Asmar RE, Levenson JA, Simon AC, London GM. Arterial dynamics, cardiac hypertrophy, and antihypertensive treatment. *Circulation* 1987;75 (Suppl. I) :I156-61.
226. Scheuer J, Tipton CM. Cardiovascular adaptations to physical training. *Annu Rev Physiol* 1977;39 :221-51.
227. Schimmeler W. Untersuchungen zu Elastizitätsproblemen der Aorta. *Arch Kreislaufforschung* 1965;47 :189-233.
228. Schoenberger JA. Epidemiology of systolic and diastolic systemic pressure elevation in the elderly. *Am J Cardiol* 1986;57 :45C-51C.

229. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. *JAMA* 1991;265 :3255-64.
230. Siche J, De Gaudemaris R, Riachi M, Mallion J. Relationship between low-frequency oscillations of blood pressure and changes in arterial diameter. *J Hypertens* 1992;10 (Suppl. 6) :S45-48.
231. Sihm I, Schroeder AP, Aalkjaer C, Holm M, Morn B, Mulvany MJ, Thygesen K, Lederballe O. Normalization of media to lumen ratio of human subcutaneous arteries during antihypertensive treatment with a perindopril based regimen. *Eur Heart J* 1993;14 :520.
232. Simon A, Levenson J. Use of arterial compliance for evaluation of hypertension. *Am J Hypertens* 1991;4 :97-105.
233. Simon A, Levenson J, Bouthier J, Maarek B. Haemodynamic basis of early modifications of the large arteries in borderline hypertension. *J Hypertens* 1987;5 :179-84.
234. Simon AC, Laurent S, Levenson JA, Bouthier JE, Safar ME. Estimation of forearm arterial compliance in normal and hypertensive men from simultaneous pressure and flow measurements in the brachial artery, using a pulsed Doppler device and a first-order arterial model during diastole. *Cardiovasc Res* 1983;17 :331-38.
235. Simon AC, Levenson J, Bouthier JD, Safar ME. Effects of chronic administration of enalapril and propranolol on the large arteries in essential hypertension. *J Cardiovasc Pharmacol* 1985;7 :856-61.
236. Simon AC, Levenson J, Cambien F, Bouthier J. Combined effects of gender and hypertension on the geometric design of large arteries. Sexual differences in normal and hypertensive forearm arteries. *Am J Hypertens* 1988;1 :119-23.
237. Simon AC, Levenson J, Pithois-Merli I. Large arteries in hypertension: heterogenous haemodynamic response to beta-adrenoceptor antagonists with and without intrinsic sympathomimetic activity. *Br J Clin Pharm* 1987;24 :45S-9S.
238. Simon AC, Levenson JA, Bouthier JL, Safar ME. Captopril induced changes in large arteries in essential hypertension. *Am J Med* 1984;76 :71-75.
239. Simon AC, Levenson JA, Levy BY, Bouthier JE, Peronneau PP, Safar ME. Effect of nitroglycerin on peripheral large arteries in hypertension. *Br J Clin Pharm* 1982;14 :241-46.
240. Simon AC, Levenson JA, Safar ME. Hemodynamic mechanisms of and therapeutic approach to systolic hypertension. *J Cardiovasc Pharmacol* 1985;7 (Suppl. 2) :S22-27.
241. Sinoway LI, Musch TI, Minotti JR, Zelis R. Enhanced maximal metabolic vasodilatation in the dominant forearms of tennis players. *J Appl Physiol* 1986;61 :673-78.
242. Smulyan H, Mookherjee S, Warner RA. The effect of nitroglycerin on forearm arterial distensibility. *Circulation* 1986;73 :1264-69.
243. Smulyan H, Vardan S, Griffiths A, Gribbin B. Forearm arterial distensibility in systolic hypertension. *J Am Coll Cardiol* 1984;3 :387-93.
244. Somers VK, Leo KC, Shields R, Clary M, Mark AL. Forearm endurance training attenuates sympathetic nerve response to isometric handgrip in normal humans. *J Appl Physiol* 1992;72 :1039-43.
245. Spek JJ, Hoeks APG, Struijker Boudier HAJ, Van Bortel LMAB. Differences in vessel wall properties of large arteries in obese and lean subjects. *J Hypertens* 1994;12 (Suppl. 3) :S210:P1157.
246. Stefanadis C, Wooley CF, Bush CA, Kolibash AJ, Boudoulas H. Aortic distensibility abnormalities in coronary artery disease. *Am J Cardiol* 1987;59 :1300-1304.
247. Stout RW. Insulin as a mitogenic factor: role in the pathogenesis of cardiovascular disease. *Am J Med* 1991;90 (Suppl. 2A) :62S-5S.
248. Struijk PC, Wladimiroff JW, Hop WCJ, Simonazzi E. Pulse pressure assessment in the human fetal descending aorta. *Ultrasound Med Biol* 1992;18 :39-43.
249. Struyker Boudier HAJ, Van Bortel LMAB, De Mey JGR. Remodeling of the vascular tree in hypertension: drug effects. *TIPS* 1990;11 :240-45.
250. Tardy Y, Hayoz D, Mignot JP, Richard P, Brunner HR, Meister JJ. Dynamic non-invasive measurements of arterial diameter and wall thickness. *J Hypertens* 1992;10 (Suppl. 6) :S105-9.
251. Tardy Y, Meister JJ, Perret F, Brunner HR, Arditi M. Non-invasive estimate of the mechanical properties of peripheral arteries from ultrasonic and photoplethysmographic measurements. *Clin Phys Physiol Meas* 1991;12 :39-54.
252. Teuscher A, Egger M, Herman JB. Diabetes and hypertension. Blood pressure in clinical diabetic patients and a control population. *Arch Intern Med* 1989;149 :1942-45.

253. Thordarson H, Thorgeirsson G, Helgason T. Aortic stiffness in insulin-dependent diabetics: an echocardiographic study. *Diabetic Med* 1986;3 :449-54.
254. Toto-Moukoko JJ, Achimastos A, Asmar RG, Hugues CJ, Safar ME. Pulse wave velocity in patients with obesity and hypertension. *Am Heart J* 1986;112 :136-40.
255. Trazzi S, Omboni S, Santucci C, Parati G, Mancia G. Variability in arterial diameter and compliance: compliance modulation reserve. *J Hypertens* 1992;10 (Suppl. 6) :S41-43.
256. Treese N, Ungern-Sternberg v A, Cordes U, Beyer J. Influence of norepinephrine on vessel geometry of the intact femoral artery in juvenile insulin-dependent diabetics. Evidence of early diabetic angiopathy in central arteries. *Z Kardiol* 1982;71 :60-64.
257. Trimarco B, Lembo G, De Luca N, Ricciardelli B, Rosiello G, Volpe M, Orefino G, Condorelli M. Effects of celiprolol on systemic and forearm circulation in hypertensive patients: a double-blind cross-over study versus metoprolol. *J Clin Pharmacol* 1987;27 :593-600.
258. Van de Water JM, Falchuk SC, Toh SH, Indech RB. Noninvasive assessment of vascular disease in the lower limbs of diabetics. *J Cardiovasc Surg* 1980;21 :469-74.
259. Wahlqvist ML, Lo CS, Myers KA, Simpson RW, Simpson JM. Putative determinants of arterial wall compliance in NIDDM. *Diabetes Care* 1988;11 :787-90.
260. Weber MA, Smith DHG, Neutel JM, Graettinger WF. Arterial properties of early hypertension. *J Hum Hypertens* 1991;5 :417-23.
261. Wendelhag I, Wiklund O, Wikstrand J. Arterial wall thickness in familial hypercholesterolemia. *Arterioscler Thromb* 1992;12 :70-77.
262. Wijnen JA, Kool MJ, Kooman JP, van Baak M, Hoeks AP, Struijker Boudier HA, Van Bortel LM. Vessel wall properties of large arteries and endurance training. *J Hypertens* 1993;11 (Suppl. 5) :S88-89.
263. Wildi E, Knutti JW, Allen HV, Meindl JD. Dynamics and limitations of blood/muscle interface detection using Doppler power returns. *IEEE Trans Biomed Eng* 1980;27 :565-73.
264. Williams RR, Hunt SC, Hasstedt SJ, Hopkins PN, Wu LL, Berry TD, Stults BM, Barlow GK, Schumacher MC, Linton RP, Lalouel JM. Are there interactions and relations between genetic and environmental factors predisposing to high blood pressure? *Hypertension* 1991;18(1) :29-37.
265. Woolam GL, Schnur PL, Vallbona C, Hoff HE. The pulse wave velocity as an early indicator of atherosclerosis in diabetic subjects. *Circulation* 1962;25 :533-39.
266. Wright JS, Cruickshank JK, Kontis S, Dor C, Gosling RG. Aortic compliance measured by non-invasive Doppler ultrasound: description of a method and its reproducibility. *Clin Sci* 1990;78 :463-68.
267. Yaginuma T, Avolio A, O'Rourke M, Nichols W, Morgan JJ, Roy P, Baron D, Branson J, Feneley M. Effect of glyceryl trinitrate on peripheral arteries alters left ventricular hydraulic load in man. *Cardiovasc Res* 1986;20 :153-60.
268. Yin FCP, Brin KP, Ting CT, Pyeritz RE. Arterial hemodynamic indexes in Marfan's syndrome. *Circulation* 1989;79 :854-62.
269. Yin FCP, Ting CT. Compliance changes in physiological and pathological states. *J Hypertens* 1992;10 (Suppl. 6) :S31-33.
270. Zanchetti A, Chalmers J, Arakawa K, Gyarfas I, Hamet P, Hansson L, Julius S, MacMahon S, Mancia G, Menard J, Omae T, Reid J, Safar M. Guidelines for the management of mild hypertension. Memorandum from a WHO/ISH meeting. *ISH Hypertension news* 1993;june :3-15.

CHAPTER 2

METHODS USED FOR HAEMODYNAMIC MEASUREMENTS

2.1 Vessel wall properties

The vessel wall movement detector system as used in the present thesis was developed by Hoeks et al (6). The system consists of a conventional B-mode echo imaging system (Ultramark V; ATL, Bothell, Washington, USA) and a data acquisition system connected to a personal computer. With a 7.5 MHz transducer a two dimensional B-mode image is created from the vessel of interest (Figure 2.1.1). An M-line perpendicular to the vessel is selected. After the echo system is switched to M-mode, storage of data starts. During 5-6 cardiac cycles radiofrequency (RF) signals are digitised and temporarily stored in an 1 Mbyte memory. The R-top of the simultaneously recorded electrocardiogram (ECG) was used as a trigger to maintain a constant time-relationship between the distension measurement of the vessel and the ECG. The first RF line acquired is used to identify the wall lumen interfaces. The position of the anterior and posterior vessel walls are marked by the observer using two data windows on the first RF signal stored (Figure 2.1.2). Line after line the data are transferred to a personal computer. The distance between both

Figure 2.1.1. B-mode two-dimensional image of the common carotid artery of a presumed young healthy volunteer.

Figure 2.1.2. An example of a radiofrequency (RF) signal as a function of depth obtained from the common carotid artery of a presumed healthy volunteer. The anterior and posterior walls are marked by the relatively large signal and represent the initial diameter. The white boxes at the baseline indicate the sample volumes.

Figure 2.1.3. Displacement waveform of the anterior (top tracing) and posterior (middle tracing) wall of the common carotid artery during 5 heart cycles. The difference between these two results in the distension waveform (bottom tracing). The cross indicates the occurrence of the ECG trigger. Ant=anterior wall movement; Post=posterior wall movement; Dist=distension:change in diameter during the heart cycle.

sample volumes corresponds to the initial diameter of the vessel lumen (minimum diameter at end diastole). The cumulative change in phase between the successive RF lines is calculated for the anterior and posterior wall windows, where the position of the sample gates is continuously adjusted according to the detected displacement (tracking principle). After processing all lines, the displacement waveform of the arterial walls is displayed on the screen (Figure 2.1.3). The distension waveform, i.e. the change in diameter as a function of time, is obtained by subtracting the posterior displacement waveform from the anterior waveform (difference in displacement between the anterior and posterior wall). The above procedure is an off-line analysis and provides data on arterial diastolic diameter (D) and distension (ΔD) for each captured beat. An advantage of this approach is that a change in mean position of the artery caused by probe movements and/or changes in vessel position will not really influence the outcome of the measurement. The assumption is made that the increase in arterial volume during systole is caused by an increase in cross-sectional area rather than by a change in arterial length (L) (11,12). Distensibility is defined as the relative change in cross-sectional area ($\Delta A/A$) per unit of pressure. Compliance coefficient is the change in volume per unit of length divided by the change in pressure (cross-sectional compliance). Compliance is related to distensibility and arterial volume (5). To minimise fluctuations over a short period of time (7) data represent the mean of about 15 heart beats (3 recordings). Consequently, arterial diameter and change in diameter during the heart cycle (ΔD , distension) were recorded during approximately 5-6 s and the means of 3 consecutive measurements were taken as the patient's reading. If within one measurement of approximately 5 heart beats parameters differed more than 10%, probably due to motion artifacts, the measurement was not accepted. Simultaneously with the vessel wall measurements arm blood pressure was recorded with a Dinamap (see section 2.4). Pulse pressure is defined as systolic minus diastolic pressure. From vessel wall motion data (D , ΔD) and pulse pressure (ΔP), vessel wall properties were calculated according to the following equations (12):

$$DC \text{ (distensibility coefficient)} = (\Delta A/A)/\Delta P \approx 2 \cdot (\Delta D/D)/\Delta P$$

$$CC \text{ (compliance coefficient)} = (\Delta V/L)\Delta P = \Delta A/\Delta P \approx \pi \cdot D \cdot \Delta D/2\Delta P = DC \cdot A$$

Distensibility reflects the elastic properties of the arterial wall, while compliance reflects the buffering capacity of the arterial system. With this device vessel wall properties of superficial large arteries were

measured (carotid, femoral, brachial arteries). With the same device the time required for the upslope from the 10% to the 90% level (rise time) could be derived from the distension waveform. In addition, the delay time from the R-top of the ECG to the 10% level of the ascending limb of the distension waveform can be assessed. The delay time estimates the transit time between the heart and the site of recording, taking into account the electro-mechanical dissociation component. The delay time of the carotid and femoral arteries was used as an estimate of carotido-femoral transit time. For each heart beat these delay times are given by the device with a technical accuracy of 2 ms. The delay time (T) of the carotid and femoral arteries was used as an estimate of carotido-femoral transit time. The distances from the upper side of the sternum to the site of measurement in the neck (carotid artery) and the groin (femoral artery) were determined with a tape measurer. The difference between these two distances was used as the length (L) of the arterial segment corresponding to the carotido-femoral transit time (1). The distance between the upper side of the sternum and the carotid artery was subtracted from the total distance in order to take into account pulse wave travelling in the opposite direction (9). The average pulse wave velocity (PWV) in this arterial segment can be estimated from the following formula:

$$PWV = L / T$$

where PWV provides an estimation of the stiffness of the aortic pathway (10). Reflection waves in the femoral artery do not disturb this observation since they always arrive later than the 10% level of the ascending limb of the distension curve. An *in vitro* study showed that with this device arterial wall displacements of a few micrometers may be measured. However, the accuracy and reproducibility *in vivo* may differ from these *in vitro* data (chapter 3). Additional pro's and cons of the technique are also described in chapter 3.

2.2 Venous compliance

Apart from arterial compliance, venous compliance is also important. Venous compliance determines the volume-pressure relationship of the haemodynamically active part of the venous system in the resting state. It is determined by the visco-elastic properties of the venous wall, which is mainly composed from collagen, elastin and smooth muscle with a thin endothelial layer (8). The pressure-volume relationship has been found linear over the physiological range of pressures. From these curves the unstressed volume can be derived. The unstressed volume describes the haemodynamically inactive compartment, which is 60% of total blood volume. Mobilisation of the unstressed volume may be achieved by venous tone influenced by sympathetic activity (4,13). Venous compliance may differ in different venous vascular beds (4). In addition to a change in venous compliance, a change in unstressed volume may contribute to a change in venous pressure, which is an important determinant of cardiac preload. In the present thesis mercury strain-gauge venous occlusion plethysmography was used (Periflow; Janssen Scientific Instruments, Beerse, Belgium), as described by Forconi et al (3) to assess venous hemodynamics. With this technique a cuff, placed around the most voluminous part of the upper extremity, was inflated to occlude the venous circulation. This results in an increase in volume of the extremity since only arterial inflow and not venous outflow is possible. The volume changes are estimated by recording changes in electrical resistance of a mercury thread which is applied to the extremity. The increase in electrical resistance is directly related to changes in limb volume (3). A cannula was inserted into an antecubital vein to record venous pressure. The unstressed venous volume was determined by the distension of the forearm at an intravenous pressure of 10 mm Hg. Venous compliance was defined as the slope of the pressure-volume curve, as determined with linear regression analysis. With plethysmography only relative changes (per 100 ml tissue) can be assessed. In addition, only compliance of muscular and cutaneous veins can be measured.

2.3 Cardiac output

Cardiac output, together with peripheral resistance determines mean arterial pressure (MAP). Several invasive techniques to assess cardiac output are well known. However, in the last few decades also non-invasive techniques have been developed. In the present thesis, an echo Doppler technique has been used (Ultramark V; ATL, Bothel, Washington, USA). With the patient in left lateral position aortic diameter (AD) was measured from a standard 2-dimensional long-axis parasternal view at the site of the aortic annulus. Maximal blood flow velocity at the site of the aortic valve was measured with a continuous wave transducer (1.9 MHz). Heart rate was derived from a simultaneously recorded ECG. Stroke volume was calculated from the aortic diameter (AD) and the velocity time integrals (FVI) over the aortic valve as $0.25\pi(AD)^2 \times FVI$. Cardiac output was defined as stroke volume $\times$ heart rate. The mean of 6 heart beats was taken as the patient's reading. Cardiac output and stroke volume were divided by body surface (2) to compute cardiac index and stroke index, respectively. Systemic vascular resistance index was defined as mean arterial pressure/cardiac index.

2.4 Blood pressure and heart rate

Supine blood pressure and heart rate were measured non-invasively at the left brachial artery, using a semi-automated oscillometric device (Dinamap; Critikon, Tampa, Florida, USA). Depending on the study every 1 to 3 minutes recordings were made. Approximately 10 recordings were averaged and taken as the patient's reading. Pulse pressure (ΔP) was defined as systolic (SBP) minus diastolic (DBP) blood pressure.

2.5 Other measurements and analyses

All other methodologies used in the studies of this thesis as well as the methods of data analysis are presented in the methods sections of each individual chapter.

References

1. Demolis PD, Asmar RG, Levy BI, Safar ME. Non-invasive evaluation of the conduit function and the buffering function of large arteries in man. *Clin Physiol* 1991;11 :553-64.
2. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. *Arch Intern Med* 1916;17 :863-71.
3. Forconi S, Jagenau A, Guerrini M, Pecchi S, Cappelli R. Strain gauge plethysmography in the study of circulation of the limbs. *Angiology* 1979;30 :487-97.
4. Greenway CV, Loutt WW. Blood volume, the venous system, preload, and cardiac output. *Can J Physiol Pharmacol* 1986;64 :383-87.
5. Guyton AC. Physics of blood, blood flow, and pressure: hemodynamics. In: Drebelbis D, ed. *Textbook of medical physiology* 7th ed. Philadelphia: W.B. Saunders Company, 1986 :218-229.

6. Hoeks APG, Brands PJ, Smeets FAM, Reneman RS. Assessment of the distensibility of superficial arteries. *Ultrasound Med Biol* 1990;16 :121-28.
7. Hofstra L, Willigers JM, Huvers FC, Schaper NC, Kester ADM, Kitslaar PJEHM, Hoeks APG. Short-term variation in the elastic properties of a muscular artery in humans. *Clin Sci* 1994;86 :567-74.
8. Junqueira, LJ, Carneiro, J. *Basic Histology*. 4th ed. Lange Medical Publications, Los Altos, 1983.
9. London GM, Marchais SJ, Safar ME, Genest AF, Guerin AP, Metivier F, Chedid K, London AM. Aortic and large artery compliance in end-stage renal failure. *Kidney Int* 1990;37 :137-42.
10. O'Rourke MF. Function of arteries as vascular conduits. In: O'Rourke MF, ed. *Arterial function in health and disease* Edinburgh London Melbourne New York: Churchill Livingstone, 1982 :53-64.
11. Reneman RS, van Merode T, Hick P, Hoeks APG. Cardiovascular applications of multi-gate pulsed doppler systems. *Ultrasound Med Biol* 1986;12 :357-70.
12. Reneman RS, Van Merode T, Hick P, Muijtens AMM, Hoeks APG. Age-related changes in carotid artery wall properties in men. *Ultrasound Med Biol* 1986;12 :465-71.
13. Rothe CF. Venous system: physiology of capacitance vessels. In: *Handbook of Physiology Vol. 3, Peripheral circulation and organ blood flow*. Bethesda: American Physiological Society, 1983:397-452.

CHAPTER 3

EVALUATION OF REPRODUCIBILITY OF A VESSEL WALL MOVEMENT DETECTOR SYSTEM FOR ASSESSMENT OF LARGE ARTERY PROPERTIES

M.J.F. Kool, *T. van Merode, *R.S. Reneman, **A.P.G. Hoeks, H.A.J. Struijker Boudier, and
L.M.A.B. Van Bortel

Departments of Pharmacology, *Physiology and **Biophysics, Cardiovascular Research
Institute Maastricht, University of Limburg, the Netherlands

Based on Cardiovascular Research 1994, 28:610-614

Summary

Arterial distensibility (DC) and compliance (CC) are vessel wall properties of large arteries that can be measured non-invasively with a custom made vessel wall movement detector system (VWMDS). This study investigates reproducibility of this device in 10 volunteers.

To investigate intraobserver intrasession and intraobserver intersession variability, arterial diameter (D) and relative change in diameter during the heart cycle ($\Delta D/D$) were measured in the elastic common carotid artery, and in the muscular femoral and brachial arteries. Interobserver intrasession variability was examined in the common carotid artery by two observers, while interobserver variability on the same image was assessed for the common carotid and femoral arteries. Variability was expressed as the coefficient of variation.

For the common carotid artery, intraobserver intrasession variability was $7.9 \pm 1.6\%$ ($\Delta D/D$), $4.5 \pm 1.1\%$ (D), $8.3 \pm 1.3\%$ (DC), and $9.1 \pm 2.6\%$ (CC), respectively. In the femoral artery it was $12.4 \pm 2.2\%$ ($\Delta D/D$), $2.7 \pm 0.6\%$ (D), $13.4 \pm 2.2\%$ (DC), and $12.5 \pm 2.1\%$ (CC). For the brachial artery it was $13.4 \pm 2.8\%$ ($\Delta D/D$), $2.5 \pm 0.5\%$ (D), $16.1 \pm 2.5\%$ (DC), and $15.6 \pm 2.6\%$ (CC). Intraobserver intersession variability was comparable to intraobserver intrasession variability for all vessels. Interobserver intrasession variability for the common carotid artery was $11.3 \pm 2.6\%$ ($\Delta D/D$) and $8.6 \pm 1.9\%$ (D), but was larger for DC and CC. Interobserver variability on the same image was $<5\%$ for the common carotid and femoral arteries.

In conclusion, the vessel wall movement detector system has a good technical reproducibility. Intraobserver intrasession and intersession variability are comparable, and are larger in muscular arteries. This might be due to a larger variation in tone of these arteries, which are under permanent neurohumoral control. Interobserver intrasession variability was larger than intraobserver variability and might be influenced by differences in observers' skill and spontaneous variation in vessel wall properties.

Introduction

Distensibility and compliance are vessel wall properties of large arteries. The relative change in arterial diameter, due to the change in local blood pressure during systole, is determined by arterial distensibility. Distensibility is an one-dimensional parameter, reflecting the elastic properties of the arterial wall. The capacity to store the blood volume, ejected with each heart beat, is determined by arterial compliance (three-dimensional parameter).

Knowledge about vessel wall properties is likely to be valuable in the management of cardiovascular diseases. For example, when compliance is decreased, the afterload for the heart is likely to increase with a subsequent higher risk for cardiac hypertrophy and heart failure (23,30,32). With a lower compliance, pulse pressure increases, as does systolic blood pressure. Consequently, the risk for stroke will be enhanced (14). A decreased compliance might also play a role in the onset of atherosclerosis (6,10,35). Compliance and distensibility are decreased in essential hypertension (31,34) and also in borderline (16,37) hypertensive patients. With increasing age arteries become stiffer, resulting in a diminished distensibility and compliance (17).

In the past, data on mechanical properties of large arteries have been derived from studies on isolated vessels (3,19). It has been demonstrated that these data underestimate the real vessel wall movements *in vivo* (7). *In vivo*, arterial compliance has been estimated from pressure-volume/diameter curves in animals that were studied with invasive techniques or under conditions of anaesthesia (1,22). However, these data cannot fully be extrapolated to the human situation *in vivo*. In addition, regional pulse wave velocity measurements have been widely used to assess distensibility of a certain arterial segment. However, with this technique no direct data on arterial compliance can be obtained (29), while there is some debate on its variability (29,33).

A few years ago ultrasound devices became available to study vessel wall properties of large arteries non-invasively (2,5,8,15,18,27). In addition, arterial diameter-pressure curves were analysed by combined photoplethysmographic and ultrasonic recordings (36). Hoeks et al (13) have developed a vessel wall movement detector system that allows accurate non-invasive assessment of the arterial diameter and relative diameter changes during the cardiac cycle. The first device of this kind used wall velocities in static sample volumes in a multigate pulsed Doppler system to measure on line relative changes in arterial diameter during the heart cycle (26). The second generation device directly employs the radiofrequency signal of tracking sample volumes to detect changes in arterial diameter. The accuracy of this device is improved. *In vitro* experiments have demonstrated that the latter technique can resolve diameter changes of the order of a few microns (13). Vessel wall movements of superficial arteries, such as the carotid, the femoral and the brachial arteries can be studied with this system.

The aim of the present study was to evaluate the reproducibility of the new technique in man. Therefore, reproducibility measurements were performed in healthy volunteers to assess intraobserver intrasession and intersession variability, as well as interobserver variability.

Methods

Subjects — Intraobserver intrasession and intersession variability was investigated in 10 healthy volunteers, nine males and one female. Mean age was 38 years (17-56), mean weight 72 kg (55-87) and mean height 175 cm (161-186). Interobserver variability was investigated in 10 healthy male volunteers. The mean age of these subjects was 38 years (21-57), mean weight was 76 kg (59-87) and mean height 176 cm (161-184). The mean values of vessel wall measurements of each measured vessel are given in Table 1.

Table 1. Mean values of vessel wall parameters in healthy volunteers.

	ΔD (μm)	D (mm)	DC (10^{-3} /kPa)	CC (mm^2 /kPa)
<i>Intraobserver values</i>				
Common carotid artery	504 $\pm$ 31	6.90 $\pm$ 0.17	22.8 $\pm$ 1.3	0.84 $\pm$ 0.04
Femoral artery	575 $\pm$ 27	8.98 $\pm$ 0.30	21.0 $\pm$ 1.7	1.28 $\pm$ 0.09
Brachial artery	424 $\pm$ 23	4.43 $\pm$ 0.07	30.5 $\pm$ 2.1	0.47 $\pm$ 0.03
<i>Interobserver values</i>				
Common carotid artery	469 $\pm$ 32	6.24 $\pm$ 0.16	23.6 $\pm$ 1.4	0.70 $\pm$ 0.03

ΔD , distension; D, arterial diameter; DC, distensibility coefficient; CC, compliance coefficient; Data are mean $\pm$ s.e.m.

Study design—The designs for the different parts of the study are shown in Figure 1. All measurements were performed in a recumbent position after 15 min of supine rest. Simultaneously with the vessel wall measurements arterial blood pressure was recorded, using a non-invasive device as described below.

Intraobserver intrasession variability (Figure 1A)

Within one session three repeated measurements of the right elastic common carotid artery, and of the right muscular common femoral and brachial arteries were taken in random order. After each measurement, the volunteer regained his original position and ultrasound gel was removed from the skin to blind the observer for the site of the previous measurement.

Intraobserver intersession variability (Figure 1B)

For intersession variability, common carotid, femoral, and brachial arteries of the volunteers were examined twice, with an interval of at least 4 days between the two sessions. To avoid an influence of diurnal variation each subject was studied at the same time of the day.

Interobserver intrasession variability (Figure 1C)

Interobserver variability of common carotid artery was assessed between two observers. In five subjects one observer started the measurements, while the other five were measured first by the second observer.

Interobserver variability on the same radiofrequency signal (Figure 1D)

Finally, interobserver variability on the same radiofrequency (RF) signal was carried out. Alternately, each observer made five recordings of common carotid and femoral arteries in one subject. The two observers independently processed the RF signal of each recording.

Methods and Equipment—The vessel wall movement detector system has been described in detail in Chapter 2. Briefly, with a 7.5 MHz transducer a two dimensional B-mode image is created from the vessel of interest. An M-line perpendicular to the vessel axis is selected. After the echo system is switched to M-mode storage of data starts. During 5-6 cardiac cycles radiofrequency (RF) signals are digitised and temporarily stored in an 1 Mbyte memory. The position of the anterior and posterior vessel walls are marked manually by the observer by setting two data windows on the first RF signal stored. Line after line the data are transferred to a personal computer. The cumulative change in phase between the successive RF lines is calculated for both the anterior and posterior wall windows, where the position of the sample windows

A. Intraobserver intrasession variability (n=10)

15' supine rest	observer	X		
	measurements	1	2	3

B. Intraobserver intersession variability (n=10)

15' supine rest	observer	X		
	session 1 measurements	1	2	3
	session 2 measurements	1	2	3

C. Interobserver intrasession variability (n=10)

15' supine rest	observer	X			Y		
	measurements n=5	1	2	3	1	2	3
	observer	Y			X		
	measurements n=5	1	2	3	1	2	3

D. Interobserver variability on same RF signal (n=1)

15' supine rest	observer	XY	YX	XY	YX	XY	YX	XY	YX	XY	YX
	measurements	1	2	3	4	5	6	7	8	9	10

Figure 1. Study protocol for assessment of reproducibility (see text for details).

X=observer X; Y=observer Y; XY=measurement by observer X and RF signal processed by observer X, followed by processing of the same RF signal by observer Y; YX=measurement by observer Y and RF signal processed by observer Y, followed by processing of the same RF signal by observer X.

Figure 2. Recording of the vessel wall movement of the common carotid artery during five heart cycles. Ant, anterior wall movement; Post, posterior wall movement; Dist, distension: change in diameter during the heart cycle.

is continuously adjusted according to the detected displacement (tracking). After processing all lines, the displacement of the arterial walls is displayed (Figure 2). The difference in displacement between the anterior and posterior wall represents arterial distension, which is the change in diameter during the heart cycle. This procedure is an off-line analysis and provides data on arterial diastolic diameter (D) and distension (ΔD) for each captured heart beat.

Arm blood pressure was recorded non-invasively at the left brachial artery, using the Dinamap (Chapter 2). Blood pressure was measured every 2 min and the mean of all recordings was taken. From arterial diameter, distension and pulse pressure, vessel wall properties were calculated according to the equations mentioned in Chapter 2.

Data analysis — With respect to intraobserver intrasession variability, the coefficient of variation (CV) between the three measurements of each vessel and between the three pulse pressure recordings was calculated for each subject (mean/standard deviation) and expressed as a percentage. Each measurement was the mean of approximately 5 heart beats.

Intraobserver intersession variability was calculated for each volunteer as the coefficient of variation between the mean of three recordings (on average 15 heart beats) of each vessel and of pulse pressure at the first and second session. For each subject the mean of three recordings of the common carotid artery and of pulse pressure for observer 1 and 2 was compared to estimate interobserver intrasession variability. Interobserver variability on the same RF signal was assessed as the coefficient of variation between the observers for each recording of the common carotid and femoral artery. Finally, variability is presented as the mean $\pm$ s.e.m. coefficient of variation. Statistical differences between the mean coefficients of variation for the different parameters were analysed with a Mann-Whitney test.

Results

The results for the variability of the vessel wall measurements are shown in Table 2.

Intraobserver variability. Intraobserver intrasession and intersession variability was less than 10% for the common carotid artery. In the femoral and brachial arteries intraobserver variability within one session and between two sessions was <5% for arterial diameter. The variability in distension, distensibility and compliance was on the average 10 to 15% in these arteries.

Interobserver variability. Interobserver intrasession variability in the common carotid artery was on the average 10% for arterial diameter and distension, but was higher for distensibility and compliance (20%). Interobserver variability on the same RF signal was less than 5% for all parameters in the carotid and the femoral artery.

Mean pulse pressure was 48 ± 1.5 mmHg for the intraobserver, and 49 ± 2 mmHg for the interobserver measurements. Pulse pressure variability was $3.3 \pm 0.6\%$ within one session, $4.7 \pm 0.9\%$ between two sessions, and $4 \pm 1.0\%$ when interobserver variability was assessed.

Discussion

In the past, ultrasound techniques (B-mode, M-mode, continuous wave Doppler, pulsed Doppler, multigate pulsed Doppler) have been developed to measure arterial diameter and to detect diameter changes, in order to estimate vessel wall properties of large arteries.

When applied to images in B-mode, these measurements are time consuming and inaccurate, due to the limited spatial resolution of the echo system (11). Wall movements derived from M-mode recordings (2,18)

Table 2. Mean coefficient of variation (%) in measurements of vessel wall properties with VWMDS.

	ΔD	D	DC	CC
<i>Intraobserver intrasession variability</i>				
Common carotid artery	7.9 $\pm$ 1.6	4.5 $\pm$ 1.1	8.3 $\pm$ 1.3	9.1 $\pm$ 2.6
Common femoral artery	12.4 $\pm$ 2.2	2.7 $\pm$ 0.6	13.4 $\pm$ 2.2	12.5 $\pm$ 2.1
Brachial artery	13.4 $\pm$ 2.8	2.5 $\pm$ 0.5	16.1 $\pm$ 2.5	15.6 $\pm$ 2.6
<i>Intraobserver intersession variability</i>				
Common carotid artery	9.2 $\pm$ 0.9	2.1 $\pm$ 0.5	7.1 $\pm$ 2.2	8.5 $\pm$ 1.5
Common femoral artery	12.8 $\pm$ 3.0	3.0 $\pm$ 1.1	15.2 $\pm$ 3.7	14.2 $\pm$ 2.5
Brachial artery	12.5 $\pm$ 2.8	3.3 $\pm$ 0.6	14.2 $\pm$ 2.5	12.6 $\pm$ 2.8
<i>Interobserver intrasession variability</i>				
Common carotid artery	11.3 $\pm$ 2.6	8.6 $\pm$ 1.9	16.9 $\pm$ 2.8	24.9 $\pm$ 8.5
<i>Interobserver variability same RF signal</i>				
Common carotid artery	3.4 $\pm$ 0.7	2.1 $\pm$ 0.6	4.3 $\pm$ 0.8	4.0 $\pm$ 0.9
Common femoral artery	2.9 $\pm$ 0.9	2.5 $\pm$ 0.7	3.9 $\pm$ 1.6	4.3 $\pm$ 1.8

VWMDS, vessel wall movement detector system; ΔD , distension; D, arterial diameter; DC, distensibility coefficient; CC, compliance coefficient. Data are mean $\pm$ s.e.m.

also suffer from an insufficient resolution, in particular when the adventitia and intima induce distinct echoes (11). Continuous wave Doppler systems can be used to detect vessel wall motion (20), but they can only do so under the assumption that both walls move with the same speed in opposite directions. In addition, these systems do not provide information on the initial arterial diameter. With the pulsed Doppler technique blood flow velocities are measured and changes in the width of the velocity profile can be used to determine changes in arterial diameter (39). Therefore, this approach is only applicable to arteries with both systolic and diastolic flow. Multigate pulsed Doppler systems may be suitable for detection of changes in arterial diameter (25), but here the assumption must be made that the anterior and posterior walls of the vessel do not leave the sample volumes coinciding with the vessel walls. As the artery as a whole may move and the position of the probe may vary, this assumption will not always be valid. Also structures in the vicinity of the arterial wall may enter the sample volume and hence disturb accurate measurements. The vessel wall movement detector system, as used in this study, overcomes many of these problems. The method is based on phase tracking of the radiofrequency signals as arising from the arterial walls.

In clinical and experimental studies a new measurement technique has to be compared with a gold standard in order to prove its value. However, a gold standard for our technique does not exist. Nevertheless, reproducibility tests can be carried out without such a standard.

The vessel wall movement detector system, as used in this study, has a good technical reproducibility. This has been shown in *in vitro* experiments (13) and is supported in the present study by the low coefficient of variation found for interobserver variability on the same RF signal.

Intraobserver intrasession variability for the common carotid artery was lower than 10% for all parameters. Variability in arterial distension was slightly higher in the muscular femoral and brachial arteries, but variability in arterial diameter was even less in the muscular arteries than in the elastic carotid artery. A

higher skill needed for proper measurements on the muscular arteries may be responsible for this phenomenon, but it might also be explained by a larger spontaneous variation in tone in muscular arteries, since these are under permanent neurohumoral control (5).

Because subjects are often examined on different days, intraobserver intersession variability was also studied. For no parameter did the variability between two sessions change much from intraobserver intrasession variability. On the average the elastic artery again showed less variability than the muscular arteries.

Interobserver intrasession variability was only examined in one artery, since there was a difference in skill between the two observers for the other arteries. Variability between the observers was within the same range (approximately 10%) for the actually measured parameters (distension and diameter). It tended to be larger for the calculated parameters (distensibility, compliance), although these differences were not statistically significant. This finding is not unexpected, since variation of each parameter used in the calculation (D , ΔD) can increase the variation of the result (DC , CC).

Interobserver variability tended to be larger than intraobserver variability and for DC this difference reached the level of statistical significance ($p < 0.05$). This aspect could be due to different reasons. Firstly, interobserver variability might be influenced by differences in observers' skill. With regard to this skill, for example the creation of B-mode and M-mode images, and the pressure of the transducer on the skin are important. Both high and low pressure applied to the skin can diminish reproducibility. The minimal pressure necessary to obtain reliable measurements requires training of the observer. Secondly, short-term variations in vessel wall properties themselves may also contribute to the variability. In addition, variations in local pulse pressure might have influenced interobserver variability. Since variability in pulse pressure was only 4%, this will not have had much influence on variability. Finally, it was thought that a different interpretation of the RF signal could enhance interobserver variability. However, when calculations were made on the same image, the coefficient of variation was less than 5% for all parameters and thus this factor only seems to influence variability slightly.

The advantage of the current method is that it is rather insensitive to interaction of echo signals from closely related objects. Interference of echo signals influences the overall amplitude and may therefore result in a wrong estimation of displacement as a function of time (13). Since the vessel wall movement detector system is not based on amplitude tracking, but on detecting phase differences in the RF signal, the measurement of changes in arterial diameter is more accurate. The technique in its present form does not allow real time calculations. However, off-line postprocessing restricts the recording time, resulting in less observer bias. With on-line postprocessing the observer has to perform calculations and simultaneously the transducer must be kept immobile for a limited period of time. This enhances the risk for observer bias. Another advantage of off-line analysis is that computations can be repeated on the same RF signal if the observer is not satisfied with the distension waveform obtained.

Pulse pressure was measured non-invasively with a Dinamap. Assessment of pulse pressure with this device has shown a good correlation with invasive intra-arterial pressure monitoring and with other non-invasive pressure recording techniques (4,21,24,28). Non-invasive monitoring of local pulse pressure at the site of measurement is not possible yet, but a positive relationship has been found between pulse pressure in the brachial artery and the distension in the common carotid artery (25). New techniques to assess local pulse pressure are being developed, but they still need evaluation (12).

In conclusion, the present study has shown that with the recently developed vessel wall movement detector system, arterial diameter and diameter changes during the heart cycle can be measured reproducibly in human subjects. The intraobserver variability within one session and between sessions was comparable for all vessels. Variability was larger in the muscular femoral and brachial arteries than in the elastic carotid artery, but overall the results were quite reproducible. Interobserver intrasession variability of the elastic CCA was around 10% for the actually measured parameters D and ΔD . On the other hand, interobserver variability for the calculated parameters distensibility and compliance was higher than intraobserver variability. This stresses the need for adequate training of each observer, although spontaneous

haemodynamic variations might also play a role. In any case, the interpretation of the RF signal seemed not to contribute substantially to the differences between the observers in the present study.

This non-invasive method measures arterial distensibility and compliance more directly than previous techniques. In addition, it can be applied to a wide range of vessels. Compared to other haemodynamic techniques (9,38), the measurements with the vessel wall movement detector system seem quite reproducible. The vessel wall movement detector system may therefore be a valuable tool for evaluation of vessel wall properties of large arteries.

References

1. Altura BT, Altura BM. Pentobarbital and contraction of vascular smooth muscle. *Am J Physiol* 1975;229 :1635-40.
2. Arndt JO, Klauske J, Mersch F. The diameter of the intact carotid artery in man and its change with pulse pressure. *Pflügers Arch* 1968;301 :230-40.
3. Bergel DH, Schultz DL. Arterial elasticity and fluid dynamics. In: Bergel DH, ed. *Cardiovascular fluid dynamics* London, New York: Academic Press, 1972 :3-36.
4. Borow KM, Newburger JW. Noninvasive estimation of central aortic pressure using the oscillometric method for analyzing systemic artery pulsatile blood flow: comparative study of indirect systolic, diastolic, and mean brachial artery pressure with simultaneous direct ascending aortic pressure measurements. *Am Heart J* 1982;103 :879-86.
5. Demolis PD, Asmar RG, Levy BI, Safar ME. Non-invasive evaluation of the conduit function and the buffering function of large arteries in man. *Clin Physiol* 1991;11 :553-64.
6. Farrar DJ, Bond MG, Riley WA, Sawyer JK. Anatomic correlates of aortic pulse wave velocity and carotid artery elasticity during atherosclerosis progression and regression in monkeys. *Circulation* 1991;83 :1754-63.
7. Gow BS, Hadfield CD. The elasticity of canine and human coronary arteries with reference to postmortem changes. *Circ Res* 1979;45 :588-94.
8. Gustafsson D, Stale H, Bjorkman J, Gennser G. Derivation of haemodynamic information from ultrasonic recordings of aortic diameter changes. *Ultrasound Med Biol* 1989;15 :189-99.
9. Haites NE, Mowat DHR, McLennan FM, Rawles JM. How far is cardiac output? *Lancet* 1984;2 (8410) :1025-27.
10. Hirai T, Sasayama S, Kawasaki T, Yagi S. Stiffness of systemic arteries in patients with myocardial infarction. A noninvasive method to predict severity of coronary atherosclerosis. *Circulation* 1989;80 :78-86.
11. Hoeks APG, Brands PJ, Reneman RS. Technical aspects of compliance assessment. *Arch Mal Coeur Vaiss* 1991;84 :77-81.
12. Hoeks APG, Brands PJ, Reneman RS. Assessment of the arterial distension waveform using Doppler signal processing. *J Hypertens* 1992;10 (Suppl. 6) :S19-22.
13. Hoeks APG, Brands PJ, Smeets FAM, Reneman RS. Assessment of the distensibility of superficial arteries. *Ultrasound Med Biol* 1990;16 :121-28.
14. Kannel WB, Wolf PA, McGee DL, Dawber TR, McNamara P, Castelli WP. Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. *JAMA* 1981;245 :1225-29.
15. Levenson JA, Peronneau PA, Simon A, Safar ME. Pulsed Doppler: determination of diameter, blood flow velocity, and volume flow of brachial artery in man. *Cardiovasc Res* 1981;15 :164-70.
16. van Merode T, Hick PJJ, Hoeks APG, Rahn KH, Reneman RS. Vessel wall properties of the carotid artery in normotensive and borderline hypertensive young male volunteers. *J Hypertens* 1987;5 (Suppl. 5) :S471-73.
17. van Merode T, Hick PJJ, Hoeks APG, Rahn KH, Reneman RS. Carotid artery wall properties in normotensive and borderline hypertensive subjects of various ages. *Ultrasound Med Biol* 1988;14 :563-69.

18. Mozersky DJ, Sumner DS, Hokanson DE, Strandness DE. Transcutaneous measurement of the elastic properties of the human femoral artery. *Circulation* 1972;46 :948-55.
19. Nichols WW, O'Rourke MF. Pulsatile pressure/flow relations. In: Nichols WW, O'Rourke MF, eds. *Mc Donald's Blood Flow in Arteries. Theoretic, experimental and clinical principles* 3rd ed. London: E. Arnold, 1990 :125-42.
20. Olsen CF. Doppler ultrasound: A technique for obtaining arterial wall motion parameters. *IEEE Trans Biomed Eng* 1977;SU-24 :354-58.
21. Pace NL, East TD. Simultaneous comparison of intraarterial, oscillometric, and finapres monitoring during anesthesia. *Anesth Analg* 1991;73 :213-20.
22. Pagani M, Schwartz PJ, Bishop VS, Malliani A. Reflex sympathetic changes in aortic diastolic pressure-diameter relationship. *Am J Physiol* 1975;229 :286-90.
23. Pannier BM, London GM, Safar ME. The possible impact of arterial compliance on cardiac hypertrophy in arterial hypertension. *Scand J Clin Lab Invest* 1989;49 (Suppl. 196) :22-27.
24. Pessenhofer H. Single cuff comparison of two methods for indirect measurement of arterial blood pressure: standard auscultatory method versus automatic oscillometric method. *Basic Res Cardiol* 1986;81 :101-9.
25. Reneman RS, van Merode T, Hick P, Hoeks AP. Cardiovascular applications of multi-gate pulsed Doppler systems. *Ultrasound Med Biol* 1986;12 :357-70.
26. Reneman RS, Van Merode T, Hick P, Muytjens AMM, Hoeks APG. Age-related changes in carotid artery wall properties in men. *Ultrasound Med Biol* 1986;12 :465-71.
27. Riley WA, Barnes RW, Evans GW, Burke GL. Ultrasonic measurement of the elastic modulus of the common carotid artery. The atherosclerosis risk in communities (ARIC) study. *Stroke* 1992;23 :952-56.
28. Rutten AJ, Ilsley AH, Skowronski GA, Runciman WB. A comparative study of the measurement of mean arterial pressure using automatic oscillometers, arterial cannulation and auscultation. *Anaesth Intensive Care* 1986;14 :58-65.
29. Safar M. Therapeutic trials and large arteries in hypertension. *Am Heart J* 1988;115 :702-10.
30. Safar ME, Pannier BP, Lacolley PJ, Levy BI. Cardiac mass and aortic distensibility following calcium blockade in hypertension. *J Cardiovasc Pharmacol* 1991;17 (Suppl. 2) :S75-80.
31. Safar ME, Simon AC, Levenson JA. Structural changes of large arteries in sustained essential hypertension. *Hypertension* 1984;6 (III) :III117-21.
32. Safar ME, Toto-Moukoko JJ, Bouthier JA, Asmar RE, Levenson JA, Simon AC, London GM. Arterial dynamics, cardiac hypertrophy, and antihypertensive treatment. *Circulation* 1987;75 (Suppl. I) :I156-61.
33. Simon A, Levenson J. Use of arterial compliance for evaluation of hypertension. *Am J Hypertens* 1991;4 :97-105.
34. Simon AC, Laurent S, Levenson JA, Bouthier JE, Safar ME. Estimation of forearm arterial compliance in normal and hypertensive men from simultaneous pressure and flow measurements in the brachial artery, using a pulsed Doppler device and a first-order arterial model during diastole. *Cardiovasc Res* 1983;17 :331-38.
35. Simon AC, Pithois-Merli I, Levenson J. Physiopharmacological approach to mechanical factors of hypertension in the atherosclerotic process. *J Hum Hypertens* 1991;5 (Suppl. 1) :15-21.
36. Tardy Y, Meister JJ, Perret F, Brunner HR, Arditi M. Non-invasive estimate of the mechanical properties of peripheral arteries from ultrasonic and photoplethysmographic measurements. *Clin Phys Physiol Meas* 1991;12 :39-54.
37. Ventura H, Messerli FH, Oigman W, Suarez DH, Dreslinski GR, Dunn FG, Reisin E, Frohlich ED. Impaired systemic arterial compliance in borderline hypertension. *Am Heart J* 1984;108 :132-35.
38. White SW, Quail AW, de Leeuw PW, Traugott FM, Brown WJ, Porges WL, Cottee DB. Impedance cardiography for cardiac output measurement: an evaluation of accuracy and limitations. In: Robertson JIS, Birkenhger WH, eds. *Cardiac output measurement* Corsendonk, Belgium: Janssen Biomedical Science Series, 1990 :79-92.
39. Wildi E, Knutti JW, Allen HV, Meindl JD. Dynamics and limitations of blood/muscle interface detection using Doppler power returns. *IEEE Trans Biomed Eng* 1980;27 :565-73.

CHAPTER 4.1

DIURNAL PATTERN OF VESSEL WALL PROPERTIES OF LARGE ARTERIES IN HEALTHY MEN

Mirian J. Kool, Joseph A. Wijnen, *Arnold P. Hoeks, Harry A. StruijkerBoudier, and Luc M. Van Bortel

Departments of Pharmacology, Division of Clinical Pharmacology and *Department of Biophysics, University of Limburg, the Netherlands

Based on J Hypertens 1991, 9 (suppl 6): S108-S109

Summary

Diurnal variation in blood pressure and heart rate is well documented. Vessel wall properties (distensibility and compliance) are important determinants of pulse pressure and, therefore, may also fluctuate throughout the day. In 12 healthy male volunteers (19-29 years) arterial diameter (D) and change in diameter during the heart cycle (ΔD , distension) of the elastic common carotid artery (CCA) and the muscular brachial artery (BA) were studied non-invasively with a vessel wall movement detector system. Vessel wall properties were measured every two hours. Simultaneously arm blood pressure was measured every hour with a semi-automated device. From diameter, distension and pulse pressure, distensibility and compliance were calculated.

Blood pressure (day: $118 \pm 3/66 \pm 1$ mmHg) was significantly ($p < 0.05$) lower during the night (night: $113 \pm 4/64 \pm 2$ mmHg). Pulse pressure (day: 52 ± 2 mmHg) was also lower at night (49 ± 2 mmHg; $p < 0.01$). Diameter of CCA (day: 6.47 ± 0.12 mm) increased during the night (6.64 ± 0.11 mm; $p < 0.05$). Similar changes were seen for diameter of the brachial artery. Distensibility of CCA and BA tended to decrease at night (n.s.), while compliance of both arteries was preserved during the night.

In conclusion, a diurnal pattern in arterial diameter and distensibility of elastic and muscular large arteries was found. Compliance, the buffering capacity of larger arteries, was preserved at night.

Introduction

Large arteries have a conduit and a buffering function (9). They transform the systolic flow jet from the heart into a more continuous flow for tissue perfusion. Arterial distensibility and compliance are vessel wall properties that determine the buffering function of large arteries. These properties can now be measured non-invasively with ultrasound techniques (3). A decrease in arterial distensibility and compliance increases pulse pressure and left ventricular load, and may play a role in the onset of atherosclerosis (7).

Diurnal variability in arterial blood pressure and heart function has been well documented (5). Whether vessel wall properties also show a circadian pattern has not been studied. In the present study, therefore, we investigated the fluctuations of vessel wall properties of large arteries in healthy volunteers over a 24-hour period.

Subjects and methods

Subjects — Twelve healthy male volunteers entered the study, aged 22 years (range 19-29 years), weighing 71 kg (48-92 kg) and standing 184 cm tall (165-192 cm).

Study design — After an overnight fast, the subjects came to the laboratory for 26 hours. Standard meals were given at 9 a.m., 1 and 7 p.m. During the night (11 p.m. to 8 a.m.) the volunteers stayed in bed. All haemodynamic measurements were performed in the recumbent position after 15 minutes of supine rest. Blood pressure was measured at 1-hour intervals and vessel wall properties at 2-hour intervals. Vessel wall properties of the elastic right common carotid artery (CCA) and the muscular right brachial artery (BA) were assessed with the vessel wall movement detector system, as described in Chapter 2.

Simultaneously with the recordings of vessel wall movement, arm blood pressure was measured every 2 minutes, using a Dinamap (Chapter 2). Vessel wall properties, distensibility and compliance were calculated according to the equations mentioned in Chapter 2.

Data analysis — Mean values during the day (08:00 to 23:00) and the night (midnight to 07:00) were calculated for each subject. Statistical analysis of day-night differences was performed with the non-parametric matched, paired, signed-rank Wilcoxon test. $p < 0.05$ was considered statistically significant. Twenty four-hour curves were created for vessel wall properties of the investigated arteries. They show the average data at each time point during the observation period. The data are presented as means $\pm$ s.e.m.

Results

Table 1 summarises day-night changes in blood pressure and vessel wall properties. Systolic and diastolic blood pressure (day: $118 \pm 3/66 \pm 1$; night: $113 \pm 4/64 \pm 2$ mmHg) and pulse pressure (day: 52 ± 2 ; night: 49 ± 2 mmHg) were lower at night ($p < 0.05$ and $p < 0.01$, respectively). The 24-hour curve of blood pressure followed the well-known day-night pattern and rose when the volunteers awoke, but were still in bed.

Figure 1 shows day-night changes on vessel wall properties of the common carotid and brachial artery. In addition, the 24-hour curve of the common carotid artery is shown. The 24-hour profile of the brachial artery is similar to this pattern.

Figure 1. A) Left panel: day-night difference in arterial diameter of the common carotid artery (CCA) and brachial artery (BA); Right panel: diurnal variation in arterial diameter of CCA; **B)** Left panel: day-night difference in change in diameter during the heart cycle of the common carotid artery (CCA) and brachial artery (BA); Right panel: diurnal variation in change in diameter during the heart cycle of CCA; **C)** Left panel: day-night difference in distensibility of the common carotid artery (CCA) and brachial artery (BA); Right panel: diurnal variation in distensibility of CCA; **D)** Left panel: day-night difference in compliance of the common carotid artery (CCA) and brachial artery (BA); Right panel: diurnal variation in compliance of CCA; Data are mean $\pm$ s.e.m.; $\square$ =D (day); $\blacksquare$ =N (night); * $p<0.05$ (difference between mean day and mean night values).

Table 1. Diameter (D), relative change in diameter during the heart cycle (ΔD), distensibility coefficient (DC), and compliance coefficient (CC) of the right common carotid artery (CCA) and the right brachial artery (BA).

	Day	Night
BP (mm Hg)	118±3/66±1	113±/64±2*
ΔP (mm Hg)	52±2	49±2**
D_{CCA} (mm)	6.47±0.12	6.64±0.11*
D_{BA} (mm)	3.45±0.17	3.60±0.16
ΔD_{CCA} (μm)	674±37	617±33*
ΔD_{BA} (μm)	340±26	308±21
DC_{CCA} ($10^{-3}/kPa$)	30.9±1.7	28.9±2.0
DC_{BA} ($10^{-3}/kPa$)	31.0±2.8	27.7±2.5
CC_{CCA} (mm^2/kPa)	0.76±0.05	0.75±0.05
CC_{BA} (mm^2/kPa)	0.21±0.03	0.20±0.02

BP, blood pressure, ΔP , pulse pressure. Day, 08:00 to 23:00, mean of all values; night, midnight to 07:00, mean of all values. * $p<0.05$, ** $p<0.01$.

At night the diameter of the elastic common carotid artery was larger (day:6.47±0.12; night:6.64±0.11 mm; $p<0.05$), while its distension decreased (day:674±37; night:617±33 μm ; $p<0.05$). Although not statistically significant, similar changes were seen for the muscular brachial artery: an increased arterial diameter (day:3.45±0.17; night:3.60±0.16 mm) and a decreased distension (day:340±26; night:308±21 μm) at night. Apart from the value at 5 p.m., which was an outlier, the 24-hour curve nicely shows that during night arterial diameter increased and distension decreased.

Distensibility of the common carotid artery (day:30.9±1.7; night:28.9±2.0 $10^{-3}/kPa$) and the brachial artery (day:31.0±2.8; night:27.7±2.5 $10^{-3}/kPa$) tended to decrease at night. At night, all values for distensibility were lower than during the day. Carotid artery compliance (day:0.76±0.05; night:0.75±0.05 mm^2/kPa) and brachial artery compliance (day:0.21±0.03; night:0.20±0.02 mm^2/kPa) hardly changed between day and night. The 24-hour curve on compliance confirms these data.

Discussion

Like previous work (5,6,8), this study showed a decrease in blood pressure and pulse pressure at night. In the present study the subjects were not physically active and were examined in the supine position. This might explain the relative small day-night differences in blood pressure compared with other studies (1,2,8). The diameter of the elastic common carotid artery increased at night, despite a lower nocturnal blood pressure. This vasodilation might be due to a lower sympathetic tone at night (2,4). In contrast, the relative change in diameter of the common carotid artery during the heart cycle decreased at night, which could be explained by a smaller nocturnal pulse pressure and a decrease in distensibility. Although not statistically significant, this smaller distensibility may have been due to an already larger diastolic diameter at night. As a result of a smaller distensibility and a larger diastolic diameter, vascular compliance did not change, since from the equation for compliance (Chapter 2), compliance can also be defined as $DC \times D^2 \times \pi/4$. This indicates that the buffering function of large arteries is preserved at night.

Similar changes in vessel wall properties were seen in the brachial artery, also suggesting the presence of a day-night pattern. These changes were not statistically significant because of a larger short-term intra-individual variation in the diameter and in the relative change in diameter during the heart cycle. It is not clear whether this larger variation in the vessel wall properties of the brachial artery is caused by a technical difficulty in the recording procedure or reflects a real haemodynamic variation in the muscular arteries, which are predominantly under neurohumoral control (10).

In conclusion, the results of the present study indicate the presence of a diurnal pattern in the diameter and distensibility of muscular as well as elastic arteries. The day-night pattern of distensibility was similar to the diurnal variation in blood pressure, while day-night changes in arterial diameter were inversely related to blood pressure. Compliance of large arteries barely changed during the night. This suggests that, despite a diurnal change in elastic properties, the buffering function of large arteries is preserved throughout the day.

References

1. Clark LA, Denby L, Pregibon D, Harshfield GA, Pickering TG, Blank S, Laragh JH. A quantitative analysis of the effects of activity and time of day on the diurnal variations of blood pressure. *J Chron Dis* 1987;40 :671-81.
2. Furlan R, Guzzetti S, Crivellaro W, Dassi S, Tinelli M, Baselli G, Cerutti S, Lombardi F, Pagani M, Malliani A. Continuous 24-hour assessment of the neural regulation of systemic arterial pressure and RR variabilities in ambulant subjects. *Circulation* 1990;81 :537-47.
3. Hoeks APG, Brands PJ, Smeets FAM, Reneman RS. Assessment of the distensibility of superficial arteries. *Ultrasound Med Biol* 1990;16 :121-28.
4. Linsell CR, Lightman SL, Mullen PE, Brown MJ, Causon RC. Circadian rhythms of epinephrine and norepinephrine in man. *J Clin Endocrinol Metab* 1985;60 :1210-15.
5. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. *Lancet* 1978;i :795-97.
6. Mori H. Circadian variation of haemodynamics in patients with essential hypertension. *J Hum Hypertens* 1990;4 :384-89.
7. O'Rourke M. Arterial stiffness, systolic blood pressure, and logical treatment of arterial hypertension. *Hypertension* 1990;15 :339-47.
8. Pickering TG, Harshfield GA, Kleinert HD, Blank S, Laragh JH. Blood pressure during normal daily activities, sleep, and exercise. *JAMA* 1982;247 :992-96.
9. Safar M. Therapeutic trials and large arteries in hypertension. *Am Heart J* 1988;115 :702-10.
10. Safar ME, London GM. Arterial and venous compliance in sustained essential hypertension. *Hypertension* 1987;10 :133-39.

CHAPTER 4.2

DIURNAL VARIATION IN PRORENIN IN RELATION TO OTHER HUMORAL FACTORS AND HAEMODYNAMICS

Mirian J. Kool, Joseph A. Wijnen, *Frans H. Derkx, Harry A. Struijker Boudier, and Luc M. Van Bortel

Departments of Pharmacology, Cardiovascular Research Institute Maastricht, University of Limburg, and *Department of Internal Medicine, Erasmus University, Rotterdam, The Netherlands

Based on A J H 1994, 7: 723-730

Summary

Diurnal variation has been demonstrated for blood pressure and heart function. Several hormones influence these haemodynamic parameters. This study investigates the diurnal variation in plasma prorenin in relation to renin, atrial natriuretic peptide (ANP), noradrenalin and haemodynamic changes. Circulating plasma prorenin may be able to serve as a marker for the activity of the local renin-angiotensin system. In 12 healthy male volunteers who were allowed to carry out quiet activity, haemodynamic factors and the plasma levels of hormones were monitored at 2-hour intervals for 26 hours. Blood pressure was measured every hour.

In accordance with the literature, during the night blood pressure (4%), cardiac index (19%), stroke index (10%), and heart rate (10%) decreased in a classic day-night pattern. Systemic vascular resistance increased during the night (23%). No classic day-night pattern was found for ANP, although it increased (15%) at night and showed a peak early in the night. This peak seemed to be influenced by posture. A classic day-night pattern was demonstrated for noradrenalin and prorenin. Noradrenalin was lower (18%) at night and increased as soon as the subjects awoke, while they were still in bed. Therefore, plasma noradrenalin levels seemed to be related to awakening. Plasma prorenin decreased at night (6%). Renin fluctuated throughout the day, but showed no clear day-night pattern.

In conclusion, renin fluctuated throughout the day and did not show a classic day-night pattern. In contrast, prorenin fluctuated less and showed 6% higher levels during the day compared to the night. The origin and clinical significance of this small diurnal variation in prorenin is not clear yet.

Introduction

Cardiovascular function is influenced by several hormones. Neurohumoral factors such as cortisol and aldosterone may influence haemodynamic variations in humans (11,16). Catecholamines and the renin-angiotensin system contribute significantly to the regulation of cardiovascular haemodynamics. Except for prorenin, diurnal variation of these hormones has been extensively investigated (13,14,18,25,34).

Like catecholamines, which are released at two sites, the adrenal medulla and nerve endings, there are two forms of the renin-angiotensin system (RAS). However, the significance of the various components of the RAS is not yet fully understood. The classic circulating RAS is a real endocrine system. The components of the circulating RAS originate from various organs (kidneys, lungs, liver) and are released into the circulation. On the other hand, local renin-angiotensin systems have been demonstrated in extrarenal tissues, such as the human reproductive organs (37) and blood vessels (10,29). In addition, in animal studies the existence of a local RAS in the heart, brain, blood vessels, adrenal gland and testes has been demonstrated (37), but its presence in the corresponding human tissues (29) is less clear. With regard to haemodynamics, it has been suggested that the local vascular RAS may be particularly important in the long-term control of the cardiovascular system, while the circulating system could provide short-term renal and circulatory homeostasis (10). The main source for circulating renin is the kidney (15). Animal studies and *in vitro* data suggest that renin may also be produced locally, *i.e.*, in the heart and the vessel walls (5,10,29), but there are no data available from human *in vivo* studies. Renin may be synthesised in the vascular wall itself (20) or may be taken up from the plasma into the arterial wall (10). The majority of circulating renin is present in the inactive form prorenin (7). Prorenin levels in plasma are 10 times higher than renin levels (37). The clinical importance of prorenin has not yet been fully established. Prorenin has always been thought to be the inactive precursor of renin, but a more direct and active role has recently been claimed for prorenin in the generation of angiotensin I (6,7,37). Like renin, the majority of prorenin (two-thirds) is produced in the kidney. Some authors have postulated that one-third of prorenin is synthesised at tissue sites, mainly in the reproductive organs (15,37).

It has been assumed that the kidney-derived prorenin reaches the circulation and may - directly or indirectly - lead to the formation of local angiotensin I (Agl) and angiotensin II (AglI) (1). Prorenin from extrarenal tissues could result in direct local generation of AgI and AgII (15,37). In addition, animal data provide no evidence for the conversion of prorenin to renin in the circulation or that circulating prorenin has the same physiological properties as renin (24). Prorenin may serve as a reservoir of potential renin, have a transport function for renin or act directly on the cardiovascular system (31). It has also been suggested that prorenin may play a locally protective vasodilator role, opposing the vasoconstrictive role played by the renin system. This would ensure adequate blood flow within certain tissues. Thus, prorenin has been considered to have an autoregulatory function (23). Recent work has also shown that prorenin may cause vascular damage as a result of hyperperfusion injury (23). Various states of disease have been linked with enhanced prorenin concentrations (7). After bilateral nephrectomy, substantial amounts of prorenin could be detected, while renin levels were low. Therefore, plasma concentrations of prorenin are suggested as a marker for the activity of the local RAS (37).

Both the systemic and local RAS lead to the formation of AgII, a potent vasoconstrictor with effects on body fluid homeostasis, vascular tone, myocardial function, and cardiovascular structure (10,17).

Taken together, prorenin is thought to play an important role in cardiovascular haemodynamics. A diurnal variation in blood pressure (26), angina pectoris (40), and myocardial infarction (45) has been described earlier. The relationships between these variations and other hormones have been investigated (11,12,16,34), but the relationship with prorenin is not known.

The present study investigates the fluctuations of prorenin throughout the day in relation to the diurnal variation in renin, atrial natriuretic peptide (ANP), noradrenalin and haemodynamic changes. It is hypothesised that prorenin plays a role in cardiovascular pathophysiology and therefore variations in prorenin may interfere with haemodynamic control.

Subjects and methods

Subjects—Twelve healthy male volunteers, aged 19 to 29 years, with weights ranging from 48 to 92 kg and heights from 165 to 192 cm, participated in the study. Young male volunteers were chosen to avoid the well-known effects of age and the menstrual cycle on prorenin levels (7,15).

Study Design—The volunteers came to the laboratory after an overnight fast and remained in a quiet room for 26 hours. Before the start of the study an intravenous catheter was applied to the left forearm. All haemodynamic examinations were performed in the recumbent position after 15 min of supine rest and blood samples were taken after at least 40 min of supine rest. Between the examination periods volunteers were allowed to carry out quiet activities, eg, reading, studying, quiet walking. Between 23:00 and 07:00 they stayed in bed. At 07:00 the subjects were awakened. Standard meals were given at 09:00, 13:00, and 19:00. Salt intake was within the normal range (6 g/day). Subjects did not change their dietary habits. There was no salt restriction that could have activated the renin-angiotensin system. Smoking and the use of caffeine were not allowed.

Blood pressure was measured every hour. Heart function was investigated at 2-hour intervals and plasma samples were also collected every 2 hours. The study was approved by the Medical Ethics Committee of the University of Limburg. Written informed consent was received from all subjects.

Methods—Arm blood pressure was recorded non-invasively with a semi-automated device at the left brachial artery as described in Chapter 2 (Dinamap; Critikon, Tampa, Florida, USA). Recordings were performed every 2 min for 20 min and the mean of 10 recordings was taken.

Cardiac index, stroke index, and heart rate were monitored non-invasively on a beat-to-beat basis with bioimpedance electrocardiography (NCCOM3-R7; BoMed Medical Manufacturing Ltd, Irvine, California, USA), as described previously (28). Cardiac index, stroke index and heart rate were measured continuously for 20 min. The systemic vascular resistance index was calculated as the ratio of mean arterial pressure and cardiac index.

Venous blood samples for determination of ANP, noradrenalin, renin, and prorenin were taken with the subjects in the recumbent position from an indwelling catheter. Blood samples were collected in 5-ml polystyrene tubes (ANP, renin) and 10-ml (noradrenalin) polystyrene chilled tubes, kept on ice water. Tubes for ANP and renin contained EDTA (1 mg). Those for noradrenalin were heparinised and contained 12 mg of glutathione. For ANP the peptidase inhibitor aprotinin (10,000 U/l) was added. After collection the samples were centrifuged immediately at 4°C for 30 min at 1500 g for noradrenalin and for 15 minutes at 1500 g for the other hormones. Plasma was stored at -70°C until assayed.

ANP was determined with an indirect RIA (INC-star; Stillwater, USA) after extraction on SepPak C18 cartridges (Waters associates; Milford, Massachusetts, USA). The intra-assay coefficient of variation was 8.6% and the interassay coefficient of variation 11.6% (41). Renin and prorenin were quantified with an indirect RIA as described by Derkx et al (8). Renin and prorenin concentrations as measured by this method have proven to give a valid estimate of the real prorenin content in human plasma. The risk of cryoactivation of a small portion of the prorenin may be neglected, as the period between collection and centrifuging of the blood was less than 15 minutes. In addition, a protease inhibitor was used (7,8). Normal ranges for renin (4.8 to 71.4; mean 16.9 μ U/ml) and prorenin (77 to 354; mean 171 μ U/ml) have been published previously (7). Noradrenalin levels were measured by means of HPLC with fluorescence detection, according to Van der Hoorn et al (42). The intra-assay coefficient of variation was 4.0% and the interassay coefficient of variation 6.9%. The detection limit was 20 pg/ml. In addition, diurnal variation in plasma volume was monitored indirectly, using plasma albumin levels.

Data Analysis—The first measurements, at 09:00, were used to familiarise the subjects with the procedure. The analysis was based on the measurements from 11:00 until 09:00 the next day. Mean

daytime values (08:00 to 23:00) and mean nighttime values (midnight to 07:00) were calculated for each subject. Day-night differences were analysed with the non-parametric matched, paired, signed-rank Wilcoxon test. $p < 0.05$ was considered statistically significant.

Twenty four-hour curves were created for each parameter. They show the average data at each time point during the observation period. A classic day-night pattern is defined as the well-known day-night difference in blood pressure with higher values during the day than during the night. All results are presented as mean $\pm$ s.e.m.

Results

Table 1 gives a summary of day-night changes in haemodynamic and hormonal parameters. Figure 1 shows the data for arterial blood pressure.

Table 1. Day-night differences in haemodynamics and hormonal parameters.

	Day	Night
<i>Haemodynamics</i>		
Blood pressure (mmHg)	$118 \pm 3/66 \pm 1$	$113 \pm 4/64 \pm 2^*$
Mean arterial pressure (mmHg)	83 ± 2	$80 \pm 2^{**}$
Cardiac index (L/min.m ²)	4.2 ± 0.2	$3.4 \pm 0.1^{***}$
Stoke index (mL/m ²)	70 ± 4	$63 \pm 3^{***}$
Heart rate (beats/min)	62 ± 2	$55 \pm 2^{***}$
SVRI (dyn.s.cm ⁻⁵ .m ²)	1622 ± 78	$1993 \pm 103^{***}$
<i>Hormones</i>		
ANP (pg/mL)	16.6 ± 1.8	$19.1 \pm 2.0^*$
Noradrenalin (pg/mL)	129 ± 9	$106 \pm 11^{**}$
PRA (pmol/mL/h)	1.1 ± 0.2	1.2 ± 0.2
Plasma renin (μ U/mL)	18.0 ± 2.5	19.7 ± 2.0
Prorenin (μ U/mL)	173 ± 17	

ANP, Atrial natriuretic peptide; PRA, plasma renin activity; SVRI, systemic vascular resistance index. Data are mean $\pm$ s.e.m.; * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

Figure 1. Diurnal variation in arterial blood pressure. SBP, systolic blood pressure; DBP, diastolic blood pressure; data are mean $\pm$ s.e.m.; $\square$ =D (day); $\blacksquare$ =N (night); * $p < 0.05$ (difference between mean day and mean night values).

Figure 2. Diurnal variation in cardiac function; data are mean $\pm$ s.e.m. ; $\square$ =D (day); $\blacksquare$ =N (night); *** p <0.001 (difference between mean day and mean night values).

Figure 3. Diurnal variation in systemic vascular resistance index; data are mean $\pm$ s.e.m. ; $\square$ =D (day); $\blacksquare$ =N (night); *** p <0.001 (difference between mean day and mean night values).

Figure 4. Diurnal variation in hormones; data are mean $\pm$ s.e.m. ; $\square$ =D (day); $\blacksquare$ =N (night); * p <0.05, *** p <0.001 (difference between mean day and mean night values).

Systolic and diastolic pressure (day: $118 \pm 3/66 \pm 1$; night: $113 \pm 4/64 \pm 2$ mmHg) decreased at night ($p < 0.05$). Mean arterial pressure (day: 83 ± 2 ; night: 80 ± 2 mm Hg) was also lower ($p < 0.01$) during the night. Apart from the value at 05:00, the 24-hour curve of blood pressure followed the well-known day-night pattern. Blood pressure rose sharply at 07:00, when the volunteers were awake, but still in bed. The cardiac index (day: 4.2 ± 0.2 ; night: 3.4 ± 0.1 L/min.m²), stroke index (day: 70 ± 4 ; night: 63 ± 3 mL/m²), and heart rate (day: 62 ± 2 ; night: 55 ± 2 beats/min) decreased significantly ($p < 0.001$) at night (Figure 2). These parameters demonstrated a day-night pattern, similar to the classic blood pressure cycle, with a decrease after the subjects went to bed and an increase after awakening.

The systemic vascular resistance index (Figure 3) was higher at night (day: 1622 ± 78 ; night: 1993 ± 103 dyn.s.cm⁻⁵.m²; $p < 0.001$). Systemic vascular resistance index showed an inverse day-night pattern: as soon as the volunteers fell asleep there was a steep increase in vascular resistance and the values remained elevated during the night.

Plasma albumin levels did not differ between day (39.9 ± 0.6 g/L) and night (39.3 ± 0.4 g/L), and in fact varied little. There was a slight increase in albumin at 03:00, 3% higher than other albumin levels during the night. Hormonal changes are depicted in Figure 4. ANP increased at night (day: 16.6 ± 1.8 ; night: 19.1 ± 2.0 pg/mL; $p < 0.05$) with a peak 2 hours after the subjects assumed a constant recumbent position. Noradrenalin (day: 129 ± 9 ; night: 106 ± 11 pg/mL) decreased during the night ($p < 0.01$). This is also clear from the 24-hour curve. A marked increase in noradrenalin was already present when the subjects woke up, while still in bed. The mean plasma renin concentration (day: 18.0 ± 2.5 ; night: 19.7 ± 2.0 μ U/mL) did not differ significantly between day and night. Renin fluctuated throughout the day, with peaks, at 05:00, 11:00, and 15:00, but showed no clear day-night pattern. In contrast to renin, prorenin levels (day: 173 ± 17 ; night: 162 ± 16 μ U/mL) were decreased ($p < 0.001$) at night. Prorenin showed an obvious day-night pattern with all values at night lower than during the day.

Discussion

In accordance with other authors (26,27), the present study showed clear day-night differences in haemodynamics. Systolic, diastolic and mean arterial pressure decreased at night, but this decrease (5%) was somewhat smaller than those found by others (26,33). The small diurnal variation in blood pressure could be due to 1) the non-invasive blood pressure monitoring (32) or 2) the subjects' low level of physical activity in the laboratory (33).

A crucial point in the present study is whether the volunteers slept well. Although not objectively controlled, the volunteers apparently had an undisturbed sleep and clear day-night differences in haemodynamics were observed. If it is assumed that the volunteers did not sleep well, then, with an undisturbed sleep, even larger day-night changes would be expected.

Bioimpedance electrocardiography is an elegant method for cardiac monitoring during the night since sleep is not disturbed by the measurements. The feasibility and reproducibility of the technique has proven to be good in healthy subjects and in patients with cardiac disease (28). In general, the correlation with other techniques (i.e., thermodilution, echo Doppler) is high (28,44). In the present study, the cardiac index decreased markedly at night (19%) as a result of a diminished stroke volume (10%) and a lower heart rate (10%). These changes may be due to a lower sympathetic activity during night (12,25). The cardiac index, heart rate and stroke volume rose after breakfast and lunch, while vascular resistance decreased. A postprandial high output-low resistance state has also been reported by other authors (19). As in the current study, blood pressure and plasma catecholamines generally do not change after the ingestion of food (19,25). The most likely explanation for the postprandial increase in cardiac output and reduction in total peripheral resistance is a redistribution of blood volume to the splanchnic vascular bed. The cause of the nocturnal increase (23%) in total peripheral resistance is less clear. Studies in humans (27) and animals (38,39) have also reported a significant increase in systemic vascular resistance together with low cardiac

output at night. Talan and Engel have postulated that this low output-high resistance state may be mediated by a redistribution of blood and by a reduction in total blood volume (39). The higher peripheral resistance at night suggests a vasoconstriction of the smaller blood vessels. A nocturnal increase in the diameter of large arteries has been described (21), suggesting that large and small vessels do not behave similarly. Some authors have recently reported diurnal variation in plasma volume (2), suggesting that the hormonal changes might, at least in part, be due to haemodilution. However, in the present study no day-night differences were found in plasma albumin levels, which can serve also as a measure of plasma volume, so haemodilution is not likely to have been a factor.

ANP was higher (15%) at night, but had no classic day-night pattern and was not obviously related to haemodynamic changes. The ANP variation seems to be influenced by body posture, as ANP showed a peak 2 hours after the subjects assumed a constant recumbent position. A peak of ANP early in the night has also been described by others (4,9,34). In addition, an independent effect of posture on ANP levels - possibly due to a circulatory overload, but not related to changes in plasma volume - has been demonstrated (30).

Noradrenalin decreased significantly at night (18%). This might reflect a lower sympathetic activity, as described previously (12). Noradrenalin levels rose when the subjects awoke, while they were still in bed. The increase in noradrenalin was positively related to the blood pressure increase at the same time. This was also found in other studies, which measured an increase in noradrenalin of about 30% with awakening, while no changes were found in noradrenalin levels between the different sleep stages (25). Indeed, Furlan et al (12) found increased sympathetic activity immediately after awakening. Renin levels and (although not shown) plasma renin activity varied throughout the day, but no clear day-night pattern could be demonstrated. Variations in renin levels were probably not due to changes in posture (3,34), because subjects were in the supine position for at least 45 min. No clear explanation for the two peaks during the day was found. An influence from eating might be supposed, but no peak was found with the evening meal. It has been suggested that the peak in the second part of the night might be an adaptive mechanism of the body to prevent further natriuresis as caused by the preceding elevated ANP level (4,9). However, it has also been suggested that the variation in renin may be associated with a diurnal variation in renal perfusion (22). Several interactions between the hormones measured in the present study may be of importance (10,35,43).

This study is the first to describe a diurnal variation in prorenin. In contrast to renin, circulating plasma prorenin showed a classic day-night pattern with all values at night being lower (6%) than during the day. Prorenin seems not to be influenced by posture, as it began to decrease before the subjects took up a constant recumbent position. Besides, it was always measured after at least 40 min of supine rest. An interaction between ANP and the renin-angiotensin system has been presumed (36), but data are not consistent (35). From these data it is not clear whether the effect of ANP on plasma renin activity is a direct or indirect feature. In the present study, no relation between prorenin and ANP could be detected. However, it might be that other factors, such as neurohormones, may play an underlying regulatory role.

The lower circulating prorenin at night may be due to a decreased renal or extrarenal release or to enhanced clearance. With regard to this, different pathways could be posited. Decreased production of prorenin or an increased breakdown of prorenin at night might decrease renin, and subsequently AgI and AgII formation, leading to less vasoconstriction. On the other hand, prorenin has been proposed as a vasodilating agent (23). Consequently, a decrease in prorenin could result in more vasoconstriction. In addition, an enhanced local uptake of prorenin could lead to higher plasma clearance at night. As a result, more AgI and AgII could be formed at night, which would lead to more vasoconstriction. Thus, if prorenin contributes to the increased peripheral resistance at night, the latter two possibilities might be involved. In conclusion, the present study showed a classic diurnal pattern for blood pressure, heart rate and cardiac function, with decreased values at night. This could be due to a lower sympathetic activity during the night. On the other hand, an inverse diurnal pattern was seen for systemic vascular resistance: resistance increased at night. ANP and renin had no classic day-night pattern, but mean ANP levels were higher at night, while renin did not differ between day and night. ANP seemed to be influenced by body posture, as

it reached a peak after the subjects were in a constant recumbent position. For plasma noradrenalin a classic day-night pattern could be demonstrated. Noradrenalin increased after awakening, when the subjects were still in bed. In contrast to renin, prorenin showed a classic day-night pattern, with lower values at night than during the day. The origin and significance of the diurnal variation in prorenin is not yet clear. If the lower levels of prorenin contribute to the nocturnal increase in peripheral resistance, the possible direct vasodilating effect of prorenin at night might be surmised to play a role.

References

1. Admiraal PJJ, Derkx FHM, Danser AHJ, Pieterman H, Schalekamp MADH. Intrarenal de novo production of angiotensin I in subjects with renal artery stenosis. *Hypertension* 1990;16 :555-63.
2. Bell GM, Atlas SA, Pecker M, Sealey JE, James G, Laragh JH. Diurnal and postural variations in plasma atrial natriuretic factor, plasma guanosine 3':5'-cyclic monophosphate and sodium excretion. *Clin Sci* 1990;79 :371-76.
3. Chau NP, Chanudet X, Larroque P. Inverse relationship between upright plasma renin activity and twenty-four hour blood pressure variability in borderline hypertension. *J Hypertens* 1990;8 :913-18.
4. Colantonio D. Is atrial natriuretic peptide important in the circadian rhythm of arterial blood pressure? *Am J Cardiol* 1989;63 :1166.
5. Danser AHJ, Koning MMG, Admiraal PJJ, Sassen LMA, Derkx FHM, Verdouw PD, Schalekamp MADH. Production of angiotensins I and II at tissue sites in intact pigs. *Am J Physiol* 1992;263 :H429-437.
6. Derkx FHM, Deinum J, Lipovski M, Verhaar M, Fischli W, Schalekamp MADH. Nonproteolytic "activation" of prorenin by active site-directed renin inhibitors as demonstrated by renin-specific monoclonal antibody. *J Biol Chem* 1992;267 :22837-42.
7. Derkx FHM, Schalekamp MADH. Human prorenin: pathophysiology and clinical implications. *Clin Exp Hypertens [A]* 1988;A10 :1213-25.
8. Derkx FHM, Stuenkel C, Schalekamp MPA, Visser W, Huisveld JH, Schalekamp MADH. Immunoreactive renin, prorenin, and enzymatically active renin in plasma during pregnancy and in women taking oral contraceptives. *J Clin Endocrinol Metab* 1986;63 :1008-15.
9. Donckier J, Anderson JV, Yeo T, Bloom SR. Diurnal rhythm in the plasma concentration of atrial natriuretic peptide. *N Engl J Med* 1986;315 :710-11.
10. Dzau VJ. Significance of the vascular renin-angiotensin pathway. *Hypertension* 1986;8 :553-59.
11. Farsang C, Vajda L, Kapocsi J, Malisák Z, Alföldi S, Varga K, Juhász I, Kunos G. Diurnal rhythm of beta endorphin in normotensive and hypertensive patients: the effect of clonidine. *J Clin Endocrinol Metab* 1983;56 :865-67.
12. Furlan R, Crivellaro W, Dell'Orto S, Gentile E, Piazza S, Pagani MR, Tinelli M, Cerutti S, Lombardi F, Pagani M, Malliani A. Circadian changes in vascular sympathetic activity in ambulant subjects. *J Hypertens* 1989;7 (Suppl. 6) :S30-31.
13. Gordon RD, Wolfe LK, Island DP, Liddle GW. A diurnal rhythm in plasma renin activity in man. *J Clin Invest* 1966;45 :1587-95.
14. Halberg F, Cornelissen G, Marte - Sorenson K. Important time, through not causal, relations in atrial natriuretic peptide, cortisol and renin. *Chronobiologia* 1986;13 :361-64.
15. Hsueh WA, Baxter JD. Human prorenin. *Hypertension* 1991;17 :469-79.
16. Imai Y, Abe K, Sasaki S, Minami N, Munakata M, Nihei M, Sekino H, Yoshinaga K. Exogenous glucocorticoid eliminates or reverses circadian blood pressure variations. *J Hypertens* 1989;7 :113-20.
17. Johnston CI. Biochemistry and pharmacology of the renin-angiotensin system. *Drugs* 1990;39 (Suppl. 1): 21-31.

18. Katz FH, Romfh P, Smith JA. Diurnal variation of plasma aldosterone, cortisol and renin activity in supine man. *J Clin Endocrinol Metab* 1975;40 :125-34.
19. Kelbaek H, Munck O, Christensen NJ, Godtfrendsen J. Central haemodynamic changes after a meal. *Br Heart J* 1989;61 :506-9.
20. Kifor I, Dzau VJ. Endothelial renin - angiotensin pathway: evidence for intracellular synthesis and secretion of angiotensins. *Circ Res* 1987;60 :422-28.
21. Kool MJ, Wijnen JA, Hoeks AP, Struyker-Boudier HA, Van Bortel LM. Diurnal pattern of vessel-wall properties of large arteries in healthy men. *J Hypertens* 1991;9 (Suppl. 6) :S108-109.
22. Koopman MG, Koomen GCM, Krediet RT, de Moor EAM, Hoek FJ, Arisz L. Circadian rhythm of glomerular filtration rate in normal individuals. *Clin Sci* 1989;77 :105-11.
23. Laragh JH. The renin system and four lines of hypertension research. Nephron heterogeneity, the calcium connection, the prorenin vasodilator limb, and plasma renin and heart attack. *Hypertension* 1992;20 :267-79.
24. Lenz T, Sealey JE, Maack T, James GD, Heinrikson RL, Marion D, Laragh JH. Half-life, hemodynamic, renal, and hormonal effects of prorenin in cynomolgus monkeys. *Am J Physiol* 1991;260 :R804-10.
25. Linsell CR, Lightman SL, Mullen PE, Brown MJ, Causon RC. Circadian rhythms of epinephrine and norepinephrine in man. *J Clin Endocrinol Metab* 1985;60 :1210-15.
26. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. *Lancet* 1978;i :795-97.
27. Mori H. Circadian variation of haemodynamics in patients with essential hypertension. *J Hum Hypertens* 1990;4 :384-89.
28. Northridge DB, Findlay JN, Wilson J, Henderson E, Dargie HJ. Non-invasive determination of cardiac output by Doppler echocardiography and electrical bioimpedance. *Br Heart J* 1990;63 :93-97.
29. Okamura T, Aimi Y, Kimura H, Murakami K, Toda N. Existence of renin in the endothelium of human artery. *J Hypertens* 1992;10 :49-53.
30. Orlandini G, Bruschi G, Cavatorta A, Ceresini MB, Manca C, Pucci F, Borghetti A. Physiological stimuli to atrial natriuretic peptide secretion in normal humans. *J Hypertens* 1987;5 (Suppl. 5) :S67-70.
31. Osmond DH, Sealey JE, McKenzie JK. Activation and function of prorenin: different viewpoints. *Can J Physiol Pharmacol* 1991;91 :1308-14.
32. Parati G, Pomidossi G, Casadei R, Mancia G. Lack of alerting reactions to intermittent cuff inflations during non-invasive blood pressure monitoring. *Hypertension* 1985;7 :597-601.
33. Pickering TG. The influence of daily activity on ambulatory blood pressure. *Am Heart J* 1988;116 :1141-45.
34. Portaluppi F, Bagni B, D'Uberti E, Montanari L, Cavallini R, Trasforini G, Margutti A, Ferlini M, Zanella M, Parti M. Circadian rhythms of atrial natriuretic peptide, renin, aldosterone, cortisol, blood pressure and heart rate in normal and hypertensive subjects. *J Hypertens* 1990;8 :85-95.
35. Richards AM, Tonolo G, Fraser R, Morton JJ, Leckie BJ, Bau SG, Robertson JIS. Diurnal change in plasma atrial natriuretic peptide concentrations. *Clin Sci* 1987;73 :489-95.
36. Roy LE, Ogilvie RJ, Larochele P, Hamet P, Leenen FHH. Cardiac and vascular effects of atrial natriuretic factor and sodium nitroprusside in healthy men. *Circulation* 1989;79 :383-92.
37. Sealey JE, Rubattu S. Prorenin and renin as separate mediators of tissue and circulating systems. *Am J Hypertens* 1989;2 :358-66.
38. Smith TL, Coleman TG, Stanek KA, Murphy WR. Hemodynamic monitoring for 24 h in unanesthetized rats. *Am J Physiol* 1987;253 :H1335-41.
39. Salan MI, Engel BT. Effect of sympathetic blockade on diurnal variation of hemodynamic patterns. *Am J Physiol* 1989;256 :R778-85.
40. Taylor CR, Hodge EM, White DA, the Amlodipine angina study group. Circadian rhythm of angina: similarity to circadian rhythms of myocardial infarction, ischemic ST segment depression, and sudden cardiac death. *Am Heart J* 1989;118 :1098-99.
41. Van Bortel LMAB, Schiffrers PMH, Böhm ROB, Mooij JMV, Struijker-Boudier HAJ. The influence of chronic treatment with verapamil on plasma atrial natriuretic peptide levels in young and elderly hypertensive patients. *Eur J Clin Pharmacol* 1990;39 (Suppl. 1) :S39-40.

42. Van der Hoorn FAJ, Boomsma F, Man in 't Veld AJ, Schalekamp MADH. Determination of catecholamines in human plasma by high-performance liquid chromatography: comparison between a new method with fluorescence detection and an established method with electrochemical detection. *J Chromatogr* 1989;487 :17-28.
43. Volpe M, DeLuca N, Atlas SA, Camargo MJ, Indolfi C, Lembo G, Trimarco B, Condorelli M, Laragh JH. Reduction of atrial natriuretic factor circulating levels by endogenous sympathetic activation in hypertensive patients. *Circulation* 1988;77 :997-1002.
44. Walley HWKNGT, Tsao Y, Breckenridge AM. Comparison and reproducibility of transthoracic bioimpedance and dual beam Doppler ultrasound measurement of cardiac function in healthy volunteers. *Br J Clin Pharm* 1991;32 :275-82.
45. Willich SN, Linderer T, Wegscheider K, Leizorovicz A, Alamercury J, Schroder R, ISAM study group. Increased morning incidence of myocardial infarction in the ISAM study: absence with prior β -blockade. *Circulation* 1989;80 :853-58.

CHAPTER 5

SHORT- AND LONG-TERM EFFECTS OF SMOKING ON ARTERIAL WALL PROPERTIES IN HABITUAL SMOKERS

Mirian J.F. Kool, *Arnold P.G. Hoeks, Harry A.J. Struijker Boudier, **Robert S. Reneman, and Luc M.A.B. Van Bortel

Departments of Pharmacology, Division of Clinical Pharmacology, Departments of *Biophysics and **Physiology, Cardiovascular Research Institute Maastricht, University of Limburg, Maastricht, The Netherlands

Based on J Am Coll Cardiol 1993, 22: 1881-1886

Summary

This study investigated the short-term effects of smoking on haemodynamic function and distensibility and compliance of large arteries in habitual smokers. In addition, the effect of smoking was not measured in non-smokers, but vessel wall properties were compared between smokers and non-smokers (basal state). Smoking is a well-known risk factor for atherosclerosis. Loss of distensibility and compliance of large arteries may play a role in the onset of atherosclerosis.

The distensibility and compliance coefficients of the common carotid and brachial arteries were determined from the arterial wall displacement during systole and the end-diastolic diameter by using a vessel wall movement detector and from the pulse pressure as assessed in the upper arm. Cardiac function (cardiac output, stroke volume) was measured with Doppler echocardiography. Systemic vascular resistance was calculated as mean arterial pressure divided by cardiac output.

In habitual smokers, smoking one cigarette caused a sharp increase in blood pressure (6%) and heart rate (14%). Cardiac index increased (16%), mainly because of the marked increase in heart rate. Stroke volume and systemic vascular resistance indexes did not change significantly. Smoking enhanced forearm blood flow after wrist occlusion (17%), but total forearm blood flow was unchanged, suggesting an increase in muscle blood flow and a decrease in skin flow. Because of higher blood pressure, the diameter of the elastic common carotid artery increased by 3% (passive phenomenon). Distensibility of the carotid artery decreased (7%) and, as a result, carotid compliance was preserved. In contrast, despite higher blood pressure, the diameter of the muscular brachial artery did not change, suggesting an increased vascular tone. Brachial distensibility and compliance decreased (18% and 19%, respectively).

In steady state, habitual smokers were comparable to non-smokers with regard to blood pressure, cardiac function, vascular resistance and vessel wall properties of large arteries. Heart rate was higher in habitual smokers (14%).

In conclusion, these data indicate that in habitual smokers, smoking one cigarette causes short-term increases in arterial wall stiffness that might be harmful to the artery and increase the risk for plaque rupture. Except for a higher heart rate, no obvious long-term effect of smoking was observed on haemodynamic variables and arterial stiffness. Because acute cardiovascular events are mainly due to plaque rupture, the short-term effects of smoking might be a more important risk than long-term effects for these acute ischaemic events.

Introduction

In western countries cigarette smoking is a major risk factor for cardiovascular mortality and morbidity independent of other risk factors, such as hypertension, hypercholesterolaemia and diabetes mellitus (21). Hammond and Horn (17) have linked smoking to coronary artery disease and atherosclerosis. Since the time of these original observations the prevalence of smoking and mortality from coronary heart disease have declined, but 25% of all cardiovascular deaths in the developed countries are still attributable to cigarette smoking (27). Even in countries where the incidence of coronary heart disease is relatively low, smoking shows a relation to cardiovascular disease (22), and even passive smoking has been reported to increase the risk of death from ischaemic heart disease and myocardial infarction (14). Epidemiological studies have demonstrated a close association of smoking not only with coronary heart disease (27) but also with stroke (7), sudden death (21) and occlusive peripheral arterial disease (24). In addition, cigarette smoking seems to interact with hypertension, as indicated in the large hypertension trials in which one third of hypertensive men are smokers (5,9).

All studies have demonstrated a dose dependency of smoking and cardiovascular risk, but the risk appears not obviously related to the duration of the smoking habit (3). The Framingham study has shown that for each 10 cigarettes/day, cardiovascular mortality in men is increased by 18% and in women with 31% (21). However, the effect of smoking on cardiovascular disease seems to be reversible. In the Framingham study those who refrained from smoking had a 50% reduction in the risk for coronary heart disease. The risk for cardiovascular death in smokers was comparable to that of non-smokers within one year after cessation, although for peripheral arterial disease the risk was not completely reversed (21). From the aforementioned studies, it can be concluded that cigarette smoking unfavourably affects the cardiovascular system by increasing the risk for atherosclerosis and cardiovascular events.

Increased arterial wall stiffness might play an important role in atherosclerotic disease and the occurrence of acute coronary events (10,32). Arterial distensibility and compliance are important determinants of the load on the arterial wall. These vessel wall properties can now be assessed non-invasively with a vessel wall movement detector system. In the present study, the short-term effect of smoking on large arteries and other haemodynamic data was investigated in habitual smokers (Study 1). In addition, these variables were compared with those in non-smoking subjects (Study 2).

Methods

Subjects — Fourteen healthy smokers participated in the study. They had been smoking an average of 23 cigarettes/day (range 13 to 60) for 17 years (range 5 to 30). The short-term effects of smoking (Study 1) were studied in 12 of them. In addition, smokers were compared with 14 healthy persons who had never smoked (Study 2). The groups were matched for gender, age, weight, height and physical activity. Demographic data are shown in Table 1.

Study design — The subjects were not allowed to use caffeine-containing beverages or meals, and the smokers had to refrain from smoking for at least 4 hours before examination. All haemodynamic measurements were performed after 15 to 20 min of supine rest in a quiet room ($23 \pm 1^\circ\text{C}$). Written informed consent was obtained from all subjects.

Table 1. Demographic data for Smokers and Non-smokers.

	Smoker (n=14)	Non-smokers (n=14)
Gender	9 Males/5 Females	9 Males/ 5 Females
Age (years)	37 (25-55)	37 (25-54)
Weight (kg)	73 (55-88)	72 (52-93)
Height (cm)	175 (158-186)	174 (161-183)
BSA (m ²)	1.9 (1.6-2.1)	1.9 (1.6-2.0)

Values in parentheses are ranges. BSA, body surface area, calculated according to the formula of Du Bois and Du Bois (Arch Intern Med 1916;17:863-871).

Study 1

Measurements were performed before and immediately after smoking one cigarette containing 1.3 mg of nicotine (Caballero filter). The cigarette was smoked under standardised conditions: every 20 s, a puff of 5 s was taken, and the whole cigarette had to be smoked within 5 min.

Vessel wall properties of the right elastic common carotid artery and the right muscular brachial artery were measured in separate sessions. Simultaneously, blood pressure and heart rate were recorded every minute. In addition, cardiac function and forearm blood flow were determined before and after smoking.

Study 2

With the same techniques used in study 1, vessel wall properties of the carotid and brachial arteries and cardiac function were assessed in smokers and non-smokers. Blood pressure and heart rate were recorded every 2 min.

Measurements of haemodynamic function and vessel wall properties — Arm blood pressure and heart rate were measured with a Dinamap (Chapter 2) on the left arm. Vessel wall properties were measured in the recumbent position with the vessel wall movement detector system, as described in Chapter 2. Briefly, with this system, arterial diameter (D) and the distension during the cardiac cycle (ΔD) were measured for 5 to 6 s. The in vitro accuracy of the device is 3 μm for distension and 100 μm for arterial diameter. Reproducibility of the system is good (Chapter 3). The means of three consecutive measurements were taken. Vessel wall properties were calculated from arterial diameter, distension and pulse pressure, according to the equations mentioned in Chapter 2.

Cardiac output was examined in the left lateral position, using Doppler echocardiography and forearm blood flow was determined by mercury strain gauge plethysmography (Chapter 2).

Concerning plethysmography, the whole arm was placed in an incubator to keep environmental temperature constant (28°C). In addition, the skin temperature of this arm was controlled by a skin electrode thermometer. In all subjects, skin temperature was similar before and after smoking (mean temperature 32.4°C). Hand circulation was eliminated by inflating a wrist cuff to suprasystolic pressure (220 mm Hg) for 4 min. After stabilization, a basal value was obtained without (5 min) and with (4 min) wrist occlusion. Only the last 3 min after wrist occlusion were used for evaluation.

Data analysis — The short-term effects of smoking in the smoking group (Study 1) were analysed with the non-parametric, matched paired signed-rank Wilcoxon test. Comparisons between smokers and non-smokers in Study 2 were made by the non-parametric Mann-Whitney U-test. Results of both studies are presented as means $\pm$ s.e.m. $p < 0.05$ was considered statistically significant.

Results

Study 1

Results for blood pressure, cardiac function and plethysmography are presented in Table 2. After smoking, systolic and diastolic blood pressure increased significantly. Mean arterial pressure and heart rate were also elevated. Changes in pulse pressure were not statistically significant. Cardiac index increased after smoking, but stroke and systemic vascular resistance indexes were almost the same before and after smoking. Total forearm blood flow did not change after smoking. However, blood flow increased after wrist occlusion.

Table 2. Effect of one cigarette on haemodynamic variables.

	Before smoking	After smoking
<i>Pressures (mmHg)</i>		
Systolic	112 $\pm$ 2	118 $\pm$ 3***
Diastolic	69 $\pm$ 1	73 $\pm$ 1***
Mean arterial	83 $\pm$ 2	88 $\pm$ 2***
Pulse	43 $\pm$ 2	45 $\pm$ 2
<i>Heart rate (beats/min)</i>		
	64 $\pm$ 3	73 $\pm$ 2***
<i>Cardiac function</i>		
Cardiac index (L/min.m ²)	3.1 $\pm$ 0.1	3.6 $\pm$ 0.1*
Stroke index (mL/m ²)	48 $\pm$ 2	47 $\pm$ 2
SVRI (dyn.s.cm ⁻⁵ .m ²)	1751 $\pm$ 94	1699 $\pm$ 81
<i>Forearm blood flow</i>		
Total forearm blood flow (mL/100mL.min)	4.6 $\pm$ 0.7	4.5 $\pm$ 0.5
Flow after wrist occlusion (mL/100mL.min)	2.7 $\pm$ 0.2	3.2 $\pm$ 0.2*

SVRI, systemic vascular resistance index. Values presented are mean $\pm$ s.e.m. * $p < 0.05$, *** $p < 0.001$.

Data for vessel wall properties are shown in Figure 1. After smoking, the arterial diameter of the common carotid artery increased slightly (before smoking 6.01 ± 0.17 , after smoking 6.17 ± 0.2 mm, $p < 0.05$), and carotid distensibility tended to decrease (before 30.6 ± 1.2 , after 28.5 ± 1.6 10^{-3} /kPa, $p = 0.06$). Arterial distension decreased significantly (before 518 ± 30 , after 488 ± 28 μ m, $p < 0.05$). Compliance of the carotid

Figure 1. The short-term effect of smoking on vessel wall properties of large arteries before (□) and after (■) smoking one cigarette. DC, distensibility coefficient; CC, compliance coefficient; CCA, common carotid artery; BA, brachial artery. Data are mean $\pm$ s.e.m. * $p<0.05$, ** $p<0.01$ (difference between period before and after smoking).

artery was preserved after smoking (before 0.87 ± 0.05 , after 0.85 ± 0.06 mm^2/kPa). Brachial artery diameter did not change after smoking (before 3.65 ± 0.12 , after 3.67 ± 0.15 mm), whereas arterial distension decreased (before 229 ± 22 , after 195 ± 18 μm , $p<0.01$). Distensibility (before 22.5 ± 2.3 , after 18.4 ± 2.0 $10^{-3}/\text{kPa}$, $p<0.01$) and compliance (before 0.24 ± 0.03 , after 0.20 ± 0.02 mm^2/kPa , $p<0.05$) decreased in the brachial artery.

Study 2

Table 3 shows the haemodynamic data in smokers and non-smokers. Blood pressure (systolic, diastolic, mean and pulse pressures) and cardiac, stroke and systemic vascular resistance indexes did not differ between smokers and non-smokers. Vessel wall properties (diameter, distension, distensibility, compliance) of the elastic common carotid and muscular brachial arteries were also comparable between the two groups. However, heart rate was higher in smokers (71 ± 3 beats/min) than in non-smokers (61 ± 3 beats/min, $p<0.05$).

Table 3. Haemodynamic data for Smokers and Non-smokers.

	Smokers	Non-smokers
<i>Pressures (mmHg)</i>		
Systolic	117±3	116±3
Diastolic	71±2	73±1
Mean arterial	87±2	87±2
Pulse	46±2	43±3
<i>Heart rate (beats/min)</i>		
	71±3	61±3*
<i>Cardiac function</i>		
Cardiac index (L/min.m ²)	3.2±0.1	3.0±0.1
Stroke index (mL/m ²)	45±1	51±2
SVRI (dyn.s.cm ⁻⁵ .m ²)	2131±95	2346±129
<i>Vessel wall properties</i>		
<i>Carotid artery</i>		
Diameter (mm)	6.05±0.17	5.88±0.1
Distension (μm)	488±38	421±32
DC (10 ⁻³ /kPa)	27.1±2.2	25.8±2.3
CC (mm ² /kPa)	0.78±0.07	0.69±0.06
<i>Brachial artery</i>		
Diameter (mm)	3.56±0.11	3.67±0.13
Distension (μm)	202±19	242±26
DC (10 ⁻³ /kPa)	19.1±1.8	23.5±2.2
CC (mm ² /kPa)	0.19±0.02	0.25±0.03

SVRI, systemic vascular resistance index; DC, distensibility coefficient; CC, compliance coefficient; Values presented are mean ± s.e.m. *p<0.05.

Discussion

Tobacco contains as many as 4,000 constituents. At present, nicotine is regarded as mainly responsible for the short-term haemodynamic effects of smoking. Nicotine has a biphasic effect. At low doses it causes ganglionic stimulation, with release of noradrenalin from nerve endings, release of adrenalin from the adrenal medulla and an enhanced neural discharge in the central nervous system. At high doses, ganglionic blockade, vagal stimulation or direct depression of the brain may result in opposite effects. The ultimate response is the net result of the stimulating and depressing effects of nicotine in each organ (31). In the present study, sham smoking experiments were not performed because previous studies in general could not demonstrate any effect of sham smoking (6,15). To achieve full regression of tolerance with nicotine (3), a 4-hour non-smoking period before examination was chosen. In general, heart rate increases 1 to 2 min after the start of smoking, and the effect lasts for 75 min (4), with a peak value after 5 to 10 min (34). Our examinations were performed after 5 min of smoking, which was at peak effect.

Long-term effect — In habitual smokers, smoking one cigarette caused a sharp increase in blood pressure (6%) and heart rate (14%). Cardiac index increased (16%), primarily due to a higher heart rate, whereas systemic vascular resistance was not altered. Forearm blood flow increased (17%) after wrist occlusion but remained unchanged without wrist occlusion. This observation suggests an increase in muscle blood flow and a reduced skin flow. Although published data are not always conclusive with regard to the effects of smoking, our findings are consistent with other studies (18,28,34). As in our study, in these studies the increment in blood pressure generally is lower than the increase in heart rate. Taken together, these haemodynamic effects of smoking can be explained by the nicotine-induced sympathetic activation. Nicotine induces the release of both adrenalin and noradrenalin. Because efferent sympathetic nerve activity has been shown to be reduced in smoking (15), the increase in plasma catecholamines (8) instead reflects stimulation of the adrenal medulla or interaction with peripheral mechanisms (eg, a reduced noradrenalin clearance) (15). The net effect of smoking will be dependent on the mixed effects of adrenalin and noradrenalin at the different organ levels (33).

Short-term effect — Smoking one cigarette clearly influenced vessel wall properties of the elastic common carotid and muscular brachial arteries, although these vessels were affected differently. The arterial diameter of the carotid artery increased slightly (3%) after smoking. The vasodilation might be considered a passive phenomenon because in the same period arterial blood pressure was also higher. Distensibility of the carotid artery decreased after smoking (7%), and compliance of this artery was preserved because the decrease in distensibility was associated with an increased diastolic diameter. In contrast, the diameter of the brachial artery did not change after smoking despite a higher blood pressure. This finding suggests an active mechanism, such as elevated vascular tone of this muscular artery. Elevated muscular tone could be due to an increase in plasma catecholamines. Because total forearm flow did not change, a flow-dependent effect is not likely. Distensibility of this artery decreased markedly (18%). Because of an unchanged diameter and decreased distensibility, arterial compliance of the brachial artery was significantly reduced under these circumstances (19%). The differences between the common carotid and brachial arteries may be due to a difference in muscular content of the arterial wall in these arteries. In addition, it may be that with a larger diameter the carotid artery could distend less, resulting in a decreased distensibility.

These findings indicate increased arterial wall stiffness after smoking. Other studies using indirect techniques, such as pulse wave velocity (4) and multigate pulsed Doppler (6), also found transitory increases in stiffness of radial and femoral arteries after smoking, without changes in arterial diameter of these muscular arteries (13).

After a 4-hour non-smoking period, heart rate at rest was higher in habitual smokers than in non-smokers. The difference could not be explained by differences in physical activity level in the two groups because, on average, smokers and non-smokers performed the same daily work and their sports activities were comparable. In previous studies, in long-term smokers (16) the heart rate has been persistently found to be elevated during abstinence, as a kind of withdrawal phenomenon. Blood pressure in the smokers in our study was not different from that in non-smokers. Other studies have been inconsistent with regard to blood pressure in habitual smokers. Overall (2,16), casual as well as ambulatory blood pressure values in habitual smokers have previously been found to be lower or similar to values in non-smokers. In the present study, cardiac function was comparable in smokers and non-smokers. Previous data on vascular resistance and cardiac function in long-term smokers are scanty, although long-term smoking has been associated with a reduced stroke volume (19). In the present smoking group, stroke volume was slightly reduced, but not significantly different from values in the control group. Vessel wall properties of the elastic and muscular large arteries were similar in habitual smokers and non-smokers. Although no other published data are available for differences in vessel wall properties, particularly at the microcirculatory and arteriolar levels, functional and structural differences could not be demonstrated between smokers and non-smokers (12,18). Thus, although the risk for cardiovascular disease is increased in habitual smokers (21,27), no

effect on haemodynamic variables could be detected in this group of young habitual smokers in the present study.

Although smoking is related to atherosclerotic disease, little is known about the underlying mechanisms. Postmortem studies have shown that atherosclerotic lesions are more common in the aorta and the iliac, cerebral and coronary arteries of smokers than of non-smokers, although findings in the latter vessels are inconsistent. In vivo, atherosclerotic disease was more extensively present in the carotid arteries of smokers than of non-smokers (23). In addition, the effect seems to be age dependent because young smokers had far fewer lesions than older smokers (30). It cannot be excluded that changes in vessel wall properties could not yet be detected in the relatively young group of smokers in the present study.

Smoking may promote atherogenesis by different mechanisms, such as 1) a higher blood pressure, 2) a direct toxic effect of nicotine on the endothelium (10), 3) increased permeability of the arterial wall and 4) reduced clearance properties of the wall (1). Other risk factors for atherosclerosis may also be involved in the hazardous effects of smoking, such as an unfavourably changed lipid profile (25,34), increased blood viscosity and alterations in platelet function and haemostasis (20,26,34).

In addition, according to the current view of atherosclerotic disease, plaque rupture is an important feature. It has been demonstrated that most of the acute coronary syndromes are due to the disruption of small, non-stenotic plaques (11). These small plaques are generally not detected with the present diagnostic techniques and might already be present in young smokers (11). Increased arterial wall stiffness, increased blood pressure and a higher heart rate are short-term effects of smoking that enhance the load on the vessel wall. In addition, at the site of atherosclerotic plaques, the distribution of circumferential and tensile stress is altered, which might further increase the load at the plaque (29). The smoking-induced increased load at the atherosclerotic plaque may induce plaque rupture and lead to acute ischaemic events.

In conclusion, in habitual smokers, one cigarette induced haemodynamic changes compatible with a nicotine-induced sympathetic activation. In addition, smoking caused a short-term increase in arterial wall stiffness of both elastic and muscular arteries. Habitual smokers did not differ from non-smokers in haemodynamic variables and properties of large arteries. Nevertheless, these young smokers might still be at risk for cardiovascular complications of atherosclerotic disease because each cigarette causes a short-term increase in the load on the arterial wall that might result in atherosclerotic plaque rupture and subsequent ischaemic events.

References

1. Allen DR, Browse NL. The effect of cigarette smoke, nicotine and carbon monoxide on arterial wall permeability and arterial wall uptake of 125I-fibrinogen. *Adv Exp Med Biol* 1990;273 :95-106.
2. Asmar RG, Girerd XJ, Brahimi M, Safavian A, Safar ME. Ambulatory blood pressure measurement, smoking and abnormalities of glucose and lipid metabolism in essential hypertension. *J Hypertens* 1992;10 :181-87.
3. Benowitz NL. Pharmacological aspects of cigarette smoking and nicotine addiction. *N Engl J Med* 1988;319 :1318-30.
4. Berlin I, Cournot A, Renout P, Duchier J, Safar M. Peripheral haemodynamic effects of smoking in habitual smokers. A methodological study. *Eur J Clin Pharmacol* 1990;38 :57-60.
5. Böhler FR, Vesanen K, Watters JT, Bolli P. Impact of smoking on heart attacks, strokes, blood pressure control, drug dose, and quality of life aspects in the International Prospective Primary Prevention Study in Hypertension. *Am Heart J* 1988;115 :282-87.
6. Caro CG, Lever MJ, Parker KH, Fish PJ. Effect of cigarette smoking on the pattern of arterial blood flow: possible insight into mechanisms underlying the development of arteriosclerosis. *Lancet* 1987;ii :11-13.

7. Cruickshank JM, Neil-Dwyer G, Dorrance DE, Hayes Y, Patel S. Acute effects of smoking on blood pressure and cerebral blood flow. *J Hum Hypertens* 1989;3 :443-49.
8. Cryer PE, Haymond MW, Santiago JV, Shah SD. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. *N Engl J Med* 1976;295 :573-77.
9. Dollery C, Brennan PJ. The Medical Research Council Hypertension Trial: The smoking patient. *Am Heart J* 1988;115 :276-80.
10. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. *N Engl J Med* 1992;326 :242-50.
11. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. *N Engl J Med* 1992;326 :310-18.
12. Gasser P. Video-nailfold-microscopy and local cold test: morphological and hemodynamic correlates in 124 healthy subjects. *Vasa* 1991;20 :244-51.
13. Giannattasio C, Cattaneo BM, Carugo S, Mangoni AA, Grassi G, Mancia G. Cigarette smoking (CS) and radial artery (RA) compliance in man. *J Hypertens* 1992;10 (Suppl. 4) :S94.
14. Glantz SA, Parmley WW. Passive smoking and heart disease. Epidemiology, physiology and biochemistry. *Circulation* 1991;83 :1-12.
15. Grassi G, Seravalle G, Calhoun DA, Bolla G, Mancia G. Cigarette smoking and the adrenergic nervous system. *Clin Exp Hypertens [A]* 1992;A14 :251-60.
16. Green MS, Jucha E, Luz Y. Blood pressure in smokers and nonsmokers: epidemiologic findings. *Am Heart J* 1986;111 :932-40.
17. Hammond EC, Horn D. Smoking and death rates - Report on forty-four months of follow-up of 187,783 men. *JAMA* 1958;166 :1294-1308.
18. Jacobs MC, Lenders J, Kapma JA, Smits P, Thien T. The effect of smoking on vascular relaxation. *Pharmaceut Wkbl Sci Ed* 1991;13 (Suppl. L) :L4.
19. Jain AC, Bowyer AF, Marshall RJ, Asato H. Left ventricular function after cigarette smoking by chronic smokers: comparison of normal subjects and patients with coronary artery disease. *Am J Cardiol* 1977;39 :27-31.
20. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: Insights from the Framingham study. *Am Heart J* 1987;113 :1006-10.
21. Kannel WB, Higgins M. Smoking and hypertension as predictors of cardiovascular risk in population studies. *J Hypertens* 1990;8 (Suppl. 5) :S3-S8.
22. Kiyohara Y, Ueda K, Fujishima M. Smoking and cardiovascular disease in the general population in Japan. *J Hypertens* 1990;8 (Suppl. 5) :S9-S15.
23. Lassila R, Seyberth HW, Haapanen A, Schweer H, Koskenvuo M, Laustiola KE. Vasoactive and atherogenic effects of cigarette smoking: a study of monozygotic twins discordant for smoking. *BMJ* 1988;297 :955-57.
24. Lepäntalo M, Lassila R. Smoking and occlusive arterial disease. *Eur J Surg* 1991;157 :83-87.
25. Mjos OD. Lipid effects of smoking. *Am Heart J* 1988;115 :272-75.
26. Nowak J, Murray J, Oates JA, FitzGerald GA. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. *Circulation* 1987;76 :6-14.
27. Peto R, Lopez A, Boreham J, Thun M, Heath C. Mortality from tobacco in developed countries: indirect estimation from national vital statistics. *Lancet* 1992;339 :1268-78.
28. Richardson D. Effects of tobacco smoke inhalation on capillary blood flow in human skin. *Arch Env Health* 1987;42 :19-25.
29. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. *Lancet* 1989;21 okt :941-44.
30. Strong JP, Richards ML. Cigarette smoking and atherosclerosis in autopsied men. *Atherosclerosis* 1976;23 :451-76.
31. Taylor P. Ganglionic stimulating and blocking agents. In: Goodman Gilman A, Goodman LS, Rall TW, Murad F, eds. Goodman and Gilman's the pharmacological basis of therapeutics 7th ed. New York: Macmillan Publishing Company, 1985: 215-21.

32. Van Bortel LM, Hoeks APG, Kool MJF, Struijker-Boudier HA. Introduction to large artery properties as a target for risk reduction by antihypertensive therapy. *J Hypertens* 1992;10 (Suppl. 6) :S123-26.
33. Weiner N. Norepinephrine, epinephrine, and the sympathomimetic amines. In: Goodman Gilman A, Goodman LS, Rall TW, Murad F, eds. *Goodman and Gilman's The Pharmacological Basis of Therapeutics* 7th ed. New York: MacMillan Publishing Company, 1985 :145-80.
34. Winniford MD. Smoking and cardiovascular function. *J Hypertens* 1990;8 (Suppl. 5) :S17-23.

CHAPTER 6

VESSEL WALL PROPERTIES OF LARGE ARTERIES IN UNCOMPLICATED INSULIN-DEPENDENT DIABETES MELLITUS (IDDM)

Mirian J. Kool, **Jan Lambert, **Coen D. Stehouwer, *Arnold P. Hoeks,
Harry A. Struijker Boudier, and Luc M. Van Bortel

Departments of Pharmacology, Division of Clinical Pharmacology, Department of *Biophysics, Cardiovascular Research Institute Maastricht, University of Limburg, Maastricht, and Departments of Internal Medicine, Institute for Cardiovascular Research, Free University Hospital, Amsterdam, The Netherlands

Based on Diabetes Care 1995,18 :618-624

Summary

Patients with insulin-dependent diabetes mellitus (IDDM) are at high risk for cardiovascular disease. Arterial distensibility and compliance are vessel wall properties of large arteries. Altered large artery wall properties can be an early feature of vascular dysfunction. This study investigates vessel wall properties in 30 patients with uncomplicated IDDM and 30 matched healthy control subjects.

Vessel wall properties of the elastic common carotid (CCA), and the muscular femoral (FA) and brachial arteries (BA) were measured with a vessel wall movement detector system. Blood pressure and heart rate were recorded simultaneously with a semi-automated device. Aortic pulse wave velocity was estimated from the carotido-femoral transit time.

Blood pressure (IDDM patients: $118 \pm 2/69 \pm 1$ mmHg), pulse pressure (IDDM patients: 49 ± 1 mmHg) and heart rate (IDDM patients: 65 ± 2 beats/min) were similar in IDDM patients and control subjects. No statistically significant changes between IDDM and control subjects were found for diameter, distensibility and compliance of the elastic common carotid artery and the muscular brachial artery. Distensibility (IDDM patients: 16.9 ± 1.2 ; Control subjects: $22.4 \pm 2.2 \cdot 10^{-3}/\text{kPa}$) of the muscular femoral artery was decreased in IDDM ($p < 0.05$). However, femoral artery compliance (IDDM patients: 0.80 ± 0.05 ; Control subjects: $0.94 \pm 0.07 \text{ mm}^2/\text{kPa}$) and femoral artery diameter (IDDM patients: 7.87 ± 0.20 ; Control subjects: 7.57 ± 0.20 mm) did not differ statistically between IDDM patients and control subjects. Aortic pulse wave velocity was the same in IDDM patients and control subjects (IDDM patients: 5.1 ± 0.1 m/s). No relation was found between vessel wall properties and duration of disease, actual glucose level, and HbA1c for all three arteries (CCA, BA, and FA). But the groups might have been too small to draw definite conclusions.

In conclusion, the results of the present study show that in this group of patients with uncomplicated IDDM, vessel wall properties of elastic and muscular large arteries were not obviously reduced when compared with healthy controls. However, distensibility of the femoral artery was lower in IDDM. Early atherosclerotic changes in IDDM frequently occur at this site. A difference related to the duration of diabetes could not be excluded.

Introduction

Today, approximately one of 300 people will acquire insulin-dependent diabetes mellitus (IDDM) (35). In patients with IDDM, morbidity and mortality are higher than in non-diabetic patients, with 75% of total diabetes-related mortality being due to macrovascular disease (2,13). In young patients with IDDM, the extent of coronary artery lesions in autopsy material has been shown to be increased (4). In addition, in IDDM the prevalence of hypertension is about twofold higher than in healthy control subjects (8). Systolic blood pressure is more involved than diastolic blood pressure, as shown by the high prevalence of isolated systolic hypertension in young diabetic patients (8). High systolic blood pressure is a well-known risk factor for cardiovascular disease (28).

Systolic hypertension in IDDM patients suggests premature ageing of the arterial system and vascular rigidity. Vascular rigidity may increase vascular stress and endothelial damage. The latter factor is known to promote atherosclerotic disease in large arteries (11). The positive correlation found in IDDM between systolic blood pressure and von Willebrand factor - a marker for endothelial damage - supports this hypothesis (30). Compliance and distensibility are vessel wall properties of large arteries that determine the buffering capacity and elastic properties of the arterial wall. Recently, Hoeks et al (14) have developed a vessel wall movement detector system by which vessel wall properties of superficial large arteries can be measured accurately and non-invasively.

The aim of the present study was to investigate whether vessel wall properties of large arteries in young subjects with uncomplicated IDDM are already altered before organ damage is present. Therefore, large artery properties in IDDM were compared with those in apparently healthy control subjects. In addition, differences in these parameters between short-term and long-term IDDM were evaluated. The relation between vessel wall properties and duration of disease, actual glucose levels, and HbA1c was investigated.

Subjects and methods

Subjects — The study population consisted of 30 patients with uncomplicated IDDM (19 men and 11 women) from an outpatient clinic. Insulin-dependent diabetes was defined as onset before 40 years of age

Table 1. Patient and control group characteristics.

	IDDM patients	Control subjects
Gender	19 men/11 women	19 men/11 women
Age (years)	26 (16-37)	26 (17-37)
Weight (kg)	74.2 (54-92)	74.4 (52-98)
Height (cm)	180 (155-196)	180 (162-201)
Smokers	8	8
Cigarettes/day	12 (4-25)	12 (5-20)
Oral contraceptives	n=9	n=6
Duration of IDDM (years)	9.7 (0.5-23.5)	NA
Glucose (mmol/L)	9.3 (2.2-18.5)	NA
HbA1c (%)	7.8 (5.7-11.2)	NA

Data are means (ranges); IDDM, insulin-dependent diabetes mellitus; NA, not applicable/not measured.

in combination with insulin dependence from diagnosis. Uncomplicated IDDM was defined as diabetes without retinopathy (fundoscopy), nephropathy (urinary albumin secretion < 30 mg/24 hour), or clinical signs of neuropathy. The median duration of diabetes was 9 years (0.5-23.5 years). The control group included 30 (19 men and 11 women) apparently healthy volunteers. The two groups were matched for sex, age, weight, height, and blood pressure.

The IDDM group was divided into two subgroups, which were comparable except for the duration of the disease: 13 patients with short-term (defined as ≤ 9 years, the median duration of diabetes in the study population) and 17 with long-term (defined as > 9 years, the median duration of diabetes in the study population) IDDM were analysed. Patient and control group characteristics are shown in Table 1.

None of the subjects was taking any drugs except for insulin (IDDM patients) and oral contraceptives (nine female diabetic subjects and six female control subjects). Pregnancy was an exclusion criterion. All patients received appropriate insulin treatment and a diet. Patients regularly controlled their own blood glucose levels. Fasting glucose levels were reported between 3 and 10 mmol/L. None of the subjects showed clinical signs of hypoglycaemia during the examination period.

The study was performed in accordance with the principles of the Declaration of Helsinki (revised 1983) and was approved by the Ethical Committee. Informed consent was obtained from all subjects.

Study design and methods — All subjects refrained from smoking or consuming caffeine for at least two hours before examination. All haemodynamic measurements were performed after at least 15 min of supine rest in a quiet room. All measurements were made by the same observer.

Blood pressure and heart rate

Blood pressure and heart rate were recorded every 3 min on the left arm with a semi-automated device (Chapter 2) and the mean of these recordings (approximately 9) was taken as the patient's reading.

Vessel wall properties

Vessel wall properties of the right elastic common carotid artery (CCA), and the right muscular common femoral (FA) and brachial (BA) arteries were assessed with the patient in the recumbent position with the vessel wall movement detector system, as described in Chapter 2.

From arterial diameter, distension and pulse pressure, vessel wall properties were calculated with the equations mentioned in Chapter 2. The system used in the present study has been validated previously and has shown acceptable reproducibility (Chapter 3).

The delay time of the carotid and femoral arteries was used as an estimate of carotido-femoral transit time (Chapter 2). The average pulse wave velocity in the carotido-femoral segment provides an estimation of the stiffness of the aortic pathway (21). Only 25 subjects in each group were studied for aortic pulse wave velocity, since the length of the arterial segment in 5 patients was not available.

Laboratory tests

After the haemodynamic measurements, the actual blood glucose level was determined (One Touch 2, Lifescan, Tilburg, The Netherlands). Glycolysated haemoglobin (HbA1c) was measured by high-performance liquid chromatography (HPLC; normal range 4.3-6.1%; intra-assay variation 2.6%) and obtained within 3 months before the start of the study.

Data analysis — Differences between diabetic and control subjects were analysed by a Student's t-test for unpaired data. Correlations were made between vessel wall properties of the three arteries and HbA1c, plasma glucose levels, and duration of diabetes using Spearman's correlation coefficient. Results are presented as means $\pm$ s.e.m. $p < 0.05$ was considered statistically significant.

Results

The diabetic group did not differ from the control group with regard to gender, age, weight, height and smoking habits. None of the patients or control subjects was hypertensive (defined as $< 160/95$ mmHg) at the time of the study. Patients had neither a history of coronary heart disease nor peripheral arterial disease, nor could overt atherosclerotic lesions be detected with B-mode scanning at the time of examination. Intima-media thickness was not measured, since there is as yet no consensus about the accuracy of this parameter with the current techniques (7,25,31,39).

According to the HbA1c-levels ($7.8 \pm 0.3\%$), short-term regulation of IDDM was fair. Actual blood glucose levels (9.3 ± 0.9 mmol/L) showed a large interindividual variation (Table 1).

Haemodynamic data in IDDM patients and control subjects are presented in Table 2. Blood pressure, pulse pressure, and heart rate were comparable in both groups. No statistically significant differences existed between IDDM patients and control subjects for arterial diameter, distension, distensibility, and compliance of the elastic common carotid artery. Brachial artery diameter as well as brachial distension, distensibility and compliance were comparable for the two groups. Femoral artery distensibility was decreased ($p < 0.05$) in IDDM patients, but femoral artery diameter and compliance did not differ between the two groups. Aortic pulse wave velocity was similar in IDDM patients and control subjects. Arterial diameter, distensibility and compliance of the carotid artery were related neither to the duration of the disease nor to the actual glucose level (Figure 1).

Table 2. Haemodynamic data in IDDM patients and healthy control subjects.

	IDDM patients	Control subjects
<i>Blood pressure, heart rate</i>		
Blood pressure (mmHg)	$118 \pm 2/69 \pm 1$	$115 \pm 2/68 \pm 1$
Pulse pressure (mmHg)	49 ± 1	48 ± 2
Heart rate (beats/min)	65 ± 2	62 ± 2
<i>Vessel wall properties</i>		
Common carotid artery		
Diameter (mm)	5.79 ± 0.08	5.61 ± 0.05
Distension (μm)	547 ± 21	537 ± 30
DC ($10^{-3}/\text{kPa}$)	29.7 ± 1.4	30.3 ± 1.3
CC (mm^2/kPa)	0.77 ± 0.03	0.75 ± 0.03
Common femoral artery		
Diameter (mm)	7.87 ± 0.20	7.57 ± 0.20
Distension (μm)	416 ± 23	498 ± 39
DC ($10^{-3}/\text{kPa}$)	16.9 ± 1.2	$22.4 \pm 2.2^*$
CC (mm^2/kPa)	0.80 ± 0.05	0.94 ± 0.07
Brachial artery		
Diameter (mm)	3.40 ± 0.08	3.43 ± 0.07
Distension (μm)	263 ± 11	260 ± 16
DC ($10^{-3}/\text{kPa}$)	24.3 ± 1.1	24.9 ± 1.8
CC (mm^2/kPa)	0.22 ± 0.01	0.23 ± 0.02
Aortic PWV (m/s)	5.1 ± 0.1 (n=25)	5.2 ± 0.1 (n=25)

Data are mean $\pm$ s.e.m.; IDDM, insulin-dependent diabetes mellitus; DC, distensibility coefficient; CC, compliance coefficient; PWV pulse wave velocity; * $p < 0.05$.

Figure 1. Relation between duration of diabetes and arterial diameter (a), distensibility (b), and compliance (c) of the carotid artery (CCA). DC, distensibility coefficient; CC, compliance coefficient.

+ subjects with glucose 4-10 mmol/L; ● subjects with glucose < 4 mmol/L; ▲ subjects with glucose > 10 mmol/L as measured with Lifescan.

In addition, no significant relation could be demonstrated between HbA1c and diameter ($r=-0.17$), distensibility ($r=0.04$) and compliance ($r=0.04$) of the common carotid artery. The same pattern was found for the muscular femoral and brachial arteries.

Haemodynamic data and vessel wall properties in patients with short-term and long-term IDDM are shown in Table 3. No statistically significant differences were observed between the two subgroups for all parameters.

Table 3. Haemodynamic differences between short-term and long-term IDDM patients.

	<9 years IDDM	>9 years IDDM
<i>Blood pressure, heart rate</i>		
Blood pressure (mmHg)	119±3/69±2	115±2/68±1
Pulse pressure (mmHg)	50±2	48±2
Heart rate (beats/min)	64±2	62±2
<i>Vessel wall properties</i>		
Common carotid artery		
Diameter (mm)	5.82±0.15	5.78±0.10
Distension (μm)	592±36	513±24
DC (10 ⁻³ /kPa)	31.7±2.6	28.2±1.5
CC (mm ² /kPa)	0.82±0.05	0.73±0.03
Common femoral artery		
Diameter (mm)	8.12±0.30	7.68±0.27
Distension (μm)	407±32	423±33
DC (10 ⁻³ /kPa)	15.5±1.5	18.0±1.7
CC (mm ² /kPa)	0.80±0.08	0.80±0.06
Brachial artery		
Diameter (mm)	3.45±0.10	3.36±0.12
Distension (μm)	266±16	260±17
DC (10 ⁻³ /kPa)	23.6±1.4	24.9±1.7
CC (mm ² /kPa)	0.22±0.02	0.21±0.01
Aortic PWV (m/s)	4.9±0.2 (n=11)	5.3±0.1 (n=14)

Data are mean ± s.e.m.; IDDM, insulin-dependent diabetes mellitus; DC, distensibility coefficient; CC, compliance coefficient; PWV pulse wave velocity; *p<0.05.

Discussion

In the present study, patients with uncomplicated IDDM were compared with matched healthy control subjects. Blood pressure, pulse pressure, and heart rate neither were different between patients and controls nor were different between short-term (defined as ≤ 9 years duration of disease) and long-term (defined as > 9 years duration of disease) IDDM. None of the patients suffered from hypertension. Microangiopathic changes are a well-known complication in diabetic subjects (24), but macrovascular pathological changes are also an important feature of IDDM. It is hypothesised that a close correlation exists between microvascular and macrovascular changes in IDDM (5,30). However, most data about diabetes and vascular compliance are based on studies with non-insulin-dependent diabetes mellitus (NIDDM) patients. Large artery disease in IDDM is supposed to affect predominantly distal arteries (27). Rubba et al (27) showed that early arterial disease was enhanced in IDDM patients compared with control subjects, but it is not known whether these patients had microalbuminuria or to what extent they had other complications. In this study, abnormalities mainly consisted of stenosing lesions in the femoral, popliteal and tibial arteries, while pelvic vessel disease was nearly absent. But, also in the proximal common carotid artery of IDDM patients more atherosclerotic changes were found than in control subjects (20).

Changes in the vessel wall properties of large arteries might play a role in arterial ageing and might facilitate development of atherosclerotic disease, which is a major complication in diabetic subjects (1). Changes in vessel wall properties (distensibility and compliance) may be an early feature of vascular dysfunction. Such changes might be expressed differently in elastic and muscular large arteries. Therefore, vessel wall properties of the elastic common carotid artery and the muscular femoral and brachial arteries were studied. Several authors have investigated the elastic behaviour of large arteries in diabetic patients. In general, distensibility was found to be decreased (16,22,26,29,32,34,41). In contrast, Lehmann et al showed a higher aortic distensibility in young patients with uncomplicated IDDM one year after diagnosis, when compared with age- and sex-matched control subjects (18). However, these subjects were not matched for blood pressure and this could have influenced the results.

Most of the above cited studies used the pulse wave velocity technique, which is only an indirect measure of arterial distensibility (14,32). In addition, the results were often based on observations in a poorly defined population of mixed IDDM and NIDDM patients, with a large age distribution, with and without complications, treated with a variety of regimens, and with a highly variable duration of disease. Therefore, these data are difficult to interpret and may not be comparable with ours. The only studies available with regard to IDDM also use other techniques to assess large artery properties (18,32). The minimal change in aortic distensibility in these studies was 32%. In the present study, a larger sample size (30 subjects per group) was used. This made it possible to demonstrate with a power of 80% a difference in distensibility of 5% for the aorta, of 10% for the common carotid artery, and of 15% for the brachial and femoral arteries. In the present study, no gross changes in arterial wall properties could be demonstrated between IDDM patients and a matched control group. Arterial diameter, distensibility and compliance of the elastic and muscular arteries, as well as aortic pulse wave velocity - a measure of aortic distensibility - were not statistically significantly affected by diabetes. Using the data of the present study for sample size calculation, we calculated that more than 52,000 subjects should be included in each group to find a significant difference ($p < 0.05$) with an 80% power. With such a number of patients, there is the question whether these statistical differences are also clinically relevant. In contrast, previous studies studying arterial compliance in different groups of diabetics have shown statistical differences with relatively small numbers of patients (18,19,32,37,38).

Nevertheless, in the present study some trends could be seen. Arterial diameter of the carotid and femoral arteries were slightly larger in IDDM patients. During the early stages of atherosclerotic disease, arterial diameter indeed may become increased (10,40). Since the carotid and femoral arteries, in contrast to the brachial artery, are most prone to atherosclerosis in diabetic patients, the presence of early - still below the detection limit of B-mode scanning - atherosclerosis cannot be excluded. In addition, femoral artery distensibility was considerably decreased and compliance of the femoral artery also tended to be diminished in IDDM patients compared with controls (25% vs. 15%, respectively). This might be due to vascular dysfunction, and endothelial changes in particular could be suspected. It is not clear whether this increased stiffness of the femoral artery is also an early feature of atherosclerotic disease.

In the present study, heart rate did not differ between IDDM patients and control subjects, although data from the literature have shown increased basal heart rate and decreased heart rate variability in IDDM patients (9,15,17,33,43). The higher heart rate in diabetics has been related to the presence of autonomic neuropathy and other microvascular complications (33). In addition, the presence of microalbuminuria is closely related to autonomic neuropathy in IDDM (17,23,43). Microalbuminuria was absent in all IDDM patients in the present study. Therefore, the low heart rate of the diabetic subjects in our study can be explained by the thoroughly selected group of patients with uncomplicated IDDM without microalbuminuria and autonomic neuropathy, whereas it is not probable that a high fitness level of the IDDM patients plays a major role.

Like the previous studies, IDDM patients with a highly variable duration of disease were investigated, and this might have equalised possible differences between IDDM patients and control subjects, if duration of the disease has any influence. But within the subgroups of patients with short-term and long-term disease, we were unable to demonstrate obvious differences. Nevertheless, the arterial diameters of the three

arteries were slightly smaller in long-term IDDM. Distensibility and compliance of the elastic common carotid artery tended to be decreased, and aortic distensibility also tended to be diminished in long-term IDDM, while vessel wall properties of the muscular arteries were less affected. Thus, despite the small number of subjects in each subgroup, some trends were visible. Therefore, a possible influence of the duration of the disease cannot be excluded.

At present, it is not completely clear how large arteries are influenced by diabetes in case of IDDM, but various mechanisms have been postulated. Changes in various vascular hormones and haemostatic abnormalities in IDDM have been extensively investigated, but their role has not been clarified yet (8,12). Injury to the vascular endothelium, resulting in endothelial dysfunction, may play an important role in the pathogenesis of small and large vessel disease in diabetes (5). Hyperinsulinaemia may also occur in IDDM (6,42) and has been indirectly associated with increased arterial wall stiffness, narrowing of the vascular lumen, and increased vascular resistance (1). It is well known that chronic hyperglycaemia is an important cause for the development of diabetic complications (3,36). Longstanding hyperglycaemia has been proposed as an independent cardiovascular risk factor (8). One of the pathophysiological consequences of hyperglycaemia is the formation of advanced glycosylation end-products (AGE). Accumulation of AGE products may impair endothelial function and increase vascular permeability. In addition, the extracellular matrix is irreversibly changed via increased cross-linking between collagen fibrils (3). This results in a stiffer vessel that might become more sensitive to endothelial injury and subsequent atherosclerosis (3,36). In the present study, no clear evidence was found for a relation between the actual glucose levels or HbA1c and arterial wall haemodynamics.

In conclusion, femoral artery distensibility was decreased in a group of patients with uncomplicated IDDM. These data suggest early, still not detectable, diabetes-induced vascular disease of the femoral artery. No gross changes in haemodynamics and vessel wall properties of other elastic and muscular large arteries could be demonstrated when compared with a matched control group.

No obvious relation was found between vessel wall properties and the duration of the disease, the actual glucose level, and HbA1c, but since the groups were small, a mild influence of the duration of diabetes cannot be excluded.

References

1. Bierman EL. Atherogenesis in diabetes. *Arterioscler Thromb* 1992;12 :647-56.
2. Borch-Johnsen K, Nissen H, Salling N, Henriksen E, Kreiner S, Deckert T, Nerup J. The natural history of insulin-dependent diabetes in Denmark. 2. Long-term survival: who and why. *Diabetic Med* 1987;4 :211-16.
3. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. *N Engl J Med* 1988;318 :1315-21.
4. Crall FV, Roberts WC. The extramural and intramural coronary arteries in juvenile diabetes mellitus. *Am J Med* 1978;64 :220-30.
5. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. *Diabetologia* 1989;32 :219-26.
6. DeFronzo RA, Hendler R, Simonson D. Insulin resistance is a prominent feature of insulin-dependent diabetes. *Diabetes* 1982;31 :795-801.
7. Devereux RB, Waeber B, Roman MJ. Conclusions on the measurement of arterial wall thickness: anatomic, physiologic and methodologic considerations. *J Hypertens* 1992;10 (Suppl. 6) :S119-21.
8. Epstein M, Sowers JR. Diabetes mellitus and hypertension. *Hypertension* 1992;19 :403-18.

9. Ewing DJ, Neilson JMM, Shapiro CM, Stewart JA, Reid W. Twenty four hour heart rate variability: effects of posture, sleep, and time of day in healthy controls and comparison with bedside tests of autonomic function in diabetic patients. *Br Heart J* 1991;65 :239-44.
10. Filitti V, Giral P, Simon A, Merli I, Del Pino M, Levenson J. Enhanced constriction of the peripheral large artery in response to acute induction of a low-flow state in human hypercholesterolemia. *Arterioscler Thromb* 1991;11 :161-66.
11. Fuster V, Badimon L, Badimon JJ, Chesebrough JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. *N Engl J Med* 1992;326 :242-50.
12. Ganda OP. Pathogenesis of macrovascular disease in the human diabetic. *Diabetes* 1980;29 :931-42.
13. Green A, Borch-Johnsen K, Andersen PK, Hougaard P, Keiding N, Kreiner S, Deckert T. Relative mortality of type 1 (insulin-dependent) diabetes in Denmark: 1933-1981. *Diabetologia* 1985;28 :339-42.
14. Hoeks APG, Brands PJ, Smeets FAM, Reneman RS. Assessment of the distensibility of superficial arteries. *Ultrasound Med Biol* 1990;16 :121-28.
15. Jensen T, Richter EA, Feldt-Rasmussen B, Kelbaek H, Deckert T. Impaired aerobic work capacity in insulin dependent diabetics with increased urinary albumin excretion. *BMJ* 1988;296 :1352-54.
16. Katz HP, Cheitlin MD, Wasser AH. Observations on the pulse wave velocity and tissue biopsy in children with diabetes mellitus. *Bull Johns Hopkins Hosp* 1970;127 :336.
17. Kelbaek H, Jensen T, Feldt-Rasmussen B, Christensen NJ, Richter EA, Deckert T, Nielsen SL. Impaired left-ventricular function in insulin-dependent diabetic patients with increased urinary albumin excretion. *Scand J Clin Lab Invest* 1991;51 :467-73.
18. Lehmann ED, Gosling RG, Snksen PH. Arterial wall compliance in diabetes. *Diabetic Med* 1992;9 :114-19.
19. Lo CS, Relf IRN, Myers KA, Wahlqvist ML. Doppler ultrasound recognition of preclinical changes in arterial wall diabetic subjects: compliance and pulse-wave damping. *Diabetes Care* 1986;9 :27-31.
20. Merrin PK, Renton S, Fisher C, Nicholaides A, Elkeles RS. Arterial wall abnormalities in type 1 and type 2 diabetes. *Diabetic Med* 1992;9 (Suppl. 1) :30A.
21. O'Rourke MF. Function of arteries as vascular conduits. In: O'Rourke MF, ed. *Arterial function in health and disease* Edinburgh London Melbourne New York: Churchill Livingstone, 1982 :53-64.
22. Oxlund H, Rasmussen LM, Andreassen TT, Heickendorff L. Increased aortic stiffness in patients with Type 1 (insulin-dependent) diabetes mellitus. *Diabetologia* 1989;32 :748-52.
23. Parving HH, Hommel E, Mathiesen E, Skott P, Edsberg B, Bahnsen M, Lauritzen M, Hougaard P, Lauritzen E. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. *BMJ* 1988;296 :156-60.
24. Parving HH, Viberli GC, Keen H, Christiansen JS, Lassen NA. Hemodynamic factors in the genesis of diabetic microangiopathy. *Metabolism* 1983;32 :943-49.
25. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. *Circulation* 1986;74 :1399-1406.
26. Pillsbury HC, Hung W, Kyle MC, Freis ED. Arterial pulse waves and velocity and systolic time intervals in diabetic children. *Am Heart J* 1974;87 :783-90.
27. Rubba P, Riccardi G, Paucillo P, Vaccaro O, Carbone L, Mancini M. Different localization of early arterial lesions in insulin-dependent diabetes mellitus and in familial hypercholesterolemia. *Metabolism* 1989;38 :962-66.
28. Rutan GH, Kuller LH, Neaton JD, Wentworth DN, McDonald RH, Smith WM. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. *Circulation* 1988;77 :504-14.
29. Scarpello JHB, Martin TRP, Ward JD. Ultrasound measurements of pulse-wave velocity in the peripheral arteries of diabetic subjects. *Clin Sci* 1980;58 :53-57.
30. Stehouwer CDA, Zellenrath P, Polak B, Baarsma GS, Nauta JJP, Donker AJM. Von Willebrand factor and early diabetic retinopathy: no evidence for a relationship in patients with type 1 (insulin-dependent) diabetes mellitus and normal urinary albumin excretion. *Diabetologia* 1992;35 :555-59.
31. Tardy Y, Hayoz D, Mignot JP, Richard P, Brunner HR, Meister JJ. Dynamic non-invasive measurements of arterial diameter and wall thickness. *J Hypertens* 1992;10 (Suppl. 6) :S105-9.

32. Thordarson H, Thorgeirsson G, Helgason T. Aortic stiffness in insulin-dependent diabetics: an echocardiographic study. *Diabetic Med* 1986;3 :449-54.
33. Thuesen L, Christiansen JS, Mogensen CE, Henningsen P. Cardiac hyperfunction in insulin-dependent diabetic patients developing microvascular complications. *Diabetes* 1988; 37 :851-56.
34. Treese N, Ungern-Sternberg v A, Cordes U, Beyer J. Influence of norepinephrine on vessel geometry of the intact femoral artery in juvenile insuline-dependent diabetics. Evidence of early diabetic angiopathy in central arteries. *Z Kardiol* 1982;71 :60-64.
35. Vaandrager GJ, Bruining GJ, Veenhof FJ, Drayer NM. Incidence of childhood diabetes in the Netherlands: a decrease from north to south in North-Western Europe? *Diabetologia* 1984;27 :203-7.
36. Vlassara H, Brownlee M, Cerami A. Nonenzymatic glycosylation: role in the pathogenesis of diabetic complications. *Clin Chem* 1986;32 :B37-41.
37. Wahlqvist ML, Lo CS, Myers KA. Fish intake and arterial wall characteristics in healthy people and diabetic patients. *Lancet* 1989;21 okt :944-46.
38. Wahlqvist ML, Lo CS, Myers KA, Simpson RW, Simpson JM. Putative determinants of arterial wall compliance in NIDDM. *Diabetes Care* 1988;11 :787-90.
39. Wendelhag I, Wiklund O, Wikstrand J. Arterial wall thickness in familial hypercholesterolemia. *Arterioscler Thromb* 1992;12 :70-77.
40. Wikstrand J, Wiklund O. Frontiers in cardiovascular science. Quantitative measurements of atherosclerotic manifestations in humans. *Arterioscler Thromb* 1992;12 :114-19.
41. Woolam GL, Schnur PL, Vallbona C, Hoff HE. The pulse wave velocity as an early indicator of atherosclerosis in diabetic subjects. *Circulation* 1962;25 :533-39.
42. Yki-Järvinen H, Koivisto VA. Natural course of insulin resistance in type I diabetes. *N Engl J Med* 1986;315 :224-30.
43. Zander E, Schulz B, Heinke P, Grimmberger E, Zander G, Gottschling HD. Importance of cardiovascular autonomic dysfunction in IDDM subjects with diabetic nephropathy. *Diabetes Care* 1989;12 :259-64.

CHAPTER 7

THE INFLUENCE OF PERINDOPRIL AND THE DIURETIC COMBINATION AMILO-
RIDE/HYDROCHLOROTHIAZIDE ON THE VESSEL WALL PROPERTIES OF
LARGE ARTERIES IN HYPERTENSIVE PATIENTS

Mirian J.F. Kool, *Frans A.T. Lustermans, **Johan G.S. Breed, Harry A.J. Struijker Boudier,
***Arnold P.G. Hoeks, *Robert S. Reneman, and Luc M.A.B. Van Bortel

Departments of Pharmacology, *Physiology, ***Biophysics, Cardiovascular Research Institute
Maastricht, University of Limburg, Departments of Internal Medicine, *De Wever Hospital
Heerlen and **St. Jansgasthuis Weert, the Netherlands

Based on J Hypertens 1995 (in press)

Summary

The aim of the present study was to compare cardiovascular effects of a 6-month treatment with the ACE inhibitor perindopril (P) or with the diuretic amiloride/hydrochlorothiazide (A/H) and to study possible persistence of the observed treatment effects after discontinuation of the antihypertensive therapy.

A placebo run-in period was followed by an active treatment phase during 6 months in 41 patients with essential hypertension, according to a double-blind, randomised, parallel design. Patients received perindopril 4 mg o.d. or A/H 2.5/25 mg o.d. Subsequently, patients were studied during a 3-month single blind placebo run-out period.

After 6 months of treatment, supine systolic blood pressure was reduced ($p<0.01$) by P (11%) and A/H (8%). Diastolic blood pressure decreased more ($p<0.05$) with P (8%) than with A/H (4%). Cardiac index increased with P (6%), due to an increased stroke index (5%), while during A/H cardiac function was unchanged. Systemic vascular resistance index decreased more ($p<0.05$) with P (14%) than with A/H (8%), indicating a more pronounced vasodilation of small vessels with P. Effects on diameter of the elastic common carotid artery (CCA) and the muscular femoral (FA) and brachial (BA) arteries did not differ between P and A/H. Distensibility of CCA was significantly enhanced by P (16%), but unchanged with A/H (1%). The difference between P and A/H for carotid distensibility was statistically significant ($p<0.01$). Compliance of CCA tended to be more increased ($p=0.067$) with P (7%) than with A/H, which induced a decrease (5%; n.s.) in carotid compliance. After withdrawal of therapy, for both P and A/H all treatment-induced changes reversed to pre-treatment values within 7 weeks.

In conclusion, these data show that distensibility of the elastic common carotid artery was increased by perindopril, but not by amiloride/hydrochlorothiazide. Large artery properties of the muscular arteries and systemic vascular resistance improved with both drugs, but in general the changes were more pronounced with perindopril than with amiloride/hydrochlorothiazide. These results indicate a more pronounced effect of perindopril at both the macro and microcirculatory level, which consequently will lead to a larger decrease in cardiac afterload. After discontinuation of therapy all parameters returned to baseline values within 7 weeks.

Introduction

From epidemiological studies it is known that hypertension is related to a high cardiovascular risk (14). In hypertension functional and structural changes of the cardiovascular system are observed (27). Changes at the level of the arterioles result in an enhanced peripheral resistance with an elevation of mean arterial pressure (24). However, the increase in peripheral resistance is not the leading cause of death in hypertension. Hypertension-related mortality is primarily due to changes in large arteries, leading to stroke, cardiac failure and myocardial infarction (14). Vessel wall properties of large arteries (distensibility and compliance) may play an important role in the ill-effects of hypertension. Distensibility reflects the elastic properties of the arterial wall, while compliance determines the capacity of large arteries to store the blood volume, ejected with each heart beat. In essential hypertension the elastic and buffering function of the arterial system is diminished (24). This can be due to the higher blood pressure and is not necessarily due to alterations in intrinsic properties, at least for the radial artery (12). For a given stroke volume, a decrease in arterial distensibility and compliance and increased pulse wave reflections, will enhance pulse pressure. Increased pulse pressure has been associated with increased cardiovascular morbidity (14,19).

Thiazide diuretics are frequently used in the management of hypertension, but the influence of diuretics on vessel wall properties of large arteries has not been extensively investigated. One short-term study in systolic hypertension suggested an increase in arterial compliance with thiazides (32).

Converting enzyme inhibitors not only decrease blood pressure, but they may also be more effective in reversing cardiac hypertrophy than other antihypertensive drugs (11). ACE inhibitors improved vessel wall properties of human large arteries (3,4,23,25,30,31), but these are all short-term or uncontrolled studies. Animal data have shown a regression of structural changes in the vessel wall with these compounds (17) and human data suggested a regression of structural changes in arterioles (29). If such a change also occurs in the vessel wall of large arteries in humans, (partial) improvement of large artery properties after withdrawal of the drug might persist.

Therefore, the aim of the present study was to compare the *long-term* effects of antihypertensive treatment with the ACE inhibitor perindopril to treatment with the diuretic amiloride/hydrochlorothiazide. Apart from the effects on blood pressure, heart rate and cardiac function, effects on vessel wall properties of 3 different arteries were evaluated: the elastic common carotid artery and the muscular common femoral and brachial arteries. A secondary aim was to determine if, after withdrawal of the chronic treatment, the observed effects on vessel wall properties persist.

Patients and methods

Patients — 86 Outpatients with mild to moderate essential hypertension were selected for the study. Patients had to be between 18 and 65 years of age. Patients were excluded for the following reasons: secondary and malignant hypertension, congestive heart failure, severe cardiopulmonary disease, myocardial infarction or cerebrovascular accident within the past 6 months, overt atherosclerotic lesions, diabetes mellitus treated with insulin or oral antidiabetics, significant renal or hepatic disease (serum creatinine $> 180 \mu\text{mol/l}$; ALAT and $\gamma\text{-GT}$ 2x upper normal limit), abnormal plasma protein values, and serum potassium $> 5.5 \text{ mmol/l}$. Concomitant medication that may affect blood pressure (eg, antidepressants, nitrates, corticosteroids etc) or treatment with an ACE inhibitor < 3 months prior to the study was not allowed. Pregnant or nursing women, patients with severe concurrent disease, and patients with known adverse reactions to ACE inhibitors or diuretics were also excluded. After 6 weeks of single blind placebo-treatment, 41 patients were found eligible for inclusion.

The two treatment groups consisted of 20 patients (14 males, 6 females) in the perindopril group and 21 (10 males, 11 females) in the amiloride/hydrochlorothiazide (A/H) group. Demographic data are shown in

Table 1. Demographic data at baseline (week 0).

	Perindopril	Amloride/HCTZ
Number of patients	20	21
Male/female	14/6	10/11
Age (years)	50 (34-63)	52 (35-63)
Weight (kg)	78.7 (48.0-101.0)	76.5 (58.0-99.5)
Height (cm)	171 (155-182)	169 (153-182)
Body surface area (m ²)	1.9 (1.5-2.2)	1.9 (1.6-2.2)

HCTZ, hydrochlorothiazide; Data are mean (range).

Table 1. Two smokers were present in the perindopril group and 4 in the A/H group, which smoked on average 11 and 16 cigarettes a day, respectively. Seven patients in the perindopril group and 10 in the A/H group had an alcohol consumption of more than one glass per day. Alcohol consumption never exceeded 4 glasses per day. In the perindopril group 17 subjects and in the A/H group 18 subjects were previously treated with antihypertensive drugs. The mean duration of hypertension was 8.1 (0.8-16.6) years in the perindopril group and 7.5 (0.6-30.0) years in the A/H group. Thirteen patients in the perindopril group and eight in the A/H group used a salt restricting diet.

Study design — The study was a multicentre double-blind, randomised, parallel study. Throughout the study patients were not allowed to change their normal diet and daily salt intake.

Single-blind placebo run-in period (week -6 to 0)

A general physical and routine laboratory examination was carried out and a full medical history was taken at the first visit (week -6). Blood pressure, cardiac function and vessel wall measurements were performed to familiarise to the examination procedures. An electrocardiogram was performed and an echographic screening of the carotid and femoral arteries was made to exclude overt atherosclerotic lesions. All previous antihypertensive therapy was withdrawn within the first week of the run-in period and all other forbidden medications were discontinued. Patients received placebo once daily in the morning for 6 weeks. At week -4, -1 and 0 body weight, blood pressure, heart rate, and clinical acceptability were determined. Vessel wall properties and cardiac function were assessed at week -1 and 0 and blood samples were taken at week -1. Patients were excluded if sitting diastolic blood pressure (DBP) was >110 mmHg or sitting systolic blood pressure (SBP) was >180 mmHg, or because of development of the aforementioned exclusion criteria.

Double-blind active treatment period (week 0 to 24)

After 6 weeks placebo, patients with a sitting DBP between 95 and 110 mmHg were included (mean of 3 measurements at week -1 and 0). They were randomly assigned to either oral treatment with 4 mg perindopril or 2.5 mg/25 mg A/H for 6 months. After 1 or 3 months the dose was doubled once if sitting DBP was ≥90 mmHg. Major exclusion criteria were a sitting DBP >110 mmHg (at maximal dose), or >100 mmHg after 3 months. Treatment was also discontinued in patients that developed serious adverse effects

or met other exclusion criteria, or in the case of poor patient compliance. Weight, blood pressure, heart rate and clinical acceptability were assessed at each visit during the active treatment period (week 4, 12 and 24). Routine laboratory tests, vessel wall measurements and cardiac function were performed after 3 and 6 months of active treatment (week 12 and 24, respectively).

Single placebo run-out period (week 24 to 37)

After 6 months of active treatment, the therapy was stopped and replaced by a single-blind placebo run-out period up to 3 months, depending on DBP levels. Placebo was used once daily, corresponding to the dose in the active treatment phase. Patients were examined at week 30 and 37. If, after 7 weeks of placebo, sitting DBP was >110 mmHg or SBP was >180 mmHg, or when other exclusion criteria developed, the patient was withdrawn.

The study was performed in accordance with the principles of the Declaration of Helsinki (revised 1983) and was approved by the Ethical Committees of each participating centre. Informed consent was obtained from all patients.

Methods — All haemodynamic measurements were performed after at least 15 min of supine rest in a quiet room. For each patient measurements were carried out at the same time of the day. All measurements were made by the same observer.

Blood pressure and heart rate

Sitting blood pressure was measured on the same arm at the end of each visit with a mercury sphygmomanometer. Korotkoff phase V (disappearance of sound) was used to define DBP. The mean of 3 measurements with at least a 1 min interval was taken as the patient's reading. Sitting heart rate was determined at the end of each visit by palpation of the radial artery for 30 sec. Simultaneously with the vessel wall measurements, supine systolic, diastolic and mean arterial blood pressure (MAP) were recorded every 3 min on the left arm with a Dinamap (Chapter 2) and the mean of these recordings (at least 9) was taken as the patient's reading.

Vessel wall properties

Vessel wall properties of the right elastic common carotid artery (CCA), and the right muscular common femoral (FA) and brachial (BA) arteries were assessed in recumbent position with the vessel wall movement detector system, described in Chapter 2. From arterial diameter, distension and pulse pressure, vessel wall properties, distensibility and compliance, were calculated with the equations mentioned in Chapter 2.

Cardiac function

Cardiac function was measured with the patient in left lateral position, using an echo Doppler technique (Chapter 2).

Laboratory tests

Venous blood samples were analysed for potassium, sodium, uric acid, creatinine, glucose, transaminases (ALAT, ASAT), γ -GT, alkaline phosphatase, protein and albumin.

Drug adherence

Patients were asked for their drug adherence at each visit. In addition, the number of capsules returned at the end of each treatment period was counted.

Data analysis—With regard to body weight, blood pressure, heart rate, vessel wall measurements and cardiac function the mean of two consecutive sessions at the end of each period was taken: placebo run-in period (week -1 and 0), active treatment (week 11 and 12; week 23 and 24), and placebo run-out period (week 30 and 31; week 36 and 37). Initial comparability of the 2 treatment groups at inclusion was assessed by a Student's *t*-test for unpaired observations (quantitative criteria) and by a χ^2 -test (qualitative criteria). During the active treatment period and during run-out, changes over time within each treatment group as well as comparisons between the 2 treatment groups were assessed with a 2-way ANOVA. In case of a significant time course effect additional Newman-Keuls tests were performed at each time point. Data are presented as mean $\pm$ s.e.m. $p < 0.05$ was considered statistically significant.

Results

At baseline (week 0), no significant differences existed between the two study groups with regard to demographic data (Table 1), haemodynamics and laboratory values. Six patients in the perindopril group and eight in the diuretic group used concomitant medication at baseline and this was not changed throughout the study. Medication consisted of NSAID's, cholesterol lowering drugs, benzodiazepines, allopurinol, levothyroxine, hydroxycobalamin, carbasalate calcium and paracetamol.

During the active treatment period (week 0 to 24), drug adherence was high in both groups (mean 99%, range 80%-115%). The total number of drop-outs was similar for the 2 drugs: 2 in patients treated with perindopril (1 undesirable adverse effect; 1 with sitting DBP > 100 mmHg after 3 months treatment), and 1 in the diuretic group (sitting DBP > 100 mmHg after 3 months treatment). Based on sitting DBP, the dose was doubled in 27 out of 41 patients (13 P, 14 A/H) after 1 month, while 29 out of 38 patients completed the study with a double dose (13 P, 16 A/H).

The changes in laboratory values - including serum potassium - were not clinically significant, except for uric acid, which was elevated more during A/H (17%) than during P (1%) treatment. Weight decreased during treatment with A/H (2%) and P (1%), the effect being most obvious during the first 3 months of treatment.

Results on blood pressure and cardiac function are shown in Table 2. After 6 months of treatment with perindopril, sitting SBP and DBP decreased (10%, 11%, respectively). Supine SBP and DBP were reduced (11%, 8%, respectively), as well as supine pulse pressure (15%) and supine mean arterial pressure (9%). Heart rate was unchanged. With A/H sitting SBP and DBP decreased (11%, 9%, respectively). Supine blood pressure was also lower after A/H (SBP 8%; DBP 4%). Supine pulse pressure and mean arterial pressure decreased by 14% and 5%, respectively. Heart rate remained unchanged. Supine DBP was significantly more reduced ($p < 0.05$) after perindopril than after the diuretic. At the end of the active treatment period 13 (34%) patients had a sitting DBP ≤ 90 mmHg, 5 (28%) with perindopril and 8 (40%) in the diuretic group.

With perindopril cardiac index and stroke index increased slightly, 6% and 5%, respectively. A/H did not induce changes in cardiac index or stroke index. Systemic vascular resistance index decreased with both P (13%) and A/H (8%), but the decrease was significantly larger with perindopril ($p < 0.05$).

Data on vessel wall properties are shown in Figures 1-3. Compared to baseline (T0), after 6 months of treatment (T6) with perindopril, the diameter of the common carotid artery (CCA) decreased with P (T0: 6.54 ± 0.19 ; T6: 6.37 ± 0.18 mm; $p < 0.01$). After P, distensibility (T0: 14.7 ± 0.9 ; T6: 17.0 ± 0.7 10^{-3} /kPa; $p < 0.01$) and compliance of the CCA (T0: 0.51 ± 0.05 ; T6: 0.54 ± 0.03 mm²/kPa; $p = 0.01$) were increased. With the diuretic, the diameter of CCA decreased (T0: 6.54 ± 0.15 ; T6: 6.32 ± 0.15 mm; $p < 0.05$), but the distensibility of the CCA remained unchanged (T0: 13.5 ± 0.8 ; T6: 13.7 ± 0.7 10^{-3} /kPa). The effect of P was significantly larger ($p < 0.05$) than the effect of A/H for carotid distensibility and tended ($p = 0.067$) to be larger with P for carotid compliance.

Table 2. Changes in blood pressure and cardiac function during treatment (titrated dose) with perindopril versus amiloride/hydrochlorothiazide and during placebo run-out

		Baseline	Treatment 3 months	Treatment 6 months	Run-out 7 weeks	Run-out 13 weeks
<i>Blood pressure</i>						
SBP _{sitting} (mmHg)	P	150±2	131±2**	135±2**	148±2 [■]	150±2**
	A/H	156±2	136±2**	138±2**	153±2 [■]	154±3**
DBP _{sitting} (mmHg)	P	104±1	90±1**	93±1**	102±1 [■]	103±1**
	A/H	103±1	92±2**	94±2**	100±1 [■]	102±1**
SBP _{supine} (mmHg)	P	142±3	124±2**	127±3**	142±3 [■]	142±2**
	A/H	143±2	129±3**	132±3**	142±3 [■]	144±3**
DBP _{supine} (mmHg)	P	89±1	80±1**	82±1**†	90±2 [■]	89±2**
	A/H	86±1	81±2**	83±2**	85±2 [■]	87±2**
ΔP _{supine} (mmHg)	P	53±2	44±1**	45±2**	53±2 [■]	54±2**
	A/H	57±2	48±2**	49±2**	57±2 [■]	57±3**
MAP _{supine} (mmHg)	P	106±2	94±2**	97±2**	107±2 [■]	107±2**
	A/H	105±2	97±2**	99±2**	104±2 [■]	106±2**
<i>Cardiac function</i>						
Heart rate (beats/min)	P	68±2	69±2	69±2	70±2	69±2
	A/H	70±2	68±2	71±2	68±2	71±2
Cardiac index (L/min.m ²)	P	3.2±0.1	3.4±0.1	3.4±0.1*	3.4±0.1	3.4±0.1
	A/H	3.3±0.1	3.2±0.1	3.4±0.1	3.3±0.1	3.3±0.1
Stroke index (mL/m ²)	P	48±2	49±2	50±2*	50±2	49±2
	A/H	47±1	47±1	47±1	49±1	48±2
SVRI (dyn.s.cm ⁻⁵ .m ²)	P	2704±102	2298±90**	2341±108**†	2572±119 [■]	2620±110**
	A/H	2611±80	2476±83	2402±91*	2584±73*	2581±93**

P: Perindopril, n=18 (active treatment period), n=17 (placebo run-out); A/H: amiloride/hydrochlorothiazide, n=20 (active treatment period), n=19 (placebo run-out); SBP, systolic blood pressure; DBP, diastolic blood pressure; ΔP, pulse pressure; MAP, mean arterial pressure; SVRI, systemic vascular resistance index. Data are mean ± s.e.m.

*p<0.05, **p<0.01, 3 months of treatment versus baseline; †p<0.05, **p<0.01, 6 months of treatment versus baseline; *p<0.05, [■]p<0.01, 7 weeks of placebo run-out versus 6 months of active treatment; †p<0.05, **p<0.01, 13 weeks of placebo run-out versus 6 months of active treatment; ‡p<0.05, difference between P and A/H.

Figure 1. Changes in arterial diameter during treatment with perindopril and amiloride/hydrochlorothiazide. Perindopril, n=18; A/HCTZ, amiloride/hydrochlorothiazide, n=20. Data are mean $\pm$ s.e.m.; *p<0.05, **p<0.01, differences versus baseline.
 [Cross-hatched] T0, baseline. [Diagonal lines] T3, after 3 months active treatment. [White] T6, after 6 months active treatment.

Figure 2. Changes in arterial distensibility during treatment with perindopril and amiloride/hydrochlorothiazide. Perindopril, $n=18$; A/HCTZ, amiloride/hydrochlorothiazide, $n=20$. DC, distensibility coefficient. Data are mean $\pm$ s.e.m.; * $p<0.05$, ** $p<0.01$, differences versus baseline; ## $p<0.01$, differences between perindopril and A/HCTZ.

▨ T0, baseline. ▨ T3, after 3 months active treatment. □ T6, after 6 months active treatment.

Figure 3. Changes in arterial compliance during treatment with perindopril and amiloride/hydrochlorothiazide. Perindopril, n=18; A/HCTZ, amiloride/hydrochlorothiazide, n=20. CC, compliance coefficient. Data are mean $\pm$ s.e.m.; *p<0.05, **p<0.01, differences versus baseline;

▨ T0, baseline. ▨ T3, after 3 months active treatment. □ T6, after 6 months active treatment.

During the whole treatment period the diameter of the common femoral artery (FA) remained unchanged with P (T0:8.16±0.23; T6:8.17±0.21 mm). Distensibility (T0:9.5±0.7; T6:13.2±1.3 10⁻³/kPa; p=0.002) and compliance (T0:0.49±0.04; T6:0.68±0.07 mm²/kPa; p<0.001) of the FA increased significantly with P. The diameter of the FA was not changed by A/H (T0:8.28±0.21; T6:8.22±0.23 mm). Distensibility of FA increased after A/H (T0:9.7±0.7; T6:11.2±0.8 10⁻³/kPa; p<0.05). Percentual changes in femoral distensibility and compliance were approximately three times higher with P (39% and 40%, respectively) than with A/H (15% and 13%, respectively). The diameter of the brachial artery (BA) slightly decreased with P (T0:4.03±0.14; T6:3.93±0.13 mm; p<0.01). Brachial artery distensibility (T0:14.9±0.9; T6:22.3±1.9 10⁻³/kPa; p<0.01) and compliance of BA (T0:0.19±0.01; T6:0.27±0.03 mm²/kPa; p<0.01) were enhanced by P. Treatment with A/H did not significantly reduce the diameter of BA (T0:3.92±0.10; T6:3.85±0.11 mm). Distensibility (T0:15.4±1.0; T6:21.1±1.2 10⁻³/kPa; p<0.01) and compliance (T0:0.19±0.02; T6:0.25±0.02 mm²/kPa; p<0.01) improved after A/H.

Table 3. Changes in vessel wall properties of large arteries during active treatment and placebo run-out.

		Baseline	Treatment 6 months	Run-out 7 weeks	Run-out 13 weeks
<i>Common carotid artery</i>					
Diameter (mm)	P	6.49±0.20	6.34±0.18**	6.46±0.20**	6.47±0.19**
	A/H	6.61±0.14	6.36±0.15**	6.49±0.14	6.59±0.15**
Distensibility (10 ⁻³ /kPa)	P	14.3±0.8	16.8±0.7**	14.3±0.8**	13.7±0.7**
	A/H	13.2±0.8	14.0±0.7	13.4±0.7	13.4±0.9
Compliance (mm ² /kPa)	P	0.49±0.04	0.53±0.03*	0.47±0.04**	0.46±0.03**
	A/H	0.46±0.03	0.45±0.03	0.45±0.03	0.46±0.04
<i>Femoral artery</i>					
Diameter (mm)	P	8.21±0.24	8.19±0.22	8.27±0.24	8.14±0.25
	A/H	8.28±0.22	8.22±0.24	8.18±0.24	8.15±0.25
Distensibility (10 ⁻³ /kPa)	P	9.3±0.7	13.3±1.4**	9.0±0.6**	9.2±0.7**
	A/H	9.6±0.7	11.2±0.9	9.9±0.8	10.0±0.7
Compliance (mm ² /kPa)	P	0.49±0.04	0.70±0.07**	0.48±0.03**	0.47±0.03**
	A/H	0.52±0.05	0.60±0.06	0.54±0.06	0.53±0.05
<i>Brachial artery</i>					
Diameter (mm)	P	4.02±0.15	3.92±0.14*	3.95±0.15	3.95±0.15
	A/H	3.90±0.11	3.85±0.12	3.88±0.11	3.78±0.11
Distensibility (10 ⁻³ /kPa)	P	15.1±0.9	22.9±1.9**	15.9±1.1**	16.2±1.1**
	A/H	15.4±1.1	21.0±1.3**	17.2±1.4**	18.5±1.2*
Compliance (mm ² /kPa)	P	0.19±0.02	0.28±0.03**	0.20±0.02**	0.20±0.02**
	A/H	0.19±0.02	0.25±0.02**	0.20±0.02**	0.21±0.02**

P: perindopril, n=17; A/H: amiloride/hydrochlorothiazide, n=19; Data are mean ± s.e.m.

*p<0.05, **p<0.01, 6 months of treatment versus baseline; *p<0.05, **p<0.01, 7 weeks of placebo run-out versus 6 months of active treatment; *p<0.05, **p<0.01, 13 weeks of placebo run-out versus 6 months of active treatment.

After discontinuation of the active medication (week 24 to 37), 1 patient in the perindopril-group and 1 in the diuretic group were withdrawn from the study, both because of a sitting DBP >110 mmHg after 7 weeks of placebo. During run-out, after 7 weeks body weight in both groups had returned to baseline values. Laboratory values remained within the normal ranges and changes were not clinically significant. Within the A/H group, uric acid returned to normal at the end of the study. Table 2 summarises the changes in blood pressure and cardiac function during the run-out phase as compared to values at baseline and at 6 months of treatment. Almost all haemodynamic parameters reached pretreatment values after 7 weeks of placebo and remained unchanged until the end of the study. Parameters related to arterial wall properties also reached the pretreatment values in both groups and for each vessel, the effect being already visible after 7 weeks of placebo (Table 3).

Discussion

In contrast to previous studies, the present study compares the *long-term* effects of an ACE inhibitor (perindopril) with those of a diuretic combination (amiloride/hydrochlorothiazide) on vessel wall properties of large arteries. The effect on 3 different arteries was studied: the common carotid artery, an elastic artery, the brachial artery, a muscular artery where atherosclerosis is uncommon, and the femoral artery, a muscular artery where atherosclerosis is common. This is also the first controlled study, investigating whether after long-term treatment (6 months) the effects persist after withdrawal of medication.

Perindopril was used in a dose of 4 mg, which is the recommended starting dose in hypertension (18). The widely used combination diuretic amiloride/hydrochlorothiazide was used at a starting dose of 2.5 mg/25 mg. Doses were titrated and at the end of the active treatment period, mean daily doses were 7 mg for perindopril (n=18) and 4.5 mg/45 mg for amiloride/hydrochlorothiazide (n=20).

In the present study, at the time of inclusion both treatment groups were comparable for demographic, biochemical and haemodynamic parameters, although baseline supine diastolic blood pressure tended (non-significantly) to be lower in the diuretic group. As expected, during the active treatment period, weight decreased more with A/H than with perindopril. Both drugs were well tolerated and drug adherence was high. The drop-out rate was relatively low (7%) and equally distributed over both groups. After 6 months, the percentage of controlled patients (sitting DBP $\leq$ 90 mmHg) was not statistically different between the 2 groups. The average reduction in blood pressure is consistent with previous findings (2,33). In the present study, the effect of the diuretic on blood pressure was somewhat smaller. In addition, perindopril caused a significantly larger decrease in supine diastolic blood pressure compared to the diuretic combination.

Diameter of the elastic common carotid artery was slightly reduced during treatment with perindopril as well as with A/H. This could be due to a lower blood pressure (passive phenomenon). With a smaller diameter an artery might be able to distend more (8,26). This might contribute to an increase in distensibility of the carotid artery. However, although arterial diameter was reduced, vessel wall properties of the carotid artery remained unchanged with A/H and increased with perindopril. The difference in effect between the two drugs was significant for distensibility and almost significant ($p=0.067$) for compliance of CCA. Despite a large reduction in blood pressure, arterial diameter of the muscular femoral and brachial arteries did not change or decreased only slightly. A slight decrease in arterial diameter has also been reported by others (6,22). Distensibility and compliance of the two muscular arteries, however, increased considerably. The changes tended to be larger with perindopril and were somewhat more pronounced in the brachial than in the femoral artery. Since the decrease in blood pressure was not statistically different between A/H and perindopril, the more pronounced effects of perindopril suggest an additional drug-induced effect on vessel wall properties.

Data on the effect of diuretics on vessel wall properties of large arteries are inconsistent. Some authors report an unchanged distensibility with a decrease in blood pressure (7,15). In an open study, short-term therapy with a thiazide diuretic increased arterial distensibility (32). In the present long-term double-blind

study, the increase in vessel wall properties with A/H was approximately half of those seen with perindopril. Previous studies have also demonstrated improvement of vessel wall properties after treatment with ACE inhibitors and have shown that these effects are probably mediated through a combined effect of reduction in blood pressure and a drug-induced relaxation of arterial smooth muscle (3,28).

Chronic treatment with either perindopril or A/H did not change heart rate. Cardiac index increased only with perindopril and this was mainly due to an increase in stroke index. Previous data on cardiac function parameters after long-term treatment with ACE inhibitors in essential hypertensive patients are consistent with our findings (35).

ACE inhibitors induce arteriolar vasodilation and a reduction of vascular resistance (27). In the present study systemic vascular resistance index decreased significantly more with perindopril than A/H, indicating a more pronounced dilating effect of perindopril at the arteriolar level. Anyhow, the improvement in vessel wall properties and a lower systemic vascular resistance, as shown in the current study, may result in a reduction of cardiac afterload, since afterload is largely determined by vascular resistance and arterial compliance (34). This might explain the slight increase in stroke index seen with perindopril.

The changes in biochemical parameters were not clinically significant, except for uric acid in the A/H group, which increased by 17%. This is a well-known adverse effect of diuretic therapy (21).

In this study, pulse pressure in the brachial artery was used for the calculation of vessel wall properties at different sites. Ideally, pulse pressure should be studied at the site where the vessel wall movement is measured. However, non-invasive methods for measuring pulse pressure are scarce and yet not fully accepted. Therefore, could pulse pressure in this study be influenced by a methodological error? As far as a group of patients is concerned the pulse pressure in the brachial artery is very similar to the pulse pressure in the femoral artery (5). However, due to pulse wave reflections, the pulse pressure in the carotid artery might not be represented by that in the brachial artery (20). Since vasodilating agents (like ACE inhibitors) diminish pulse wave reflections, pulse pressure in the carotid artery might decrease more with perindopril than with A/H. Using the brachial artery as a substitute for the pressure in the carotid artery might therefore overestimate pulse pressure more during perindopril than during A/H. In that case, the difference in distensibility and compliance between perindopril and the diuretic would be more pronounced and will not change the main conclusions of this study.

After withdrawal of medication, blood pressure, cardiac function and biochemical changes rapidly (after only 7 weeks of placebo) returned to baseline values in both treatment groups. This has been demonstrated in other studies with hypertensive patients (3). In the present study, also arterial diameter, distensibility and compliance of the elastic and muscular arteries regained pre-treatment values. In resistance vessels antihypertensive treatment can induce only a partial reversal of structural changes (1,13). Although the data of the present study do not provide evidence for a regression in structural alterations in large arteries, a partial reversal of structural changes cannot be excluded, since arterial biopsies were not taken.

Literature data are contradictory with regard to reversibility of structural vascular changes, depending on the models used and treatments given. With diuretics, on the average no reversal effects could be demonstrated (10). Animal as well as human data have shown that after withdrawal of a chronic treatment with perindopril a dissociation between the cardiac and the arterial effects has been shown (3,16). Most antihypertensive drugs lower blood pressure adequately, while only marginally affecting vascular structure (9). Vascular restructuring probably may need a longer time to occur and therefore the duration of the present study might have been too short.

The present study was a double-blind comparative study with a considerable treatment period. Since it was not placebo-controlled, a period effect cannot be excluded for both drugs as far as time-related drug changes are concerned.

In conclusion, at the dosages used, the present study shows in general a more pronounced effect on haemodynamics and large artery properties after long-term treatment with the ACE inhibitor perindopril, as compared to the diuretic, amiloride/hydrochlorothiazide. After discontinuation of either therapy, all effects were rapidly reversed, which suggests rapid reversal of functional changes and does not provide evidence for structural changes in the arterial wall, although small structural changes cannot be excluded. In addition,

the more favourable effects at the macro as well as at the microcirculatory level with perindopril are likely to cause a lower load for the heart, which, in turn, may diminish the cardiovascular risk (14).

References

1. Aalkjaer C, Mulvany MJ, Jespersen B, Kjaer T, Sorensen SS, Pedersen EB. Morphological and functional abnormalities of resistance vessels from patients with essential hypertension are not normalized by antihypertensive therapy. *J Hypertens* 1988;6 (Suppl. 4) :S702.
2. Andrejak M, Santoni JP, Carrā A, Deruyttere M, Magometschnigg D, Gotzen R, Stumpe KO. A double-blind comparison of perindopril and hydrochlorothiazide-amiloride in mild to moderate essential hypertension. *Fundam Clin Pharmacol* 1991;5 :185-92.
3. Asmar RG, Pannier B, Santoni JP, Laurent S, London GM, Levy BI, Safar ME. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. *Circulation* 1988;78 :941-50.
4. Benetos A, Asmar R, Vasmant D, Thiāry P, Safar M. Long lasting arterial effects of the ACE inhibitor ramipril. *J Hum Hypertens* 1991;5 :363-68.
5. Benetos A, Laurent S, Hoeks AP, Boutouyrie PH, Safar ME. Arterial alterations with aging and high blood pressure. A noninvasive study of carotid and femoral arteries. *Arterioscler Thromb* 1993;13 :90-97.
6. Benetos A, Santoni JP, Safar ME. Vascular effects of intravenous infusion of the angiotensin converting enzyme inhibitor perindoprilat. *J Hypertens* 1990;8 :819-26.
7. Bouthier JA, Safar ME, Deschamps E, Tarrade T. Haemodynamic effects of an antihypertensive diuretic substance on the forearm circulation of patients with essential hypertension. *Drugs Exp Clin Res* 1988;XIV :221-24.
8. Chau NP, Simon A, Vilar J, Cabrera-Fischer E, Pithois-Merli I, Levenson J. Active and passive effects of antihypertensive drugs on large artery diameter and elasticity in human essential hypertension. *J Cardiovasc Pharmacol* 1992;19 :78-85.
9. Christensen KL, Jespersen LT, Mulvany MJ. Development of blood pressure in spontaneously hypertensive rats after withdrawal of long - term treatment related to vascular structure. *J Hypertens* 1989;7 :83-90.
10. Dahlöf B. Regression of cardiovascular structural changes - a preventive strategy. *Clin Exp Hypertens [A]* 1990;A12 :877-96.
11. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. *Am J Hypertens* 1992;5 :95-110.
12. Hayoz D, Rutschmann B, Perret F, Niederberger M, Tardy Y, Mooser V, Nussberger J, Waeber B, Brunner HR. Conduit artery compliance and distensibility are not necessarily reduced in hypertension. *Hypertension* 1992;20 :1-6.
13. Heagerty AM, Bund SJ, Aalkjaer C. Effects of drug treatment on human resistance arteriole morphology in essential hypertension: direct evidence for structural remodelling of resistance vessels. *Lancet* 1988;II :1209-12.
14. Kannel WB, Wolf PA, McGee DL, Dawber TR, McNamara P, Castelli WP. Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. *JAMA* 1981;245 :1225-29.
15. Laurent S, Lacolley PM, Cuhe JL, Safar ME. Influence of diuretics on brachial artery diameter and distensibility in hypertensive patients. *Fundam Clin Pharmacol* 1990;4 :685-93.
16. Levy BI, Michel J, Salzmänn JL, Azizi M, Poitevin P, Camilleri JP, Safar ME. Arterial effects of angiotensin converting enzyme inhibition in renovascular and spontaneously hypertensive rats. *J Hypertens* 1988;6 (Suppl. 3) :S23-25.
17. Levy BI, Michel J-B, Salzmänn J-L, Azizi M, Poitevin P, Safar M, Camilleri J-P. Effects of chronic inhibition of converting enzyme on mechanical and structural properties of arteries in rat renovascular hypertension. *Circ Res* 1988;63 :227-39.
18. Luccioni R, Frances Y, Gass R, Gilgenkrantz JM. Evaluation of the dose-effect relationship of perindopril in the treatment of hypertension. *Clin Exp Hypertens [A]* 1989;A11 (Suppl. 2) :S21-34.

19. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. *Hypertension* 1994;23 :395-401.
20. O'Rourke M. Arterial compliance and wave reflection. *Arch Mal Coeur Vaiss* 1991;84 :45-48.
21. Raftery EB. The metabolic effects of diuretics and other antihypertensive drugs: a perspective as of 1989. *Int J Cardiol* 1990;28 :143-50.
22. Richer C, Thuillez C, Giudicelli JF. Perindopril, converting enzyme blockade, and peripheral arterial hemodynamics in the healthy volunteers. *J Cardiovasc Pharmacol* 1987;9 :94-102.
23. Safar M, Asmar R, Bouthier J, Lacolley P, Laurent S. Converting enzyme inhibition and the common carotid circulation in older patients with sustained essential hypertension. *Eur Heart J* 1988;9 (Suppl. D) :75-78.
24. Safar ME. Pulse Pressure in essential hypertension: clinical and therapeutical implications. *J Hypertens* 1989;7 :769-76.
25. Safar ME, Laurent SL, Bouthier JD, London GM, Mimran AR. Effect of converting enzyme inhibitors on hypertensive large arteries in humans. *J Hypertens* 1986;4 (Suppl. 5) :S285-89.
26. Safar ME, Levy BI, Laurent S, London GM. Hypertension and the arterial system: clinical and therapeutic aspects. *J Hypertens* 1990;8 (Suppl. 7) :S113-19.
27. Safar ME, Levy BI, London GM. Arterial structure in hypertension and the effects of angiotensin converting enzyme inhibition. *J Hypertens* 1992;10 (Suppl. 5) :S51-57.
28. Santoni JP, Asmar R, Safar ME. Angiotensin converting enzyme inhibition, pulse wave velocity and ambulatory blood pressure measurements in essential hypertension. *Clin Exp Hypertens [A]* 1989;A11 (Suppl. 2) :535-44.
29. Sihm I, Schroeder AP, Aalkjaer C, Holm M, Morn B, Mulvany MJ, Thygesen K, Lederballe O. Normalization of resistance artery structure and left ventricular morphology with a perindopril-based regimen. *Can J Cardiol* 1994;10 (Suppl. D) :30D-2D.
30. Simon AC, Levenson J, Bouthier JD, Safar ME. Effects of chronic administration of enalapril and propranolol on the large arteries in essential hypertension. *J Cardiovasc Pharmacol* 1985;7 :856-61.
31. Simon AC, Levenson JA, Safar AM, Bouthier JD, Safar ME. ACE inhibition and brachial artery haemodynamics in hypertension. *Br J Clin Pharm* 1984;18 (Suppl. 2) :243S-7S.
32. Smulyan H, Vardan S, Griffiths A, Gribbin B. Forearm arterial distensibility in systolic hypertension. *J Am Coll Cardiol* 1984;3 :387-93.
33. Thurston H, Mimran A, Zanchetti A, Creytsens G, Rorive G, Brown CL, Santoni JP. A double blind comparison of perindopril and atenolol in essential hypertension. *J Hum Hypertens* 1990;4 :547-52.
34. Van Bortel LM, Hoeks APG, Kool MJF, Struijker-Boudier HA. Introduction to large artery properties as a target for risk reduction by antihypertensive therapy. *J Hypertens* 1992;10 (Suppl. 6) :S123-26.
35. Veerman DP, Douma CE, Jacobs MC, Thien T, van Montfrans GA. Effects of ACE-inhibition on autonomic vascular control as assessed by spectral analysis and on hemodynamics. *J Hypertens* 1992;10 (Suppl. 4) :S63.

CHAPTER 8

DOES LOWERING OF CHOLESTEROL LEVELS INFLUENCE FUNCTIONAL PROPERTIES OF LARGE ARTERIES ?

M. Kool, *F. Lustermaans, *H. Kragten, H. Struijker Boudier, **A. Hoeks,
*R. Reneman, **H. Rilla, **I. Hoogendam, and L. Van Bortel

Departments of Pharmacology, **Biophysics and *Physiology, Cardiovascular Research
Institute Maastricht, University of Limburg, Departments of Internal Medicine and
Cardiology, *De Wever Hospital, Heerlen, ** BMS Medical Department, Woerden,
the Netherlands

Based on Eur J Clin Pharmacol 1995 (in press)

Summary

Hypercholesterolaemia is a risk factor for atherosclerosis and induces endothelial dysfunction. Endothelial dysfunction may increase vascular tone and arterial stiffness and as a consequence may decrease arterial distensibility (DC) and arterial compliance (CC). It is hypothesised that lipid-lowering therapy may enhance DC and CC. Therefore, the present study investigates the effect of lipid-lowering therapy with pravastatin on haemodynamics, DC and CC of the elastic common carotid artery (CCA), and the muscular femoral (FA) and brachial (BA) arteries in patients with primary hypercholesterolaemia.

After a 8-week placebo run-in period with a low-cholesterol diet, 19 patients with a total cholesterol between 6.5 and 9.0 mmol/L and triglycerides <4 mmol/L entered a double-blind placebo controlled cross-over study. Patients received pravastatin 40 mg o.d. or placebo, each for 8 weeks. Throughout the study the lipid-lowering diet was continued.

With pravastatin, total cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglycerides were decreased (total cholesterol:26%; LDL-C:35%; triglycerides:16%), while high-density lipoprotein cholesterol (HDL-C) was not changed. Other laboratory values remained within the normal range. Blood pressure, heart rate, cardiac function and systemic vascular resistance were not influenced by pravastatin. Compared to placebo, diameter, distensibility and compliance of all arteries were not statistically significantly changed with pravastatin.

These data suggest that, in patients with mild to moderate primary hypercholesterolaemia short-term lowering of plasma cholesterol does not alter haemodynamics and vessel wall properties of large arteries.

Introduction

In Western countries, atherosclerosis is a major cause of cardiovascular mortality and morbidity (31). Atherosclerosis is a multifactorial disease and primarily affects large arteries (32). High cholesterol levels are considered a primary risk factor for the development of atherosclerotic disease, while lowering of total and LDL-cholesterol has been shown to reduce the incidence of ischaemic heart disease and retard the development of coronary atherosclerosis (10,27). The early detection of atherosclerosis, before ischaemic vascular complications develop, is a major step in the assessment of human hypercholesterolaemia. Ultrasound techniques permit the detection of atherosclerotic plaques, a relatively late feature in the process of atherosclerosis (16). However, early in the development of atherosclerosis, functional disturbances already occur at the site of the endothelium (9). These endothelial changes are associated with a diminished release of endothelium-derived relaxing factor (EDRF), which may influence vascular tone and, hence, arterial stiffness (33). Therefore, decreased compliance might be an early feature of endothelial dysfunction, representing early vascular injury in atherosclerosis, and a higher compliance might protect large arteries from early atherosclerotic changes.

Hypercholesterolaemia itself also may induce these arterial wall changes (12). Cholesterol is an important rigidifier of natural cell membranes (22). Hypercholesterolaemia may potentiate chronic mild endothelial injury and interfere with membrane fluidity (12). An increased membrane cholesterol content enhances membrane microviscosity and decreases sodium and calcium pump activity. Changes in calcium handling in vascular smooth muscle may be involved in alteration of vascular tone and vessel wall properties of large arteries (22). From these data it can be imagined that - via interaction with endothelial and membrane alterations - patients with hypercholesterolaemia demonstrate *functional* changes in vessel wall behaviour, measured as decreased arterial wall properties. Therefore, lipid-lowering agents may improve vessel wall properties by lowering cholesterol which could lead to a lower cardiovascular risk.

Pravastatin is a relatively new, hydrophilic agent in the class of the 3-hydroxy-3-methylglutaryl(HMG)-CoA-reductase inhibitors (26). Clinical studies have shown that HMG-CoA-reductase inhibitors are more effective in lowering cholesterol and cause fewer adverse effects than the other hypolipidaemic agents (26).

The present study investigates the effect of short-term (8 weeks) treatment with pravastatin on functional arterial wall properties of elastic and muscular large arteries in mild to moderate hypercholesterolaemic patients. Arterial wall properties (distensibility and compliance) were determined with a vessel wall movement detector system, with which distensibility and compliance can be studied more directly and accurately than with previous techniques (18). In addition, the effect of pravastatin on blood pressure, cardiac function and systemic vascular resistance was evaluated.

Patients and methods

Patients — Twenty two outpatients between 18 and 65 years of age and with a known total cholesterol level of >6.5 mmol/L, determined at least within one year prior to the start of the study, were selected and started with a placebo run-in period (week -8 to 0). At the end of the run-in period two patients were excluded because of high cholesterol levels (>9 mmol/L) and one because of use of oestrogens. Nineteen patients (11 males, 8 females) entered the double-blind cross-over study. Patient characteristics at baseline (week 0) are shown in Table 1.

The hypercholesterolaemic patients were compared with 18 normocholesterolaemic controls (total cholesterol: 5.8 ± 0.1 mmol/L). Groups were matched for age, weight, height and blood pressure (Table 1).

Table 1. Characteristics of volunteers and patients.

	Patients	Volunteers
Number of subjects	19	18
<i>Demographics</i>		
Gender (male/female)	11/8	11/7
Age (years)	52 (35-64)	51 (35-64)
Weight (kg)	74 (62-98)	73 (52-92)
Height (cm)	171 (157-184)	171 (149-186)
<i>Risk factors</i>		
Alcohol use	7	6
glasses/day	1-3	1-3
Smokers	8	6
cigarettes/day	16 (4-25)	13 (2-25)
<i>Haemodynamics</i>		
Systolic blood pressure (mmHg)	126 (97-145)	121 (98-155)
Diastolic blood pressure (mmHg)	77 (59-92)	76 (67-89)
Heart rate (beats/min)	64 (45-89)	65 (50-82)
<i>Lipids</i>		
Total cholesterol (mmol/L)	7.7 $\pm$ 0.6	5.8 $\pm$ 0.1
LDL-cholesterol (mmol/L)	5.6 $\pm$ 0.2	n.a.
HDL-cholesterol (mmol/L)	1.1 $\pm$ 0.1	n.a.
Triglycerides (mmol/L)	2.1 $\pm$ 0.2	n.a.

Data are mean (range) or mean $\pm$ s.e.m.; n.a.: not applicable.

Study design — The study was a multicentre, double-blind, randomised, placebo-controlled cross-over study. At the first visit (week -8) a general medical history was taken. A lipid determination, a routine laboratory screening and a general physical examination were performed. Vessel wall properties and other haemodynamic parameters were assessed in order to familiarise the patients with the examination procedures. Major exclusion criteria were: homozygous familial hypercholesterolaemia, secondary hyperlipidaemia of any cause, established diagnosis of type I, III, or V hyperlipidaemia, fasting triglyceride >4.0 mmol/l, clinical evidence of overt atherosclerotic plaques detected with ultrasound, myocardial infarction, unstable angina pectoris, poorly controlled congestive heart failure, systolic blood pressure >160 mmHg or diastolic blood pressure >95 mmHg, severe renal, hepatic or gastrointestinal disease, Quetelet index >30, diabetes mellitus, and thyroid dysfunction. Patients using concomitant treatment with corticosteroids, sex hormones, antacids, fish oil preparations, lipid-lowering drugs, antihypertensive and anti-anginal drugs, and inhibitors of blood clotting were also excluded.

Selected patients received a lipid-lowering diet and placebo once daily (single-blind) for 8 weeks.

Any lipid-lowering drug was withdrawn at least 8 weeks prior to the first basal lipid determination (week -2). At the end of the placebo run-in period, patients with a total plasma cholesterol $\geq$ 6.5 mmol/L and <9 mmol/L and a plasma total triglyceride <4 mmol/L, based on the mean of 2 fasting samples one week apart, were included. During the active treatment period (week 0 to 16) patients received pravastatin 40 mg tablets or identical placebo tablets once daily. Each treatment period lasted 8 weeks. Patients were encouraged to continue their dietary habits. Weight, arterial wall properties, blood pressure, heart rate and cardiac function were assessed at baseline and at the end of each treatment period (weeks 8 and 16). Patients were also checked for drug adherence, concomitant diseases, use of concomitant medication and adverse events.

Blood samples for lipid determination and safety haematology/biochemistry were taken at baseline and at the end of each treatment period. For safety reasons, additional liver function tests were carried out in weeks 6 and 14. Patients were withdrawn in the case of serious laboratory abnormalities, serious adverse events or development of exclusion criteria.

The study was performed in accordance with the principles of the Declaration of Helsinki (revised 1983) and approved by the Ethical Committees of each participating centre. Informed consent was obtained from all patients.

Methods — All haemodynamic measurements were performed in a quiet room after 15 min of supine rest. For each patient measurements were carried out at the same time of the day. All measurements were made by the same observer. Smoking was not allowed for 24 hours preceding the examination. Laboratory assessments were performed after patients had fasted (sample at least 10 hours after previous meal). Dietary advice (low-cholesterol, low-fat diet) was given by the physician at the start of the study.

Blood pressure and heart rate

Supine blood pressure and heart rate were recorded every 3 min on the left arm with a Dinamap and the means of these recordings (approximately 10) were taken as the patient's reading (Chapter 2).

Vessel wall properties

Simultaneously with blood pressure, vessel wall properties of the right elastic common carotid artery (CCA; 1 cm proximal to the bifurcation), and the right muscular common femoral (FA; 1-2 cm proximal to the bifurcation) and brachial (BA) arteries were assessed in recumbent position with the vessel wall movement detector system, as described in Chapter 2. From arterial diameter, distension and pulse pressure, vessel wall properties were calculated according to the equations mentioned in Chapter 2.

Cardiac function

Cardiac function was assessed with the patient in left lateral position, using an echo Doppler technique (Chapter 2).

Laboratory tests

All blood samples were analysed in the same laboratory (De Wever Hospital, Heerlen). To minimise bias, lipid values were withheld from the investigator until the end of the study. Fasting venous blood samples were analysed for total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG). Low-density lipoprotein cholesterol (LDL-C) was calculated as $TC - (HDL-C + TG/2.2)$, according to the Friedewald equation (11). Because of intraindividual biological variation (5), the mean of 2 lipid samples, drawn one week apart, was taken. In addition, samples were analysed for creatinine, glucose, total bilirubin, transaminases (ALAT, ASAT), γ -GT, alkaline phosphatase, creatine kinase, total protein, albumin, haemoglobin and haematocrit, and a blood cell count was performed.

Drug adherence

Patients were asked for their drug adherence at each visit. In addition, the number of tablets, returned at the end of each treatment period, was counted.

Data analysis—Statistical analysis was performed for the efficacy-analysable population (n=17), using the procedure as described by Pocock (29) with non-parametric tests for the cross-over design. Wilcoxon tests were used to test period effects, while Mann-Whitney tests were used for treatment-period interaction. Adverse events were analysed by means of a χ^2 -test. Data are presented as mean $\pm$ s.e.m. $p<0.05$ was considered statistically significant.

Results

Normocholesterolaemic subjects did not differ from the hypercholesterolaemic patients with regard to arterial diameter of the elastic common carotid and muscular femoral and brachial arteries. Hypercholesterolaemic patients had a lower femoral artery distensibility (24%; $p<0.05$).

No carry-over effects could be demonstrated during the intervention study. Drug adherence was 96% (86%-105%) during treatment with pravastatin and 97% (84%-102%) during placebo. Three patients used concomitant medication (psyllium 14 g/day; digoxin 0.25 mg 4x/week; allopurinol 300mg 3x/week), which remained unchanged throughout the study. Two patients - both receiving pravastatin - dropped out, one because of acute myocardial infarction, and one because of concomitant antihypertensive medication. Adverse events occurred in 4 patients, treated with pravastatin (bowel hyperreactivity, fatigue during exercise, sleeplessness, palpitations) and in 2 patients using placebo (headache, nausea). Adverse events were generally very mild and did not lead to discontinuation or interventional therapy. Laboratory values remained within the normal range, except for creatine kinase that showed a 5-fold transitory rise without clinical symptoms in 1 patient with placebo during the first treatment period and in 1 patient with pravastatin. Mean body weight remained unchanged during the study. Changes in the lipid profile during the double-blind treatment period are shown in Table 2. Compared to placebo, total cholesterol (TC) and LDL-

Table 2. Changes in weight, haemodynamics and lipids during placebo and treatment with pravastatin for 8 weeks.

	Baseline	Placebo	Pravastatin
Weight (kg)	74 $\pm$ 2	74 $\pm$ 2	73 $\pm$ 2
<i>Blood pressure, heart rate</i>			
Systolic blood pressure (mmHg)	126 $\pm$ 4	121 $\pm$ 3	124 $\pm$ 4
Diastolic blood pressure (mmHg)	76 $\pm$ 2	74 $\pm$ 2	75 $\pm$ 2
Pulse pressure (mmHg)	64 $\pm$ 3	66 $\pm$ 3	66 $\pm$ 3
Heart rate (beats/min)	66 $\pm$ 3	66 $\pm$ 3	66 $\pm$ 3
Cardiac index (L/min.m ²)	3.2 $\pm$ 0.1	3.3 $\pm$ 0.1	3.2 $\pm$ 0.1
Stroke index (mL/m ²)	51 $\pm$ 2	51 $\pm$ 2	49 $\pm$ 2
SVRI (dyn.s.cm ⁻⁵ .m ²)	2387 $\pm$ 110	2226 $\pm$ 86	2356 $\pm$ 120
<i>Lipids</i>			
Total cholesterol (mmol/L)	7.8 $\pm$ 0.2	7.6 $\pm$ 0.3	5.6 $\pm$ 0.2***
LDL-cholesterol (mmol/L)	5.7 $\pm$ 0.2	5.5 $\pm$ 0.3	3.6 $\pm$ 0.2***
HDL-cholesterol (mmol/L)	1.2 $\pm$ 0.1	1.3 $\pm$ 0.1	1.3 $\pm$ 0.1
Triglycerides (mmol/L)	1.9 $\pm$ 0.2	1.9 $\pm$ 0.2	1.6 $\pm$ 0.2*

n=17; Data are mean $\pm$ s.e.m.; * $p<0.05$, *** $p<0.001$, differences between pravastatin and placebo. SVRI, systemic vascular resistance index.

cholesterol (LDL-C) decreased significantly with pravastatin (TC:26%; LDL-C:35%; $p<0.001$). Triglycerides also decreased with pravastatin (16%; $p<0.05$), but HDL-cholesterol (HDL-C) did not change significantly versus placebo. The calculated TC/HDL-C ratio decreased from 6.5 to 4.5 with pravastatin. Blood pressure, heart rate, cardiac function and systemic vascular resistance index did not differ between pravastatin and placebo (Table 2).

Table 3. Changes in vessel wall properties during placebo and treatment with pravastatin for 8 weeks.

	Controls	Hypercholesterolaemia		
		Baseline	Placebo	Pravastatin
<i>Common carotid artery</i>				
Diameter (mm)	6.07±0.08	6.07±0.16	6.18±0.15	6.17±0.15
DC (10 ⁻³ /kPa)	18.6±1.3	16.5±1.8	17.1±1.5	17.6±1.9
CC (mm ² /kPa)	0.54±0.04	0.49±0.06	0.52±0.05	0.54±0.07
<i>Common femoral artery</i>				
Diameter (mm)	7.57±0.26	7.81±0.21	7.80±0.23	7.88±0.19
DC (10 ⁻³ /kPa)	17.1±1.5	13.0±1.2*	13.5±1.2	14.5±1.3
CC (mm ² /kPa)	0.77±0.09	0.62±0.06	0.65±0.06	0.71±0.07
<i>Brachial artery</i>				
Diameter (mm)	3.99±0.10	3.66±0.08	3.68±0.10	3.67±0.10
DC (10 ⁻³ /kPa)	21.4±1.4	21.8±2.3	21.4±2.3	22.9±2.5
CC (mm ² /kPa)	0.28±0.02	0.23±0.03	0.23±0.03	0.25±0.03

Controls, normocholesterolaemic subjects, n=18; hypercholesterolaemic patients, n=17; Data are mean ± s.e.m.; DC, distensibility coefficient; CC, compliance coefficient. * $p<0.05$, difference between normocholesterolaemic subjects and baseline values of hypercholesterolaemic patients.

Data on vessel wall properties are shown in Table 3. Arterial diameter of the elastic common carotid artery and the muscular femoral and brachial arteries was not changed either with pravastatin or placebo. In addition, no statistically significant changes were found for arterial distensibility and compliance in all arteries, when compared to placebo.

Discussion

In the present study the effect of lipid-lowering therapy on vessel wall properties of large arteries was investigated in mild to moderate primary hypercholesterolaemia. An improvement in arterial distensibility and compliance might protect these patients from the complications of atherosclerotic disease. In contrast to other studies (4,6,25), the present study was directed towards detection of functional changes in vessel wall behaviour rather than to structural changes of the vessel wall, such as atherosclerosis.

A number of epidemiological studies have provided evidence for the relationship between serum cholesterol levels and atherosclerotic cardiovascular disease (19,20,34). Stroke and peripheral vascular disease seem

to be less related to cholesterol levels than coronary heart disease (20). In addition, cholesterol lowering has been shown to reduce the risk of coronary heart disease (27). Atherosclerosis mainly affects large arteries. The carotid bifurcation, lower abdominal aorta and femoral artery are pre-election sites (32).

Early in the process of atherosclerosis, the endothelial cells, located at sites that are prone to atherosclerosis, appear to be morphologically and functionally different from normal endothelial cells (9). At this point, vessels already exhibit altered responses to various stimuli because of endothelial dysfunction. In hypercholesterolaemia, endothelium-dependent relaxation was found to be attenuated (33). This has been explained by a decreased release of endothelium-derived relaxing factor (EDRF). In addition, augmented vasoconstrictor responses, as well as increased release of endothelium-derived contracting factors (EDCFs) have been demonstrated (24,33).

Chronic endothelial dysfunction may facilitate atherogenesis. Arterial distensibility and compliance could be decreased by endothelial dysfunction associated with hypercholesterolaemia. These altered vessel wall properties - indicating a higher arterial stiffness - might in turn increase the load on the vessel wall and enhance the risk for plaque rupture. The atherosclerotic plaques, found in hypercholesterolaemia, are usually small, weak and lipid-rich. They often can not be detected with the current diagnostic techniques, while precisely these plaques are most prone to disruption (13). Plaque rupture, which is influenced by the circumferential tensile stress, may eventually lead to acute ischaemic events (30).

Studies on arterial distensibility and compliance in hypercholesterolaemia without the presence of overt atherosclerotic lesions are scarce. In man, the relation between cholesterol and distensibility was found to be weak. Age seemed to be more important for changes in arterial stiffness than atherosclerosis (2). Despite a large difference in the severity of atherosclerosis between different populations, aortic distensibility was found similar (28). However, in patients with arteriosclerosis obliterans of the lower leg, which was used as a model for atherosclerosis, brachial artery distensibility was decreased (23), which would suggest a more generalised modification of large vessels in these patients. Recent studies showed no differences between normocholesterolaemic and hypercholesterolaemic subjects with regard to arterial compliance of the radial and common carotid arteries (1,15). However, the number of patients in these studies was small ($n=9$ and $n=8$, respectively) and it is unlikely that differences between normocholesterolaemic and hypercholesterolaemic patients could be detected. Moreover, comparing vessel wall properties of patients in the present study with 18 controls - matched for age, sex, weight, height and blood pressure - a significantly smaller distensibility of the femoral artery in hypercholesterolaemic patients was shown. This could suggest an early involvement of the femoral artery in the development of atherosclerotic changes. In this study, pulse pressure of the brachial artery was used for calculation of vessel wall properties at different sites. Ideally, pulse pressure should be sampled at the site where the vessel wall movement is measured. However, non-invasive methods for measuring pulse pressure are scarce and have not been fully accepted. On the other hand, as far as a group of patients is concerned, the pulse pressure in the brachial artery is very similar to that in the femoral artery, whereas pulse pressure in the carotid artery - due to pulse wave reflections - is lower than that in the brachial artery (3). Therefore, because brachial pulse pressure is used as a substitute for carotid pulse pressure, the results on vessel wall properties of the carotid artery might be somewhat underestimated. However, since this concept holds for both treatment groups, it is not likely that the main conclusions will be changed.

In previous studies the influence of lipid-lowering therapy on progression and regression of atherosclerotic lesions was on the average relatively small (21). However, human intervention studies hitherto have primarily focussed on the aspect of reversal of plaques, which are in fact a late feature in atherosclerotic disease. The primary aim of the present study was to investigate whether lipid-lowering therapy could improve vessel wall properties of large arteries at an early stage of the disease by improving *functional* properties of large arteries.

An 8-week treatment period with the HMG-CoA reductase inhibitor pravastatin resulted in a significant reduction in total cholesterol, LDL-cholesterol and triglycerides. The total cholesterol/HDL ratio fell by 31%, which emphasises the favourable action of pravastatin on the lipid profile. These data are consistent with the results of other studies (26).

Cardiac function, systemic vascular resistance and blood pressure were not affected by the lipid-lowering therapy. As far as is known, hitherto no controlled studies have been performed to investigate the influence of pravastatin on these parameters.

Pravastatin did not induce significant changes in arterial diameter, distensibility or compliance of elastic and muscular large arteries. Diameter of the carotid artery has been reported to be decreased in hypercholesterolaemic patients when compared to controls (35). However, in this group of patients mean total cholesterol and LDL-cholesterol levels were rather high and the study population also contained patients with cardiovascular complications, including hypertension. Literature data have shown that, in the brachial artery, diameter and blood flow were not different from normocholesterolaemic subjects in patients with hypercholesterolaemia, although the arterial diameters tended to be somewhat larger in the hypercholesterolaemic group (8). In the latter study it was suggested that cholesterol probably does not influence the arterial circulation under basal conditions, but might be still able to alter large artery reactivity. In general, it is thought that adaptive and compensatory mechanisms tend to preserve an adequate arterial lumen early during atherosclerotic disease (36). The concept is that atherosclerotic arteries undergo remodelling, which preserves the vascular lumen until the lesion becomes moderately advanced (17). The lack of effect on arterial diameter during intervention with pravastatin in the present study might be related to this phenomenon.

Although changes were not statistically significant, a slight increase in distensibility and compliance could be demonstrated with pravastatin. Sample size calculation suggested that 27 patients had to be included to allow a change in distensibility and compliance of more than 20% to be detected with 80% power. However, an interim analysis after 19 patients showed that significant results could only be reasonably expected in large numbers ($n=240$) of patients. However, then it is questionable what the clinical relevance is of statistical changes.

Recently, animal studies have shown that reversal of the decrease in distensibility with atherosclerosis, if any, must be a very slow process. A cholesterol reduction for at least one year was required in monkeys to affect distensibility (7). In addition, a 10-week treatment period with lovastatin only partially reversed the altered vascular responses, associated with endothelial dysfunction and also only partially prevented atherosclerotic plaque formation (14). Therefore, it is possible that the treatment period in the present study was too short to induce functional changes or to improve vessel wall properties. However, as far as the radial artery is concerned, a 6-month treatment period with simvastatin in non-familial hypercholesterolaemic patients did not improve vessel wall properties (15).

In summary, the results of the present study indicate that short-term therapy with the cholesterol-lowering agent pravastatin in mild to moderate hypercholesterolaemia improved the lipid profile, but did not induce obvious functional changes in the arterial wall as far as large artery properties are concerned. It may be that cholesterol has only a minor effect on vessel wall endothelium or that endothelial function is not related to vessel wall properties of large arteries. In addition, with the findings of the present study it can not be ruled out that: 1) regression of possible hypercholesterolaemic arterial dysfunction is not achieved within 8 weeks of treatment, or that 2) more severe hypercholesterolaemia is needed to demonstrate an improvement of arterial wall properties and, as a consequence, a reduction of the load on the arterial wall and the risk for future atherosclerotic complications.

References

1. Arcaro G, Zenere M, Travia D, Covi G, Muggeo M, Lechi A. Hypercholesterolemia and human endothelial function and vascular distensibility. Abstractbook Ric Sci Educaz Perm 1993 (Suppl. 95) :23.

2. Avolio AP, Chen SG, Wang RP, Zhang CL, Li MF, O'Rourke MF. Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community. *Circulation* 1983;68 :50-58.
3. Benetos A, Laurent S, Hoeks AP, Boutouyrie PH, Safar ME. Arterial alterations with aging and high blood pressure. A noninvasive study of carotid and femoral arteries. *Arterioscler Thromb* 1993;13 :90-97.
4. Blankenhorn DH. Prevention or reversal of atherosclerosis: review of current evidence. *Am J Cardiol* 1989;63 :38H-41H.
5. Bookstein L, Gidding SS, Donovan M, Smith FA. Day-to-day variability of serum cholesterol, triglyceride, and high-density lipoprotein cholesterol levels. Impact on the assessment of risk according to the national cholesterol education program guidelines. *Arch Intern Med* 1990;150 :1653-57.
6. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J, Kaplan C, Zhao X, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. *N Engl J Med* 1990;323 :1289-98.
7. Farrar DJ, Bond MG, Riley WA, Sawyer JK. Anatomic correlates of aortic pulse wave velocity and carotid artery elasticity during atherosclerosis progression and regression in monkeys. *Circulation* 1991;83 :1754-63.
8. Filitti V, Giral P, Simon A, Merli I, Del Pino M, Levenson J. Enhanced constriction of the peripheral large artery in response to acute induction of a low-flow state in human hypercholesterolemia. *Arterioscler Thromb* 1991;11 :161-66.
9. Flavahan NA. Atherosclerosis or lipoprotein-induced endothelial dysfunction. *Circulation* 1992;85 :1930-38.
10. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen J, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjolom T, Nikkila EA. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. *N Engl J Med* 1987;317 :1237-45.
11. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultra-centrifuge. *Clin Chem* 1971;18 :499-502.
12. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. *N Engl J Med* 1992;326 :242-50.
13. Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. *Circulation* 1990;82 (Suppl. II) :II-47-II-59.
14. Galle J, Busse R, Bassenge E. Hypercholesterolemia and atherosclerosis change vascular reactivity in rabbits by different mechanisms. *Arterioscler Thromb* 1991;11 :1712-18.
15. Giannattasio C, Mangoni AA, Carugo S, Stella ML, Cuspidi C, Stefanoni P, Bombelli M, Sega R, Grassi G, Vergani C, Mancia G. Arterial compliance in men with familial hypercholesterolemia. *Abstractbook Ric Sci Educaz Perm* 1993 (Suppl. 95) :264.
16. Giral P, Filitti V, Levenson J, Pithois-Merli I, Plainfosse M, Mainardi C, Gold A, Simon A, PCV Metra Group. Relation of risk factors for cardiovascular disease to early atherosclerosis detected by ultrasonography in middle-aged normotensive hypercholesterolemic men. *Atherosclerosis* 1990;85 :151-59.
17. Heistad DD, Lopez AG, Baumbach GL. Hemodynamic determinants of vascular changes in hypertension and atherosclerosis. *Hypertension* 1991;17 (III) :III7-III11.
18. Hoeks APG, Brands PJ, Smeets FAM, Reneman RS. Assessment of the distensibility of superficial arteries. *Ultrasound Med Biol* 1990;16 :121-28.
19. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, Nealon J, Nelson J, Potter J, Rifkind B, Rossouw J, Shekelle R, Yusuf S. Report of the conference on low blood cholesterol: mortality associations. *Circulation* 1992;86 :1046-60.
20. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. *Ann Intern Med* 1971;74 :1-12.
21. Kramsch DM, Blankenhorn DH. Regression of atherosclerosis: which components regress and what influences their reversal. *Wien Klin Wochenschr* 1992;104 :2-9.
22. Le Quan-Sang KH, Levenson J, Simon A, Meyer P, Devynck M. Platelet cytosolic free Ca²⁺ concentration and plasma cholesterol in untreated hypertensives. *J Hypertens* 1987;5 (Suppl. 5) :S251-54.
23. Levenson JA, Simon AC, Maarek BE, Gitelman RJ, Fiessinger JN, Safar ME. Regional compliance of brachial artery and saline infusion in patients with arteriosclerosis obliterans. *Arteriosclerosis* 1985;5 :80-87.

24. Lopez JA, Armstrong ML, Piegors DJ, Heistad DD. Effect of early and advanced atherosclerosis on vascular responses to serotonin, thromboxane A₂, and ADP. *Circulation* 1989;79 :698-705.
25. McGovern ME, Mellies MJ. Long-term experience with pravastatin in clinical research trials. *Clinical Therapeutics* 1993;15 :57-64.
26. McTavish D, Sorkin EM. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolemia. *Drugs* 1991;42 :65-89.
27. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. *BMJ* 1990;301 :309-14.
28. Nakashima T, Tanikawa J. A study of human aortic distensibility with relation to atherosclerosis and aging. *Angiology* 1971;22 :477-87.
29. Pocock SJ. Crossover trials. In: Pocock SJ, ed. *Clinical trials: a practical approach* 8th ed. Chichester: John Wiley & Sons, 1990 :110-22.
30. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. *Lancet* 1989;2 (8677) :941-44.
31. Ross R. The pathogenesis of atherosclerosis-an update. *N Engl J Med* 1986;314 :488-500.
32. Rubba P, Riccardi G, Pauciullo P, Vaccaro O, Carbone L, Mancini M. Different localization of early arterial lesions in insulin-dependent diabetes mellitus and in familial hypercholesterolemia. *Metabolism* 1989;38 :962-66.
33. Shimokawa H, Vanhoutte PM. Impaired endothelium-dependent relaxation to aggregating platelets and related vasoactive substances in porcine coronary arteries in hypercholesterolemia and atherosclerosis. *Circ Res* 1989;64 :900-914.
34. Stamler J. Review of primary prevention trials of coronary heart disease. *Acta Med Scand* 1985;701 :100-128.
35. Wendelhag I, Wiklund O, Wikstrand J. Arterial wall thickness in familial hypercholesterolemia. *Arterioscler Thromb* 1992;12 :70-77.
36. Wikstrand J, Wiklund O. Frontiers in cardiovascular science. Quantitative measurements of atherosclerotic manifestations in humans. *Arterioscler Thromb* 1992;12 :114-19.

CHAPTER 9

ACUTE AND SUBACUTE EFFECTS OF NICORANDIL AND ISOSORBIDE
DINITRATE ON VESSEL WALL PROPERTIES OF LARGE ARTERIES AND
HAEMODYNAMICS IN HEALTHY VOLUNTEERS

Mirian J. Kool, Janneke J. Spek, Harry A. Struijker Boudier, *Arnold P. Hoeks, **Robert S.
Reneman, †René H. van Herwaarden, and Luc M. Van Bortel.

Departments of Pharmacology, *Biophysics and **Physiology, Cardiovascular Research Institute
Maastricht, University of Limburg, †E. Merck Nederland B.V., Amsterdam, the Netherlands

Based on Cardiovasc Drugs Therapy 1995, 9 :331-337

Summary

Nicorandil (N) and Isosorbide dinitrate (ISDN) are vasodilator drugs used in patients with angina. In 24 healthy male volunteers (18-32 years) the acute effect of a single oral dose (20 mg) of N and ISDN on arterial diameter, distensibility, and compliance of the elastic common carotid artery (CCA) and the muscular femoral (FA) and brachial (BA) arteries were investigated. The effects on systolic and diastolic blood pressure (SBP, DBP), heart rate, cardiac index, systemic vascular resistance index, and venous haemodynamics were also assessed. In addition, the subacute effects after 8 days of treatment with N (2x20 mg/day) and ISDN (3x20 mg/day) on these parameters were evaluated.

After a 20 mg single oral dose, blood pressure decreased significantly more with ISDN (SBP:6%; DBP:14%) than with N (SBP:2%; DBP:6%), but after 8 days this decrease in blood pressure was not statistically different between ISDN and N. The diameter of CCA increased more with ISDN (11%) than N (5%) acutely as well as subacutely (ISDN:12%; N:9%). Heart rate increased only with ISDN (7% acutely, 3% subacutely). No differences between ISDN and nicorandil were found for acute and subacute effects on systemic vascular resistance index, venous haemodynamics, diameter of muscular arteries (FA, BA), and the distensibility and compliance of elastic (CCA) and muscular (FA, BA) arteries. Day₁ to day₈ changes in heart rate and cardiac index were small but differed between ISDN and nicorandil. These differences were due to a smaller increase in heart rate and cardiac index at day 8 than at day 1 with ISDN. Data on blood pressure and heart rate are in accordance with drug tolerance seen with ISDN but not with nicorandil. However, ISDN drug tolerance was not seen for the diameter of large arteries.

In conclusion, with dosages used in angina, compared to nicorandil - a drug with both a potassium channel opening property and a nitratelike action - the pure nitrate ISDN showed a more pronounced decrease in systolic and diastolic blood pressure, a slight increase in heart rate, and more vasodilation of CCA. ISDN drug tolerance was shown for blood pressure and heart rate. In contrast to the well-known venous tolerance during ISDN, there was no ISDN drug tolerance for the effects on diameter of large arteries. No drug tolerance was seen with nicorandil.

Introduction

Vasodilator drugs are commonly used in the management of angina pectoris (16,23). They may decrease systemic vascular resistance and influence vessel wall properties of large arteries. Vessel wall properties of large arteries (distensibility and compliance) reflect arterial stiffness and the buffering capacity of the arterial system. Recently, non-invasive investigation of vessel wall properties of superficial large arteries has become possible by ultrasound techniques (2,12,21,26,34). Hoeks et al have developed a vessel wall movement detector system with which distensibility and compliance can be measured more directly and accurately than with previous techniques (13). An improvement in arterial compliance may decrease pulse pressure, while a decrease in systemic vascular resistance decreases mean arterial pressure. Together, both arterial compliance and systemic vascular resistance determine left ventricular load. Consequently, an improvement in compliance and/or a decrease in vascular resistance may diminish the risk for cardiovascular mortality and morbidity (6,24,28).

Nicorandil, a nicotinamide derivative, is a recently developed anti-anginal drug that exerts dilatory effects on the venous and arterial system, and induces coronary vasodilation. Consequently, a reduction of cardiac preload and afterload may be achieved (3,35). The precise mechanism of action of nicorandil is not completely defined. Nicorandil has a dual action. In addition to potassium channel opening properties, it exerts a nitrate-like action. Potassium channel openers act by hyperpolarisation of arterial smooth muscle, resulting in vasorelaxation, especially of small arterioles (32,33). They have also shown to dilate vessels in ischaemic tissue (25). The nitrate moiety of nicorandil induces predominantly venous and large artery dilation. Finally, an increased prostaglandin I₂ production has been proposed to contribute to its vasodilating properties (30). Isosorbide dinitrate (ISDN), like nicorandil, is used in the management of angina pectoris, but it has a partial different mechanism of action. ISDN is an organic nitrate and a well-known direct vasodilator. Venous and arterial smooth muscle are relaxed by ISDN. At low concentrations this predominantly results in venodilation, while at higher doses both arteries and veins dilate (1,23).

Both nicorandil and ISDN are nitric oxide donors. This property could be responsible for their vasorelaxing capacity. Nicorandil and ISDN have been reported to reduce systolic blood pressure more than diastolic blood pressure (19). This might be due to a favourable influence on large artery compliance with a reduction in pulse pressure (27). ISDN has been thought to preferentially affect the venous system (preload reduction), while nicorandil might have a more pronounced effect on large arteries (afterload reduction) (3,4). The subacute effects of each compound as well as the haemodynamic differences between nicorandil and ISDN have not been extensively investigated yet.

The aim of the present study was to evaluate and compare in healthy volunteers the effect of nicorandil and ISDN at dosages commonly used in angina. Healthy volunteers were used because they were able to abstain from co-medication during the study. Venous haemodynamics, blood pressure, cardiac function, and vessel wall properties of elastic and muscular large arteries were studied after a single oral dose (acute effect) and after a 1-week administration period (subacute effect) of each drug. The drugs were given in doses recommended for the treatment of angina pectoris (20 mg) (5,15). In addition, these doses are known to induce a similar anti-anginal effect.

Subjects and methods

Subjects—Twenty four apparently healthy male volunteers were recruited by local advertising and found eligible to participate in the study. At selection, their mean age was 23 (18-32) years, their mean weight was 73 (61-86) kg, their mean height was 185 (175-201) cm, and their mean body surface area was 2.0 (1.7-2.1) m². At baseline, the electrocardiograms, haemodynamic, and laboratory parameters were within

the normal range. All volunteers were normotensive ($115 \pm 2/65 \pm 1$ mmHg) and had a normal resting heart rate (59 ± 2 beats/min). Twenty out of 24 volunteers reported using alcohol regularly and 8 were smokers. Mean alcohol consumption never exceeded 4 glasses/day, and mean cigarette consumption was 10 per day (range 1-20).

Study design — The study was designed as a double-blind, randomised, cross-over study.

Volunteer selection

At the first screening visit a general medical history was taken. Demographic data were collected, and patients were checked for risk factors, concomitant diseases, and use of concomitant medications. A general physical examination, a routine laboratory screening, and an electrocardiogram were performed. Venous blood samples were analysed for creatinine, glucose, transaminases (ALAT, ASAT), γ -GT, alkaline phosphatase, total protein, and albumin. Vessel wall properties and haemodynamic parameters were assessed in order to familiarise the volunteers with the examination procedures.

Exclusion criteria were hypertension (systolic >160 mmHg or diastolic >90 mmHg), angina pectoris, a myocardial infarction or stroke in the preceding 6 months, symptomatic atherosclerosis or presence of overt plaques detected with ultrasound, diabetes mellitus, hepatic or renal disease, and a body mass index >30 kg/m². Concomitant medication was not allowed, except for paracetamol.

Active treatment period (day 1-8)

Baseline values for each parameter were assessed on day 0. On day 1 each volunteer started to use nicorandil 20 mg (tablets) or ISDN 20 mg (capsules), following a fixed time schedule. Identical placebo tablets and capsules were provided according to a double-dummy method. One tablet together with one capsule were taken three times daily with a 6-hour interval between each dose. The first dose of the day was always taken 12 hours after the last dose of the preceding day. As a consequence, during the ISDN treatment period, ISDN was given three times daily in an asymmetric dose schedule. During the nicorandil treatment period the second dose was a placebo. Thus, in fact, nicorandil was given twice daily with a 12-hour interval. Treatment was continued for 8 days, and the two treatment periods were separated by a washout period of at least 3 weeks.

On day 1 and 8 of each treatment period, measurements started 0.5 hour after drug administration and lasted up to 2 hours after ingestion of the drug, which was at the peak effect of both drugs. At each session, vessel wall properties, blood pressure, heart rate, cardiac function, and venous haemodynamics were always assessed by the same investigator. Measurements were performed in a fixed order. Data on concomitant diseases, use of concomitant medication, and adverse events were obtained by questionnaire. Treatment was discontinued in the case of severe adverse events, development of exclusion criteria, or poor drug adherence.

The study was approved by the Ethical Committee of the University of Limburg and was performed in accordance with the Declaration of Helsinki (revised version 1983). Written informed consent was obtained from all subjects.

Methods — All haemodynamic measurements were performed in a quiet room with a constant temperature ($23-25^{\circ}$ C) after at least 30 minutes of supine rest. Smoking and use of caffeine were not allowed 4 hours prior to examination. Throughout the study each visit was carried out at the same time of the day and by the same investigators. At the start of each session, an indwelling venous cannula was placed in an antecubital vein of the left arm.

Blood pressure and heart rate

Supine blood pressure and heart rate were recorded every 3 minutes on the left arm with a Dinamap and the mean of all recordings during 30 min was taken (Chapter 2). Mean arterial pressure (MAP) was directly measured with this device.

Vessel wall properties

Vessel wall properties of the right elastic common carotid artery (CCA), and the right muscular common femoral (FA) and brachial (BA) arteries were assessed in recumbent position with the vessel wall movement detector system, as described in Chapter 2. From arterial diameter, distension, and pulse pressure, vessel wall properties were calculated according to the equations mentioned in Chapter 2.

Cardiac function

Cardiac function was measured with the patient in the left lateral position, using an echo Doppler technique (Chapter 2).

Venous compliance

Venous compliance was measured with mercury strain-gauge plethysmography (Chapter 2). Patients were in the supine position with the right arm at heart level. In the left arm a cannula (Venflon) was inserted into an antecubital vein to record peripheral venous pressure. Changes in forearm volume were recorded by inflating an upperarm cuff at increasing cuff pressures (20-50 mmHg). With each step (10 mmHg) pressure was kept constant for 3 minutes, unless a plateau phase was reached sooner.

The maximal value of the forearm volume was taken. The unstressed venous volume was determined by the distension of the forearm at an intravenous pressure of 10 mmHg. Venous compliance was defined as the slope of the pressure-volume curve, as determined with linear regression analysis (7).

Drug adherence

Volunteers were asked for their drug adherence at the end of each 1-week treatment period (day 8), and the number of returned tablets/capsules was counted.

Data analysis — Efficacy analysis was performed on volunteers who completed the study ($n=22$). 95% Confidence intervals of time-related changes in each drug and of differences in these time-related changes between the two drugs at each time point were calculated for each parameter. If the 95% confidence interval did not contain zero, the change or difference was considered significant. As a check for carry-over effects, mean values of the measurements of both periods were calculated for each patient and were compared between the two groups of treatment sequences with the Wilcoxon rank sum test. Data are presented as mean $\pm$ s.e.m.

Results

Drug adherence averaged 97% (at least 84%) for nicorandil and 95% (at least 70%) for ISDN as measured by pill counting. Eighteen volunteers suffered from headache during nicorandil and 22 during ISDN. Two volunteers discontinued the study in the first active treatment period due to headache, one treated with nicorandil and one with ISDN. Other adverse events were generally very mild and equally divided in both groups. The effects on haemodynamics are shown in Table 1 and those on vessel wall properties in Table 2 and in Figure 1. Statistical analysis revealed no evidence for carry-over effects. As a consequence, the cross-over design was considered valid.

Table 1. Acute and subacute effects of nicorandil and ISDN on haemodynamics.

	day 0	Nicorandil day 1	day 8	day 0	ISDN day 1	day 8
<i>Blood pressure</i>						
SBP (mmHg)	112±2	110±2*	110±2	114±2	107±1†	109±2*
DBP (mmHg)	64±1	60±1*	61±1*	64±1	55±1†	59±1*
ΔP(mmHg)	49±1	50±2	50±2	50±2	52±2	50±1
<i>Cardiac function</i>						
Heart rate (beats/min)	60±2	60±1	61±2	58±2	62±1†	60±2*
Cardiac index (L/min.m ²)	2.8±0.1	2.8±0.1	2.9±0.1*	2.8±0.1	2.9±0.1	2.8±0.1#
Stroke index (mL/m ²)	49±1	50±1	50±1	49±1	49±1	49±1
SVRI (kPa.s.L ⁻¹ .m ²)	236±8	225±7	225±8	239±7	222±7*	232±6
<i>Venous haemodynamics</i>						
Venous compliance (μL/100ml tissue/kPa)	498±17	510±18	515±20	495±22	522±19	517±31
Unstressed volume (μL/100ml tissue)	674±74	821±70	676±80	600±73	875±74*	650±81

Acute effect: after a single dose; Subacute effect: after a 1-week treatment period; N, nicorandil; ISDN, isosorbide dinitrate; SBP, systolic blood pressure; DBP, diastolic blood pressure; ΔP, pulse pressure; SVRI, systemic vascular resistance index; Unstressed volume was determined at an intravenous pressure of 10 mmHg.

n=22; Data are mean ± s.e.m.; *, statistically different changes versus baseline; †, statistically different changes from baseline between nicorandil and ISDN; #, statistically different changes versus day 1 between nicorandil and ISDN.

Table 2. Acute and subacute effects of nicorandil and ISDN on vessel wall properties.

	day 0	Nicorandil day 1	day 8	day 0	ISDN day 1	day 8
<i>Carotid artery</i>						
Diameter (mm)	5.68±0.06	5.98±0.07*	6.17±0.08*	5.64±0.07	6.28±0.08†	6.31±0.09*†
DC (10 ⁻³ /kPa)	37.7±1.5	37.9±1.3	37.0±1.5	37.2±1.1	35.0±1.2	36.8±1.3#
CC (mm ² /kPa)	0.96±0.04	1.07±0.05*	1.11±0.06*	0.93±0.02	1.09±0.05*	1.16±0.05*
<i>Femoral artery</i>						
Diameter (mm)	8.16±0.13	8.35±0.14*	8.41±0.15*	8.10±0.15	8.35±0.16*	8.36±0.15*
DC (10 ⁻³ /kPa)	18.5±1.5	18.9±1.6	17.8±1.2	18.2±1.8	17.2±1.3	17.2±1.3
CC (mm ² /kPa)	0.96±0.08	1.03±0.08	1.0±0.07	0.93±0.08	0.93±0.06	0.95±0.07
<i>Brachial artery</i>						
Diameter (mm)	3.50±0.06	3.88±0.07*	3.38±0.05*	3.48±0.06	3.85±0.06*	3.91±0.06*
DC (10 ⁻³ /kPa)	27.6±2.0	27.3±1.40	27.2±1.4	26.5±1.6	27.3±1.7	27.1±1.8
CC (mm ² /kPa)	0.27±0.02	0.33±0.02*	0.32±0.02*	0.25±0.02	0.32±0.02*	0.32±0.02*

Acute effect: after a single dose; Subacute effect: after a 1-week treatment period; N, nicorandil; ISDN, isosorbide dinitrate; DC, distensibility coefficient; CC, compliance coefficient.

n=22; Data are mean ± s.e.m.; *, statistically different changes versus baseline; †, statistically different changes from baseline between nicorandil and ISDN; # statistically different changes versus day 1 between nicorandil and ISDN.

Figure 1. The acute (single dose) and subacute (1-week treatment) effect of nicorandil and ISDN on vessel wall properties of the common carotid artery; DC, distensibility coefficient; CC, compliance coefficient; data are mean $\pm$ s.e.m.; * significant changes between day 1 or day 8 versus baseline; 95% confidence intervals; # significant changes between nicorandil and ISDN; 95% confidence intervals. day 0. day 1. day 8.

Changes from baseline, acute effects

Systolic and diastolic blood pressure were reduced with ISDN (6% and 14%, respectively) and with nicorandil (2% and 6%, respectively). Heart rate only increased with ISDN (7%). Systemic vascular resistance index (SVRI) significantly decreased with ISDN (7%). Venous volume at 10 mmHg was enhanced with ISDN (46%).

With both nicorandil and ISDN arterial diameters of the elastic common carotid artery (N:5%; ISDN:11%), and the muscular femoral (N:2%; ISDN:3%) and brachial arteries (N:11%; ISDN:11%) were increased. Arterial compliance of the carotid artery increased with nicorandil (12%) and ISDN (17%), and also compliance of the brachial artery was higher with both nicorandil (22%) and ISDN (28%).

Changes from baseline, subacute effects

Systolic blood pressure was reduced with ISDN (4%) only. Diastolic blood pressure was reduced with ISDN (8%) and nicorandil (5%). Heart rate only increased with ISDN (3%). Cardiac index was slightly enhanced with nicorandil (4%).

The diameter of the elastic common carotid artery increased with ISDN and nicorandil (ISDN:12%; N:9%). The diameter of the muscular femoral and brachial arteries was also increased by nicorandil (FA:3%; BA:9%) and ISDN (FA:3%; BA:12%). Compliance of the carotid and brachial arteries was enhanced with nicorandil (CCA:16%; BA:19%) and ISDN (CCA:25%; BA:28%).

Differences between nicorandil and ISDN

The primary aim of the study was to detect differences between nicorandil and ISDN. Systolic as well as diastolic blood pressure decreased more with ISDN than with nicorandil at day 1. In contrast to nicorandil, heart rate increased with ISDN. Statistically different effects on blood pressure and heart rate between ISDN and nicorandil at day 1 did not persist at day 8. The diameter of the common carotid artery was significantly larger with ISDN than with nicorandil after a single dose and the effect was maintained after 8 days. Day₁ to day₈ changes differed statistically between ISDN and nicorandil for heart rate, cardiac index, and diameter and distensibility of the common carotid artery.

Discussion

The primary aim of the present study was to compare the haemodynamic effects of a relatively new anti-anginal drug, nicorandil, with those of a widely used agent, isosorbide dinitrate (ISDN). The effects of nicorandil and ISDN were studied at dosages commonly used in the treatment of angina pectoris, which induced a similar anti-anginal effect (8,15). Headache accounted for most of the reported adverse events during the treatment period. As in previous studies (3,5), the adverse events with nicorandil were milder than with ISDN. All haemodynamic measurements were performed at the peak effect of both drugs (3,8). Since the study was a comparative study and not placebo-controlled, differences versus baseline have to be interpreted with caution. Systolic and diastolic blood pressure decreased with ISDN and nicorandil. But, after a single oral dose blood pressure was more reduced with ISDN than with nicorandil. These data are consistent with the literature (9,19,20). However, this larger decrease in blood pressure with ISDN did not persist after 8 days. Pulse pressure remained unchanged with both drugs.

In contrast to ISDN, heart rate did not change with nicorandil, and this is consistent with previous studies (5,15,31). The increase in heart rate with ISDN has been suggested to be a compensation for the decrease in blood pressure (9). As for blood pressure, with ISDN effects on heart rate were attenuated at day 8 compared to day 1.

In accordance with literature data (1,14,30), changes in cardiac index were absent or small with both agents and in our opinion are of no clinical relevance. Although the systemic vascular resistance index tended to decrease versus baseline with both drugs, the decrease was only statistically significant after a single oral dose of ISDN. Literature data are not conclusive with respect to the effects of both drugs on systemic vascular resistance, but in general it remains relatively unaffected (19,23,30).

Changes in venous compliance versus baseline were not statistically significant with both drugs. In hypertensive patients venous compliance was also not affected with nicorandil (19). Venous return to the heart is not only influenced by venous compliance, but may also depend on the amount of blood in the "unstressed" volume, which represents the haemodynamically inactive compartment of the venous system (11). In the case of decreased venous tone, blood will be transported from the haemodynamically active compartment into the unstressed volume, while venodilation has been associated with an increased unstressed volume (11). Due to large intra and interindividual variation, which is reflected in an unstable baseline and large s.e.m., in the present study data on unstressed volume are difficult to interpret. However, data on unstressed venous volume are compatible with the well-known venous tolerance seen with ISDN (10,36). It is not clear whether venous tolerance might also occur with nicorandil.

Arterial diameter of the elastic common carotid and muscular femoral and brachial arteries increased versus baseline with both drugs. Previous studies with ISDN and nicorandil also have demonstrated an acute vasodilation of large arteries (9,18,19). With a decrease in blood pressure, arterial diameter was expected to decrease passively. However, for a larger decrease in blood pressure, arterial diameter increased similarly or even more (i.e., the common carotid artery) with ISDN than with nicorandil, which suggests a larger direct relaxing effect on large artery smooth muscle at the dosages used. This arterial dilation was not attenuated after 8 days.

Arterial distensibility remained unchanged versus baseline with both drugs. Although day₁ to day₈ changes in distensibility of the common carotid artery were statistically significant between both drugs, changes were small and within the margins of error of the device (17) and, as a consequence, probably not relevant. Arterial compliance of the common carotid and brachial artery increased versus baseline with nicorandil and ISDN. An increase in large artery compliance after ISDN has been shown previously (9,18). However, as in the present study, the increased compliance after ISDN was not obligatorily associated with improvement of arterial distensibility (18,19,29). Due to the larger diameter and an unaltered distensibility, arterial compliance was enhanced in elastic and muscular arteries. This indicates an improvement in the buffering function of the arterial system, which in turn determines cardiac afterload. Compliance of the muscular femoral artery did not change with any of the two drugs. Whether this is due to a different behaviour of the femoral artery or to a lower reproducibility of compliance measurements of this artery - reflected by the larger s.e.m. - is not clear.

The attenuated effects at day 8 versus day 1 on blood pressure, heart rate, and possibly also on systemic vascular resistance are compatible with drug tolerance during ISDN. This has also been found by other authors (10,22). Data in the present study are compatible with the well-known venous tolerance with ISDN (10,22). However, there was no drug tolerance on large artery dilation. The present study did not reveal evidence for drug tolerance with nicorandil.

In conclusion, with the dosages used nicorandil had a smaller effect on blood pressure and heart rate than ISDN. Vasodilation of large arteries occurred with both drugs, but dilation of the carotid artery was more pronounced with ISDN. Arterial compliance of elastic and muscular arteries were improved both with nicorandil and ISDN. The improvement in arterial compliance was mainly due to an increase in arterial diameter. Since arterial compliance is an important determinant of cardiac afterload, an improved compliance might contribute to a lower afterload. ISDN drug tolerance could be shown for haemodynamic parameters such as blood pressure and heart rate. In contrast to the well-known venous tolerance with ISDN, no tolerance on large artery dilation could be observed. There was no evidence of drug tolerance with nicorandil.

References

1. Alpert JS. Nitrate therapy in the elderly. *Am J Cardiol* 1990;65 :23J-7J.
2. Arndt JO, Klauske J, Mersch F. The diameter of the intact carotid artery in man and its change with pulse pressure. *Pflügers Arch* 1968;301 :230-40.
3. Belz GG, Matthews J, Heinrich J, Wagner G. Controlled comparison of the pharmacodynamic effects of nicorandil (SG-75) and isosorbide dinitrate in man. *Eur J Pharmacol* 1984;26 :681-85.
4. Belz GG, Matthews JH, Beck A, Wagner G, Schneider B. Hemodynamic effects of nicorandil, isosorbide dinitrate, and dihydralazine in healthy volunteers. *J Cardiovasc Pharmacol* 1985;7 :1107-12.
5. Camm AJ, Maltz MB. A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris. *Am J Cardiol* 1989;63 :61J-5J.
6. Darne B, Girerd X, Safar M, Cambien F, Guize L. Pulsatile versus steady component of blood pressure: a cross-sectional analysis and a prospective analysis on cardiovascular mortality. *Hypertension* 1989;13 :392-400.
7. Forconi S, Jagenau A, Guerrini M, Pecchi S, Cappelli R. Strain gauge plethysmography in the study of circulation of the limbs. *Angiology* 1979;30 :487-97.
8. Frydman AM, Chapelle P, Diekmann H, Bruno R, Thebault JJ, Bouthier J, Caplain H, Ungethuem W, Gaillard C, Le Liboux A, Renard A, Gaillot J. Pharmacokinetics of nicorandil. *Am J Cardiol* 1989;63 :25J-33J.
9. Frydman AM, Safar ME, Simon AC, Levenson JA, Gaillot J, Roland E. Isosorbide dinitrate: relationship between pharmacokinetics and brachial artery hemodynamics in essential hypertension. *Angiology* 1986;37 :581-89.
10. Ghio S, de Servi S, Perotti R, Eleuteri E, Montemartini C, Specchia G. Different susceptibility to the development of nitroglycerin tolerance in the arterial and venous circulation in humans. Effects of N-acetylcysteine administration. *Circulation* 1992;86 :798-802.
11. Greenway CV, Lutt WW. Blood volume, the venous system, preload, and cardiac output. *Can J Physiol Pharmacol* 1986;64 :383-87.
12. Gustafsson D, Stale H, Björkman J, Gennser G. Derivation of haemodynamic information from ultrasonic recordings of aortic diameter changes. *Ultrasound Med Biol* 1989;15 :189-99.
13. Hoeks APG, Brands PJ, Smeets FAM, Reneman RS. Assessment of the distensibility of superficial arteries. *Ultrasound Med Biol* 1990;16 :121-28.
14. Kambara H, Nakamura Y, Tamaki S, Kawai C. Beneficial effects of nicorandil on cardiovascular hemodynamics and left ventricular function. *J Cardiovasc Pharmacol* 1987;10 (Suppl. 8) :S104-8.
15. Kinoshita M, Sakai K. Pharmacology and therapeutic effects of nicorandil. *Cardiovasc Drugs Ther* 1990;4 :1075-88.
16. Koch - Weser J. Vasodilator drugs in the treatment of hypertension. *Arch Intern Med* 1974;133 :1017-28.
17. Kool MJF, van Merode T, Reneman RS, Hoeks APG, Struyker Boudier HAJ, Van Bortel LMAB. Evaluation of reproducibility of a vessel wall movement detector system for assessment of large artery properties. *Cardiovasc Res* 1994;28 :610-14.
18. Laurent S, Arcaro G, Benetos A, Laffleche A, Hoeks A, Safar M. Mechanism of nitrate-induced improvement on arterial compliance depends on vascular territory. *J Cardiovasc Pharmacol* 1992;19 :641-49.
19. Levenson J, Bouthier J, Chau NP, Rolan E, Simon AC. Effects of nicorandil on arterial and venous vessels of the forearm in systemic hypertension. *Am J Cardiol* 1989;63 :40J-3J.
20. Levenson J, Simon A, Bouthier J, Benetos A, Safar ME. Isosorbide dinitrate and pulsatile arterial haemodynamic variables in hypertension. *Eur Heart J* 1986;7 :898-903.
21. Levenson JA, Peronneau PA, Simon A, Safar ME. Pulsed Doppler: determination of diameter, blood flow velocity, and volume flow of brachial artery in man. *Cardiovasc Res* 1981;15 :164-70.
22. Makhoul N, Dakak N, Flugeman MY, Merdler A, Shefer A, Schneeweiss A, Halon DA, Lewis BS. Nitrate tolerance in heart failure: Differential venous, pulmonary and systemic arterial effects. *Am J Cardiol* 1990;65 :28J-31J.
23. Needleman P, Corr PB, Johnson EM. Drugs used for the treatment of angina: organic nitrates, calcium channel blockers, and -adrenergic antagonists. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P, eds. *Goodman and Gilman's the pharmacological basis of therapeutics* 8th ed. New York: Pergamon Press, 1990 :764-84.

24. O'Rourke M. Systolic blood pressure: arterial compliance and early wave reflection, and their modification by antihypertensive therapy. *J Hum Hypertens* 1989;3 :47-52.
25. Quast U, Cook NS. Moving together: K⁺ channel openers and ATP-sensitive K⁺ channels. *TIPS* 1989;11 :431-35.
26. Riley WA, Barnes RW, Evans GW, Burke GL. Ultrasonic measurement of the elastic modulus of the common carotid artery. The atherosclerosis risk in communities (ARIC) study. *Stroke* 1992;23 :952-56.
27. Safar ME, Bouthier JA, Levenson JA, Simon AC. Peripheral large arteries and the response to antihypertensive treatment. *Hypertension* 1983;5 (III) :III63-68.
28. Safar ME, Levy BI, Laurent S, London GM. Hypertension and the arterial system: clinical and therapeutic aspects. *J Hypertens* 1990;8 (Suppl. 7) :S113-19.
29. Safar ME, London GM, Bouthier JA, Levenson JA, Laurent S. Brachial artery cross-sectional area and distensibility before and after arteriolar vasodilatation in men with sustained essential hypertension. *J Cardiovasc Pharmacol* 1987;9 :734-42.
30. Silke B, Verna SP, Ali MS, Goldhammer E, Taylor SH. Effects of nicorandil on left ventricular hemodynamics and volume at rest and during exercise-induced angina pectoris. *Am J Cardiol* 1989;63 :49J-55J.
31. Solal AC, Jaeger P, Bouthier J, Juliard J, Dahan M, Gourgon R. Hemodynamic action of nicorandil in chronic congestive heart failure. *Am J Cardiol* 1989;63 :44J-8J.
32. Struijker Boudier HAJ, Messing MWJ, van Essen H. Preferential small arteriolar vasodilation by the potassium channel opener, BRL 38227, in conscious spontaneously hypertensive rats. *Eur J Pharmacol* 1992;218 :191-93.
33. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. *Am J Cardiol* 1989;63 :18J-24J.
34. Tardy Y, Meister JJ, Perret F, Brunner HR, Arditi M. Non-invasive estimate of the mechanical properties of peripheral arteries from ultrasonic and photoplethysmographic measurements. *Clin Phys Physiol Meas* 1991;12 :39-54.
35. Thormann J, Schlepper M, Kramer W, Gottwik M, Kindler M. Effectiveness of nicorandil (SG-75), a new long-acting drug with nitroglycerin effects, in patients with coronary artery disease: improved left ventricular function and regional wall motion and abolition of pacing-induced angina. *J Cardiovasc Pharmacol* 1983;5 :371-77.
36. Zelis R, Mason DT. Isosorbide dinitrate, effect on the vasodilator response to nitroglycerin. *JAMA* 1975;234 :166-70.

CHAPTER 10

GENERAL DISCUSSION

I. Determinants of reproducibility of non-invasive measurements of large artery properties

Initially, most data on large artery properties (distensibility and compliance) were derived from animal and in vitro studies, but these results can not simply be extrapolated to the human situation in vivo. In addition, distensibility and compliance were used indifferently, because it was not possible to measure them separately in an accurate manner. With the vessel wall movement detector system as used in the present thesis local distensibility and compliance of superficial elastic and muscular large arteries can be assessed non-invasively and more directly than with previous techniques (Chapter 3). The reproducibility of this vessel wall movement detector system is influenced by method-related factors and by physiological variations (Table 10.1).

Table 10.1. Factors influencing reproducibility of vessel wall movement measurements.

Method-related variation	Physiological variation
<ul style="list-style-type: none">✓ Technical reproducibility✓ Observers' skill✓ Number of measurements✓ Blood pressure recording	<ul style="list-style-type: none">✓ Time-related variation<ul style="list-style-type: none">Short-term variationDiurnal variationSeasonal variation✓ Other influences i.e. meal

A Method-related factors

Technical reproducibility

Technical reproducibility of the vessel wall movement system plays a role with respect to adequate measurements of arterial distension and diameter (ΔD and D , respectively). However, the theoretical accuracy of the device is good ($3\ \mu\text{m}$ for distension).

Observers' skill

Observers' skill is determined by the presence of well-trained investigators. Intraobserver and interobserver variation is largely dependent on the investigator's skill. With the vessel wall movement system a coefficient of variation below 10% for distension and below 5% for arterial diameter is reached for the elastic common carotid artery, which means an acceptable observer reproducibility. Reproducibility of muscular large arteries is slightly lower (see physiological variation).

Number of measurements

The number of measurements may also influence reproducibility of vessel wall movement measurements. A further improvement of accuracy may be achieved by averaging a larger number of recorded heart beats

(regression to the mean). A recording time of 5-6 seconds per measurement gives approximately 5 distension waveforms on condition that heart rate is 50-60 beats/min. More measurements will result in a better accuracy. For example, the intraobserver coefficient of variation for arterial diameter and distension of the common carotid artery with 3 measurements (4.0% and 9.0%, respectively; average of approximately 15 heart beats) was improved with 4 measurements (diameter 3.6%, distension 8.9%; average of approximately 20 heart beats). However, in view of the larger cost in time needed for 4 measurements and the relatively small improvement in coefficient of variation, the 4 measurements procedure was considered not to have a better cost-benefit ratio than the 3 measurements procedure. Similar results were obtained for the muscular femoral and brachial arteries (unpublished data).

Blood pressure recording

Finally, non-invasive blood pressure recording at the site of and simultaneously with vessel wall movements detection, causes a major problem. At present, the most acceptable way of pressure recording is to choose a blood pressure recording place as close as possible to the location of vessel wall movement measurements in order to estimate local blood pressure, as accurately as possible. Whereas mean arterial pressure is relatively constant, pulse pressure differs along the arterial tree. In addition, boosting of pulse pressure by pulse wave reflections is common in the carotid artery, while it is not common in the brachial artery (67,68). In the absence of pulse wave reflections, a good correlation is found between carotid and brachial blood pressure (98). In that case, the Dinamap device - measuring blood pressure in the brachial artery non-invasively - can be used. The accuracy of the Dinamap has been evaluated and was considered good (14,20,96). The Finapres is also a semi-automated device, measuring beat-to-beat blood pressure at the finger. Finapres blood pressure recordings have been used to estimate blood pressure at the site of the brachial or radial artery (47,70). The Finapres device can accurately monitor changes in pressure (94,96,114). However, in case of peripheral vasoconstriction the Finapres pressure recorded in the finger may be considerably lower than in the systemic circulation (96,130). On the other hand, during dynamic exercise systolic finger pressure is considerably higher compared to intra-arterial brachial pressure (52). It is known that in conditions such as ageing, hypertension, vasoconstriction, or use of antihypertensive drugs the issue of wave reflections may increasingly become important. However, despite this short distance between the sites of pressure (as assessed with Finapres) and vessel wall movement recordings, estimation of pulse pressure still is not fully correct. The reason for this is that in more distal peripheral arteries pulse pressure is higher because of a smaller diameter of these vessels. In addition, interfering wave reflections may increase pulse pressure.

In this respect, we could demonstrate considerable differences between Dinamap blood pressures and Finapres blood pressures in uncomplicated diabetic subjects (Table 10.2.1). Pulse pressure of the diabetic patients did not differ from that of matched control subjects, when using the Dinamap. However, pulse

Table 10.2.1. Pulse pressure from Dinamap and Finapres in diabetic patients and controls.

	Finapres		Dinamap	
	IDDM	Controls	IDDM	Controls
SBP (mmHg)	127 ± 3	118 ± 2	118 ± 2	115 ± 2
DBP (mmHg)	61 ± 2	60 ± 2	69 ± 1	68 ± 1
ΔP (mmHg)	66 ± 2	58 ± 2*	49 ± 1	48 ± 2

IDDM, uncomplicated insulin-dependent diabetic subjects (n=25); Controls, presumed healthy subjects, matched for age, gender, and blood pressure (n=25); SBP, systolic blood pressure; DBP, diastolic blood pressure; ΔP, pulse pressure; * p<0.05; mean ± s.e.m.

Table 10.2.2. Pulse pressure from Dinamap and Finapres in habitual smokers (n=12), before and after smoking one cigarette.

	Finapres		Dinamap	
	Before	After	Before	After
SBP (mmHg)	115±4	140±3***	112±2	118±3***
DBP (mmHg)	56±2	63±2***	69±1	73±1***
ΔP (mmHg)	58±3	67±3**	43±2	45±2

SBP, systolic blood pressure; DBP, diastolic blood pressure; ΔP, pulse pressure; ** p<0.01 and ***p<0.001, difference before and immediately after smoking one cigarette; mean ± s.e.m.

pressure assessed by Finapres was significantly higher in diabetics than in controls. In addition, in habitual smokers pulse pressure was higher in the finger artery than in the brachial artery (Table 10.2.2). After smoking a cigarette these smokers showed a considerable increase in pulse pressure in the finger artery, but not in the brachial artery. These data suggest that changes in sympathetic tone (as with smoking) can change pulse pressure in the finger arteries more than in the brachial artery. The higher finger pulse pressure in the diabetic patients might be due to early changes in smaller arteries and arterioles in these subjects. It is obvious that the use of inaccurate pulse pressure data may have important consequences for the calculations of distensibility and compliance.

Another problem might arise when peripheral blood pressure values are used to reflect central aortic pressure. Due to pulse wave travelling and reflection phenomena, especially systolic blood pressure can differ as much as 20 mm Hg between central and peripheral sites (64). To overcome these problems, applanation tonometry has been proposed as a non-invasive method to record local pulse pressure (12). Applanation tonometry can not be used to record absolute pressure, but may be used to record pulse pressure. To perform accurate measurements with this technique, a solid background (bone) is necessary. If pressure measurements are performed simultaneously with arterial distension measurements, then only the contralateral site can be used for pressure measurements. In healthy volunteers that will cause no problems, but in patients with (undetected) atherosclerotic plaques this may be a source of error. Therefore, this technique is not yet fully accepted.

Finally, based on pulse wave transfer functions, resynthesis of ascending aortic pressure from recordings of brachial or radial arteries, seems to become a promising technique for adequate blood pressure recording (64).

B Physiological variations

Time-related factors

Time-related factors, such as short-term variation within minutes, diurnal variation, and seasonal variation in vessel wall properties are merely important to reproducibility of large artery properties. Short-term variation in vessel wall properties may explain the higher variability in muscular arteries when compared to elastic large arteries. A larger spontaneous short-term variation in these muscular arteries, which are under permanent neurohumoral control (50), may influence reproducibility negatively. Apart from short-term variation, a diurnal variation in vessel wall properties of elastic and muscular arteries is present (see discussion part II). Data on seasonal variation in vessel wall properties are not available, but may be suspected, since for blood pressure and for the occurrence of some cardiovascular diseases a seasonal variation has been shown (15,41).

Other influences

Other influences, such as taking meals could also interfere. However, compared to parameters of cardiac function, the influence of meals on vessel wall properties was less pronounced (Chapter 4). From the above it can be concluded that assessment of vessel wall properties with the vessel wall movement detector system can be measured with acceptable reproducibility when performed under standardised conditions, i.e. examining on the same moment of the day throughout a study.

C Future research

Future research must be directed towards improvement of blood pressure recording techniques and towards development of techniques to measure local pulse pressure simultaneously with vessel wall movements in order to improve the accuracy of the assessment of vessel wall properties. Attention must be paid to pulse wave reflections, since these interfere with accurate assessment of pulse pressure.

II. Vessel wall properties as a cardiovascular risk factor

A Influence of physiological conditions

Arterial blood pressure can be seen as the sum of a static component (mean arterial pressure) and a dynamic component (pulse pressure) superimposed on it (104). Recently, the interest in the dynamic part of blood pressure has increased. Large artery properties, distensibility and compliance, play an important role in determining the dynamic behaviour of the vessel. Distensibility reflects the elastic properties of a large artery, while compliance describes its buffering function. Related to this, distensibility is thought an important determinant of the pulsatile stress on the vessel wall, while compliance is a major determinant of cardiac afterload (124). A decrease in distensibility and compliance may have important implications for the risk of cardiovascular disease, because the risk of stroke, heart failure and atherosclerotic disease may become increased. On the other hand, a decrease in large artery properties may become a consequence of disease or physiological changes. Various physiological conditions may influence vessel wall properties and therefore, indirectly cardiovascular risk can be affected (Table 10.3). Data on arterial stiffness, which is the inverse of distensibility (92,113), and on cardiovascular risk are shown.

Table 10.3. Influence of physiological conditions on arterial stiffness and cardiovascular risk.

Physiological conditions	Arterial stiffness	Cardiovascular risk
Time-related factors		
short-term variation	↑ and ↓	?
diurnal variation	↑ at night	↑ early morning
seasonal variation	?	?
Age	↑	↑
Gender	male > female	male > female
Race*		
oriental	↓	↓
blacks	?	↑
High salt intake	↑	(↑)
High salt-sensitivity	↑	?
Obesity	= or ↑	= or ↑
Physical exercise	↓	↓
Stress	(↑)	↑
Smoking	↑#	↑

↑ increase; ↓ decrease; = no change; ? not known; () not fully established; * compared to westernised populations; # short-term effect.

Time-related factors

Short-term variation

Short-term variations in arterial stiffness may occur spontaneously and are difficult to control. These variations are probably due to alterations in vascular tone. Endothelial function plays an important role in the regulation of vascular tone. The short-term variations might be an adaptation mechanism to maintain shear forces at the site of the endothelium at a constant level (50). Due to these short-term variations, arterial stiffness may become increased during certain time periods and are decreased in other time periods. Whether these increases in stiffness are related to an enhanced cardiovascular risk is not known yet.

Diurnal variation

Like blood pressure and heart rate, arterial stiffness of elastic and muscular arteries shows a diurnal variation (Chapter 4). Nocturnal vasodilation of large arteries is probably due to a lower sympathetic tone at night. Since arterial compliance is preserved throughout the day, the buffering capacity of elastic and muscular arteries seems not affected. Diurnal variation in blood pressure and heart rate has been related to the time of occurrence of cardiovascular disease. Myocardial infarction (88), sudden cardiac death (87), myocardial ischaemia (100) and stroke (79) occur more frequently in the early morning hours. The most important trigger mechanism for this phenomenon is considered to be an increased sympathetic drive to the heart and blood vessels during the early morning hours, resulting in a higher blood pressure and heart rate (38). In addition, it is suggested that subjects that do not show a fall in blood pressure at night (non-dippers) have a higher risk of left ventricular hypertrophy and stroke when compared to those who do show a nocturnal fall of blood pressure (dippers) (91,125). Thus, the absence or presence of a diurnal blood pressure pattern might increase cardiovascular risk. For arterial stiffness the significance of the stress of awakening - with a sharp increase in noradrenalin - is not elucidated yet, neither has a clear relation been shown between a diurnal variation in arterial stiffness and an increased cardiovascular risk. It is possible that the increase in heart rate puts a higher pulsatile stress on the vascular wall and hence the risk of endothelial damage and acute cardiovascular events might become increased (124). Prospective studies are now performed to study the relation between diurnal variation and cardiovascular morbidity and mortality in more detail.

Seasonal variation

The frequency of cardiovascular events seems not equally distributed throughout the year (134,135). It might be suspected that seasonal variations influence arterial stiffness and hence may increase cardiovascular risk, but at present no data are available on this issue.

Age

It is now well known that ageing runs in parallel with a gradual increase in arterial stiffness of elastic large arteries, an increase in pulse pressure, higher pulse wave velocity and increased pulse wave reflections (66,99,105). A pathological condition, such as hypertension, may aggravate these age-related changes. Clinical studies have suggested that arterial stiffness is lowest at the age of 20 (11,84). The results of different studies suggest that after that age, arterial stiffness gradually increases (11,65,99), suggesting that irreversible changes - due to structural alterations - might have occurred in large arteries from the age of 20. The higher arterial stiffness contributes to an increase in ventricular load. An increase in peak systolic stress and pulse pressure with increasing age may enhance the pulsatile stress on the arterial wall. This

will result in a greater risk of rupture of an atherosclerotic plaque and hence acute cardiovascular complications (39,40). Epidemiological data have confirmed the increase in cardiovascular morbidity and mortality with advancing age and found it particularly related to a higher systolic pressure (61). With regard to age effects, arterial stiffness could be used as an early marker of vascular ageing.

Gender

An influence of gender on arterial stiffness has been demonstrated in a few studies, but data are inconsistent either indicating a higher arterial stiffness in males (10,123), or a higher arterial stiffness in females compared to males at all ages (85). In the latter study the number of subjects investigated was smaller, especially in the female group, which might have influenced the results. Epidemiological data show a lower incidence of cardiovascular disease in females through middle age when compared to males, but this gender difference decreases with advancing age. Maybe, a steeper increase in systolic pressure in women over 45 years of age is important for an increased risk of stroke and coronary heart disease in women of this age (60). The findings suggest an increased arterial stiffness and an increased cardiovascular risk with the onset of menopause (58), but a clear relationship between sex hormones and cardiovascular risk is lacking.

Race

Cardiovascular risk in black subjects appears to be higher than in white subjects. The prevalence and severity of hypertension in US blacks is higher than in white subjects (63,108,110). In addition, the complications of hypertension in US black individuals are more severe with regard to stroke, renal failure and congestive heart failure, while ischaemic heart disease and myocardial infarction are rare (63,108). However, blacks from the West Indies working in England had similar blood pressure compared to non-blacks, and African blacks have also low blood pressures (63). Much of the excess cardiovascular morbidity and mortality in US blacks has been related to their lower socio-economic status, less well management of hypertension in US blacks and a higher prevalence of risk factors, such as smoking, obesity, dyslipidaemia and diabetes (63). Another possible explanation for an increased cardiovascular risk in US blacks could be that they are more salt sensitive (see salt-sensitivity) and show abnormalities in salt (NaCl) transport (63). In addition, their cardiovascular system is exposed to elevated levels of blood pressure for a higher proportion of the day (46). This can imply a higher load on the arterial wall and a considerable increase in arterial stiffness, but large artery properties in black subjects have not been investigated yet.

Since arterial stiffness is higher in occidental than in oriental populations (6,8), it is likely that race forms a possible intervening risk factor. Coronary heart disease has been shown to occur more frequently in occidental populations (43). Maybe this is a gene-related problem, maybe a difference in lifestyle, because longitudinal studies in migrating populations from oriental subjects have shown that higher living standards and westernisation of communities are associated with increased cardiovascular morbidity and mortality (80). At present, also modernisation programs within one country lead to an increased prevalence of cardiovascular disease within the oriental countries themselves (8). A recent study has shown that oriental subjects showed a lower medial thickness throughout the aortic trunk, while aortic circumference was greater, when compared to occidental subjects (127). A difference in the amounts of elastin or collagen of the arterial wall between oriental and occidental populations may be suspected, explaining an increased arterial stiffness in a population with less vascular elastin. A difference in salt-handling might also play a role.

High salt intake and salt-sensitivity

Salt on itself may increase arterial stiffness (7,8), but the underlying mechanism is rather complex (106). Although epidemiological and intervention studies suggest a relation between dietary salt intake and blood pressure (36), there is controversy about the role of salt in the pathogenesis of hypertension (129) and in cardiovascular disease (13). Salt-sensitivity influences arterial stiffness. Salt-sensitive borderline hypertensive subjects showed an increase in arterial stiffness of elastic and muscular arteries, as compared to salt-resistant borderline hypertensive subjects (32).

Obesity

Arterial stiffness may increase in obese subjects, but data are scarce (Chapter 1). Obese subjects are considered to have an increased risk of cardiovascular disease (51). On the other hand, obesity in other studies had only a weak predictive value with respect to cardiovascular disease (51) or cardiovascular mortality was lower in obese subjects (31,115). In one study, hypertension even seems to be more benign when associated with obesity (9). However, an important confounding factor in the latter study could have been the use of the same cuff size for lean and obese subjects (102). Apart from that, the distribution of body fat may be more important than the overall degree of obesity with regard to cardiovascular risk (23). The relation between body mass index and arterial stiffness is probably low (123).

Physical exercise

Based on epidemiological data, regular physical exercise is generally recommended for the prevention of cardiovascular disease (33). A program of regular moderate exercise lowers resting mean arterial blood pressure, associated with a decrease in systemic vascular resistance (54). Since in the latter study cardiac function, plasma cholesterol, sympathetic activity and insulin sensitivity were also favourably influenced, it was thought that increased physical activity should reduce development of cardiovascular disease. In healthy normotensive cyclists we could demonstrate that a local adaptation takes place in the exercising limb with vasodilation and a decreased arterial stiffness. However, a training program did not affect vessel wall properties (131). It is most likely that changes in vessel wall properties need a long time to develop and are merely a pressure-related phenomenon (18). Exercise could also influence the endothelium via periodic increases in shear stress (18) and so exert a favourable influence on large artery properties.

Smoking

Cigarette smokers are at high risk of cardiovascular disease (117). Although in the study of the present thesis relatively young habitual smokers are comparable to non-smokers regarding arterial stiffness, smoking one cigarette already increases arterial stiffness in these subjects (Chapter 5). Repeated increases in arterial stiffness caused by each cigarette may accelerate vascular ageing and enhance the risk for endothelial damage and disruption of atherosclerotic plaques (39,40). In particular, relatively young people are prone to acute cardiovascular events by disruption of weak, lipid-rich, small (not detectable) plaques. Therefore, the repeated acute increases in arterial stiffness (decreases in arterial distensibility) due to one cigarette seem to be more harmful than the chronic effects. Indeed cardiovascular risk has been shown to increase with the number of cigarettes smoked per day (133). Smoking may be extra harmful to the arterial wall when other cardiovascular risk factors, such as hypertension and hypercholesterolaemia are present. Therefore, stop smoking would be advisable also in these relatively young subjects.

Stress

Excessive psychological stress has been mentioned as a cardiovascular risk factor (97). The effect of pure psychological stress on large artery properties has not been investigated, but with an increase in sympathetic activity it could be expected that stress may increase arterial stiffness. After a cold pressor test, which increases sympathetic activity, arterial stiffness of the radial artery increased, with a decrease in radial artery diameter and an increase in mean arterial finger blood pressure (55). Mental stress did not change arterial diameter of the medium-sized muscular radial artery, while blood pressure and heart rate was enhanced by this form of stress (48). In the latter study no data on arterial stiffness were available.

B Influence of pathological conditions

Apart from physiological factors, several pathological conditions may also influence arterial stiffness (arterial distensibility) (Table 10.4).

Table 10.4. Influence of pathological conditions on arterial stiffness and cardiovascular risk.

Pathological conditions	Arterial stiffness	Cardiovascular risk
Hypertension		
systolo-diastolic	↑	↑
borderline	↑	↑
isolated systolic	↑	↑
pulmonary	↑	↑
Diabetes mellitus		
non-insulin dependent	= / ↑	↑
insulin-dependent	= / ↑ / ↓	↑
Atherosclerosis	(↑)	↑
Hypercholesterolaemia	↑ / ↓	↑
Other diseases		
congestive heart failure	↑	↑
Marfan's syndrome	↑	↑
renal failure	↑	↑

↑ increase; ↓ decrease; = no change; ? not known; () not fully established.

Hypertension

In general, arterial stiffness of proximal elastic and muscular arteries is thought to be increased in essential hypertension and also in borderline hypertension (Chapter 1), although isobaric compliance of distal muscular arteries may be increased, suggesting a better buffering capacity in hypertensives (70). Isobaric compliance is of interest with regard to intrinsic wall properties of arteries. Arterial compliance at the operating pressure is an important determinant of cardiac afterload.

Borderline as well as established hypertension may induce functional (increased arterial stiffness, vasodilation) and structural changes (increased wall thickness), accelerating the ageing process of the arterial wall (83). The consequence of the increase in arterial stiffness may be that these patients are at a higher risk of cardiovascular morbidity and mortality. Indeed epidemiological data have shown that hypertensive patients bear a high cardiovascular risk and that this risk is more related to systolic than to diastolic pressure (29,61,103). In addition, patients with isolated systolic hypertension and borderline hypertension have also a higher cardiovascular risk (56,57,112). Therefore, early diagnosis of increased arterial stiffness may allow an earlier treatment of hypertension, which might be more accurate in preventing cardiovascular complications.

Diabetes mellitus

Cardiovascular risk is increased in diabetic patients (44,59). In the non-insulin dependent diabetic group arterial stiffness has been found to be increased (71,128), although a recent study could not reveal any difference in large artery compliance between non-insulin dependent diabetics and control subjects (81). In this - generally older - patient group other factors, such as age, hypertension and obesity may have been confounding variables. In insulin-dependent diabetic subjects the findings are inconsistent with a possible increase (71) or decrease (121,122) in arterial stiffness in these patients. In our own study young, uncomplicated, insulin-dependent diabetics showed no evidence of an increased arterial stiffness, nor could a relation be found between arterial stiffness and duration of the disease, actual glucose or HbA1c values (Chapter 6). However, in this relatively small group there was a trend for a greater stiffness of the femoral artery. Since the femoral artery of diabetic patients is prone to early atherosclerosis, an increased femoral stiffness might be an early feature of atherosclerotic disease and subsequently of a higher cardiovascular risk.

Atherosclerosis and hypercholesterolaemia

Subjects with hypercholesterolaemia and atherosclerosis are at high cardiovascular risk (19,42,119). Coronary and carotid atherosclerosis have been associated with an increased arterial stiffness (30,49,86,116), but in some studies the effects of age may form a confounding variable (30,90). In patients with peripheral vascular disease a regional increase in arterial stiffness was found (34), but also arterial stiffness in an artery where atherosclerosis is uncommon was increased (74). However, in the femoral arteries of atherosclerotic patients an obvious increase in stiffness could not be demonstrated (personal communication). Endothelial dysfunction (functional change) is an early feature in atherogenesis, already present in hypercholesterolaemia before atherosclerotic plaques (structural change) are present. Endothelial dysfunction may increase vascular tone and arterial stiffness. However, it was shown that the relation between cholesterol level and arterial stiffness is weak (123). In patients with hypercholesterolaemia (familial and non-familial) even a lower arterial stiffness has been reported (72). Moreover, in Japanese subjects aortic stiffness was lower and ischaemic heart disease lower in subjects using a fish diet (45), suggesting a favourable effect of low cholesterol on arterial elasticity and cardiovascular risk. In established atherosclerotic disease arterial stiffness is found increased (Chapter 1). In addition, we found

that the femoral artery was stiffer in mild to moderate hypercholesterolaemia, indicating that this artery must be early affected in the course of atherosclerosis (Chapter 8).

Other diseases

In several other diseases, such as congestive heart failure, Marfan's syndrome and renal failure an increased arterial stiffness has been shown (Chapter 1). Patients with congestive heart failure are at high cardiovascular risk (4,93). In end-stage renal failure coronary heart disease is an important cause of mortality and morbidity (101) and also patients with Marfan's syndrome are at high cardiovascular risk, mainly because of early aortic dilatation and related complications (89).

C Is increased arterial stiffness a cardiovascular risk factor ?

From the above it is clear that arterial stiffness is increased in a number of pathophysiological conditions and diseases, such as ageing, smoking and hypertension. The aforementioned conditions are considered to increase the cardiovascular risk. Since data are inconsistent or lacking in the remaining situations, future research is needed.

D Future research

Seasonal behaviour of vessel wall properties and arterial stiffness may be investigated. The relation between time-related variations (short-term, diurnal, seasonal) in vessel wall properties and cardiovascular morbidity and mortality might be of interest to know. Studies on vessel wall properties with regard to gender, race, obesity and stress also have to be extended before vessel wall properties can be used as a measure of cardiovascular risk under these conditions. In addition, the effects of weight reduction on large artery properties with a possible reduction in cardiovascular risk can give insight into the relation between obesity and arterial stiffness.

Data have to be collected in large groups of patients with insulin-dependent diabetes mellitus. As, apart from chronic hyperglycaemia and high HbA1c levels, hyperinsulinaemia has been thought to increase arterial stiffness, knowledge of insulin levels in this population is valuable. The group of non-insulin dependent diabetics could be subject of research, since previous data on these subjects largely depend on measurements with different techniques often in one arterial segment per study. Maybe from the results in these large patient groups it becomes possible to identify a cut-off point from which vessel wall properties in diabetic patients deteriorate and macrovascular complications develop. Factors postponing this point of no return are important to search for.

Future research could also be focussed on vessel wall properties and the relation with early endothelial dysfunction. Patients with severe hypercholesterolaemia could be investigated and the effects of therapy evaluated.

Early detection of increased arterial stiffness could identify subjects at risk, before they have developed irreversible arterial wall changes or vascular ischaemic complications.

Overall, evaluation of vessel wall properties in a large population study is necessary to see how distensibility and compliance values are distributed in presumed healthy people. In that case, a relation with different risk factors could be evaluated more accurately.

III. Vessel wall properties and influence of pharmacological intervention

A Antihypertensive treatment

It has been shown that antihypertensive treatment is effective in reducing cardiovascular morbidity and mortality. A meta-analysis of placebo-controlled studies showed that pharmacological antihypertensive treatment induced a 42% reduction in the incidence of stroke and a 14% reduction in coronary events (21). With a consistent reduction in the incidence of stroke, a curvilinear (J-curve) relation has been described for the extent of blood pressure reduction through antihypertensive therapy and the occurrence of myocardial infarction (2). The explanation for this feature might be that with a diastolic blood pressure below 85 mmHg, coronary perfusion pressure may become too low to provide adequate oxygen supply in patients with cardiac ischaemia (25). However, information on the J-curve is largely retrospective. Recently, it was shown that this J-curve relationship between diastolic blood pressure and myocardial infarction only is present in high risk groups, such as patients with left ventricular hypertrophy and coronary artery disease (25). In addition, the J-curve was seen especially in elderly patients (22). To date, it is suspected that blood pressure lowering due to preceding illness (62) and a high pulse pressure because of stiffer arteries (109) may increase cardiac mortality in these patients more than antihypertensive treatment on itself (22). Indeed, a high pretreatment pulse pressure may be the best predictor of cardiovascular complications in hypertensive patients (77). Since arterial distensibility (arterial stiffness) is important in determining pulse pressure, the effect of antihypertensive therapy on arterial stiffness may be of value. While the blood pressure lowering capacity of antihypertensive agents may be similar, the effect on arterial stiffness is not uniform for the different classes of antihypertensive drugs (Table 10.5).

Table 10.5. Effect of firstline antihypertensive agents on arterial stiffness and cardiovascular mortality and morbidity in hypertension.

Firstline drug	Arterial stiffness	Cardiovascular morbidity and mortality
ACE inhibitors	↓	?
Calcium antagonists		
dihydropyridine	↓	?
non-dihydropyridine	↓	?
β-Blockers		
non-selective	=	↓
selective β ₁	= / ↓	↓
vasodilating	↓	?
Diuretics	= / ↓	↓

↑ increase; ↓ decrease; = no change; ? not known.

In general, only ACE inhibitors, calcium antagonists, β -blockers with vasodilating properties, some selective β_1 -blockers and nitrates have shown a favourable effect on arterial stiffness, although real long-term studies (> 3 months) are lacking. In contrast to the idea that the widely used diuretics do not have an effect on arterial stiffness, we have shown that the long-term effect (6 months treatment) of a thiazide diuretic combination on arterial stiffness (distensibility) is beneficial (Chapter 7). On the other hand, we could demonstrate that the diuretic effect is less pronounced than that of the ACE inhibitor perindopril. The effect of perindopril on systemic vascular resistance was greater than with the diuretic. Since the afterload of the heart is largely determined by large artery properties (including arterial stiffness) and by systemic vascular resistance, these data suggest a more favourable influence on cardiac afterload for the ACE inhibitor on the long term.

It is always the question, whether the reduction in blood pressure is responsible for the improvement in vessel wall properties (indirect effect), or that large artery properties are decreased through a direct action of the drug on the vessel wall. An increased arterial compliance may be the result of [1] pure vasodilation or [2] an increased distensibility (lower stiffness) or [3] a combination of both. This pattern is different for the various antihypertensive drugs. It seems logical to select antihypertensive drugs that influence large artery properties beneficially, but it is not known whether this choice also is directly related to a decrease in cardiovascular morbidity and mortality. In addition, it remains an open question whether a decrease in distensibility (increased stiffness) and compliance due to structural changes can be reversed.

It has been demonstrated that after discontinuation of antihypertensive therapy, all positive effects on large artery properties are rapidly reversed, suggesting that functional rather than structural changes have occurred (1,5). However, it might be that vascular restructuring in hypertension still needs a longer time to occur, so that structural changes had not taken place yet. Biopsies would be necessary to investigate structural changes, but for the moment human biopsies are only available from subcutaneous vessels. With ACE inhibitors indeed a reversal of structural changes could be demonstrated in these small vessels after chronic treatment (111).

In the end, the most important effect of antihypertensive therapy is a reduction of cardiovascular morbidity and mortality, which are largely determined by a reduction in stroke, a reduction in myocardial infarction due to coronary (atherosclerotic) artery disease, or a reduction in cardiac hypertrophy, which may result in heart failure.

Stroke - No data are available of ACE inhibitors and calcium antagonists, but an indirect beneficial effect on stroke might be suspected through the blood pressure lowering effect of these drugs. β -Blockers (82,132) and diuretics (78,126) have been shown to prevent stroke in hypertensive patients.

Myocardial infarction - Calcium antagonists can slow down atherosclerotic disease (75), but a direct effect on the incidence of myocardial infarction has not been shown yet. β -Blockers reduce mortality from myocardial infarction (24,26). Diuretics are only effective for coronary heart disease prevention in the elderly (3,109).

Cardiac hypertrophy - ACE inhibitors have shown beneficial effects on ventricular hypertrophy and in patients with heart failure (27,28,95,118,120). β -Blockers are moderately effective in reversing left ventricular hypertrophy (28). Although diuretics were thought to have no effect on left ventricular hypertrophy (27), a recent meta-analysis showed that the reduction in left ventricular mass did not significantly differ with each of the aforementioned antihypertensive agents (35). This would suggest reduction of cardiac hypertrophy and subsequent improvement of cardiovascular risk with each of the classes of firstline antihypertensive drugs.

Overall, a direct relation between vessel wall properties and cardiovascular mortality and morbidity has not been shown yet, but an indirect relation by decreasing cardiac afterload and stress on the vessel wall may be suspected with some agents.

B Cholesterol lowering treatment

Lowering cholesterol in patients with hypercholesterolaemia decreases the risk of atherosclerotic complications and reduces mortality from coronary artery disease (16,17,37,76). A recent study with the cholesterol lowering agent simvastatin showed a significant reduction of cardiovascular mortality in patients with mild to moderate hypercholesterolaemia (107). On the other hand, a meta-analysis showed that in the population as a whole the relation between serum cholesterol and total mortality is not as linear as thought previously (53). In that study, a low as well as a high cholesterol level was associated with an increased total mortality. In mild to moderate hypercholesterolaemic patients we could not demonstrate an effect on arterial stiffness of an 8-week treatment period with pravastatin, a cholesterol lowering agent (Chapter 8). Since the lipid profile improved significantly, in this study there was no obvious relation between cholesterol and arterial stiffness. In addition, in a population of 250 subjects, cholesterol was only a minor determinant of arterial stiffness, compared to mean arterial pressure, age and gender (123). A longer treatment period may be needed to detect changes in arterial stiffness or larger patient groups may be necessary. However, then it is the question whether such changes would be clinically relevant.

C Angina pectoris

Patients with angina pectoris are at high risk to develop an acute coronary event. Vasodilator drugs, used to decrease cardiovascular risk, are an essential part of therapy within this patient group (69). Improvement of large artery properties has been described with the older nitrates, explaining in part the favourable effect on cardiac afterload of these drugs. However, these have all been acute studies, while in general patients use nitrates continuously.

In healthy volunteers, nicorandil, a new anti-anginal drug with nitrate-like actions and potassium channel opening properties, also increased arterial compliance through a vasodilatory effect, but the effect on arterial compliance was less pronounced than that of isosorbide dinitrate both acutely and after one week of therapy (Chapter 9). Arterial stiffness was not significantly lowered by either nicorandil or isosorbide dinitrate. An advantage of the new drug could be that it does not cause drug tolerance or reflex tachycardia. Whether these results also are valid in patients with angina has to be evaluated yet.

Nitrates are thought to preferentially reduce systolic pressure and are therefore recommended for the treatment of isolated systolic hypertension (73). In our healthy volunteers with a normal pulse pressure this effect was not seen.

D Future research

Concerning antihypertensive agents, long-term studies on reversal of structural changes deserve attention in future research. Techniques to investigate structural changes *in vivo* should be improved and used more frequently in clinical trials. Maybe non-invasive techniques that measure vessel wall thickness and smooth muscle mass more accurately than at present will become available. Ultimately, changes in functional and structural aspects of the arterial wall must be related to effects on cardiovascular morbidity and mortality. The optimal drug for the individual hypertensive patient should reduce morbidity and mortality, should be cheap, and should give a good drug adherence. Such a drug is expected [1] to provide adequate blood pressure reduction, [2] to improve large artery elasticity, [3] to reverse structural changes, if any, and [4] to have low incidence of side effects.

For nitrates it would be of interest to investigate their effect on vessel wall properties in isolated systolic hypertension as a possible way to reduce cardiovascular risk in these patients.

Long-term evaluation of different therapy regimens in hypercholesterolaemia is needed to draw conclusions on a possible reduction in arterial stiffness and cardiovascular complications.

Finally, it is possible that the predictive value of vessel wall properties with regard to future cardiovascular complications may be of more value than all these separate cardiovascular risk factors, such as smoking; cholesterol, obesity, hypertension, diabetes mellitus etc. Apart from progressive atherosclerosis (39,40), cardiac hypertrophy seems a key cardiovascular risk factor. Therefore, the consequence of additional research might be that an individual's value of large artery properties together with information on cardiac hypertrophy contributes to the individual cardiovascular risk. In addition, large artery properties might be used as a follow-up parameter for the effects of therapeutic interventions.

References

1. Aalkjaer C, Mulvany MJ, Jespersen B, Kjaer T, Sorensen SS, Pedersen EB. Morphological and functional abnormalities of resistance vessels from patients with essential hypertension are not normalized by antihypertensive therapy. *J Hypertens* 1988;6 (Suppl. 4) :S702.
2. Alderman MH, Ooi WL, Madhavan S, Cohen H. Treatment-induced blood pressure reduction and the risk of myocardial infarction. *JAMA* 1989;262 :920-24.
3. Amery A, Birkenhäger W, Brixko P, Bulpitt C, Clement D, de Leeuw P, de Plaen JF, Deruyttere M, De Schaepestryer A, Dollery C, Fagard R, Feltkamp H, Forette F, Forte J, Hamdy R, Henry JF, Koistinen A, Leonetti G, Lund-Johansen P, Morris J, Nissinen A, O'Brien E, O'Malley K, Terzoli L, Tuomilehto J, Webster J, Williams B. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. EWPHE results: subgroup analysis based on entry stratification. *J Hypertens* 1986;4 (Suppl. 6) :S642-47.
4. Applefeld MM. Chronic congestive heart failure: Where have we been ? Where are we heading ? *Am J Med* 1986;80 (Suppl. 2B) :73-77.
5. Asmar RG, Pannier B, Santoni JP, Laurent S, London GM, Levy BI, Safar ME. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. *Circulation* 1988;78 :941-50.
6. Avolio AP, Chen SG, Wang RP, Zhang CL, Li MF, O'Rourke MF. Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community. *Circulation* 1983;68 :50-58.
7. Avolio AP, Clyde KM, Beard TC, Cooke HM, Ho KKL, O'Rourke MF. Improved arterial distensibility in normotensive subjects on a low salt diet. *Arteriosclerosis* 1986;6 :166-69.
8. Avolio AP, Deng FQ, Li WQ, Luo YF, Huang ZD, Xing LF, O'Rourke MF. Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: a comparison between urban and rural communities in China. *Circulation* 1985;71 :202-10.
9. Barrett-Connor E, Khaw K. Is hypertension more benign when associated with obesity? *Circulation* 1985;72 :53-60.
10. Baskett JJ, Lewis RR, Beasley MG, Gosling RG. Changes in carotid artery compliance with age. *Age Ageing* 1990;19 :241-46.
11. Benetos A, Laurent S, Hoeks AP, Boutouyrie PH, Safar ME. Arterial alterations with aging and high blood pressure. A noninvasive study of carotid and femoral arteries. *Arterioscler Thromb* 1993;13 :90-97.
12. Benetos A, Tsoucaris-Kupfer D, Favereau X, Corcos T, Safar M. Carotid artery tonometry: an accurate non-invasive method for central aortic pulse pressure evaluation. *J Hypertens* 1991;9 (Suppl. 6) :S144-45.
13. Blaustein MP, Hamlyn JM. Pathogenesis of essential hypertension. A link between dietary salt and high blood pressure. *Hypertension* 1991;18 :III-184-III-195.

14. Borow KM, Newburger JW. Noninvasive estimation of central aortic pressure using the oscillometric method for analyzing systemic artery pulsatile blood flow: comparative study of indirect systolic, diastolic, and mean brachial artery pressure with simultaneous direct ascending aortic pressure measurements. *Am Heart J* 1982;103 :879-86.
15. Brennan PJ, Greenberg G, Miall WE, Thompson SG. Seasonal variation in arterial blood pressure. *BMJ* 1982;285 :19-23.
16. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J, Kaplan C, Zhao X, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. *N Engl J Med* 1990;323 :1289-98.
17. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smirk RD, Sawin HS, Campos CT, Hansen BJ, Tuna N, Karnegis JN, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Bissett JK, Weber FJ, Stevenson JW, Leon AS, Chalmers TC, POSCH group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. *N Engl J Med* 1990;323 :946-55.
18. Cameron JD, Dart AM. Exercise training increases total systemic arterial compliance in humans. *Am J Physiol* 1994;266 :H693-701.
19. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. *JAMA* 1986;256 :2835-38.
20. Colan SD, Fujii A, Borow KM, MacPherson D, Sanders SP. Noninvasive determination of systolic, diastolic and end-systolic blood pressure in neonates, infants and young children: comparison with central aortic pressure measurements. *Am J Cardiol* 1983;52 :867-70.
21. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure; overview of randomised drug trials in their epidemiological context. *Lancet* 1990;335 :827-38.
22. Coope J, Warrender TS. Lowering blood pressure. *Lancet* 1987;2 :518.
23. Corrao JM, Becker RC, Ockene IS, Hamilton GA. Coronary heart disease risk factors in women. *Cardiology* 1990;77 (Suppl. 2) :8-24.
24. Cruickshank JM. blockers and primary prevention revisited. *Cardiovasc Rev Rep* 1990;11 :10-16.
25. Cruickshank JM. J curve in antihypertensive therapy. Does it exist ? A personal point of view. *Cardiovasc Drugs Ther* 1994;8 :757-60.
26. Cruickshank JM, Pennert K, Sorman AE, Thorp JM, Zacharias FM, Zacharias FJ. Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta-blocker plus other hypertensives. *J Hypertens* 1987;5 :489-98.
27. Dahlöf B. Regression of cardiovascular structural changes - a preventive strategy. *Clin Exp Hypertens [A]* 1990;A12 :877-96.
28. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. *Am J Hypertens* 1992;5 :95-110.
29. Darne B, Girerd X, Safar M, Cambien F, Guize L. Pulsatile versus steady component of blood pressure: a cross-sectional analysis and a prospective analysis on cardiovascular mortality. *Hypertension* 1989;13 :392-400.
30. Dart AM, Lacombe F, Yeoh JK, Cameron JD, Jennings GL, Laufer E, Esmore DS. Aortic distensibility in patients with isolated hypercholesterolaemia, coronary artery disease, or cardiac transplant. *Lancet* 1991;338 (I) :270-73.
31. Dimond GE. Hypertension, body weight and coronary heart disease. *Arch Intern Med* 1963;112 :550.
32. Draaijer P, Kool MJ, Maessen JM, Van Bortel LM, de Leeuw PW, van Hooff JP, Leunissen KM. Vascular distensibility and compliance in salt-sensitive and salt-resistant borderline hypertension. *J Hypertens* 1993;11 :1199-1207.
33. Eichner ER. Exercise and heart disease: epidemiology of the "Exercise Hypothesis". *Am J Med* 1983;75 :1008-23.
34. Eliakim M, Sapoznikov D, Weinman J. Pulse wave velocity in healthy subjects and in patients with various disease states. *Am Heart J* 1971;82 :448-57.
35. Fagard R, Lijnen P, Staessen J, Thijs L, Amery A. Mechanical and other factors relating to left ventricular hypertrophy. *Blood Pressure* 1994;3 (Suppl. 1) :5-10.
36. Freis ED. Salt, volume and the prevention of hypertension. *Circulation* 1976;53 :589-95.

37. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen J, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjolom T, Nikkila EA. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. *N Engl J Med* 1987;317 :1237-45.
38. Furlan R, Guzzetti S, Crivellaro W, Dassi S, Tinelli M, Baselli G, Cerutti S, Lombardi F, Pagani M, Malliani A. Continuous 24-hour assessment of the neural regulation of systemic arterial pressure and RR variabilities in ambulant subjects. *Circulation* 1990;81 :537-47.
39. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. *N Engl J Med* 1992;326 :242-50.
40. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. *N Engl J Med* 1992;326 :310-18.
41. Giaconci S, Palombo C, Genovesi-Ebert A, Marabotti C, Volterrani D, Ghione S. Long-term reproducibility and evaluation of seasonal influences on blood pressure monitoring. *J Hypertens* 1988;6 (Suppl. 4) :64-66.
42. Gordon T, Kannel WB, Castelli WP, Dawber T. Lipoproteins, cardiovascular disease, and death. The Framingham study. *Arch Intern Med* 1981;141 :1128-31.
43. Gore I, Nakashima T, Imai T, White PB. Coronary atherosclerosis and myocardial infarction in Kyushu, Japan, and Boston, Massachusetts. *Am J Cardiol* 1962;10 :400-406.
44. Green A, Borch-Johnsen K, Andersen PK, Hougaard P, Keiding N, Kreiner S, Deckert T. Relative mortality of type 1 (insulin-dependent) diabetes in Denmark: 1933-1981. *Diabetologia* 1985;28 :339-42.
45. Hamazaki T, Urakaze M, Sawazaki S, Yamazaki K, Taki H, Yano S. Comparison of pulse wave velocity of the aorta between inhabitants of fishing and farming villages in Japan. *Atherosclerosis* 1988;73 :157-60.
46. Harshfield GA, Alpert BS, Willey ES, Somes GW, Murphy JK, Dupaul LM. Race and gender influence ambulatory blood pressure patterns of adolescents. *Hypertension* 1989;14 :598-603.
47. Hayoz D, Tardy Y, Perret F, Waeber B, Meister JJ, Brunner HR. Non-invasive determination of arterial diameter and distensibility by echo-tracking techniques in hypertension. *J Hypertens* 1992;10 (Suppl. 5) :S95-S100.
48. Hayoz D, Tardy Y, Rutschmann B, Waeber B, Meister J, Brunner HR. Effect of mental stress on the tone of a medium-sized muscular artery. *J Hypertens* 1992;10 (Suppl. 6) :S57-59.
49. Hirai T, Sasayama S, Kawasaki T, Yagi S. Stiffness of systemic arteries in patients with myocardial infarction. A noninvasive method to predict severity of coronary atherosclerosis. *Circulation* 1989;80 :78-86.
50. Hofstra L, Willigers JM, Huvers FC, Schaper NC, Kester ADM, Kitslaar PJEHM, Hoeks APG. Short-term variation in the elastic properties of a muscular artery in humans. *Clin Sci* 1994;86 :567-74.
51. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Study. *Circulation* 1983;67 :968-76.
52. Idema RN, van den Meiracker AH, Imholz BPM, Man in 't Veld AJ, Settels JJ, Ritsema van Eck HJ, Schalekamp MADH. Comparison of Finapres non-invasive beat-to-beat finger blood pressure with intrabrachial artery pressure during and after bicycle ergometry. *J Hypertens* 1989;7 (Suppl. 6) :S58-59.
53. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, Neaton J, Nelson J, Potter J, Rifkind B, Rossouw J, Shekelle R, Yusuf S. Report of the conference on low blood cholesterol: mortality associations. *Circulation* 1992;86 :1046-60.
54. Jennings G, Nelson L, Nestel P, Esler M, Komer P, Burton D, Bazelmans J. The effects of changes in physical activity on major cardiovascular risk factors, hemodynamics, sympathetic function and glucose utilization in man: a controlled study of four levels of activity. *Circulation* 1986;73 :30-40.
55. Joannides R, Moore N, Richard V, Godin M, Thuillez C. Adaptation mecanique des artres musculaires l'ivation aigu de la pression artrielle chez l'homme. Apports de la mesure de l'paisseur de la paroi artrielle. *Arch Mal Coeur Vaiss* 1993;86 :1219-23.
56. Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K. The association of borderline hypertension with target organ changes and higher coronary risk. *JAMA* 1990;264 :354-58.
57. Julius S, Schork MA. Borderline hypertension: a critical review. *J Chron Dis* 1971;23 :723-54.
58. Kannel WB, Hjortland MC, McNamara PM. Menopause and risk of cardiovascular disease. The Framingham Study. *Ann Intern Med* 1976;85 :447-52.

59. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham study. *Diabetes Care* 1979;2 :120-26.
60. Kannel WB, Sorlie P. Hypertension in Framingham. In: Paul O, ed. *Epidemiology and control of hypertension* New York: Grune and Stratton, 1975 :553-92.
61. Kannel WB, Wolf PA, McGee DL, Dawber TR, McNamara P, Castelli WP. Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. *JAMA* 1981;245 :1225-29.
62. Kannel W, Sorlie P, Castelli WP, McGee DL. Blood pressure and survival after myocardial infarction: the Framingham study. *Am J Cardiol* 1980;45 :326-30.
63. Kaplan NM, Venkata C, Ram S. Hypertension in ethnic subgroups. In: Swales JD, ed. *Textbook of hypertension* 1st ed. Oxford: Blackwell Scientific Publications, 1994 :811-28.
64. Karamanoglu M, O'Rourke MF, Avolio AP, Kelly RP. An analysis of the relationship between central aortic and peripheral upper limb pressure waves in man. *Eur Heart J* 1993;14 :160-67.
65. Kawasaki T, Sasayama S, Yagi S, Asakawa T, Hirai T. Non-invasive assessment of the age related changes in stiffness of major branches of the human arteries. *Cardiovasc Res* 1987;21 :678-87.
66. Kelly R, Hayward C, Avolio A, O'Rourke M. Noninvasive determination of age-related changes in the human arterial pulse. *Circulation* 1989;80 :1652-59.
67. Kelly R, Karamanoglu M, Gibbs H, Avolio A, O'Rourke M. Noninvasive carotid pressure wave registration as an indicator of ascending aortic pressure. *J Vasc Med Biol* 1989;1 :241-47.
68. Kelly RP, Gibbs HH, O'Rourke MF, Daley JE, Mang K, Morgan JJ, Avolio AP. Nitroglycerin has more favourable effects on left ventricular afterload than apparent from measurement of pressure in a peripheral artery. *Eur Heart J* 1990;11 :138-44.
69. Koch - Weser J. Vasodilator drugs in the treatment of hypertension. *Arch Intern Med* 1974;133 :1017-28.
70. Laurent S, Hayoz D, Trazzi S, Boutouyrie P, Waeber B, Omboni S, Brunner HR, Mancia G, Safar M. Isobaric compliance of the radial artery is increased in patients with essential hypertension. *J Hypertens* 1993;11 :89-98.
71. Lehmann ED, Gosling RG, Snksen PH. Arterial wall compliance in diabetes. *Diabetic Med* 1992;9 :114-19.
72. Lehmann ED, Watts GF, Fatemi-Langroudi B, Gosling RG. Aortic compliance in young patients with heterozygous familial hypercholesterolaemia. *Clin Sci* 1992;83 :717-21.
73. Levenson J, Bouthier J, Chau NP, Rolan E, Simon AC. Effects of nicorandil on arterial and venous vessels of the forearm in systemic hypertension. *Am J Cardiol* 1989;63 :40J-3J.
74. Levenson JA, Simon AC, Maarek BE, Gitelman RJ, Fiessinger JN, Safar ME. Regional compliance of brachial artery and saline infusion in patients with arteriosclerosis obliterans. *Arteriosclerosis* 1985;5 :80-87.
75. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. *Lancet* 1990;336 :172-74.
76. Lipid Research Clinics Program. The lipid research clinics coronary. Primary prevention trial results. I. Reduction in incidence of coronary heart disease. *JAMA* 1984;251 :351-74.
77. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. *Hypertension* 1994;23 :395-401.
78. Management Committee of the Australian Therapeutic Trial in Mild Hypertension. The Australian Therapeutic Trial in Mild Hypertension. *Lancet* 1980;1 :1261-67.
79. Marler JR, Price TR, Clark GL, Muller JE, Robertson T, Mohr JP, Hier DB, Wolf PA, Caplan LR, Foulkes MA. Morning increase in onset of ischemic stroke. *Stroke* 1989;20 :473-76.
80. Marmot MG, Kagan A, Kato H. Hypertension and heart disease in the Ni-Hon-San study. In: Kesteloot H, Joossens JV, eds. *Epidemiology of arterial blood pressure* 1st ed. The Hague: Martinus Nijhoff, 1980 :437-52.
81. McVeigh G, Brennan G, Hayes R, Cohn J, Finkelstein S. Vascular abnormalities in non-insulin-dependent diabetes mellitus identified by arterial waveform analysis. *Am J Med* 1993;95 :424-30.
82. Medical Research Council Working Party. MRC trial of treatment of mild hypertension; principal results. *BMJ* 1985;291 :97-104.

83. van Merode T, Brands PJ, Hoeks APG, Reneman RS. Faster aging of the carotid artery bifurcation in borderline hypertensive subjects. *J Hypertens* 1993;11 :171-76.
84. van Merode T, Hick PJJ, Hoeks APG, Reneman RS. Noninvasive assessment of artery wall properties in children aged 4-19 years. *Pediatr Res* 1988;25 :94-96.
85. van Merode T, Hick PJJ, Hoeks APG, Smeets FAM, Reneman RS. Differences in carotid artery wall properties between presumed-healthy men and women. *Ultrasound Med Biol* 1988;14 :571-74.
86. Mohiaddin RH, Underwood SR, Bogren HG, Firmin DN, Klipstein RH, Rees RS, Longmore DB. Regional aortic compliance studied by magnetic resonance imaging: the effects of age, training and coronary artery disease. *Br Heart J* 1989;62 :90-96.
87. Muller JE, Ludmer PL, Willich SN, Tofler GH, Aylmer G, Kiangos I, Stone PH. Circadian variation in the frequency of sudden cardiac death. *Circulation* 1987;75 :131-38.
88. Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisler CA, Parker C, Poole WK, Passamani E, Roberts R, Robertson T, Sobel BE, Willerson JT, Braunwald E, MILIS Study Group. Circadian variation in the frequency of onset of acute myocardial infarction. *N Engl J Med* 1985;313 :1315-22.
89. Murdoch JL, Walker BA, Halpern BL, Kuzma JW, McKusick VA. Life expectancy and causes of death in the Marfan syndrome. *N Engl J Med* 1972;286 :804-8.
90. Nakashima T, Tanikawa J. A study of human aortic distensibility with relation to atherosclerosis and aging. *Angiology* 1971;22 :477-87.
91. O'Brien E, Sheridan J, O'Malley K. Dippers and non-dippers. *Lancet* 1988 (II) :397.
92. O'Rourke M. Arterial stiffness, systolic blood pressure, and logical treatment of arterial hypertension. *Hypertension* 1990;15 :339-47.
93. Packer M. Sudden unexpected death in patients with congestive heart failure: a second frontier. *Circulation* 1985;72 :681-85.
94. Parati G, Casadei R, Groppelli A, Di Rienzo M, Mancia G. Comparison of finger and intra-arterial blood pressure monitoring at rest and during laboratory testing. *Hypertension* 1989;13 :647-55.
95. Pfeffer MA, Braunwald E, Moyà LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. *N Engl J Med* 1992;327 :669-77.
96. Pickering TG. Blood pressure measurement. In: Pickering TG, ed. *Ambulatory monitoring and blood pressure variability*. Part 1 1st ed. London: Science Press Ltd, 1990 :2.1-2.16.
97. Pickering TG. Does psychological stress contribute to the development of hypertension and coronary heart disease? *Eur J Clin Pharmacol* 1990;39 :S1-S7.
98. Reneman RS, van Merode T, Brands PJ, Hoeks APG. Inhomogeneities in arterial wall properties under normal and pathological conditions. *J Hypertens* 1992;10 (Suppl. 6) :S35-40.
99. Reneman RS, van Merode T, Hick P, Muyltjens AMM, Hoeks APG. Age-related changes in carotid artery wall properties in men. *Ultrasound Med Biol* 1986;12 :465-71.
100. Rocco MB, Barry J, Campbell S, Nabel E, Cook EF, Goldman L, Selwyn AP. Circadian variation of transient myocardial ischemia in patients with coronary artery disease. *Circulation* 1987;75 :395-400.
101. Rostand SG, Gretes JC, Kirk KA, Rutsky EA, Andreoli TE. Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis. *Kidney Int* 1979;16 :600-611.
102. Russell AE, Wing LMH, Smith SA, Aylward PE, McRitchie RJ, Hassam RM, West MJ, Chalmers JP. Optimal size of cuff bladder for indirect measurement of arterial pressure in adults. *J Hypertens* 1989;7 :607-13.
103. Rutan GH, Kuller LH, Neaton JD, Wentworth DN, McDonald RH, Smith WM. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. *Circulation* 1988;77 :504-14.
104. Safar M. Therapeutic trials and large arteries in hypertension. *Am Heart J* 1988;115 :702-10.
105. Safar M. Ageing and its effects on the cardiovascular system. *Drugs* 1990;39 (Suppl. 1) :1-8.

106. Safar M, Laurent S, Safavian A, Pannier B, Asmar R. Sodium and large arteries in hypertension. Effects of indapamide. *Am J Med* 1988;84 (Suppl. 1B) :15-19.
107. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994;344 :1383-89.
108. Seedat YK. Varying responses to hypotensive agents in different racial groups: black versus white differences. *J Hypertens* 1989;7 :515-18.
109. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. *JAMA* 1991;265 :3255-64.
110. Shulman NB. Treatment of hypertension in black patients with angiotensin-converting enzyme inhibitors. *J Natl Med Assoc* 1988;80 :265-72.
111. Sihm I, Schroeder AP, Aalkjaer C, Holm M, Morn B, Mulvany MJ, Thygesen K, Lederballe O. Normalization of resistance artery structure and left ventricular morphology with a perindopril-based regimen. *Can J Cardiol* 1994;10 (Suppl. D) :30D-2D.
112. Silagy CA, McNeil JJ. Epidemiological aspects of isolated systolic hypertension and implications for future research. *Am J Cardiol* 1992;69 :213-18.
113. Simon AC, O'Rourke M, Levenson J. Arterial distensibility and its effect on wave reflection and cardiac loading in cardiovascular disease. *Coron Artery Dis* 1991;2 :1111-20.
114. Smith T, Wesseling KH, De Wit B. Evaluation of two prototype devices producing noninvasive, pulsatile, calibrated blood pressure measurement from a finger. *J Clin Monit* 1985;1 :17-29.
115. Sokolow M, Perloff D. The prognosis of essential hypertension treated conservatively. *Circulation* 1961;23 :697.
116. Stefanadis C, Wooley CF, Bush CA, Kolibash AJ, Boudoulas H. Aortic distensibility abnormalities in coronary artery disease. *Am J Cardiol* 1987;59 :1300-1304.
117. Stokes J, Kannel WB, Wolf PA, Cupples LA, D'Agostino RB. The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35-64 years: 30 years of follow-up in the Framingham study. *Circulation* 1987;75 (Suppl. V) :V65-73.
118. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. *N Engl J Med* 1987;316 :1429-35.
119. The Expert Panel. Report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. *Arch Intern Med* 1988;148 :36-69.
120. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med* 1991;325 :293-302.
121. Thordarson H, Thorgeirsson G, Helgason T. Aortic stiffness in insulin-dependent diabetics: an echocardiographic study. *Diabetic Med* 1986;3 :449-54.
122. Treese N, Ungern-Sternberg v A, Cordes U, Beyer J. Influence of norepinephrine on vessel geometry of the intact femoral artery in juvenile insulin-dependent diabetics. Evidence of early diabetic angiopathy in central arteries. *Z Kardiol* 1982;71 :60-64.
123. Van Bortel L, Laurent S, Laloux B, Kool M, Boutouyrie P, Struijker Boudier H, Chatellier G, Safar M. Le tabagisme et le cholestérol total sont de faibles déterminants des propriétés fonctionnelles des artères carotide et fémorale. *Arch Mal Coeur Vaiss* 1993;86 (Suppl. 14).
124. Van Bortel LM, Hoeks APG, Kool MJF, Struijker-Boudier HA. Introduction to large artery properties as a target for risk reduction by antihypertensive therapy. *J Hypertens* 1992;10 (Suppl. 6) :S123-26.
125. Verdecchia P, Schillaci G, Guerriero M, Gatteschi C, Benemio G, Boldrini F, Porcellati C. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. *Circulation* 1990;81 :528-36.
126. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. *JAMA* 1970;213 :1143-52.
127. Virmani R, Avolio AP, Mergner WJ, Robinowitz M, Herderick EE, Cornhill JF, Guo SY, Liu TH, Ou DY, O'Rourke M. Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis. *Am J Pathol* 1991;139 :1119-29.

128. Wahlqvist ML, Lo CS, Myers KA, Simpson RW, Simpson JM. Putative determinants of arterial wall compliance in NIDDM. *Diabetes Care* 1988;11 :787-90.
129. Watt GCM, Foy CJW. Dietary sodium and arterial pressure: problems of studies within a single population. *J Epidemiol Commun Health* 1982;36 :197-201.
130. Wesseling KH, Settels JJ, Van Der Hoeven GMA, Nijboer JA, Butijn MWT, Dorlas JC. Effects of peripheral vasoconstriction on the measurement of blood pressure in a finger. *Cardiovasc Res* 1985;19 :139-45.
131. Wijnen JA, Kool MJ, Kooman JP, van Baak M, Hoeks AP, Struijker Boudier HA, Van Bortel LM. Vessel wall properties of large arteries and endurance training. *J Hypertens* 1993;11 (Suppl. 5) :S88-89.
132. Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmstedt D, Berglund G. Primary prevention with metoprolol in patients with hypertension: mortality results from the MAPHY study. *JAMA* 1988;259 :1976-82.
133. Willett WC, Green A, Stampfer MJ, Speizer FE, Colditz GA, Rosner B, Monson RR, Stason W, Hennekens CH. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. *N Engl J Med* 1987;317 :1303-9.
134. Woodhouse PR, Khaw KT, Plummer M. Seasonal variation of blood pressure and its relationship to ambient temperature in an elderly population. *J Hypertens* 1993;11 :1267-74.
135. Woodhouse PR, Khaw KT, Plummer M, Foley A, Meade TW. Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. *Lancet* 1994;343 (I) :435-39.

CHAPTER 11

SUMMARY

Summary

Distensibility and compliance are vessel wall properties of large arteries describing the elastic properties and buffering capacity of these vessels, respectively. Distensibility is the relative change in volume of an artery per change in pressure and represents the elasticity of large arteries. It is an important determinant of the pulsatile stress on the vessel wall. Compliance is defined by the absolute change in volume per change in pressure. Since it reflects the buffering capacity of large arteries, it is an important determinant of left ventricular afterload. A decrease in distensibility or compliance is thought to be related to a higher risk of stroke, heart failure and atherosclerotic disease. Vessel wall properties of large arteries may be a valuable tool to identify a person's individual cardiovascular risk.

Chapter 1 reviews the significance of vessel wall properties in general and for cardiovascular disease more particularly. Determinants of arterial compliance are discussed and an overview is given of different techniques to evaluate large artery properties in humans. The effects of age, gender, race, obesity, salt intake and physical exercise on large artery properties are reviewed (1.3). While several physiologic conditions may negatively influence distensibility and compliance, a decrease in distensibility or compliance may enhance the risk of cardiovascular disease, in turn. Data on vessel wall properties and some important pathologic conditions, such as hypertension, diabetes mellitus and atherosclerosis are reported (1.4). The effects of different antihypertensive agents on vessel wall properties are mentioned in 1.5.

Chapter 2 describes the methods for haemodynamic measurements as used in the studies in the present thesis. As large artery properties were investigated with a recently developed and modified vessel wall movement detector system, a detailed description of this system is given. With the present device, arterial distensibility and compliance of elastic and muscular large arteries can be determined. Reproducibility measurements were necessary to evaluate this new technique. In *Chapter 3* data on reproducibility of the vessel wall movement detector system are presented. The system shows a good technical reproducibility and a fairly good intraobserver variability with a coefficient of variation lower than 10% for distension and diameter of the common carotid artery. In the muscular femoral and brachial arteries variation was larger (about 12-13%), most likely due to a greater spontaneous variation in distension in these vessels, which are under permanent neurohumoral control. Interobserver variability was larger than intraobserver variability and might be influenced by differences in observers' skill and short-term variation in vessel wall properties.

A day-night pattern could be demonstrated for vessel wall properties in healthy volunteers (*Chapter 4*). Nocturnal vasodilation may be due to a lower sympathetic activity at night. Although elastic properties also decreased at night, arterial compliance (buffering capacity) was preserved throughout the day (4.1). The influence of several hormones, such as atrial natriuretic peptide, noradrenalin, renin and prorenin were investigated (4.2), but they do not seem to have a simple relation with vessel wall properties. A classic day-night pattern, such as known from blood pressure and heart rate, was found for noradrenalin and prorenin. Noradrenalin increased in the morning when the subjects were still in bed and therefore is likely to be related to the stress of awakening.

Various cardiovascular risk factors have shown to be associated with a decrease in distensibility and compliance. The acute and chronic effects of cigarette smoking were investigated in *Chapter 5*. Results indicated that in habitual smokers smoking one cigarette causes an acute decrease in distensibility and compliance of both elastic and muscular arteries, while - except for a higher heart rate - no obvious long-term effects of smoking could be demonstrated in these middle-aged subjects. The acute effects of smoking on the long term may be harmful to the endothelium and may form a risk for acute coronary events rather than the chronic effects.

In young, uncomplicated insulin-dependent diabetic patients vessel wall properties of elastic and muscular large arteries were not obviously reduced when compared with healthy controls (*Chapter 6*). However, femoral artery distensibility was decreased in diabetic patients, suggesting an early vascular dysfunction at this site. Therefore, this artery may be more prone to atherosclerotic changes in these patients. No

correlation could be detected between duration of disease, actual glucose or HbA1c levels and vessel wall properties.

The effect of therapeutic intervention on distensibility and compliance depends on the disease treated and the agents used. In essential hypertension long-term treatment (6 months) with an ACE inhibitor (perindopril) resulted in a more pronounced improvement of vessel wall properties than treatment with a thiazide drug (amiloride/hydrochlorothiazide) combination, although the effect on blood pressure was comparable (*Chapter 7*). This suggests that the effect on vessel wall properties in case of the ACE inhibitor is not only due to a decrease in blood pressure (indirect), but also due to a direct action on the arterial wall. Consequently, the afterload of the heart will be more decreased with the ACE inhibitor than with the diuretic. Total peripheral resistance was also more reduced with perindopril than with amiloride/hydrochlorothiazide, indicating another beneficial influence of the ACE inhibitor on cardiac afterload. However, after cessation of therapy, the basal situation returned, suggesting a need for a longer treatment period.

Hypercholesterolaemia is considered another risk factor of atherosclerosis. An early feature of atherosclerosis is endothelial dysfunction which may increase vascular tone and arterial stiffness. In mild to moderate hypercholesterolaemic patients a short-term (8 weeks) lowering of plasma cholesterol with pravastatin did not alter haemodynamics or improve vessel wall properties of large arteries, while there was a significant improvement of the lipid profile (*Chapter 8*). Since vessel wall properties were almost similar between mild hypercholesterolaemic subjects and controls, the lack of effect of cholesterol lowering on vessel wall properties was to be expected. On the other hand, there was a trend for a decrease in arterial stiffness of the femoral artery during cholesterol lowering therapy. A longer treatment period may be necessary to improve vessel wall properties and reduce cardiovascular risk.

In *Chapter 9* the acute and subacute effects of isosorbide dinitrate (ISDN) and nicorandil, a nitrate-like agent with potassium channel opening properties, on arterial and venous parameters were investigated in healthy volunteers. In dosages used in angina pectoris, the pure nitrate ISDN induced a more pronounced decrease of blood pressure and greater vasodilation of the common carotid artery, compared to nicorandil. ISDN drug tolerance could be demonstrated for blood pressure, heart rate and venous dynamics, but not for arterial dynamics. No drug tolerance was seen with nicorandil.

Finally, in *Chapter 10* different factors that could influence and improve the vessel wall movement measuring technique are discussed. Issues for future research are proposed. They include studies on physiologic factors that influence vessel wall properties (i.e. gender, race) in order to define more precisely the different risk factors with regard to distensibility and compliance. The consequence of additional research might be that an individual's value of large artery properties could contribute to a more personal cardiovascular risk profile, while it also may become a follow-up parameter for the effects of therapeutic interventions.

CHAPTER 12

SAMENVATTING

Samenvatting

Distensibiliteit en compliantie zijn vaatwandeigenschappen van grote arteriën die respectievelijk de elastische eigenschappen en de bufferende capaciteit van deze arteriën beschrijven. Distensibiliteit is gedefinieerd als de relatieve verandering in volume van een arterie per verandering in druk. Distensibiliteit geeft aldus de elasticiteit van een grote arterie weer en is een belangrijke determinant voor de intermitterende (pulsatiele) stress op de vaatwand. Compliantie is gedefinieerd als de absolute verandering in volume van een arterie per verandering in druk. Compliantie bepaalt het bufferend vermogen van grote arteriën, d.w.z. de mate waarin grote arteriën telkens opnieuw de systolische vloedgolf vanuit het hart kunnen opvangen. Compliantie is een belangrijke determinant voor de nabelasting van de linker ventrikel van het hart. De gedachte is dat een vermindering van distensibiliteit en compliantie geassocieerd is met een hoger risico op het ontwikkelen van cerebrovasculaire accidenten (met name stroke), hartfalen en atherosclerotische vaatwandveranderingen. Vaatwandeigenschappen van grote arteriën zouden een waardevol instrument kunnen zijn om iemands persoonlijk algeheel cardiovasculair risico aan te geven.

In *Hoofdstuk 1* wordt de betekenis en het belang van vaatwandeigenschappen in het algemeen en van vaatwandeigenschappen bij cardiovasculaire aandoeningen meer in het bijzonder besproken en toegelicht. Bepalende factoren ten aanzien van arteriële compliantie worden bediscussieerd. Een overzicht wordt gegeven van de verschillende technieken waarmee vaatwandeigenschappen in de humane situatie onderzocht kunnen worden. Tevens wordt een overzicht gegeven van de effecten van leeftijd, geslacht, ras, obesitas, zoutinname en fysieke inspanning op de vaatwandeigenschappen (1.3). Enerzijds kunnen verscheidene fysiologische condities distensibiliteit en compliantie negatief beïnvloeden. Anderzijds kan een vermindering van distensibiliteit en compliantie op zijn beurt het risico op cardiovasculaire aandoeningen verhogen. De gegevens die bekend zijn met betrekking tot vaatwandeigenschappen en enkele belangrijke pathologische condities, zoals hypertensie, diabetes mellitus en atherosclerose worden in paragraaf 1.4 gerapporteerd. De effecten van de verschillende klassen antihypertensiva op vaatwandeigenschappen worden in paragraaf 1.5 besproken.

In *Hoofdstuk 2* worden de methoden, die gebruikt zijn voor de hemodynamische metingen in de studies van dit proefschrift, beschreven. Aangezien de vaatwandeigenschappen onderzocht werden met een recent ontwikkeld en gemodificeerd vaatwand detector systeem, wordt een gedetailleerde beschrijving van dit systeem gegeven. Met het huidige systeem kunnen distensibiliteit en compliantie van elastische en musculaire grote arteriën bepaald worden. Reproduceerbaarheidsmetingen waren noodzakelijk om deze nieuwe techniek op zijn waarde te kunnen beoordelen.

In *Hoofdstuk 3* worden de resultaten van de reproduceerbaarheidsstudie van het vaatwand detector systeem gepresenteerd. Het systeem heeft een goede technische reproduceerbaarheid. De variatie binnen één onderzoeker (intraobserver variabiliteit) is, met een variatiecoëfficiënt van minder dan 10% voor distensie en diameter van de elastische a. carotis communis, vrij goed te noemen. De variatiecoëfficiënt voor deze parameters van de musculaire a. femoralis en a. brachialis was groter (12-13%). Zeer waarschijnlijk is dit een gevolg van een grotere spontane variatie in distensie van deze bloedvaten, die aan een permanente neurohumorale controle onderhevig zijn. De variatie tussen verschillende onderzoekers (interobserver variabiliteit) was groter dan de intraobserver variabiliteit. Dit zou te maken kunnen hebben met verschillen in ervaring tussen de onderzoekers en korte-termijn variatie in vaatwandeigenschappen zelf.

In een groep van gezonde vrijwilligers kon een dag-nacht patroon aangetoond worden voor vaatwandeigenschappen (*Hoofdstuk 4*). Vasodilatatie gedurende de nacht kan een gevolg zijn van een lagere activiteit van het sympathisch zenuwstelsel. Hoewel de elastische eigenschappen (distensibiliteit) ook afnamen 's nachts, bleef het bufferend vermogen (compliantie) behouden gedurende dag en nacht (4.1). De invloed van verschillende hormonen, zoals ANP (atrial natriuretic peptide), noradrenaline, renine en prorenine, werd onderzocht in relatie tot het dag-nacht patroon van vaatwandeigenschappen (4.2), doch deze relatie lijkt, indien aanwezig, zeer complex. Een klassiek dag-nacht patroon, zoals dat ook gezien

wordt bij bloeddruk en hartfrequentie, werd gevonden voor noradrenaline en prörenine. De noradrenaline spiegel nam fors toe in de ochtenduren, op het tijdstip dat de vrijwilligers nog in bed lagen. Derhalve lijkt deze stijging van noradrenaline gerelateerd te zijn aan de stress van het ontwaken.

Verscheidene cardiovasculaire risicofactoren zijn geassocieerd met een verminderde distensibiliteit en compliantie. In *Hoofdstuk 5* werden in dit verband de acute en chronische effecten van het roken van sigaretten op vaatwandeigenschappen onderzocht. De resultaten van deze studie toonden aan dat in gewoonte rokers het roken van één sigaret een acute vermindering van distensibiliteit en compliantie van elastische en musculaire arteriën tot gevolg heeft. Daarentegen werden, met uitzondering van een hogere hartfrequentie, geen evidente chronische effecten van het roken van sigaretten gezien binnen deze groep van gewoonterokers van middelbare leeftijd. De telkens terugkerende acute effecten van roken kunnen op de lange termijn schadelijk zijn voor het vaatendotheel en zouden, meer dan de chronische effecten, een verhoogd risico kunnen vormen voor het ontstaan van acute coronaire aandoeningen.

Bij jonge, insuline-afhankelijke diabeten, die geen complicaties van de ziekte hadden ontwikkeld, waren de vaatwandeigenschappen van elastische en musculaire arteriën niet evident verminderd, wanneer zij vergeleken werden met gezonde vrijwilligers (*Hoofdstuk 6*). De distensibiliteit van de a. femoralis was echter wél verminderd in de groep van diabetes patiënten. Dit suggereert vasculaire dysfunctie in een vroeg stadium in dit bloedvat bij diabetes patiënten zonder aanwijzingen voor aanwezigheid van andere complicaties. Dientengevolge zou deze arterie meer gevoelig kunnen zijn voor atherosclerotische vaatwandveranderingen. In deze studie kon geen relatie aangetoond worden tussen de duur van de ziekte, de actuele glucosespiegel of het HbA1c gehalte en vaatwandeigenschappen.

Het effect van therapeutische interventies op distensibiliteit en compliantie hangt af van de aard van de ziekte die behandeld wordt en de aard van de interventie. Bij een groep patiënten met essentiële hypertensie resulteerde een langdurige behandeling (6 maanden) met een ACE-remmer (perindopril) - bij een vergelijkbaar effect op de bloeddruk - in een meer uitgesproken verbetering van vaatwandeigenschappen dan een behandeling met een thiazidecombinatie (amiloride hydrochlorothiazide) (*Hoofdstuk 7*). Deze gegevens suggereren dat het effect op vaatwandeigenschappen in het geval van de ACE-remmer niet alleen het gevolg is van een indirect effect (namelijk via een daling van de bloeddruk), doch dat het ook een direct effect op de arteriële vaatwand betreft. Als gevolg hiervan zal de nabelasting van het hart met de ACE-remmer meer gedaald zijn bij gebruik van de ACE-remmer dan bij gebruik van het diureticum. De totale perifere weerstand was eveneens meer gedaald tijdens gebruik van perindopril dan van amiloride/ hydrochlorothiazide, hetgeen een additioneel gunstig effect van de ACE-remmer op de nabelasting van het hart inhoudt. Na het staken van de therapie werd echter vrij snel voor alle parameters weer de uitgangssituatie bereikt, waarmee gesuggereerd wordt dat een nog langere behandelingsperiode noodzakelijk is.

Hypercholesterolemie wordt beschouwd als een risicofactor voor atherosclerose. In een vroege fase van atherosclerose zijn reeds kenmerken aanwezig van endotheliale dysfunctie met als mogelijke consequentie een toename van de vaatwandspanning en een verhoogde arteriële stijfheid. Bij patiënten met milde tot matige hypercholesterolemie trad geen verandering op in hemodynamische parameters of vaatwandeigenschappen ten gevolge van een kortdurende (8 weken) behandeling met pravastatine, terwijl een significante verbetering van het lipidenprofiel werd gezien (*Hoofdstuk 8*). Aangezien vaatwandeigenschappen tussen patiënten met milde hypercholesterolemie en een controlegroep nagenoeg gelijk waren, kon het uitblijven van het effect van cholesterolverlaging op vaatwandeigenschappen verwacht worden. Anderzijds was een tendens aanwijsbaar voor een verminderde stijfheid van de a. femoralis bij de patiënten die behandeld werden met pravastatine. Mogelijk is een langere behandelingsperiode noodzakelijk om de vaatwandeigenschappen bij deze patiënten te verbeteren en het cardiovasculaire risico te reduceren.

In *Hoofdstuk 9* wordt een studie gepresenteerd over de acute en subacute effecten van isosorbide dinitraat (ISDN) en nicorandil, een nitraatachtig middel met kaliumkanaalopenende eigenschappen, op arteriële en veneuze parameters van gezonde vrijwilligers. In doseringen die gebruikt worden bij de behandeling van angina pectoris, veroorzaakte het pure nitraat ISDN, vergeleken met nicorandil, een meer uitgesproken

verlaging van de bloeddruk en een grotere vasodilatatie van de a. carotis communis. Tolerantie effecten konden bij ISDN aangetoond worden voor bloeddruk, hartfrequentie en veneuze hemodynamische parameters, doch niet voor arteriële hemodynamische parameters. Tolerantie effecten werden niet aangetoond bij gebruik van nicorandil.

Tenslotte worden in *Hoofdstuk 10* de verschillende factoren die de meettechniek van vaatwande-eigenschappen kunnen beïnvloeden en verbeteren bediscussieerd. Onderwerpen voor toekomstig onderzoek op dit gebied worden voorgesteld. Hiertoe behoren studies naar fysiologische factoren die vaatwande-eigenschappen beïnvloeden (o.a. geslacht en ras). Dit, met het oogpunt om meer nauwkeurig de verschillende risicofactoren met betrekking tot distensibiliteit en compliantie in kaart te kunnen brengen. De consequentie van additioneel toekomstig onderzoek zou kunnen zijn dat de individuele waarde van iemands vaatwande-eigenschappen kan bijdragen aan een meer persoonlijk gedefinieerd cardiovasculair risicoprofiel, terwijl deze waarde ook een follow-up parameter kan zijn bij de beoordeling van de effecten van therapeutische interventies.

DANKWOOD

Dankwoord

Dit proefschrift is tot stand gekomen dankzij de medewerking en het enthousiasme van veel mensen. Hiervoor wil ik vanaf deze plaats een aantal personen met name bedanken.

Allereerst, mijn co-promotor Luc Van Bortel, die mij de mogelijkheid bood om de verschillende studies te doen, maar die vooral steun en toeverlaat is geweest, wanneer de apparatuur het begaf, de experimenten niet liepen zoals ze zouden moeten lopen of de schrijfinspiraties vastliepen. Luc, je hebt mij voortdurend de mogelijkheid geboden om ook internationaal onze studieresultaten te presenteren. Vrijwel altijd had je tijd om onze apparatuur in en buiten Nederland te verslepen en daarmee multicentrische studies mogelijk te maken. Je was altijd bereid om problemen op te lossen en mee te denken over de onderzoeksresultaten. Bedankt ook voor het geduld dat je had tijdens de schrijffase en je bereidheid, ondanks je vele andere werkzaamheden, om je kritische commentaar op de diverse stukken te leveren. De ideeën, die voortdurend ontsproten aan je brein, hebben geleid tot hard werken, maar hebben onze samenwerking alleen maar in positieve zin beïnvloed.

Mijn promotores, Prof. dr. H.A.J. Struijker Boudier, Prof. dr. R.S. Reneman en Prof. dr. A.P.G. Hoeks vormden onafhankelijk van elkaar een stimulans in de afrondingsfase van dit proefschrift. Met name denk ik aan de plezierige bijeenkomsten, waar constructief de verschillende studies en artikelen besproken konden worden. Bovendien spreek ik een extra woord van bewondering uit voor Arnold Hoeks, die een nimmer aflatend geduld toonde voor wat betreft de technische aspecten van het vaatwand detector systeem. Door zijn uitleg en kritische opmerkingen ten aanzien van de technische principes werd ik af en toe overbluft, maar dat heeft onze contacten zeker niet benadeeld.

De leden van de beoordelingscommissie, Prof. dr. P. W. de Leeuw en Prof. dr. J. de Haan dank ik voor hun bereidwilligheid om het manuscript te beoordelen. The willingness of dr. S. Laurent to review the manuscript is greatly acknowledged.

Frans Smeets, Peter Brands, Jean Willigers en Tiny van Merode waren belangrijke en soms onmisbare krachten. Frans, Peter en Jean waren altijd bereid mij in een radeloze bui te voorzien van hulp, met name wanneer "het systeem" op tilt sloeg en onze metingen ten behoeve van de verschillende studies niet dreigden door te gaan. Hoewel hierbij menig zweetdruppeltje vloeiende, konden jullie altijd wel een oplossing bedenken. Tiny heeft mij vooral in de beginperiode wegwijs gemaakt in het veld van de vaatwandeigenschappen. Samen hebben we daarna nog de reproduceerbaarheidsstudie mogen uitvoeren. Van haar specifieke ervaring op dit gebied heb ik veel geleerd.

Van Emile Cheriex heb ik de grondbeginselen van de echografische cardiac output metingen geleerd. Hem wil ik bedanken voor zijn uitleg en waardevolle aanwijzingen bij het eigen maken van de techniek. Jos Hülkenberg wil ik bedanken voor de hulp die hij tijdens de multicentrische studies heeft geboden. Zijn hulp met betrekking tot het transport van onze "vaatwandkar" was zeer welkom, maar ook van zijn rol als zogenaamde klusjesman heb ik altijd dankbaar gebruik kunnen maken. Dhr. Dooren en Frans Slangen hebben als chauffeurs een onmisbare bijgedrage geleverd aan het transport. Hiervoor mijn dank.

Monique Fuss-Lejeune was voor mij een onmisbare assistente, met name bij het opvangen van de patiënten en de verwerking van de bloedmonsters. Jet Bost heeft veel energie gestoken in de laboratoriumbepalingen. Samen wil ik hen bedanken voor de prettige wijze waarop we al die tijd hebben kunnen samenwerken.

Marita Braam-van Neer heeft bij de 24-uurs studie haar nachtrust opgeofferd om mee te helpen bij de verwerking van de bloedmonsters. De studenten Carla Oude Elberink en Willem Sanders hebben tijdens hun wetenschapsstage mij bij de rokersstudie heel fijn kunnen helpen, vooral bij de plethysmografische metingen. Mieke Aarsen heeft mij bij de diabetenstudie in Amsterdam op een hele prettige wijze kunnen bijstaan. Voor al deze mensen geldt: Bedankt !

Binnen de vakgroep farmacologie heb ik altijd op een plezierige manier kunnen werken en samenwerken. Ten gevolge van de onderzoekswerkzaamheden kon ik lang niet altijd bij iedere samenkomst van de groep aanwezig zijn, maar de ontspannen, doch accurate wijze van werken aldaar heeft mij zeer aangesproken.

Hoewel ik nu op een andere werkplek ben gestationeerd, zal ik deze periode niet snel vergeten en probeer ik de contacten met jullie niet te verliezen.

Sjef Wijnen en Janneke Spek waren en zijn nog steeds twee heel fijne collega's. Samen hebben we op onze kamertjes in het BMC en later op Randwyck heel wat uurtjes doorgebracht. We hebben elkaar daarbij altijd goed kunnen helpen bij de verschillende onderzoeken, samen veel lief en leed gedeeld, maar vooral ook veel plezier gehad. Misschien kunnen we in de toekomst (ieder vanuit zijn eigen werkplek) nog eens een geïntegreerd onderzoek doen.

Mia Hogenboom en Els Geurts vormden een steunpilaar op secretariael gebied. Bedankt met name voor de tijden dat jullie op het laatste nippertje al die abstracts hebben getikt en voor de momenten dat jullie vriendelijk bleven (maar overspannen moeten zijn geraakt) van al die bellende proefpersonen, wanneer er weer eens een advertentie voor een onderzoek was geplaatst. Bovendien bedankt voor het versturen en bezorgen van post in de tijd dat ik niet meer bij de vakgroep werkzaam was.

Dr. Lustermans, dr. Kragten, dr. Breed, dr. de Cré en zijn assistente Hedwig dank ik hartelijk voor de mogelijkheid die zij mij gaven om de onderzoeken ook in hun kliniek en met hun patiënten te kunnen uitvoeren. Zonder hun medewerking waren de multicentrische studies niet mogelijk geweest.

Bij deze wil ik ook alle patiënten en proefpersonen, die deelgenomen hebben aan de verschillende onderzoeken, bedanken. Zij hebben vaak tijd noch moeite gespaard om toch te kunnen deelnemen aan een protocol.

De financiële steun bij de interventiestudies werd geleverd door de firma's Servier, Bristol-Myers Squibb en Merck Nederland. We hebben altijd in een prettige en open sfeer met elkaar kunnen samenwerken.

Voor René wil ik ook hier mijn dank uitspreken, want hij heeft veel van zijn kostbare tijd besteed aan de lay-out van dit proefschrift. Mimi heeft heel enthousiast en creatief gewerkt om de omslag van dit boekje te verfraaien.

Mijn ouders wil ik vooral bedanken voor de mogelijkheden die zij mij telkens geboden hebben om te studeren. Samen met Lisette (en later ook Richard), François en iedereen van mijn schoonfamilie hebben jullie voortdurend interesse in mijn werk getoond, hetgeen mede een stimulans geweest is om door te zetten en dit proefschrift af te ronden.

Lieve Bert, jouw aanwezigheid is met name in de laatste fase van dit proefschrift heel erg belangrijk geweest. Je hebt de totstandkoming van dit boekje vrijwel op de voet gevolgd, je was altijd heel erg geïnteresseerd in mijn werk. Jouw optimistische attitude en voortdurende steun, gaven mij de kracht om ook tijdens minder goede momenten de draad weer op te pakken. Omdat je zelf ook met de laatste loodjes bezig bent, hebben we vele uren samen en toch onafhankelijk van elkaar kunnen werken. Met plezier en een beetje weemoed zal ik blijven terugdenken aan deze tijd. Bert, jij hebt nooit getwijfeld aan het tot stand komen van dit boekje. Nu dit er is, zal ik ook voor jou de komende tijd nog meer een steun kunnen zijn. Op dit moment is mijn laatste woord van dank voor jou, merci !

PUBLICATIONS

Papers

1. MJ Kool, JA Wijnen, AP Hoeks, HA Struyker Boudier, LM Van Bortel. Diurnal pattern of vessel-wall properties of large arteries in healthy men. *J Hypertension* 1991,9 (Suppl. 6) :S108-S109.
2. JAG Wijnen, H Kuipers, MJF Kool, APG Hoeks, MA van Baak, HAJ Struijker Boudier, FTJ Verstappen, LMAB Van Bortel. Vessel wall properties of large arteries in trained and sedentary subjects. *Bas Res Cardiol* 1991, 86 (Suppl. 1) :25-29.
3. MJ Kool, HA Struijker-Boudier, JA Wijnen, AP Hoeks, LM van Bortel. Effects of diurnal variability and exercise training on properties of large arteries. *J Hypertension* 1992, 10 (Suppl. 6) :S49-S52.
4. LM Van Bortel, AP Hoeks, MJ Kool, HA Struijker-Boudier. Introduction to large artery properties as a target for risk reduction by antihypertensive therapy. *J Hypertension* 1992, 10 (Suppl. 6) :S123-S126.
5. JA Wijnen, MJ Kool, JP Kooman, MA van Baak, AP Hoeks, HA Struijker Boudier, LM Ban Bortel. Vessel wall properties of large arteries and endurance training. *J Hypertension* 1993, 11 (Suppl. 5) :S88-S89.
6. MJ Kool, FA Lustermaans, JG Breed, HA Struyker-Boudier, AP Hoeks, LM Van Bortel. Effect of perindopril and amiloride/ hydrochlorothiazide on haemodynamics and vessel wall properties of large arteries. *J Hypertension* 1993, 11 (Suppl. 5) :S362-S363.
7. MJF Kool, APG Hoeks, HAJ Struijker Boudier, RS Reneman, LMAB Van Bortel. Short- and long-term effects of smoking on arterial wall properties in habitual smokers. *JACC* 1993, 22 :1881-1886.
8. P Draaijer, MJ Kool, JM Maessen, LM van Bortel, PW de Leeuw, JP van Hooff, KM Leunissen. Vascular distensibility and compliance in salt-sensitive and salt-resistant borderline hypertension. *J Hypertension* 1993, 11 :1199-1207.
9. MJF Kool, T van Merode, RS Reneman, APG Hoeks, HAJ Struyker Boudier, LMAB Van Bortel. Evaluation of reproducibility of a vessel wall movement detector system for assessment of large artery properties. *Cardiovascular Research* 1994, 28 :610-614.
10. MJ Kool, JA Wijnen, FH Derckx, HA Struijker Boudier, LM Van Bortel. Diurnal variation in prorenin in relation to other humoral factors and hemodynamics. *AJH* 1994, 7 :723-730.
11. JAG Wijnen, MJF Kool, MA van Baak, H Kuipers, CHA de Haan, FTJ Verstappen, HAJ Struijker Boudier, LMAB Van Bortel. Effect of exercise training on ambulatory blood pressure. *Int J Sports Med* 1994, 15 :10-15.
12. LMAB Van Bortel, MJF Kool. Vessel wall properties of large arteries in hypertension and effect of antihypertensive treatment. *Can J Cardiol* 1994, 10 (Suppl. D) :37D-40D.
13. P Draaijer, MJF Kool, LMAB Van Bortel, F Nieman, PW de Leeuw, JP van Hooff, KML Leunissen. Vascular compliance in sodium-sensitive and sodium-resistant borderline hypertensive patients. *Kidney Int* 1995, 47 :169-176.
14. MJ Kool, J Lambert, CD Stehouwer, AP Hoeks, HA Struijker Boudier, LM Van Bortel. Vessel wall properties of large arteries in uncomplicated IDDM. *Diabetes Care* 1995, 18 :618-624.
15. MJ Kool, JJ Spek, HA Struyker Boudier, AP Hoeks, RS Reneman, RH van Herwaarden, LM Van Bortel. Acute and subacute effects of nicorandil and isosorbide dinitrate on vessel wall properties of large arteries and hemodynamics in healthy volunteers. *Cardiovasc Drugs Ther* 1995, 9 :331-337.
16. MJF Starmans-Kool, MMF Fickers, MAG Pannebakker. An unwanted side effect of hydroxyurea in a patient with idiopathic myelofibrosis. *Ann Hematol* 1995, 70 :279-280.
17. LMAB Van Bortel, MJF Kool, JJ Spek. Large artery distensibility and compliance in hypertension. Disparate effects of antihypertensive drugs. *Am J Cardiol* 1995 (in press)
18. LM Van Bortel, MJ Kool, HA Struijker Boudier. Effects of antihypertensive agents on local arterial distensibility and compliance. *Hypertension* 1995 (in press)
19. M Kool, F Lustermaans, H Kragten, H Struijker Boudier, A Hoeks, R Reneman, H Rila, I Hoogendam, L Van Bortel. Does lowering of cholesterol levels influence functional properties of large arteries ? *Eur J Clin Pharmacol* 1995 (in press)
20. MJ Kool, FA Lustermaans, JG Breed, HA Struijker Boudier, AP Hoeks, RS Reneman, LM Van Bortel. The influence of perindopril and diuretic combination amiloride/hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients. *J Hypertens* 1995 (in press)

Abstracts

1. MJF Kool, LMAB Van Bortel, JAG Wijnen, APG Hoeks, HAJ Struijker Boudier. Circadian rhythm and vessel wall properties of large arteries. *Neth J Med* 1990, 37 :A38-39.
2. MJF Kool, LMAB Van Bortel, JAG Wijnen, APG Hoeks, HAJ Struijker Boudier. Circadian rhythm and vessel wall properties of large arteries. *Proceedings 31th Dutch FEDERA Meeting 1990* : 149.
3. MJF Kool, JAG Wijnen, APG Hoeks, HAJ Struijker Boudier, LMAB Van Bortel. Vessel wall properties and circadian rhythm in large arteries. *Eur J Pharmacol* 1990, 183 :825.
4. JAG Wijnen, MJF Kool, H Kuipers, MA van Baak, HAJ Struijker Boudier, FTJ Verstappen, LMAB Van Bortel. Vessel wall properties of large arteries in trained and sedentary subjects. Abstract book symposium "Pharmacology of vascular and cardiac remodelling", July 8-10, 1990
5. L Van Bortel, M Kool, J Wijnen, H Struijker Boudier. Beta- adrenoceptor blockade, and beta-1 selectivity of nebivolol and atenolol. Abstracts 1st Int Nebivolol Investigators' meeting, September 13-16, 1990 :C11
6. LMAB Van Bortel, MA van Baak, MJF Kool, JAG Wijnen, HAJ Struijker Boudier. Beta-adrenoceptor blockade, antihypertensive effect and exercise tolerance with nebivolol and atenolol. *Pharmaceut Wkbl Sci Ed* 1990, 12 (Suppl. J) :J4.
7. LMAB Van Bortel, MJF Kool, JAG Wijnen, HAJ Struijker Boudier. β -Adrenoceptor blockade and β_1 -selectivity of nebivolol and atenolol. *Drug Invest* 1991, 3 (Suppl. 1) :173.
8. LMAB Van Bortel, MJF Kool, JAG Wijnen, HAJ Struijker Boudier. β -Adrenoceptor blocking properties and antihypertensive effect differ between nebivolol and atenolol. *Neht J Med* 1991, 39 :A62.
9. MJF Kool, T van Merode, APG Hoeks, LMAB Van Bortel. Reproducibility measurements with a new vessel wall movement detector system. *Neth J Med* 1991, 39 :A66.
10. MJF Kool, JAG Wijnen, H Kuipers, MA van Baak, HAJ Struijker Boudier, LMAB Van Bortel. Do vessel wall properties of superficial arteries differ between endurance-trained and sedentary subjects? *Neth J Med* 1991, 39 :A67.
11. LMAB Van Bortel, MJF Kool, FHM Derkx, JAG Wijnen, HAJ Struijker Boudier. Diurnal variation in humoral factors. *Pharmaceut Wkbl Sci Ed* 1991, 13 (Suppl. L) :L5.
12. MJF Kool, JAG Wijnen, HAJ Struijker Boudier, LMAB Van Bortel. Vessel wall properties of large arteries show a diurnal variation. *Pharmaceut Wkbl Sci Ed* 1991, 13 (Suppl. L) :L5.
13. JAG Wijnen, MJF Kool, MA van Baak, HAJ Struijker Boudier, LMAB Van Bortel. Exercise training does not lower ambulatory blood pressure in sedentary male subjects. *Eur Heart J* 1991, 12 (Suppl.) :29.
14. MJF Kool, FHM Derkx, JAG Wijnen, HAJ Struijker Boudier, LMAB Van Bortel. Prorenin and renin do not have the same diurnal variation. *Eur Heart J* 1991, 12 (Suppl.) :151.
15. MJF Kool, JAG Wijnen, LMAB Van Bortel, HAJ Struijker Boudier. Circadian pattern of vessel wall properties of large arteries in healthy men. *Ricerca Sci Educ Perman* 1991, (Suppl. 90) :345.
16. MJF Kool, FHM Derkx, JAG Wijnen, HAJ Struijker Boudier, LMAB Van Bortel. Different diurnal variation in prorenin and renin. *Ricerca Sci Educ Perman* 1991, (Suppl. 90) :346.
17. MJF Kool, T van Merode, APG Hoeks, LMAB Van Bortel. Reproducibility of a newly developed vessel wall movement detector system. *Ricerca Sci Educ Perman* 1991, (Suppl. 90) :347.
18. JAG Wijnen, MJF Kool, H Kuipers, MA van Baak, HAJ Struijker Boudier, LMAB Van Bortel. Differences in vessel wall properties of superficial arteries in cyclists and sedentary subjects. *Ricerca Sci Educ Perman* 1991, (Suppl. 90) :773.
19. JAG Wijnen, MJF Kool, LMAB Van Bortel, MA van Baak, HAJ Struijker Boudier. Exercise training and ambulatory blood pressure in sedentary male subjects. *Ricerca Sci Educ Perman* 1991 (Suppl. 90) :774.
20. P Draaijer, M Kool, L v Bortel, K Leunissen. Arterial distensibility (DC) and compliance (CC) in salt-resistant and salt-sensitive borderline hypertensive patients (SRBHT vs SSBHT). *J Am Soc Nephrology* 1991, 2 :474.
21. HAJ Struijker-Boudier, MJF Kool, JAG Wijnen, LMAB Van Bortel. Circadian changes and effect of exercise training. Functional and structural properties of large arteries. A workshop of the ISH on arterial compliance, Paris 6th-7th March, 1992

22. LMAB Van Bortel, APG Hoeks, MJF Kool, HAJ Struijker-Boudier. Large artery properties as a target for risk reduction by antihypertensive therapy. Functional and structural properties of large arteries. A workshop of the ISH on arterial compliance, Paris 6th-7th March, 1992
23. MJF Kool, APG Hoeks, HAJ Struijker-Boudier, LMAB Van Bortel. Acute effect of smoking on large artery compliance. *Neth J Med* 1992;40 :A59.
24. MJF Kool, APG Hoeks, HAJ Struijker-Boudier, LMAB Van Bortel. Vessel wall properties in habitual smokers. *Neth J Med* 1992, 40 :A58-A59.
25. MJF Kool, APG Hoeks, HAJ Struijker-Boudier, LMAB Van Bortel. Effects of smoking on large artery compliance. *Pharmaceut Wkbl Sci Ed* 1992, 14 (Suppl. D) :D4.
26. LMAB Van Bortel, JAG Wijnen, MJF Kool, MA Van Baak, HAJ Struijker Boudier. Effect of exercise training on ambulatory blood pressure *J Hypertension* 1992, 10 (Suppl. 4) :S106.
27. P Draaijer, M Kool, L van Bortel, P de Leeuw, KML Leunissen. Arterial distensibility (DC) and compliance (CC) in salt-resistant and salt-sensitive borderline hypertensive patients (SRBHT vs SSBHT). *J Hypertension* 1992, 10 (Suppl. 4).
28. LMAB Van Bortel, MJF Kool, T van Merode, APG Hoeks, RS Reneman, HAJ Struijker Boudier. Non-invasive measurements of arterial compliance: reproducibility. Abstract book Vth World conference on clinical pharmacology and therapeutics 1992 : P-404-03.
29. LMAB Van Bortel, MJF Kool, JAG Wijnen, HAJ Struijker Boudier. Nebivolol: not only a β_1 -selective adrenoceptor antagonist. Abstract book Vth World conference on clinical pharmacology and therapeutics 1992 :P-404-03.
30. LMAB Van Bortel, MJF Kool, JGS Breed, J De Cre, FAT Lustermans, JMV Mooij, HHW Thijssen. Hemodynamic effects of nebivolol and atenolol. *Arch Pharmacol* 1992, 345 (Suppl.) :R16-63.
31. MJF Kool, J Lambert, AJM Donker, HAJ Struijker Boudier, LMAB Van Bortel. Large artery compliance in young insulin-dependent diabetes mellitus. *J Hypertension* 1993;11 (Suppl. 5) :S442.
32. M Kool, A Hoeks, H Struijker Boudier, R Reneman, L Van Bortel. Are the acute effects of smoking on arterial wall properties the trigger for acute cardiovascular events in habitual smokers? *Eur Heart J* 1993, 14 (Suppl.) :362.
33. M Kool, F Lustermans, J Breed, H Struijker Boudier, A Hoeks, L Van Bortel. Effects of Coversyl® and Moduretic mitis® on blood pressure, cardiac function and vessel wall properties of large arteries. *Eur Heart J* 1993, 14 (Suppl.) :65.
34. MJF Kool, J Lambert, AJM Donker, HAJ Struijker Boudier, LMAB Van Bortel. Vessel wall properties of large arteries in young insulin-dependent diabetes mellitus (IDDM). *Neth J Med* 1993, 43 :A30.
35. L Van Bortel, S Laurent, B Laloux, M Kool, P Boutouyrie, Struijker Boudier, G Chatellier, M Safar. Le tabagisme et le cholestérol total sont de faibles déterminants des propriétés fonctionnelles des artères carotide et fémorale. *Arch Mal Coeur Vaiss*, 16-17 décembre, 1993
36. LMAB Van Bortel, MJF Kool, FAT Lustermans, JGS Breed, APG Hoeks, HAJ Struijker Boudier. Does antihypertensive treatment with an ACE-inhibitor and a diuretic result in different effects on hemodynamics and vessel wall properties of large arteries? *Pharmaceut Wkbl Sci Ed* 1993, 15 (Suppl E.) :E4.
37. J Lambert, MJF Kool, LMAB Van Bortel, CDA Stehouwer, HAJ Struijker Boudier, AJM Donker. Vessel wall properties in insulin-dependent diabetes mellitus (IDDM). *EASD* 1993
38. P Draaijer, M Kool, L van Bortel, P de Leeuw, J van Hooff, K Leunissen. Large artery compliance in sodium-sensitive and sodium-resistant borderline hypertension. *Ricerca Sci Educ Perman* 1993, (Suppl. 95) :198.
39. LMAB Van Bortel, JA Wijnen, MJ Kool, JP Kooman, MA van Baak, HA Struyker Boudier. Vessel wall properties of large arteries and endurance training. *Ricerca Sci Educ Perman* 1993 (Suppl. 95) :784.
40. MJF Kool, APG Hoeks, HAJ Struijker Boudier, RS Reneman, LMAB Van Bortel. Acute and chronic effects of smoking on arterial wall properties in habitual smokers. *Ricerca Sci Educ Perman* 1993, (Suppl. 95) :365.
41. MJF Kool, FAT Lustermans, JGS Breed, HAJ Struyker Boudier, APG Hoeks, LMAB Van Bortel. Effects of perindopril and amiloride/hydrochlorothiazide on haemodynamics and vessel wall properties of large arteries. *Ricerca Sci Educ Perman* 1993, (Suppl. 95) :365.
42. L Van Bortel, S Laurent, B Laloux, M Kool, P Boutouyrie H Struijker Boudier, G Chatellier, M Safar. Le tabagisme et le cholestérol total sont de faibles déterminants des propriétés fonctionnelles des artères carotide et fémorale. *Arch Mal Coeur Vaiss*, 16-17 décembre, 1993, 24.

43. J Spek, M Kool, A Hoeks, H Struijker Boudier, L Van Bortel. Subacute effects of nicorandi and ISDN on vessel wall properties of large arteries and cardiac function. *Pharmaceut Wkbl Sci Ed* 1993, 15 (Suppl. L) :L5.
44. MJF Kool, FAT Lusterms, JA Kragten, HAJ Struyker Boudier, I Hoogendam, LMAB Van Bortel. An eight-week treatment with pravastatin does not improve vessel wall properties of large arteries in patients with mild hypercholesterolemia. *Pharmaceut Wkbl Sci Ed* 1994, 16 (Suppl. D) :D7.
45. LMAB Van Bortel, MJF Kool, FAT Lusterms, JGS Breed, HAJ Struijker Boudier, APG Hoeks. Effect of perindopril and amiloride/hydrochlorothiazide on blood pressure, cardiac function and vessel wall properties of large arteries. Abstractbook satellite symposium XIth World Congress of Cardiology, Berlin, September 13, 1994
46. MJF Kool, FAT Lusterms, JGS Breed, HAJ Struijker Boudier, APG Hoeks, LMAB Van Bortel. Does treatment with perindopril and amiloride/hydrochlorothiazide result in different effects on hemodynamics and vessel wall properties of large arteries. *Neth J Med* 1994, 44 :A52.
47. JJ Spek, MJF Kool, APG Hoeks, HAJ Struijker Boudier, RHBM van Herwaarden, LMAB Van Bortel. Subacute effects of nicorandil and ISDN on hemodynamics and large artery properties. *Neth J Med* 1994, 44 :A85.
48. MJF Kool, LMAB Van Bortel, S Laurent, B Laloux, G Chatellier, HAJ Struijker Boudier, M Safar. Determinants of the wall properties of the carotid and femoral arteries. *Neth J Med* 1995, 46 :A70-A71:
49. MJF Kool, FAT Lusterms, HA Kragten, HAJ Struyker Boudier, H Rilla, LMAB Van Bortel. Lowering cholesterol in patients with mild hypercholesterolemia does not improve functional properties of large arteries. *Neth J Med* 1995, 46 :A70.
50. LMAB Van Bortel, MJF Kool, HAJ Struijker Boudier. Effects of antihypertensive agents on carotid arterial compliance. Abstractbook of second workshop "Structure and function of large arteries", Paris, January 20-21, 1995
51. L Van Bortel, M Kool. Vessel wall properties of large arteries in hypertension, effects of perindopril vs. diuretic therapy. Abstractbook of symposium: "From hypertension to congestive heart failure". Istanbul, Turkey, April 29, 1995.
52. MJF Kool, FAT Lusterms, JA Kragten, HAJ Struyker Boudier, H Rilla, LMAB Van Bortel. Effect of pravastatin on vessel wall properties of large arteries in hypercholesterolemic patients. Abstractbook EAS, 1995

CURRICULUM VITAE

Curriculum Vitae

Mirian Kool

- 1964, 7 mei geboren te Heerlen, Nederland.
- 1976 - 1982 gymnasium- β opleiding aan het Sint Maartenscollege, Maastricht, Nederland.
- 1982 - 1988 studie geneeskunde aan de Rijksuniversiteit Limburg, Maastricht Nederland.
- 1986, september doctoraal diploma geneeskunde.
- 1988, december basisartsdiploma, Rijksuniversiteit Limburg, Maastricht, Nederland.
- 1989 - 1993 assistent in opleiding, vakgroep farmacologie, divisie klinische farmacologie (Dr. L.M.A.B. Van Bortel en Prof. dr. H.A.J. Struijker Boudier), Rijksuniversiteit Limburg, Maastricht, Nederland.
- 1993 - heden assistent geneeskundige in opleiding tot internist (Dr. F.A.T. Lustermans), de Wever Ziekenhuis, Heerlen, Nederland.
- 1995 erkenning als arts-klinisch farmacoloog.